Chemical compounds as inhibitors of interleukin-1 activity

ABSTRACT

The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No.16/513,621, filed Jul. 16, 2019, which is a continuation ofInternational Patent Application No. PCT/US2018/014728, filed Jan. 22,2018, which claims the benefit of U.S. Provisional Application No.62/492,813, filed May 1, 2017 and of U.S. Provisional Application No.62/449,431, filed Jan. 23, 2017, the contents of which are incorporatedherein by reference in their entireties.

FIELD OF DISCLOSURE

The present disclosure relates to novel sulfonylurea and sulfonylthiourea compounds and related compounds and their use in treating adisease or condition responsive to modulation of cytokines such as IL-1βand IL-18, modulation of NLRP3, or inhibition of the activation of NLRP3or related components of the inflammatory process.

BACKGROUND

The NOD-like receptor (NLR) family, pyrin domain-containing protein 3(NLRP3) inflammasome is a component of the inflammatory process, and itsaberrant activation is pathogenic in inherited disorders such ascryopyrin-associated periodic syndromes (CAPS) and complex diseases suchas multiple sclerosis, type 2 diabetes, Alzheimer's disease andatherosclerosis.

NLRP3 is an intracellular receptor protein that senses certaininflammatory signals. Upon activation, NLRP3 binds toapoptosis-associated speck-like protein containing a caspase activationand recruitment domain (ASC). The NLRP3-ASC complex then polymerizes toform a large aggregate known as an ASC speck. Polymerized NLRP3-ASC inturn interacts with the cysteine protease caspase-1 to form a complextermed the inflammasome. This results in the activation of caspase-1,which cleaves the proinflammatory cytokines IL-1β and IL-18 to theiractive forms and mediates a type of inflammatory cell death known aspyroptosis. The ASC speck can also recruit and activate caspase-8, whichcan process pro-IL-1β and pro-IL-18 and trigger apoptotic cell death.

Caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms, whichare secreted from the cell. Active caspase-1 also cleaves gasdermin-D totrigger pyroptosis. Through its control of the pyroptotic cell deathpathway, caspase-1 also mediates the release of alarmin molecules suchas IL-33 and high mobility group box 1 protein (HMGB1). Caspase-1 alsocleaves intracellular IL-1R2 resulting in its degradation and allowingthe release of IL-la. In human cells caspase-1 may also control theprocessing and secretion of IL-37. A number of other caspase-1substrates such as components of the cytoskeleton and glycolysis pathwaymay contribute to caspase-1-dependent inflammation.

NLRP3-dependent ASC specks are released into the extracellularenvironment where they can activate caspase-1, induce processing ofcaspase-1 substrates and propagate inflammation.

Active cytokines derived from NLRP3 inflammasome activation areimportant drivers of inflammation and interact with other cytokinepathways to shape the immune response to infection and injury. Forexample, IL-1β signalling induces the secretion of the pro-inflammatorycytokines IL-6 and TNF. IL-1β and IL-18 synergize with IL-23 to induceIL-17 production by memory CD4 Th17 cells and by γS T cells in theabsence of T cell receptor engagement. IL-18 and IL-12 also synergize toinduce IFN-γ production from memory T cells and NK cell driving a Th1response.

Other intracellular pattern recognition receptors (PRRs) are alsocapable of forming inflammasomes. These include other NLR family memberssuch as NLRP1 and NLRC4, as well as non-NLR PRRs such as thedouble-stranded DNA (dsDNA) sensors absent in melanoma 2 (AIM2) andinterferon, gamma inducible protein 16 (IFI16). NLRP3-dependent IL-1βprocessing can also be activated by an indirect, non-canonical pathwaydownstream of caspase-11.

The inherited CAPS diseases Muckle-Wells syndrome (MWS), familial coldautoinflammatory syndrome and neonatal-onset multisystem inflammatorydisease are caused by gain-of-function mutations in NLRP3, thus definingNLRP3 as a critical component of the inflammatory process. NLRP3 hasalso been implicated in the pathogenesis of a number of complexdiseases, notably including metabolic disorders such as type 2 diabetes,atherosclerosis, obesity and gout.

A role for NLRP3 in diseases of the central nervous system is emerging,and lung diseases have also been shown to be influenced by NLRP3.Furthermore, NLRP3 has a role in the development of liver disease,kidney disease and aging. Many of these associations were defined usingmice with constitutive NLRP3 activation, but there have also beeninsights into the specific activation of NLRP3 in these diseases. Intype 2 diabetes, the deposition of islet amyloid polypeptide in thepancreas activates NLRP3 and IL-1β signaling, resulting in cell deathand inflammation.

There is a need to provide compounds with improved pharmacologicaland/or physiological and or physicochemical properties and/or those thatprovide a useful alternative to known compounds.

SUMMARY

The present disclosure provides compounds that are effective in theinhibition of an inflammasome, such as the NLRP3 inflammasome. Thecompounds are also effective in modulating of interleukins. Thedisclosed compounds have desirable molecular weights, physico-chemicalproperties, and lipophilicity, which are features that help withachieving therapeutic efficacy and decreasing unintended liabilities.

The present disclosure provides compounds of Formula I:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, or tautomers thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkenyl, optionally substitutedC₁-C₆alkynyl, —(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR⁵ or N;

A¹ is NR⁵, O, S, or C(O);

each A² is independently CR⁵, C(R⁵)₂, N, NR⁵, O, S, or S(O)₂;

R² is

X² is N or CR⁵;

R³ and R⁴ are H;

each R⁵ is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶,—NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; or

two R⁵ together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; or

two geminal R⁵ can form an oxo group;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR⁵, O, S, or S(O)₂.

The present disclosure provides compounds of Formula Ia:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkenyl, optionally substitutedC₁-C₆alkynyl, —(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

X² is N or CR^(5b);

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; or

two R^(5b) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

The present disclosure provides compounds of Formula Ib:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkenyl, optionally substitutedC₁-C₆alkynyl, —(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

X² is N or CR^(5b);

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂—SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, NH(C₁-C₆alkyl), or N(C₁-C₆alkyl)₂; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; R⁶ and R⁷ are independently, at each occurrence H, D,C₁-C₈alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-5 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,and heteroaryl are optionally substituted with D, halogen, C₁-C₈alkyl,—OH, —O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

The present disclosure provides compounds of Formula Ic:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkenyl, optionally substitutedC₁-C₆alkynyl, —(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

X² is N or CR^(5b);

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OH, —O—C₁-C₆alkyl,—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

The present disclosure provides compounds of Formula Id:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkynyl,—(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, NH(C₁-C₆alkyl), orN(C₁-C₆alkyl)₂; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OH, —O—C₁-C₆alkyl,—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

The present disclosure provides compounds of Formula Ie:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a1) or N;

each A² is independently CR^(5a2), C(R^(5a2))₂, N, NR^(5a2), O, S, orS(O)₂;

R² is

X² is N or CR^(5b1);

each R^(b10), R^(b11), R^(b12), R^(b13), R^(b14), and R^(b15) isindependently H, —OH, or oxo;

R³ and R⁴ are H;

each R^(5a1) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂-NR⁶C(O)OR⁶, or—NR⁶C(O)R⁶;

each R^(5a2) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—S(O)₂—R⁶, —COR⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶;or

two geminal R^(5a2) can form an oxo group;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, or C₂-C₆alkynyl;wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a2), O, S, or S(O)₂.

The present disclosure provides compounds of Formula If:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a1) or N;

each A² is independently CR^(5a2), C(R^(5a2))₂, N, NR^(5a2), O, S, orS(O)₂;

R² is

X² is N or CR^(5b1);

R³ and R⁴ are H;

each R^(5a1) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶;

each R^(5a2) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—S(O)₂—R⁶, —COR⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶;or

two geminal R^(5a2) can form an oxo group;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, or C₂-C₆alkynyl;wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a2), O, S, or S(O)₂.

The present disclosure provides compounds of Formula Ig:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a1) or N;

each A² is independently CR^(5a2), C(R^(5a2))₂, N, NR^(5a2), O, S, orS(O)₂;

R² is

X² is N or CR^(5b1);

R³ and R⁴ are H;

each R^(5a1) is independently H, D, halogen, OH, CN, —NO₂—SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶;

each R^(5a2) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —S(O)₂—R⁶; —COR⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶; or

two geminal R^(5a2) can form an oxo group;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, or C₂-C₆alkynyl;wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a2), O, S, or S(O)₂

The present disclosure provides compounds of Formula Ih:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a1) or N;

each A² is independently CR^(5a2), C(R^(5a2))₂, N, NR^(5a2), O, S, orS(O)₂;

R² is

X² is N or CR^(5b1);

R³ and R⁴ are H;

each R^(5a1) is independently H, D, halogen, —OH, —CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶;

each R^(5a2) is independently H, D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶;

wherein at least one R^(5a2) is —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, orheterocyclyl containing N; wherein the C₁-C₆alkyl is substituted with—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and wherein the heterocyclylis optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, or C₂-C₆alkynyl;wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a2), O, S, or S(O)₂.

The present disclosure provides a pharmaceutical composition comprisinga compound of the present disclosure, and pharmaceutically acceptablesalts, prodrugs, solvates, hydrates, isomers, and tautomers thereof, anda pharmaceutically acceptable carrier, diluent and/or excipient.

The present disclosure provides a method of treatment or prevention of adisease, disorder or condition including the step of administering aneffective amount of a compound of the present disclosure, andpharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof to thereby treat or prevent the disease,disorder or condition in a subject in need thereof.

The present disclosure provides a compound of the present disclosure,and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof, or the pharmaceutical composition of thepresent disclosure for use in the treatment or prevention of a disease,disorder or condition in a subject in need thereof.

The present disclosure provides for use of a compound of the presentdisclosure, and pharmaceutically acceptable salts, prodrugs, solvates,hydrates, isomers, and tautomers thereof, for the treatment orprevention of a disease, disorder or condition in a subject in needthereof.

The present disclosure provides for use of a compound of the presentdisclosure, and pharmaceutically acceptable salts, prodrugs, solvates,hydrates, isomers, and tautomers thereof, in the manufacture of amedicament for the treatment or prevention of a disease, disorder orcondition.

In certain embodiments, the disease, disorder or condition is responsiveto inhibition of an inflammasome.

In certain embodiments, the disease, disorder or condition is responsiveto inhibition of activation of the NLRP3 inflammasome.

In certain embodiments, the disease, disorder or condition is a disease,disorder or condition of the immune system, the liver, the lung, theskin, the cardiovascular system, the renal system, the gastrointestinaltract, the respiratory system, the endocrine system, the central nervoussystem, or is a cancer or other malignancy, or is caused by orassociated with a pathogen.

The present disclosure provides a method of modulating the activity of abiological target comprising the step of exposing the biological targetto a compound of the present disclosure, and pharmaceutically acceptablesalts thereof.

The biological target may be selected from the group consisting of theNLRP3 inflammasome, IL-6, IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-22,IL-33 and Th17 cells.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows inhibition of IL-1β production in peripheral bloodmononucleocytes (PBMCs) as a result of treatment with Compound 1,Compound 2, or Compound 3.

FIG. 2 shows inhibition of IL-1β and IL-18 production, but not TNFαproduction in Kupffer cells (KCs) as a result of treatment with Compound1, Compound 4, or Compound 5.

FIG. 3 shows modulation of IL-1β in an LPS and ATP challenge model ofCompound 1 and Compound 2.

FIG. 4 shows modulation of TNFα in an LPS and ATP challenge model ofCompound 1 and Compound 2.

FIG. 5 shows modulation of IL-1β in an LPS and ATP challenge model ofCompound 3.

FIG. 6 shows inhibition of activation of Caspasel (conversion ofpro-Caspasel to active Caspasel) as a result of treatment with Compound1, Compound 4, or Compound 2.

DETAILED DESCRIPTION

As used above, and throughout this disclosure, the following terms,unless otherwise indicated, shall be understood to have the followingmeanings. If a term is missing, the conventional term as known to oneskilled in the art controls.

As used herein, the terms “including,” “containing,” and “comprising”are used in their open, non-limiting sense.

The articles “a” and “an” are used in this disclosure to refer to one ormore than one (i.e., to at least one) of the grammatical object of thearticle. By way of example, “an element” means one element or more thanone element.

The term “and/or” is used in this disclosure to mean either “and” or“or” unless indicated otherwise.

To provide a more concise description, some of the quantitativeexpressions given herein are not qualified with the term “about”. It isunderstood that, whether the term “about” is used explicitly or not,every quantity given herein is meant to refer to the actual given value,and it is also meant to refer to the approximation to such given valuethat would reasonably be inferred based on the ordinary skill in theart, including equivalents and approximations due to the experimentaland/or measurement conditions for such given value. Whenever a yield isgiven as a percentage, such yield refers to a mass of the entity forwhich the yield is given with respect to the maximum amount of the sameentity that could be obtained under the particular stoichiometricconditions. Concentrations that are given as percentages refer to massratios, unless indicated differently.

A “patient” is a mammal, e.g., a human, mouse, rat, guinea pig, dog,cat, horse, cow, pig, or non-human primate, such as a monkey,chimpanzee, baboon or rhesus. “Patient” includes both human and animals.

The term “inhibitor” refers to a molecule such as a compound, a drug,enzyme, or a hormone that blocks or otherwise interferes with aparticular biologic activity.

The terms “effective amount” or “therapeutically effective amount” whenused in connection with a compound refer to a sufficient amount of thecompound to provide the desired biological result. That result can bereduction and/or alleviation of the signs, symptoms, or causes of adisease, or any other desired alteration of a biological system. Forexample, an “effective amount” for therapeutic use is the amount of thecomposition comprising a compound as disclosed herein required toprovide a clinically significant decrease in a disease. An appropriate“effective amount” in any individual case may be determined by one ofordinary skill in the art using routine experimentation. Thus, theexpression “effective amount” generally refers to the quantity for whichthe active substance has therapeutic effects. In the present case theactive substance is the inhibitor of the inflammasome.

As used herein, the terms “treat” or “treatment” are synonymous with theterm “prevent” and are meant to indicate a postponement of developmentof diseases, preventing the development of diseases, and/or reducingseverity of such symptoms that will or are expected to develop. Thus,these terms include ameliorating existing disease symptoms, preventingadditional symptoms, ameliorating or preventing the underlying causes ofsymptoms, inhibiting the disorder or disease, e.g., arresting thedevelopment of the disorder or disease, relieving the disorder ordisease, causing regression of the disorder or disease, relieving acondition caused by the disease or disorder, or stopping or alleviatingthe symptoms of the disease or disorder.

The term “disorder” is used in this disclosure to mean, and is usedinterchangeably with, the terms disease, condition, or illness, unlessotherwise indicated.

By using the terms “pharmaceutically acceptable” or “pharmacologicallyacceptable” it is intended to mean a material which is not biologically,or otherwise, undesirable—the material may be administered to anindividual without causing any substantially undesirable biologicaleffects or interacting in a deleterious manner with any of thecomponents of the composition in which it is contained.

The term “carrier”, as used in this disclosure, encompasses carriers,excipients, and diluents and means a material, composition or vehicle,such as a liquid or solid filler, diluent, excipient, solvent orencapsulating material, involved in carrying or transporting apharmaceutical agent from one organ, or portion of the body, to anotherorgan, or portion of the body of a subject. Excipients should beselected on the basis of compatibility and the release profileproperties of the desired dosage form. Exemplary carrier materialsinclude, e.g., binders, suspending agents, disintegration agents,filling agents, surfactants, solubilizers, stabilizers, lubricants,wetting agents, diluents, spray-dried dispersions, and the like.

The term “pharmaceutically compatible carrier materials” may comprise,e.g., acacia, gelatin, colloidal silicon dioxide, calciumglycerophosphate, calcium lactate, maltodextrin, glycerine, magnesiumsilicate, sodium caseinate, soy lecithin, sodium chloride, tricalciumphosphate, dipotassium phosphate, sodium stearoyl lactylate,carrageenan, monoglyceride, diglyceride, pregelatinized starch, and thelike. See, e.g., Hoover, John E., Remington's Pharmaceutical Sciences,Mack Publishing Co., Easton, Pa. 1975.

As used herein, the term “subject” encompasses mammals and non-mammals.Examples of mammals include, but are not limited to, any member of theclass Mammalia: humans, non-human primates such as chimpanzees, andother apes and monkey species; farm animals such as cattle, horses,sheep, goats, swine; domestic animals such as rabbits, dogs, and cats;laboratory animals including rodents, such as rats, mice and guineapigs, and the like. Examples of non-mammals include, but are not limitedto, birds, fish and the like. In one embodiment of the presentdisclosure, the mammal is a human.

The present disclosure also includes “prodrugs” of compounds. The term“prodrug” means a compound which is convertible in vivo by metabolicmeans (e.g, by hydrolysis) to a disclosed compound or active ingredient.Prodrugs can be prepared by techniques known to one skilled in the art.These techniques generally modify appropriate functional, e.g, ahydroxy, amino, carboxylic, etc., groups in a given compound. Thesemodified functional groups, however, regenerate original functionalgroups by routine manipulation or in vivo. Examples of prodrugs include,but are not limited to esters (e.g, acetate, formate, and benzoatederivatives), carbamates (e.g, N,N-dimethylaminocarbonyl) of hydroxy oramino functional groups in compounds of the present disclosure, amides(e.g., trifluoroacetylamino, acetylamino, and the like), and the like.Since prodrugs are known to enhance numerous desirable qualities ofpharmaceuticals (e.g., solubility, bioavailability, manufacturing,transport, pharmacodynamics, etc.), the compounds of the presentdisclosure may be delivered in prodrug form. Prodrugs, for instance, maybe bioavailable by oral administration even when the parent drug is not.Thus, the present disclosure is intended to cover prodrugs of thepresently claimed compounds, methods of delivering the same, andcompositions containing the same. Generally speaking, prodrugs arederivatives of per se drugs that after administration undergo conversionor metabolism to the physiologically active species. The conversion maybe spontaneous, such as hydrolysis in the physiological environment, ormay be enzyme-catalyzed. Prodrugs include compounds that can beoxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated,hydrolyzed, esterified, alkylated, dealkylated, acylated, deacylated,phosphorylated, and/or dephosphorylated to produce the active compound.

The term “IC₅₀”, as used herein, refers to concentrations at which ameasurable activity, phenotype or response, for example growth orproliferation of cells such as tumor cells, is inhibited by 50%. IC₅₀values can be estimated from an appropriate dose-response curve, forexample by eye or by using appropriate curve fitting or statisticalsoftware. More accurately, IC₅₀ values may be determined usingnon-linear regression analysis.

The terms “administered”, “administration”, or “administering” as usedin this disclosure refers to either directly administering a disclosedcompound or pharmaceutically acceptable salt of the disclosed compoundor a composition to a subject, or administering a prodrug derivative oranalog of the compound or pharmaceutically acceptable salt of thecompound or composition to the subject, which can form an equivalentamount of active compound within the subject's body, including ananimal, in need of treatment by bringing such individual in contactwith, or otherwise exposing such individual to, such compound.

As used herein, “alkyl” means a straight chain or branched saturatedchain having from 1 to 10 carbon atoms. Representative saturated alkylgroups include, but are not limited to, methyl, ethyl, n-propyl,isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl,3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl,2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl,2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl,2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl,isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl and the like,and longer alkyl groups, such as heptyl, and octyl and the like. Analkyl group can be unsubstituted or substituted. Alkyl groups containingthree or more carbon atoms may be straight, or branched. As used herein,“lower alkyl” means an alkyl having from 1 to 6 carbon atoms.

As used herein, an “alkenyl” includes an unbranched or branchedhydrocarbon chain containing 2-12 carbon atoms. The “alkenyl” groupcontains at least one double bond. The double bond of an alkenyl groupcan be unconjugated or conjugated to another unsaturated group. Examplesof alkenyl groups include, but are not limited to, ethylenyl, vinyl,allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl,2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl andthe like. An alkenyl group can be unsubstituted or substituted. Alkenyl,as defined herein, may also be branched or straight.

As used herein, “alkynyl” includes an unbranched or branched unsaturatedhydrocarbon chain containing 2-12 carbon atoms. The “alkynyl” groupcontains at least one triple bond. The triple bond of an alkynyl groupcan be unconjugated or conjugated to another unsaturated group. Examplesof alkynyl groups include, but are not limited to, ethynyl, propynyl,butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl,4-propyl-2-pentynyl, 4-butyl-2-hexynyl and the like. An alkynyl groupcan be unsubstituted or substituted.

The term “hydroxyl” or “hydroxy” means an OH group;

The term “alkoxy” as used herein refers to a straight or branched chainsaturated hydrocarbon containing 1-12 carbon atoms containing a terminal“O” in the chain, i.e., —O(alkyl). Examples of alkoxy groups include,without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, orpentoxy groups.

It should also be noted that any carbon as well as heteroatom withunsatisfied valences in the text, schemes, examples and Tables herein isassumed to have the sufficient number of hydrogen atom(s) to satisfy thevalences.

As used herein, references to hydrogen may also refer to a deuteriumsubstitution if desired. The term “deuterium” as used herein means astable isotope of hydrogen having odd numbers of protons and neutrons.

The term “halo” or “halogen” refers to fluorine, chlorine, bromine, oriodine.

The term “haloalkyl” as used herein refers to an alkyl group, as definedherein, which is substituted one or more halogen. Examples of haloalkylgroups include, but are not limited to, trifluoromethyl, difluoromethyl,pentafluoroethyl, trichloromethyl, etc.

The term “haloalkoxy” as used herein refers to an alkoxy group, asdefined herein, which is substituted one or more halogen. Examples ofhaloalkyl groups include, but are not limited to, trifluoromethoxy,difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.

The term “cyano” as used herein means a substituent having a carbon atomjoined to a nitrogen atom by a triple bond, i.e.,

The term “amino” as used herein means a substituent containing at leastone nitrogen atom. Specifically, NH₂, —NH(alkyl) or alkylamino,—N(alkyl)₂ or dialkylamino, amide, carboxamide, urea, and sulfamidesubstituents are included in the term “amino”.

Unless otherwise specifically defined, the term “aryl” refers to cyclic,aromatic hydrocarbon groups that have 1 to 3 aromatic rings, includingmonocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl.Where containing two aromatic rings (bicyclic, etc.), the aromatic ringsof the aryl group may be joined at a single point (e.g., biphenyl), orfused (e.g., naphthyl). The aryl group may be optionally substituted byone or more substituents, e.g., 1 to 5 substituents, at any point ofattachment. The substituents can themselves be optionally substituted.Furthermore when containing two fused rings the aryl groups hereindefined may have an unsaturated or partially saturated ring fused with afully saturated ring. Exemplary ring systems of these aryl groupsinclude, but are not limited to, phenyl, biphenyl, naphthyl,anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl,tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.

Unless otherwise specifically defined, “heteroaryl” means a monovalentmonocyclic or polycyclic aromatic radical of 5 to 18 ring atoms or apolycyclic aromatic radical, containing one or more ring heteroatomsselected from N, O, or S, the remaining ring atoms being C. Heteroarylas herein defined also means a bicyclic heteroaromatic group wherein theheteroatom is selected from N, O, or S. The aromatic radical isoptionally substituted independently with one or more substituentsdescribed herein. The substituents can themselves be optionallysubstituted. Examples include, but are not limited to, benzothiophene,furyl, thienyl, pyrrolyl, pyridyl, pyrazinyl, pyrazolyl, pyridazinyl,pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl,indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl,thiadiazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl,imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl,indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl,pyrazolo[3,4-c]pyridinyl, benzoimidazolyl, thieno[3,2-c]pyridinyl,thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl,indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl,benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl,dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl,1,6-naphthyridinyl, benzo[de]isoquinolinyl,pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl,tetrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl,pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl,pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl,pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl,3,4-dihydro-2H-1λ²-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d]thiophene,pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl,1H-pyrido[3,4-b][1,4]thiazinyl, benzooxazolyl, benzoisoxazolyl,furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl,furo[3,2-b]pyridine, [1,2,4]triazolo[1,5-a]pyridinyl, benzo[1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl,[1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl,benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one,3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl,4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4-d]thiazolyl,imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl,and derivatives thereof. Furthermore when containing two fused rings theheteroaryl groups herein defined may have an unsaturated or partiallysaturated ring fused with a fully saturated ring.

As used herein, the term “cycloalkyl” refers to a saturated or partiallysaturated, monocyclic, fused or spiro polycyclic, carbocycle having from3 to 18 carbon atoms per ring. The cycloalkyl ring or carbocycle may beoptionally substituted by one or more substituents, e.g., 1 to 5substituents, at any point of attachment. The substituents canthemselves be optionally substituted. Examples of cycloalkyl groupsinclude, without limitations, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl,bicyclo[2.2.2]octanyl, bicyclo[2.2.2]octenyl, decahydronaphthalenyl,octahydro-1H-indenyl, cyclopentenyl, cyclohexenyl, cyclohexa-1,4-dienyl,cyclohexa-1,3-dienyl, 1,2,3,4-tetrahydronaphthalenyl,octahydropentalenyl, 3a,4,5,6,7,7a-hexahydro-1H-indenyl,1,2,3,3a-tetrahydropentalenyl, bicyclo[3.1.0]hexanyl,bicyclo[2.1.0]pentanyl, spiro[3.3]heptanyl, bicyclo[2.2.1]heptanyl,bicyclo[2.2.1]hept-2-enyl, bicyclo[2.2.2]octanyl,6-methylbicyclo[3.1.1]heptanyl, 2,6,6-trimethylbicyclo[3.1.1]heptanyl,and derivatives thereof.

As used herein, the term “cycloalkenyl” refers to a partially saturated,monocyclic, fused or spiro polycyclic, carbocycle having from 3 to 18carbon atoms per ring and contains at least one double bond. Thecycloalkenyl ring may be optionally substituted by one or moresubstituents, e.g., 1 to 5 substituents, at any point of attachment. Thesubstituents can themselves be optionally substituted.

As used herein, the term “heterocycloalkyl” or “heterocyclyl” refers toa saturated or partially unsaturated and non-aromatic monocyclic, orfused or spiro, polycyclic, ring structure of 4-to-18 atoms containingcarbon and heteroatoms taken from oxygen, nitrogen, or sulfur andwherein there is not delocalized π-electrons (aromaticity) shared amongthe ring carbon or heteroatoms. The heterocycloalkyl or heterocyclylring structure may be substituted by one or more substituents. Thesubstituents can themselves be optionally substituted. Examples ofheterocycloalkyl or heterocyclyl rings include, but are not limited to,oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl,oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl,tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl,thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide,piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, homotropanyl,dihydrothiophen-2(3H)-onyl, tetrahydrothiophene 1,1-dioxide,2,5-dihydro-1H-pyrrolyl, imidazolidin-2-one, pyrrolidin-2-one,dihydrofuran-2(3H)-one, 1,3-dioxolan-2-one, isothiazolidine 1,1-dioxide,4,5-dihydro-1H-imidazolyl, 4,5-dihydrooxazolyl, oxiranyl, pyrazolidinyl,4H-1,4-thiazinyl, thiomorpholinyl, 1,2,3,4-tetrahydropyridinyl,1,2,3,4-tetrahydropyrazinyl, 1,3-oxazinan-2-one, tetrahydro-2H-thiopyran1,1-dioxide, 7-oxabicyclo[2.2.1]heptanyl, 1,2-thiazepane 1,1-dioxide,octahydro-2H-quinolizinyl, 1,3-diazabicyclo[2.2.2]octanyl,2,3-dihydrobenzo[b][1,4]dioxine, 3-azabicyclo[3.2.1]octanyl,8-azaspiro[4.5]decane, 8-oxa-3-azabicyclo[3.2.1]octanyl,2-azabicyclo[2.2.1]heptane, 2,8-diazaspiro[5.5]undecanyl,2-azaspiro[5.5]undecanyl, 3-azaspiro[5.5]undecanyl,decahydroisoquinolinyl, 1-oxa-8-azaspiro[4.5]decanyl,8-azabicyclo[3.2.1]octanyl, 1,4′-bipiperidinyl, azepanyl,8-oxa-3-azabicyclo[3.2.1]octanyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl,5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl, 1,4-diazepanyl,phenoxathiinyl, benzo[d][1,3]dioxolyl, 2,3-dihydrobenzofuranyl,2,3-dihydrobenzo[b][1,4]dioxinyl, 4-(piperidin-4-yl)morpholinyl,3-azaspiro[5.5]undecanyl, decahydroquinolinyl, piperazin-2-one,1-(pyrrolidin-2-ylmethyl)pyrrolidinyl, 1,3′-bipyrrolidinyl, and6,7,8,9-tetrahydro-1H,5H-pyrazolo[1,2-a][1,2]diazepinyl.

Numerical ranges, as used herein, are intended to include sequentialintegers. For example, a range expressed as “from 0 to 5” would include0, 1, 2, 3, 4 and 5.

As used herein, the term “substituted” means that the specified group ormoiety bears one or more suitable substituents wherein the substituentsmay connect to the specified group or moiety at one or more positions.For example, an aryl substituted with a cycloalkyl may indicate that thecycloalkyl connects to one atom of the aryl with a bond or by fusingwith the aryl and sharing two or more common atoms.

As used herein, the term “unsubstituted” means that the specified groupbears no substituents.

The term “optionally substituted” is understood to mean that a givenchemical moiety (e.g., an alkyl group) can (but is not required to) bebonded other substituents (e.g., heteroatoms). For instance, an alkylgroup that is optionally substituted can be a fully saturated alkylchain (i.e., a pure hydrocarbon). Alternatively, the same optionallysubstituted alkyl group can have substituents different from hydrogen.For instance, it can, at any point along the chain be bounded to ahalogen atom, a hydroxyl group, or any other substituent describedherein. Thus the term “optionally substituted” means that a givenchemical moiety has the potential to contain other functional groups,but does not necessarily have any further functional groups. Suitablesubstituents used in the optional substitution of the described groupsinclude, without limitation, oxo, -halogen, C₁-C₆ alkyl, C₁-C₆alkoxy,C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, —OC₁-C₆ alkenyl, —OC₁-C₆ alkynyl,—C₁-C₆ alkenyl, —C₁-C₆ alkynyl, —OH, CN (cyano), —CH₂CN, —OP(O)(OH)₂,—C(O)OH, —OC(O)C₁-C₆ alkyl, —C(O)C₁-C₆ alkyl, —C(O)—C₀-C₆alkylenyl-cycloalkyl, —C(O)—C₀-C₆ alkylenyl-heterocycloalkyl,—C(O)—C₀-C₆ alkylenyl-aryl, —C(O)—C₀-C₆ alkylenyl-heteroaryl,—OC(O)OC₁-C₆ alkyl, NH₂, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)₂, —C(O)NH₂,—C(O)NH(C₁-C₆ alkyl), —C(O)N(C₁-C₆alkyl)₂, —C(O)NH cycloalkyl,—C(O)N(C₁-C₆ alkyl)cycloalkyl, —C(O)NHheterocycloalkyl, —C(O)N(C₁-C₆alkyl)heterocycloalkyl, —C(O)NHaryl, —C(O)N(C₁-C₆ alkyl)aryl,—C(O)NHheteroaryl, —C(O)N(C₁-C₆ alkyl)heteroaryl, —S(O)₂—C₁-C₆ alkyl,—S(O)₂—C₁-C₆ haloalkyl, —S(O)₂-cycloalkyl, —S(O)₂-heterocycloalkyl,—S(O)₂-aryl, —S(O)₂-heteroaryl —C₀-C₆ alkylenyl-S(O)₂NH₂, —S(O)₂NHC₁-C₆alkyl, —S(O)₂N(C₁-C₆ alkyl)₂, —S(O)₂NHcycloalkyl,—S(O)₂NHheterocycloalkyl, —S(O)₂NHaryl, —S(O)₂NHhetereoaryl,—NHS(O)₂C₁-C₆ alkyl, —N(C₁-C₆ alkyl)S(O)₂(C₁-C₆ alkyl), —NHS(O)₂aryl,—N(C₁-C₆ alkyl)S(O)₂ aryl, —NHS(O)₂ heteroaryl,—N(C₁-C₆alkyl)S(O)₂heteroaryl, —NHS(O)₂ cycloalkyl, —N(C₁-C₆ alkyl)S(O)₂cycloalkyl, —NHS(O)₂ heterocycloalkyl, —N(C₁-C₆ alkyl)S(O)₂heterocycloalkyl, —N(C₁-C₆ alkyl)S(O)₂ aryl, —C₀-C₆ alkylenyl-aryl,—C₀-C₆ alkylenyl-heteroaryl, —C₀-C₆ alkylenyl-cycloalkyl, —C₀-C₆alkylenyl-heterocycloalkyl, —O-aryl, —NH-aryl, and N(C₁-C₆ alkyl)aryl.The substituents can themselves be optionally substituted. When amultifunctional moiety is shown, the point of attachment to the core isindicated by a line, e.g., (cycloalkyloxy)alkyl- refers to alkyl beingthe point of attachment to the core while cycloalkyl is attached toalkyl via the oxy group. “Optionally substituted” also refers to“substituted” or “unsubstituted”, with the meanings described above.

The term “oxa” as used herein refers to an “—O—” group.

The term “oxo” as used herein refers to an “═O” group.

The term “solvate” refers to a complex of variable stoichiometry formedby a solute and solvent. Such solvents for the purpose of the presentdisclosure may not interfere with the biological activity of the solute.Examples of suitable solvents include, but are not limited to, water,methanol, ethanol, and acetic acid. Solvates wherein water is thesolvent molecule are typically referred to as hydrates. Hydrates includecompositions containing stoichiometric amounts of water, as well ascompositions containing variable amounts of water.

The term “salt(s)”, as employed herein, denotes acidic salts formed withinorganic and/or organic acids, as well as basic salts formed withinorganic and/or organic bases. In addition, when a compound of theFormula contains both a basic moiety, such as, but not limited to apyridine or imidazole, and an acidic moiety, such as, but not limited toa carboxylic acid, zwitterions (“inner salts”) may be formed and areincluded within the term “salt(s)” as used herein. Pharmaceuticallyacceptable (i.e., non-toxic, physiologically acceptable) salts arepreferred, although other salts are also useful. Salts of the compoundsof the Formula may be formed, for example, by reacting a compound ofFormula with an amount of acid or base, such as an equivalent amount, ina medium such as one in which the salt precipitates or in an aqueousmedium followed by lyophilization.

In another embodiment of the present disclosure, the compounds ofFormula (I) are enantiomers. In some embodiments the compounds are the(S)-enantiomer. In other embodiments the compounds are the(R)-enantiomer. In yet other embodiments, the compounds of Formula (I)may be (+) or (−) enantiomers.

It should be understood that all isomeric forms are included within thepresent disclosure, including mixtures thereof. If the compound containsa double bond, the substituent may be in the E or Z configuration. Ifthe compound contains a disubstituted cycloalkyl, the cycloalkylsubstituent may have a cis- or trans-configuration. All tautomeric formsare also intended to be included.

Compounds of the various Formulae, and salts, solvates, esters andprodrugs thereof, may exist in their tautomeric form (for example, as anamide or imino ether). All such tautomeric forms are contemplated hereinas part of the present disclosure.

The compounds of the various Formulae may contain asymmetric or chiralcenters, and, therefore, exist in different stereoisomeric forms. It isintended that all stereoisomeric forms of the compounds of the variousFormulae as well as mixtures thereof, including racemic mixtures, formpart of the present disclosure. In addition, the present disclosureembraces all geometric and positional isomers. For example, if acompound of the various Formulae incorporates a double bond or a fusedring, both the cis- and trans-forms, as well as mixtures, are embracedwithin the scope of the present disclosure. Each compound hereindisclosed includes all the enantiomers that conform to the generalstructure of the compound. The compounds may be in a racemic orenantiomerically pure form, or any other form in terms ofstereochemistry. The assay results may reflect the data collected forthe racemic form, the enantiomerically pure form, or any other form interms of stereochemistry.

Diastereomeric mixtures can be separated into their individualdiastereomers on the basis of their physical chemical differences bymethods well known to those skilled in the art, such as, for example, bychromatography and/or fractional crystallization. Enantiomers can beseparated by converting the enantiomeric mixture into a diastereomericmixture by reaction with an appropriate optically active compound (e.g.,chiral auxiliary such as a chiral alcohol or Mosher's acid chloride),separating the diastereomers and converting (e.g., hydrolyzing) theindividual diastereomers to the corresponding pure enantiomers. Also,some of the compounds of the various Formulae may be atropisomers (e.g.,substituted biaryls) and are considered as part of the presentdisclosure. Enantiomers can also be separated by use of a chiral HPLCcolumn.

It is also possible that the compounds of Formula (I) may exist indifferent tautomeric forms, and all such forms are embraced within thescope of the present disclosure. Also, for example, all keto-enol andimine-enamine forms of the compounds are included in the presentdisclosure.

All stereoisomers (for example, geometric isomers, optical isomers andthe like) of the present compounds (including those of the salts,solvates, esters and prodrugs of the compounds as well as the salts,solvates and esters of the prodrugs), such as those which may exist dueto asymmetric carbons on various substituents, including enantiomericforms (which may exist even in the absence of asymmetric carbons),rotameric forms, atropisomers, and diastereomeric forms, arecontemplated within the scope of the present disclosure, as arepositional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (Forexample, if a compound of the various Formulae incorporates a doublebond or a fused ring, both the cis- and trans-forms, as well asmixtures, are embraced within the scope of the present disclosure. Also,for example, all keto-enol and imine-enamine forms of the compounds areincluded in the present disclosure.) Individual stereoisomers of thecompounds of the present disclosure may, for example, be substantiallyfree of other isomers, or may be admixed, for example, as racemates orwith all other, or other selected, stereoisomers. The chiral centers ofthe present disclosure can have the S or R configuration as defined bythe IUPAC 1974 Recommendations.

The present disclosure also embraces isotopically-labelled compounds ofthe present disclosure which are identical to those recited herein, butfor the fact that one or more atoms are replaced by an atom having anatomic mass or mass number different from the atomic mass or mass numberusually found in nature. Examples of isotopes that can be incorporatedinto compounds of the present disclosure include isotopes of hydrogen,carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ²H(or D), ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, and ³⁶Cl,respectively.

Certain isotopically-labelled compounds of the various Formulae (e.g.,those labeled with ³H and ¹⁴C) are useful in compound and/or substratetissue distribution assays. Tritiated (i.e., ³H) and carbon-14 (i.e.,¹⁴C) isotopes are particularly preferred for their ease of preparationand detectability. Further, substitution with heavier isotopes such asdeuterium (i.e., ²H) may afford certain therapeutic advantages resultingfrom greater metabolic stability (e.g., increased in vivo half-life orreduced dosage requirements) and hence may be preferred in somecircumstances. Isotopically labelled compounds of the various Formulaecan generally be prepared by following procedures analogous to thosedisclosed in the Schemes and/or in the Examples herein below, bysubstituting an appropriate isotopically labelled reagent for anon-isotopically labelled reagent.

In some embodiments, the compound comprises at least one deuterium atom.For example, one or more hydrogen atoms in a compound of the presentdisclosure can be replaced or substituted by deuterium. In someembodiments, the compound comprises two or more deuterium atoms. In someembodiments, the compound comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or12 deuterium atoms.

The compounds of Formula (I) may form salts which are also within thescope of the present disclosure. Reference to a compound of the Formulaherein is understood to include reference to salts thereof, unlessotherwise indicated.

The present disclosure is directed to compounds as described herein andpharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, or tautomers thereof, and pharmaceutical compositionscomprising one or more compounds as described herein, orpharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, or tautomers thereof.

In the present disclosure, reference to Formula (Ib) includes referenceto Formula (Ib)-1 and similarly for Formula (Ic), (Id), and (Ig). In thepresent disclosure, reference to, e.g., Formula Ib-Ig includes referenceto Formula (Ib)-1, (Ic)-1, (Id)-1, (Ig)-1, and (Ih)-1

Compounds

The present disclosure provides a compound having the structure ofFormula (I),

and pharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, and tautomers thereof, where X¹, R¹, R², R³, and R⁴are as described above.

The present disclosure provides a compound having the structure ofFormula (Ia),

and pharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, and tautomers thereof, where X¹, R¹, R², R³, and R⁴are as described above.

The present disclosure provides a compound having the structure ofFormula (Ib),

and pharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, and tautomers thereof, where X⁵, R¹, R², R³, and R⁴are as described above.

In certain embodiments, the present disclosure provides a compoundhaving the structure of Formula (Ib), which is of the Formula (Ib)-1:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

X² is N or CR^(5b);

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OH, —O—C₁-C₆alkyl,—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

The present disclosure provides a compound having the structure ofFormula (Ic),

and pharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, and tautomers thereof, where X¹, R¹, R², R³, and R⁴are as described above.

In certain embodiments, the present disclosure provides a compoundhaving the structure of Formula (Ic), which is of the Formula (Ic)-1:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

X² is N or CR^(5b);

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OH, —O—C₁-C₆alkyl,—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

The present disclosure provides a compound having the structure ofFormula (Id),

and pharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, and tautomers thereof where X¹, R¹, R², R³, and R⁴are as described above.

In certain embodiments, the present disclosure provides a compoundhaving the structure of Formula (Id), which is of the Formula (Id)-1:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂—SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, NH(C₁-C₆alkyl), or N(C₁-C₆alkyl)₂; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OH, —O—C₁-C₆alkyl,—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

The present disclosure provides a compound having the structure ofFormula (Ie),

and pharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, and tautomers thereof, where X¹, R¹, R², R³, and R⁴are as described above.

The present disclosure provides a compound having the structure ofFormula (If),

and pharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, and tautomers thereof, where X¹, R¹, R², R³, and R⁴are as described above.

The present disclosure provides a compound having the structure ofFormula (Ig),

and pharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, and tautomers thereof, where X¹, R¹, R², R³, and R⁴are as described above. Compounds of Formula (If) do not contain a basicamino group in the R¹ substituent. The sulfonylurea moiety withincompounds of Formula (Ig) renders pka values for these compounds in therange of 5.2-6.2, characterizing them as weak organic acids. Compoundsof this structure may display love volumes of distribution in vivo andmay exhibit high plasma protein binding.

In certain embodiments, the present disclosure provides a compoundhaving the structure of Formula (Ig), which is of the Formula (Ig)-1:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

R² is

X² is N or CR^(5b1);

R³ and R⁴ are H;

R^(5a1a) is H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷,—NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶;

R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) areselected from independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, —NS(O)₂R⁶; or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) whichare germinal, together with the atoms to which they are attached canform C₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains1-3 heteroatoms selected from the group consisting of N, S, P and O;wherein the C₃-C₈cycloalkyl and heterocyclyl are optionally substitutedwith D, halogen, C₁-C₆alkyl, —OR⁶, —S(O)₂—R⁶; —COR⁶, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NS(O)₂R⁶; or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), andR^(5a2f) can form an oxo group;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, or C₂-C₆alkynyl;wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O.

The present disclosure provides a compound having the structure ofFormula (Ih),

and pharmaceutically acceptable salts, enantiomers, hydrates, solvates,prodrugs, isomers, and tautomers thereof, where X¹, R¹, R², R³, and R⁴are as described above. Compounds of Formula (Ih) contain a basic aminogroup. Incorporation of a basic amino group to a compound of Formula(1h), which also bears the acidic sulfonylurea moiety, would be expectedto exist as a zwitterion, having a net zero charge. Zwitterioniccompounds can have different physicochemical properties than weakorganic acids. Notably, there may be increased volumes of distributionin vivo as well as lowered plasma protein binding. In certainembodiments of Formula Ih, one or two R^(5a2) are —NHR⁶, —NR⁶R⁷,C₁-C₆alkyl, or heterocyclyl containing N; wherein the C₁-C₆alkyl issubstituted with —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and whereinthe heterocyclyl is optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶. In certainembodiments of Formula Ih, one R^(5a2) is —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, orheterocyclyl containing N; wherein the C₁-C₆alkyl is substituted with—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and wherein the heterocyclylis optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶.

In certain embodiments, the present disclosure provides a compoundhaving the structure of Formula (Ih), which is of the Formula (Ih)-1:

and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

R² is

X² is N or CR^(5b1);

R³ and R⁴ are H;

R^(5a1a) is H, D, halogen, OH, CN, —NO₂—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷,—NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶;

each R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) areindependently selected from H, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, andheterocyclyl containing N; wherein the C₁-C₆alkyl is substituted with—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and wherein the heterocyclylis optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, or C₂-C₆alkynyl;wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O.

In certain embodiments of Formula I, when R¹ is

then at least one A² is N, NR⁵, O, S, or S(O)₂. In certain embodimentsof Formulae Ia-Id, when R¹ is

then at least one A² is N, NR^(5a), O, S, or S(O)₂.

In certain embodiments of the formulae described herein, X¹ is O. Incertain embodiments, X¹ is S. In certain embodiments, X¹ is

In certain embodiments, X¹ is

In certain embodiments of the formulae described herein, R² is

In certain embodiments of Formula I, R² is

In certain embodiments of Formulae Ia-Id, R² is

In certain embodiments, R² is

In certain embodiments, R² is

In certain embodiments of the formula described herein, R² is

In certain embodiments of Formula I, R⁵ is H, D, halogen, CN, —OR⁶, orC₁-C₆alkyl. In certain embodiments, R⁵ is H, halogen, or C₁-C₆alkyl. Incertain embodiments, R⁵ is H, halogen, or methyl. In certainembodiments, R⁵ is H, fluoro, chloro, or methyl. In certain embodiments,R⁵ is H. In certain embodiments, R⁵ is halogen. In certain embodiments,R⁵ is fluoro. In certain embodiments, R⁵ is chloro. In certainembodiments, R⁵ is methyl.

In certain embodiments of Formulae Ia-Id, R^(5b) is H, D, halogen, CN,—OR⁶, or C₁-C₆alkyl. In certain embodiments, R^(5b) is H, halogen, orC₁-C₆alkyl. In certain embodiments, R^(5b) is H, halogen, or methyl. Incertain embodiments, R^(5b) is H, fluoro, chloro, or methyl. In certainembodiments, R^(5b) is H. In certain embodiments, R^(5b) is halogen. Incertain embodiments, R^(5b) is fluoro. In certain embodiments, R^(5b) ischloro. In certain embodiments, R^(5b) is methyl.

In certain embodiments of Formula I, R² is

In certain embodiments of Formula Ia-Id, R² is

In certain embodiments, n is zero, one, or two.

In certain embodiments of Formula I, each R⁵ is independently H,halogen, OH, CN, —NO₂, —OR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₃-C₈cycloalkyl. In certain embodiments, each R⁵is independently selected from the group consisting of H, halogen,C₁-C₆alkyl, C₃-C₈cycloalkyl, and —CN.

In certain embodiments of Formulae Ia-Id, each R^(5b) is independentlyH, halogen, OH, CN, —NO₂, —OR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₃-C₈cycloalkyl. In certain embodiments, eachR^(5b) is independently selected from the group consisting of H,halogen, C₁-C₆alkyl, C₃-C₈cycloalkyl, and —CN.

In certain embodiments of Formula I, R² is

In certain embodiments of Formulae Ia-Id, R² is

In certain embodiments of Formula I, R² is

In certain embodiments of Formulae Ia-Id, R² is

In certain embodiments of the formulae described herein, R² is selectedfrom the group consisting of

In certain embodiments, wherein R² is selected from the group consistingof

In certain embodiments, R² is

In certain embodiments of the formula Ie-Ih, R² is

wherein at least one of R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6)is C₁-C₆alkyl or C₃-C₈cycloalkyl, wherein the C₁-C₆alkyl andC₃-C₈cycloalkyl are optionally substituted with D, halogen, —CN, —OR⁶,—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂. In certain embodiments, atleast one of R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) isC₁-C₆alkyl or C₃-C₈cycloalkyl, wherein the C₁-C₆alkyl andC₃-C₈cycloalkyl are optionally substituted with halogen.

In certain embodiments of the formulae described herein, R¹ is anoptionally substituted C₁-C₆alkyl. In certain embodiments, R¹ isC₁-C₆alkyl. In certain embodiments, R¹ is C₁-C₃alkyl. In certainembodiments, R¹ is methyl. In certain embodiments, R¹ is an optionallysubstituted C₁-C₆alkenyl. In certain embodiments, R¹ is an optionallysubstituted C₁-C₆alkynyl. In certain embodiments, R¹ is—(CH₂)_(m)—O—(CH₂)_(m)—CH₃, each m is independently an integer from oneto 4.

In certain embodiments of the formulae described herein, R¹ is selectedfrom the group consisting

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments of the formulae described herein, the

are single bonds in the ring comprising A², thereby forming a saturatedring. In certain embodiments, one to two

are double bonds in the ring comprising A², thereby forming anunsaturated ring.

In certain embodiments of Formula I, A is CR⁵. In certain embodiments ofFormulae Ia-Id, A is CR^(5a). In certain embodiments of the formulaedescribed herein, A is N.

In certain embodiments of Formula I, A¹ is NR⁵. In certain embodimentsof Formulae Ia-Id, A¹ is NR^(5a). In certain embodiments of the formulaedescribed herein, A¹ is O. In certain embodiments of the formulaedescribed herein, A¹ is S. In certain embodiments of the formulaedescribed herein, A¹ is C(O).

In certain embodiments of the formulae described herein, each A² isindependently CH₂ or O. In certain embodiments, each A² is CH₂.

In certain embodiments of Formula I, one A is CR⁵ and the other A is N.In certain embodiments, each A² is independently C(R⁵)₂, NR⁵, or O.

In certain embodiments of Formulae Ia-Id, one A is CR^(5a) and the otherA is N. In certain embodiments, each A² is independently C(R^(5a))₂,NR^(5a), or O.

In certain embodiments of Formula I, R⁵ is independently H, D, halogen,OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶,—C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷, —NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷,—NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl. In certain embodiments, the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl is optionally substituted.

In certain embodiments of Formula Ia, each R^(5a) is independently H, D,halogen, OH, CN, —NO₂—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶,—C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷, —NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷,—NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl. In certain embodiments, the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl is optionally substituted.

In certain embodiments of Formula Ia, each R^(5b) is independently H, D,halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—,—S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷, —NR⁶S(O)₂R⁷, —S(O)R⁶,—S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl. In certain embodiments, the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl is optionally substituted.

In certain embodiments of Formula I, two R⁵ together with the atoms towhich they are attached can form C₃-C₈cycloalkyl, heterocyclyl, aryl, orheteroaryl; wherein the heterocyclyl and heteroaryl contain 1-3heteroatoms selected from the group consisting of N, S, P and O. Incertain embodiments, the C₃-C₈cycloalkyl, heterocyclyl, aryl, orheteroaryl is optionally substituted.

In certain embodiments of Formulae Ia-Id, two R^(5a) together with theatoms to which they are attached can form C₃-C₈cycloalkyl, heterocyclyl,aryl, or heteroaryl; wherein the heterocyclyl and heteroaryl contain 1-3heteroatoms selected from the group consisting of N, S, P and O. Incertain embodiments, the C₃-C₈cycloalkyl, heterocyclyl, aryl, orheteroaryl is optionally substituted. In certain embodiments, theC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionallysubstituted with D, halogen, C₁-C₆alkyl, —OH, —NH₂, NH(C₁-C₆alkyl), orN(C₁-C₆alkyl)₂, In certain embodiments, two R^(5a) together with theatoms to which they are attached can form C₃-C₈cycloalkyl, optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂.

In certain embodiments of the formulae described herein, two geminal R⁵can form an oxo group. In certain embodiments of Formula Ia-Id, twogeminal R^(5a) can form an oxo group.

In certain embodiments of Formulae Ib-Id, each R^(5a) is independentlyH, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—,—S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷, —NR⁶S(O)₂R⁷, —S(O)R⁶,—S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OH, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, Incertain embodiments, R^(5a) is C₁-C₆alkyl optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, NH(C₁-C₆alkyl), or N(C₁-C₆alkyl)₂, Incertain embodiments, R^(5a) is heterocyclyl optionally substituted withD, halogen, C₁-C₆alkyl, —OH, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂.

In certain embodiments of Formulae Ib-Id, two R^(5a) together with theatoms to which they are attached can form C₃-C₈cycloalkyl, heterocyclyl,aryl, or heteroaryl; wherein the heterocyclyl and heteroaryl contain 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OH, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂, In certain embodiments, two R^(5a) together with theatoms to which they are attached can form C₃-C₈cycloalkyl, optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂.

In certain embodiments of Formulae Ib-Id, two geminal R^(5a) can form anoxo group.

In certain embodiments of Formulae Ib-Id, each R^(5b) is independentlyH, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—,—S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷, —NR⁶S(O)₂R⁷, —S(O)R⁶,—S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, orC₂-C₆alkynyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,and C₂-C₆alkynyl are optionally substituted with D, halogen, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂.

In certain embodiments of Formula I, each R⁵ is independently H, —NHR⁶,or —NR⁶R⁷. In certain embodiments, each A² is independently C(R⁵)₂ or O;and each R⁵ is independently H, —NHR⁶, or —NR⁶R⁷.

In certain embodiments of Formulae Ia-Id, each R^(5a) is independentlyH, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, or heterocyclyl containing N, wherein theC₁-C₆alkyl is substituted with —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂, and wherein the heterocyclyl is optionally substitutedwith D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂, In certain embodiments, each A² is independentlyC(R^(5a))₂ or O; and each R^(5a) is independently H, —NHR⁶, —NR⁶R⁷,C₁-C₆alkyl, or heterocyclyl containing N, wherein the C₁-C₆alkyl issubstituted with —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and whereinthe heterocyclyl is optionally substituted with D, halogen, C₁-C₆alkyl,—OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂.

In certain embodiments of the formulae described herein, R¹ is selectedfrom the group consisting of

wherein R^(5a1a) is H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶,—NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶; and

R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) areselected from independently H, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, orheterocyclyl containing N, wherein the C₁-C₆alkyl is substituted with—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and wherein the heterocyclylis optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶.

In certain embodiments of the formulae described herein, R⁶ and R⁷ areindependently, at each occurrence H, D, C₁-C₈alkyl, C₂-C₈alkenyl,C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, orheteroaryl, wherein the heterocyclyl and heteroaryl contain 1-5heteroatoms selected from the group consisting of N, S, P and O. Incertain embodiments, the C₁-C₈alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₈alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl isoptionally substituted.

In certain embodiments of the formulae described herein, R⁶ and R⁷together with the atom to which they are attached can form heterocyclylor heteroaryl containing 1-3 heteroatoms selected from the groupconsisting of N, S, P and O. In certain embodiments, the heterocyclyl orheteroaryl is optionally substituted.

In certain embodiments of Formulae Ib-Id, R⁶ and R⁷ are independently,at each occurrence H, D, C₁-C₈alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₈alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl;wherein the heterocyclyl and heteroaryl contain 1-5 heteroatoms selectedfrom the group consisting of N, S, P and O; wherein the C₁-C₆alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, and heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OH, —O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂. In certain embodiments, R⁶ is C₁-C₆alkyl optionallysubstituted with D, halogen, C₁-C₆alkyl, —OH, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂, In certain embodiments, R⁷ is C₁-C₆alkyl optionallysubstituted with D, halogen, C₁-C₆alkyl, —OH, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂.

As described above in Formula Ie, R² can be

wherein each R^(b10), R^(b11), R^(b12), R^(b13), R^(b14), and R^(b15) isindependently H, —OH, or oxo. In certain embodiments, one of R^(b10),R^(b11), R^(b12), R^(b13), R^(b14), and R^(b15) is —OH or oxo and therest are H. In certain embodiments, one of R^(b10), R^(b11), R^(b12),R^(b13), R^(b14), and R^(b15) is —OH and the rest are H. In certainembodiments, one of R^(b10), R^(b11), R^(b12), R^(b13), R^(b14), andR^(b15) is oxo and the rest are H.

As described above in Formula Ie-Ih, X¹ is O or S. In certainembodiments of Formula Ie-Ig. X¹ is O. In certain embodiments. X¹ is S.

As described above in Formula Ie-Ih, R² is

In certain embodiments of Formula Ie-Ih, R² is

As described above in Formula Ie-Ih, X² is N or CR^(5b1). In certainembodiments of Formula Ie-Ih, X² is CR^(5b1). In certain embodiments, X²is N.

As described above in Formula Ie-Ih, R^(5b1) is H, D, halogen, —CN,—OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl, —C(O)NR⁶, —C(O)OR⁶; wherein theC₁-C₆alkyl, and C₃-C₈cycloalkyl, are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂.

In certain embodiments of Formula Ie-Ih, R^(5b1) is H, halogen, orC₁-C₆alkyl. In certain embodiments, R^(5b1) is H, halogen, or methyl. Incertain embodiments, R^(5b1) is H, fluoro, chloro, or methyl. In certainembodiments, R^(5b1) is H. In certain embodiments, R^(5b1) is halogen.In certain embodiments, R^(5b1) is fluoro. In certain embodiments,R^(5b1) is chloro. In certain embodiments, R^(5b1) is methyl. In certainembodiments of Formula Ie-Ih, R^(5b1) is an optionally substitutedC₁-C₆alkyl. In certain embodiments, R^(5b1) is C₁-C₆alkyl, optionallysubstituted with halogen. In certain embodiments, R^(5b1) is —OR⁶. Incertain embodiments, R^(5b1) is —OH.

In certain embodiments of Formula Ie-Ih, R² is

In certain embodiments, R² is

In certain embodiments of Formula Ie-Ih, R² is

As described above in Formula Ie-Ih, each R^(5b2), R^(5b3), R^(5b4),R^(5b5), and R^(5b6) is independently H, D, halogen, OH, —CN, —NO₂,—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), andR^(5b6) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl, whereinC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionallysubstituted with halogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),or —N(C₁-C₆alkyl)₂.

In certain embodiments of Formula Ie-Ih, each R^(5b2), R^(5b3), R^(5b4),R^(5b5), and R^(5b6) is independently H, D, halogen, OH, CN, —NO₂, —OR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, or C₃-C₈cycloalkyl. Incertain embodiments, each R^(5b2), R^(5b3), R^(5b4), R^(5b5), andR^(5b6) is independently selected from the group consisting of H, D,halogen, C₁-C₆alkyl, C₃-C₈cycloalkyl, and —CN. In certain embodiments,at least one of R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is nothydrogen. In certain embodiments, one of R^(5b2), R^(5b3), R^(5b4),R^(5b5), and R^(5b6) is —OR⁶. In certain embodiments, one of R^(5b2),R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is —OH.

In certain embodiments of Formula Ie-Ih, R² is

In certain embodiments of Formula Ie-Ih, R² is

In certain embodiments of Formula Ie-Ih, R² is selected from the groupconsisting of

In certain embodiments, wherein R² is selected from the group consistingof

In certain embodiments, R² is

In certain embodiments of Formula Ie-Ih, two adjacent R^(5b2), R^(5b3),R^(5b4), R^(5b5), and R^(5b6) together with the atoms to which they areattached can form C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl,wherein C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl areoptionally substituted with halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂. In certain embodiments, twoadjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) together withthe atoms to which they are attached can form C₃-C₈cycloalkyl orheterocyclyl, wherein C₃-C₈cycloalkyl and heterocyclyl are optionallysubstituted with halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂.

In certain embodiments of Formula Ie-Ih, R² is

in certain embodiments, each R^(5b2) and R^(5b4) is selected from thegroup consisting of H, D, halogen, C₁-C₆alkyl, C₃-C₈cycloalkyl, and —CN.

In certain embodiments of Formula Ie-Ih, R² is

As described above in Formula Ie-Ih, R¹ is selected from the groupconsisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring.

In certain embodiments of Formula Ie-Ih,

represents a single bond. In certain embodiments of Formula Ie-Ih,

represents a double bond. In certain embodiments, the

are single bonds in the ring comprising A², thereby forming a saturatedring.

In certain embodiments of Formula Ie-Ih, R¹ is

In certain embodiments, R¹ is

As described above in Formula Ie-Ih, each A is independently CR^(5a1) orN; and each A² is independently CR^(5a2), C(R^(5a2))₂, N, NR^(5a2), O,S, or S(O)₂.

In certain embodiments of Formula Ie-Ih, one A is CR^(5a1) and the otherA is N. In certain embodiments, each A² is independently C(R^(5a2))₂,NR^(5a2), or O.

As described above in Formula Ie-Ih, each R^(5a1) is independently H, D,halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —NR⁶C(O)R⁶,—NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶.

In certain embodiments of Formula Ie-Ih, each R^(5a1) is independentlyH, halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl, orheterocyclyl, wherein the C₁-C₆alkyl, C₃-C₈cycloalkyl, and heterocyclylare optionally substituted with halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶.

As described above in Formula Ie-Ih, each R^(5a2) is independently H, D,halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶,—C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶;or

two geminal R^(5a2) can form an oxo group;

In certain embodiments of Formula Ie, If and Ig, each R^(5a2) isindependently H, halogen, OH, —OR⁶, C₁-C₆alkyl, C₃-C₈cycloalkyl, orheterocyclyl; wherein the C₁-C₆alkyl, C₃-C₈cycloalkyl, and heterocyclylare optionally substituted with halogen, C₁-C₆alkyl, —OR⁶, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶.

In certain embodiments of Formula Ie, If, and Ih, each R^(5a2) isindependently H, halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₃-C₈cycloalkyl, or heterocyclyl; wherein the C₁-C₆alkyl,C₃-C₈cycloalkyl, and heterocyclyl are optionally substituted withhalogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶.

In certain embodiments of Formula Ie, If, and Ih, each R^(5a2) isindependently H, —NHR⁶, or C₁-C₆alkyl; wherein the C₁-C₆alkyl issubstituted with —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂. In certainembodiments, each R^(5a2) is independently H, or heterocyclyl containingN; wherein the heterocyclyl is optionally substituted with D, —CN,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶.

In certain embodiments of Formula Ie, If, each A² is independentlyC(R^(5a2))₂ or O; and each R^(5a2) is independently H, —NHR⁶, —NR⁶R⁷,C₁-C₆alkyl, or heterocyclyl containing N; wherein the C₁-C₆alkyl issubstituted with —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and whereinthe heterocyclyl is optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶.

In certain embodiments of Formula Ie-Ih, two geminal R^(5a2) can form anoxo group.

In certain embodiments of Formula Ie-If, R¹ is selected from the groupconsisting of

wherein R^(5a1a) is H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶,—NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶;

R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) areselected from independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) whichare germinal together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶;or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), andR^(5a2f) can form an oxo group.

In certain embodiments of Formula Ie-Ig, R¹ is selected from the groupconsisting of

wherein R^(5a1a) is H, D, halogen, OH, CN, —NO₂—SR⁶, —OR⁶, —NHR⁶,—NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶;

R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) areselected from H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —C(O)R⁶,—S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) whichare germinal, together with the atoms to which they are attached canform C₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains1-3 heteroatoms selected from the group consisting of N, S, P and O;wherein the C₃-C₈cycloalkyl and heterocyclyl are optionally substitutedwith D, halogen, C₁-C₆alkyl, —OR⁶, —S(O)₂—R⁶; —COR⁶, NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶; or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), andR^(5a2f) can form an oxo group.

In certain embodiments of Formula Ie-If and Ih, R¹ is selected from thegroup consisting of

wherein R^(5a1a) is H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶,—NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶; and

R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) areselected from independently H, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, orheterocyclyl containing N; wherein the C₁-C₆alkyl is substituted with—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and wherein the heterocyclylis optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶.

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments, one A is CR^(5a1) and the other A is N. Incertain embodiments, each A² is independently C(R^(5a2))₂, NR^(5a2), orO. In certain embodiments, wherein each R^(5a2) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl. In certainembodiments, wherein two R^(5a2) together with the atoms to which theyare attached can form C₃-C₈cycloalkyl or heterocyclyl.

In certain embodiments of the formulae described herein, R¹ is

which is a formula of

wherein:

A^(2ab) is selected from CR^(5a2), C(R^(5a2a))(R^(5a2b)), N, NR^(5a2),O, S, or S(O)₂;

A^(2cd) is selected from CR^(5a2), C(R^(5a2c))(R^(5a2d)), N, NR^(5a2),O, S, or S(O)₂;

A^(2ef) is selected from CR^(5a2), C(R^(5a2e))(R^(5a2f)), N, NR^(5a2),O, S, or S(O)₂;

A^(2gh) is selected from CR^(5a2), C(R^(5a2g))(R^(5a2h)), N, NR^(5a2),O, S, or S(O)₂;

each R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) are independently H, D, halogen, OH, CN, —NO₂,—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) together with the atoms to which they areattached can form C₃-C₈cycloalkyl or heterocyclyl; wherein theheterocyclyl contains 1-3 heteroatoms selected from the group consistingof N, S, P and O; wherein the C₃-C₈cycloalkyl and heterocyclyl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶; or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) can form an oxo group.

In certain embodiments of the formulae described herein, R¹ is

wherein

wherein R^(5a1a) is H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶,—NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶;

R^(5a2c) and R^(5a2d) are each independently H, D, halogen, OH, CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

R^(5a2c) and R^(5a2d) together with the atoms to which they are attachedcan form C₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclylcontains 1-3 heteroatoms selected from the group consisting of N, S, Pand O; wherein the C₃-C₈cycloalkyl and heterocyclyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),—N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶,or —NR⁶S(O)₂R⁶; or

R^(5a2c) and R^(5a2d) can form an oxo group.

In certain embodiments, each R^(5a2c) and R^(5a2d) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl. In certainembodiments, each R^(5a2c) and R^(5a2d) is independently H, halogen, OH,—OR⁶, —NHR⁶, or —NR⁶R⁷. In certain embodiments, one of R^(5a2c) andR^(5a2d) is H and the other is independently halogen, OH, —OR⁶, —NHR⁶,or —NR⁶R⁷. In certain embodiments, R^(5a2c) and R^(5a2d) together withthe atoms to which they are attached can form C₃-C₈cycloalkyl orheterocyclyl.

In certain embodiments of the formulae described herein, R¹ is

wherein

R^(5a2a) and R^(5a2b) are each independently H, D, halogen, OH, CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

R^(5a2a) and R^(5a2b) together with the atoms to which they are attachedcan form C₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclylcontains 1-3 heteroatoms selected from the group consisting of N, S, Pand O; wherein the C₃-C₈cycloalkyl and heterocyclyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),—N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶,or —NR⁶S(O)₂R⁶; or

R^(5a2a) and R^(5a2b) can form an oxo group.

In certain embodiments, each R^(5a2a) and R^(5a2b) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl. In certainembodiments, each R^(5a2a) and R^(5a2b) is independently H, halogen, OH,—OR⁶, —NHR⁶, or —NR⁶R⁷. In certain embodiments, one of R^(5a2a) andR^(5a2b) is H and the other is independently halogen, OH, —OR⁶, —NHR⁶,or —NR⁶R⁷. In certain embodiments, R^(5a2a) and R^(5a2b) together withthe atoms to which they are attached can form C₃-C₈cycloalkyl orheterocyclyl.

In certain embodiments of the formulae described herein, R¹ is.

wherein

R^(5a2e) and R^(5a2f) are each independently H, D, halogen, OH, CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

R^(5a2e) and R^(5a2f) together with the atoms to which they are attachedcan form C₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclylcontains 1-3 heteroatoms selected from the group consisting of N, S, Pand O; wherein the C₃-C₈cycloalkyl and heterocyclyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),—N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶,or —NR⁶S(O)₂R⁶; or

R^(5a2e) and R^(5a2f) can form an oxo group.

In certain embodiments, each R^(5a2e) and R^(5a2f) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl. In certainembodiments, each R^(5a2e) and R^(5a2f) is independently H, halogen, OH,—OR⁶, —NHR⁶, or —NR⁶R⁷. In certain embodiments, one of R^(5a2e) andR^(5a2f) is H and the other is independently halogen, OH, —OR⁶, —NHR⁶,or —NR⁶R⁷. In certain embodiments, R^(5a2e) and R^(5a2f) together withthe atoms to which they are attached can form C₃-C₈cycloalkyl orheterocyclyl.

In certain embodiments of the formulae described herein, R¹ is.

wherein

R^(5a2c) and R^(5a2d) are each independently H, D, halogen, OH, CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

R^(5a2c) and R^(5a2d) together with the atoms to which they are attachedcan form C₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclylcontains 1-3 heteroatoms selected from the group consisting of N, S, Pand O; wherein the C₃-C₈cycloalkyl and heterocyclyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),—N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶,or —NR⁶S(O)₂R⁶; or

R^(5a2c) and R^(5a2d) can form an oxo group.

In certain embodiments, each R^(5a2c) and R^(5a2d) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl. In certainembodiments, each R^(5a2c) and R^(5a2d) is independently H, halogen, OH,—OR⁶, —NHR⁶, or —NR⁶R⁷. In certain embodiments, one of R^(5a2c) andR^(5a2d) is H and the other is independently halogen, OH, —OR⁶, —NHR⁶,or —NR⁶R⁷. In certain embodiments, R^(5a2c) and R^(5a2d) together withthe atoms to which they are attached can form C₃-C₈cycloalkyl orheterocyclyl.

In certain embodiments of the formulae described herein, R¹ is selectedfrom the group consisting of

wherein - - - is connection to the rest of the compound.

In certain embodiments in the formulae described herein, R¹ is selectedfrom the group consisting of

wherein - - - is connection to the rest of the compound.

In certain embodiments of the formulae described herein, R¹ is selectedfrom the group consisting of

wherein - - - is connection to the rest of the compound.

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments, one A is CR^(5a1) and the other A is N. Incertain embodiments, each A² is independently C(R^(5a2))₂, NR^(5a2), orO. In certain embodiments, wherein each R^(5a2) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl. In certainembodiments, wherein two R^(5a2) together with the atoms to which theyare attached can form C₃-C₈cycloalkyl or heterocyclyl.

In certain embodiments of the formulae described herein, R¹ is

which is a formula of

wherein.

A^(2ab) is selected from CR^(5a2), C(R^(5a2a))(R^(5a2b)), N, NR^(5a2),O, S, or S(O)₂;

A^(2cd) is selected from CR^(5a2), C(R^(5a2c))(R^(5a2d)), N, NR^(5a2),O, S, or S(O)₂;

A^(2ef) is selected from CR^(5a2), C(R^(5a2e))(R^(5a2f)), N, NR^(5a2),O, S, or S(O)₂;

A^(2gh) is selected from CR^(5a2), C(R^(5a2g))(R^(5a2h)), N, NR^(5a2),O, S, or S(O)₂;

A^(2ij) is selected from CR^(5a2), C(R^(5a2i))(R^(5a2j)), N, NR^(5a2),O, S, or S(O)₂;

each R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), R^(5a2h), R^(5a2i), and R^(5a2j) are independently H, D,halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶,—C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), R^(5a2h), R^(5a2i), and R^(5a2j) together with the atoms towhich they are attached can form C₃-C₈cycloalkyl or heterocyclyl;wherein the heterocyclyl contains 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl andheterocyclyl are optionally substituted with D, halogen, C₁-C₆alkyl,—OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶,NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶; or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), R^(5a2h), R^(5a2i), and R^(5a2j) can form an oxo group.

In certain embodiments the formulae described herein, R¹ is

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments, one A is CR^(5a1) and the other A is N. Incertain embodiments, each A² is independently C(R^(5a2))₂, NR^(5a2), orO. In certain embodiments, wherein each R^(5a2) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl. In certainembodiments, wherein two R^(5a2) together with the atoms to which theyare attached can form C₃-C₈cycloalkyl or heterocyclyl.

In certain embodiments the formulae described herein, R¹ is

which is a formula of

wherein.

A^(2ab) is selected from C(R^(5a2a))(R^(5a2b)), NR^(5a2), O, S, orS(O)₂;

A^(2cd) is selected from C(R^(5a2c))(R^(5a2d)), NR^(5a2), O, S, orS(O)₂;

A^(2ef) is selected from C(R^(5a2e))(R^(5a2f)), NR^(5a2), O, S, orS(O)₂;

each R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) areindependently H, D, halogen, OH, CN, —NO₂—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷,—C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶,—NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f)together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶;or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), andR^(5a2f) can form an oxo group.

In certain embodiments the formulae described herein, R¹ is

In certain embodiments of the formulae described herein, R¹ is

In certain embodiments, one A is CR^(5a1) and the other A is N. Incertain embodiments, each A² is independently C(R^(5a2))₂, NR^(5a2), orO. In certain embodiments, wherein each R^(5a2) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl. In certainembodiments, wherein two R^(5a2) together with the atoms to which theyare attached can form C₃-C₈cycloalkyl or heterocyclyl.

In certain embodiments the formulae described herein, R¹ is

which is a formula of

wherein.

A^(2ab) is selected from CR^(5a2), C(R^(5a2a))(R^(5a2b)), N, NR^(5a2),O, S, or S(O)₂;

A^(2cd) is selected from CR^(5a2), C(R^(5a2c))(R^(5a2d)), N, NR^(5a2),O, S, or S(O)₂;

A^(2ef) is selected from CR^(5a2), C(R^(5a2e))(R^(5a2f)), N, NR^(5a2),O, S, or S(O)₂;

A^(2gh) is selected from CR^(5a2), C(R^(5a2g))(R^(5a2h)), N, NR^(5a2),O, S, or S(O)₂;

each R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) are independently H, D, halogen, OH, CN, —NO₂,—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶ or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) together with the atoms to which they areattached can form C₃-C₈cycloalkyl or heterocyclyl; wherein theheterocyclyl contains 1-3 heteroatoms selected from the group consistingof N, S, P and O; wherein the C₃-C₈cycloalkyl and heterocyclyl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶ or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) can form an oxo group.

The present disclosure provides a compound of formula Ie-If, wherein

X¹ is O;

R¹ is selected from the group consisting of

wherein

represents a single bond;

each A² is independently C(R^(5a))₂ or O;

X² is CR^(5b1);

each R^(5a1) is independently H or C₁-C₆alkyl; wherein the C₁-C₆alkyl isoptionally substituted with D, halogen, —OR⁶, —NH₂, NH(C₁-C₆alkyl),N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶;

each R^(5a2) is independently H, halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷,C₁-C₆alkyl, or heterocyclyl; wherein the C₁-C₆alkyl and heterocyclyl areoptionally substituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),—N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶; or

two R^(5a2) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, or—S(O)₂—R⁶; or

two geminal R^(5a2) can form an oxo group;

R^(5b1) is H, D, halogen, or C₁-C₆alkyl;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, —CN, —OR⁶, C₁-C₆alkyl, or C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, and C₃-C₈cycloalkyl, are optionally substituted with D,halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) together with theatoms to which they are attached can form C₃-C₈cycloalkyl, heterocyclyl,or heteroaryl, wherein C₃-C₈cycloalkyl, heterocyclyl, or heteroaryl areoptionally substituted with halogen or C₁-C₆alkyl; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkynyl, or aryl; wherein the C₁-C₈alkyl, C₂-C₈alkynyl, and aryl,are optionally substituted with D, halogen or C₁-C₆alkyl.

In certain embodiments, the compound is of formula:

In certain embodiments, the compound is of formula:

In certain embodiments of formula (I), X is O and R² is

In certain embodiments of formula (I), X¹ is O and R¹ is

In certain embodiments of formula (I), R¹ is

and R² is

In some embodiments, the present disclosure provides a compound offormula (I),

having one, two, or three of the following features:

a) X is O; b) R¹ is

c) R² is

d) X² is CH or CF.

In some embodiments, the present disclosure provides a compound offormula (I),

having one, two, or three of the following features:

a) X is O; b) R¹ is

c) R² is

d) X² is CH.

In some embodiments, the present disclosure provides a compound offormula (I),

having one, two, or three of the following features:

a) X is S; b) R¹ is

c) R² is

d) X² is CH.

In some embodiments, the present disclosure provides a compound offormula (I),

having one, two, or three of the following features:

a) X is O;

b) R¹ is methyl;

c) R² is

d) X² is CH.

In some embodiments, the present disclosure provides a compound offormula (I),

having one, two, or three of the following features:

a) X is S;

b) R¹ is methyl;

c) R² is

d) X² is CH.

In some embodiments, the present disclosure provides a compound offormula (I),

having one, two, or three of the following features:

a) X is O; b) R¹ is

c) R² is

d) X² is CH.

In some embodiments, the present disclosure provides a compound offormula Ie-If,

having one, two, or three of the following features:

a) X is O; b) R¹ is

c) one of R^(5a2c) and R^(5a2d) is H and the other is independentlyhalogen, OH, —OR⁶, —NHR⁶, or —NR⁶R⁷;

d) R² is

e) X² is CH or CF.

In some embodiments, the present disclosure provides a compound offormula (I),

having one, two, or three of the following features:

a) X is O; b) R¹ is

c) R² is

In certain embodiments, the present disclosure provides for

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideand pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provides for

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonamideand pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provides for

and pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provides for

and pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provides for

and pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provides for

and pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provides for

and pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provides for

and pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provides for

and pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provides for

and pharmaceutically acceptable salts thereof.

In certain embodiments, the present disclosure provide for a compound,and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof, selected from the group consisting of:

In certain embodiments, the present disclosure provide for a compound,and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof, selected from the group consisting of:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

In certain embodiments, the present disclosure provides for thefollowing compounds, and pharmaceutically acceptable salts, prodrugs,solvates, hydrates, isomers, and tautomers thereof:

Unless otherwise stated, structures depicted herein are also meant toinclude compounds which differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructure except for the replacement of a hydrogen atom by deuterium ortritium, or the replacement of a carbon atom by ¹³C or ¹⁴C, or thereplacement of a nitrogen atom by ¹⁵N, or the replacement of an oxygenatom with ¹⁷O or ¹⁸O are within the scope of the present disclosure.Such isotopically labeled compounds are useful as research or diagnostictools.

Methods of Treatment

The disclosed compounds (e.g., compounds of formula I, Ia, Ib, Ic, Id,Ie, If, Ig, and Ih), and their pharmaceutically acceptable salts haveactivity as pharmaceuticals, as discussed herein.

The present disclosure provides a method of treatment or prevention of adisease, disorder or condition including the step of administering aneffective amount of a compound of the present disclosure, andpharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof to thereby treat or prevent the disease,disorder or condition in a subject in need thereof.

The present disclosure provides a compound of the present disclosure,and pharmaceutically acceptable salts, prodrugs, solvates, hydrates,isomers, and tautomers thereof, or the pharmaceutical composition of thepresent disclosure for use in the treatment or prevention of a disease,disorder or condition in a subject in need thereof.

The present disclosure provides for use of a compound of the presentdisclosure, and pharmaceutically acceptable salts, prodrugs, solvates,hydrates, isomers, and tautomers thereof, for the treatment orprevention of a disease, disorder or condition in a subject in needthereof.

The present disclosure provides for use of a compound of the presentdisclosure, and pharmaceutically acceptable salts, prodrugs, solvates,hydrates, isomers, and tautomers thereof, in the manufacture of amedicament for the treatment or prevention of a disease, disorder orcondition.

In certain embodiments, the disease, disorder or condition is one whichis responsive to inhibition of activation of an inflammasome. In oneparticular embodiment, the disease, disorder or condition is one whichis responsive to inhibition of activation of the NLRP3 inflammasome.

According to this embodiment, the compound of the present disclosure, orpharmaceutically effective salt, solvate or prodrug thereof is aspecific inhibitor of NLRP3.

In a further embodiment, the disease, disorder or condition isresponsive to modulation of one or more of IL-6, IL-1β, IL-17, IL-18,IL-1α, IL-37, IL-22, IL-33, and Th17 cells. In certain embodiments, thedisease, disorder or condition is responsive to modulation of one ormore of IL-1β and IL-18.

In one embodiment, the modulation is inhibition of one or more of IL-6,IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-22, and IL-33. In one embodiment,the modulation is inhibition of one or more of IL-1β and IL-18.

In one embodiment, the modulation of Th17 cells is by inhibition ofproduction and/or secretion of IL-17.

In general embodiments, the disease, disorder or condition is a disease,disorder or condition of the immune system, the cardiovascular system,the endocrine system, the gastrointestinal tract, the renal system, therespiratory system, the central nervous system, is a cancer or othermalignancy and/or is caused by or associated with a pathogen.

It will be appreciated that these general embodiments defined accordingto broad categories of diseases, disorders and conditions are notmutually exclusive. In this regard any particular disease, disorder orcondition may be categorized according to more than one of the abovegeneral embodiments. A non-limiting example is Type I diabetes which isan autoimmune disease and a disease of the endocrine system.

In one embodiment, the disease, disorder or condition is of the immunesystem. In particular embodiments, the disease, disorder or condition isan inflammatory disease, disorder or condition or an autoimmune disease,disorder or condition.

In one embodiment, the disease, disorder or condition is of the liver.

In one embodiment, the disease, disorder or condition is of the lung.

In one embodiment, the disease, disorder or condition is of the skin.

In one embodiment, the disease, disorder or condition is of thecardiovascular system.

In one embodiment, the disease, disorder or condition is a cancer, tumoror other malignancy. As used herein, cancers tumors and malignancies,refer to diseases, disorders or conditions, or to cells or tissuesassociated with the diseases, disorders or conditions, characterized byaberrant or abnormal cell proliferation, differentiation and/ormigration often accompanied by an aberrant or abnormal molecularphenotype that includes one or more genetic mutations or other geneticchanges associated with oncogenesis, expression of tumor markers, lossof tumor suppressor expression or activity and/or aberrant or abnormalcell surface marker expression. In general embodiments, cancers, tumorsand malignancies may include sarcomas, lymphomas, leukemias, solidtumors, blastomas, gliomas, carcinomas, melanomas and metastaticcancers, although without limitation thereto. A more comprehensivelisting of cancers tumors and malignancies may be found at the NationalCancer Institutes websitehttp://www.cancer.gov/cancertopics/types/alphalist, which is herebyincorporated by reference in its entirety.

In one embodiment, the disease, disorder or condition is of the renalsystem.

In one embodiment, the disease, disorder or condition is of thegastro-intestinal tract.

In one embodiment, the disease, disorder or condition is of therespiratory system.

In a further embodiment, the disease, disorder or condition is of theendocrine system.

In one embodiment, the disease, disorder or condition is of the centralnervous system (CNS).

In one embodiment, the disease, disorder or condition is caused by, oris associated with, a pathogen. The pathogen may be a virus, abacterium, a protist, a worm or a fungus or any other organism capableof infecting a mammal, although without limitation thereto.

Non-limiting examples of viruses include influenza virus,cytomegalovirus, Epstein Barr Virus, human immunodeficiency virus (HIV),alphavirus such as Chikungunya and Ross River virus, flaviviruses suchas Dengue virus, Zika virus and papillomavirus, although withoutlimitation thereto.

Non-limiting examples of pathogenic bacteria include Staphylococcusaureus, Helicobacter pylori, Bacillus anthracis, Bordatella pertussis,Corynebacterium diptheriae, Clostridium tetani, Clostridium botulinum,Streptococcus pneumoniae, Streptococcus pyogenes, Listeriamonocytogenes, Hemophilus influenzae, Pasteureiia multicida, Shigelladysenteriae, Mycobacterium tuberculosis, Mycobacterium leprae,Mycoplasma pneumoniae, Mycoplasma hominis, Neisseria meningitidis,Neisseria gonorrhoeae, Rickettsia rickettsii, Legionella pneumophila,Klebsiella pneumoniae, Pseudomonas aeruginosa, Propionibacterium acnes,Treponema pallidum, Chlamydia trachomatis, Vibrio cholerae, Salmonellatyphimurium, Salmonella typhi, Borrelia burgdorferi and Yersinia pestis,although without limitation thereto.

Non-limiting examples of protists include Plasmodium, Babesia, Giardia,Entamoeba, Leishmania and Trypanosomes, although without limitationthereto.

Non-limiting examples of worms include helminths inclusive ofschistisimes, roundworms, tapeworms and flukes, although withoutlimitation thereto.

Non-limiting examples of fungi include Candida and Aspergillus species,although without limitation thereto.

In particular embodiments, the disease, disorder or condition isselected from the group consisting of constitutive inflammationincluding the cryopyrin-associated periodic syndromes (CAPS):Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome(FCAS) and neonatal-onset multisystem inflammatory disease (NOMID);including autoinflammatory diseases: familial Mediterranean fever (FMF),TNF receptor associated periodic syndrome (TRAPS), mevalonate kinasedeficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome(H IDS), deficiency of interleukin 1 receptor (DIRA) antagonist, Majeedsyndrome, pyogenic arthritis, pyoderma gangrenosum and acne (PAPA),haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis(PGA), PLCG2-associated antibody deficiency and immune dysregulation(PLAID), PLCG2-associated autoinflammation, antibody deficiency andimmune dysregulation (APLAID), sideroblastic anemia with B-cellimmunodeficiency, periodic fevers, and developmental delay (SIFD); Sweets syndrome, chronic nonbacterial osteomyelitis (CNO), chronic recurrentmultifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis,hyperostosis, osteitis syndrome (SAPHO); autoimmune diseases includingmultiple sclerosis (MS), type-1 diabetes, psoriasis, rheumatoidarthritis, Behcet's disease, Sjogren's syndrome and Schnitzler syndrome;respiratory diseases including idiopathic pulmonary fibrosis (IPF),chronic obstructive pulmonary disorder (COPD), steroid-resistant asthma,asbestosis, silicosis and cystic fibrosis; central nervous systemdiseases including Parkinson's disease, Alzheimer's disease, motorneuron disease, Huntington's disease, cerebral malaria and brain injuryfrom pneumococcal meningitis; metabolic diseases including Type 2diabetes, atherosclerosis, obesity, gout, pseudo-gout; ocular diseasesincluding those of the ocular epithelium, age-related maculardegeneration (AMD), corneal infection, uveitis and dry eye; kidneydisease including chronic kidney disease, oxalate nephropathy anddiabetic nephropathy; liver disease including non-alcoholicsteatohepatitis and alcoholic liver disease; inflammatory reactions inskin including contact hypersensitivity and sunburn; inflammatoryreactions in the joints including osteoarthritis, systemic juvenileidiopathic arthritis, adult-onset Still's disease, relapsingpolychondritis; viral infections including alpha virus (Chikungunya,Ross River) and flavivirus (Dengue and Zika Virus), flu, HIV;hidradenitis suppurativa (HS) and other cyst-causing skin diseases;cancers including lung cancer metastasis, pancreatic cancers, gastriccancers, myelodisplastic syndrome, leukemia; polymyositis; stroke;myocardial infarction; Graft versus Host Disease; hypertension; colitis;helminth infection; bacterial infection; abdominal aortic aneurism;wound healing; depression, psychological stress; pericarditis includingDressler's syndrome, ischaemia reperfusion injury and any disease wherean individual has been determined to carry a germline or somaticnon-silent mutation in NLRP3.

In one non-limiting example of those described, the disease, disorder orcondition being treated is NASH. NLRP3 inflammasome activation iscentral to inflammatory recruitment in NASH, and inhibition of NLRP3 mayboth prevent and reverse liver fibrosis. Compounds of the presentdisclosure, by interrupting the function of NLRP3 inflammasomes in livertissue, can cause histological reductions in liver inflammation,decreased recruitment of macrophages and neutrophils, and suppression ofNF-κB activation. Inhibition of the NLRP3 can reduce hepatic expressionof pro-IL-1β and normalized hepatic and circulating IL-1β, IL-6 andMCP-1 levels thereby assisting in treatment of the disease.

In a further non-limiting example of those described, the disease,disorder or condition being treated is severe steroid resistant (SSR)asthma. Respiratory infections induce an NLRP3inflammasome/caspase-1/IL-1β signaling axis in the lungs that promotesSSR asthma. The NLRP3 inflammasome recruits, and activates,pro-caspase-1 to induce IL-1β responses. NLRP3 inflammasome-induced IL-βresponses are therefore important in the control of infections, however,excessive activation results in aberrant inflammation and has beenassociated with the pathogenesis of SSR asthma and COPD. Theadministration of compounds of the present disclosure that targetspecific disease processes, are more therapeutically attractive thannon-specifically inhibiting inflammatory responses with steroids orIL-1β. Targeting the NLRP3 inflammasome/caspase-1/IL-1β signaling axiswith the compounds of the present disclosure may therefore be useful inthe treatment of SSR asthma and other steroid-resistant inflammatoryconditions.

In one further non-limiting example of those described, the disease,disorder or condition being treated is Parkinson's disease. Parkinson'sis the most common neurodegenerative movement disorder and ischaracterized by a selective loss of dopaminergic neurons, accompaniedby the accumulation of mis-folded a-synuclein (Syn) into Lewy bodiesthat are pathological hallmarks of the disease. Chronic microglialneuroinflammation is evident early in the disease, and has been proposedto drive pathology.

A central role for microglial NLRP3 is postulated in Parkinson'sprogression. The NLRP3 inflammasome is activated by fibrillar Syn via aSyk kinase dependent mechanism, and also occurs in the absence of Synpathology at the early stages of dopaminergic degeneration, and drivesneuronal loss. The compounds of the present disclosure may block NLRP3inflammasome activation by fibrillar Syn or mitochondrial dysfunctionand thereby confer effective neuroprotection of the nigrostriataldopaminergic system and assist with treatment of Parkinson's.

In certain embodiments, the method treats or prevents a disease ordisorder, including, but not limited to, a bacterial infection, a viralinfection, a fungal infection, inflammatory bowel disease, celiacdisease, colitis, intestinal hyperplasia, cancer, metabolic syndrome,obesity, rheumatoid arthritis, liver disease, liver fibrosis, hepaticsteatosis, fatty liver disease, non-alcoholic fatty liver disease(NAFLD), and non-alcoholic steatohepatitis (NASH).

In certain embodiments, the disease, disorder or condition is selectedfrom the group consisting of NASH (nonalcoholic steatohepatitis); CAPS(Cryopyrin Associated Periodic Syndromes); IPF (Idiopathic pulmonaryfibrosis); MI (R/I) (myocardial infarction and reperfusion injury);Gout; I/O (immuno-oncology); Asthma; IBD (inflammatory bowel disease);Renal fibrosis; adult onset Still's disease; systemic juvenileidiopathic arthritis; tumour necrosis factor receptor-associatedperiodic syndrome (TRAPS); colchicine-resistant familial Mediterraneanfever (FMF); hyper IgD syndrome (HIDS)/Mevalonate Kinase Deficiency(MKD); traumatic brain injury; Parkinson's Disease; moderate to severeinflammatory acne; acute non-anterior non-infectious uveitis (NIU); AD(Alzheimer's disease); COPD (Chronic Obstructive Pulmonary Disease);Sepsis; MS (multiple sclerosis); Behcet's disease; RA (rheumatoidarthritis); erosive osteoarthritis; T1D (Type 1 diabetes); T2D (Type 2diabetes); Obesity; osteoporosis; cystic fibrosis; alcoholic liverdisease; aging; HCC (hepatocellular carcinoma); depression;endometriosis; pyoderma gangrenosum (“PG”), a rare ulcerative skindisease; Lupus Nephritis; Epilepsy; ischemic stroke; deafness; sicklecell disease; SLE (Systemic Lupus Erythematosus); and Spinal cordinjury.

For the above-mentioned therapeutic uses the dosage administered will,of course, vary with the compound employed, the mode of administration,the treatment desired and the disorder indicated. For example, the dailydosage of the compound of the present disclosure, if inhaled, may be inthe range from about 0.05 micrograms per kilogram body weight (μg/kg) toabout 100 micrograms per kilogram body weight (μg/kg). Alternatively, ifthe compound is administered orally, then the daily dosage of thecompound of the present disclosure may be in the range from about 0.01micrograms per kilogram body weight (μg/kg) to about 100 milligrams perkilogram body weight (mg/kg).

Pharmaceutical Compositions

The disclosed compounds (e.g., compounds of formula I, Ia, Ib, Ic, Id,Ie, If, Ig, and Ih), and pharmaceutically acceptable salts thereof maybe used on their own but will generally be administered in the form of apharmaceutical composition in which the disclosed compound/salt (e.g.,compounds of formula I, Ia, Ib, Ic, Id, Ie, If, Ig, and Ih and saltsthereof) (active ingredient) is in association with a pharmaceuticallyacceptable adjuvant, diluent or carrier. Conventional procedures for theselection and preparation of suitable pharmaceutical formulations aredescribed in, for example, “Pharmaceuticals—The Science of Dosage FormDesigns”, M. E. Aulton, Churchill Livingstone, 1988, which is herebyincorporated by reference in its entirety.

Depending on the mode of administration, the pharmaceutical compositionwill comprise from about 0.05 to about 99% w (percent by weight), moreparticularly from about 0.05 to about 80% w, still more particularlyfrom about 0.10 to about 70% w, and even more particularly from about0.10 to about 50% w, of active ingredient, all percentages by weightbeing based on total composition.

The present disclosure also provides a pharmaceutical compositioncomprising a disclosed compound (e.g., compound of formula I, Ia, Ib,Ic, Id, Ie, If, Ig, and Ih), or a pharmaceutically acceptable saltthereof as hereinbefore defined, in association with a pharmaceuticallyacceptable adjuvant, diluent or carrier.

The present disclosure further provides a process for the preparation ofa pharmaceutical composition of the present disclosure which comprisesmixing a disclosed compound (e.g., compound of formula I, Ia, Ib, Ic,Id, Ie, If, Ig, and Ih), or a pharmaceutically acceptable salt thereofas hereinbefore defined with a pharmaceutically acceptable adjuvant,diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. tothe skin or to the lung and/or airways) in the form, e.g., of creams,solutions, suspensions, heptafluoroalkane (HFA) aerosols and dry powderformulations, for example, formulations in the inhaler device known asthe Turbuhaler®; or systemically, e.g. by oral administration in theform of tablets, capsules, syrups, powders or granules; or by parenteraladministration in the form of a sterile solution, suspension or emulsionfor injection (including intravenous, subcutaneous, intramuscular,intravascular or infusion); or by rectal administration in the form ofsuppositories.

Dry powder formulations and pressurized HFA aerosols of the compounds ofthe present disclosure (including pharmaceutically acceptable salts) maybe administered by oral or nasal inhalation. For inhalation, thecompound is desirably finely divided. The finely divided compoundpreferably has a mass median diameter of less than 10 micrometres (μm),and may be suspended in a propellant mixture with the assistance of adispersant, such as a C₈-C₂₀ fatty acid or salt thereof, (for example,oleic acid), a bile salt, a phospholipid, an alkyl saccharide, aperfluorinated or polyethoxylated surfactant, or other pharmaceuticallyacceptable dispersant.

The compounds of the present disclosure may also be administered bymeans of a dry powder inhaler. The inhaler may be a single or a multidose inhaler, and may be a breath actuated dry powder inhaler.

One possibility is to mix the finely divided compound of the presentdisclosure with a carrier substance, for example, a mono-, di- orpolysaccharide, a sugar alcohol, or another polyol. Suitable carriersare sugars, for example, lactose, glucose, raffinose, melezitose,lactitol, maltitol, trehalose, sucrose, mannitol; and starch.Alternatively the finely divided compound may be coated by anothersubstance. The powder mixture may also be dispensed into hard gelatincapsules, each containing the desired dose of the active compound.

Another possibility is to process the finely divided powder into sphereswhich break up during the inhalation procedure. This spheronized powdermay be filled into the drug reservoir of a multidose inhaler, forexample, that known as the Turbuhaler® in which a dosing unit meters thedesired dose which is then inhaled by the patient. With this system theactive ingredient, with or without a carrier substance, is delivered tothe patient.

Another possibility is to process the compound as an amorphousdispersion in a polymer matrix such as hydroxypropyl methylcellulose(HPMC) or hydroxypropyl methylcellulose acetate succinate (HPMCAS). Asthe name suggests, spray-dried dispersions (SDDs) are obtained bydissolving drug and polymer in an organic solvent, atomizing theresulting solution into droplets, and evaporation to dried solidparticles. SDDs are usually amenable for use a variety of final oraldosage forms, including capsules and tablets.

For oral administration the compound of the present disclosure may beadmixed with an adjuvant or a carrier, for example, lactose, saccharose,sorbitol, mannitol; a starch, for example, potato starch, corn starch oramylopectin; a cellulose derivative; a binder, for example, gelatin orpolyvinylpyrrolidone; and/or a lubricant, for example, magnesiumstearate, calcium stearate, polyethylene glycol, a wax, paraffin, andthe like, and then compressed into tablets. If coated tablets arerequired, the cores, prepared as described above, may be coated with aconcentrated sugar solution which may contain, for example, gum arabic,gelatin, talcum and titanium dioxide. Alternatively, the tablet may becoated with a suitable polymer dissolved in a readily volatile organicsolvent.

For the preparation of soft gelatin capsules, the compound of thepresent disclosure may be admixed with, for example, a vegetable oil orpolyethylene glycol. Hard gelatin capsules may contain granules of thecompound using either the above-mentioned excipients for tablets. Alsoliquid or semisolid formulations of the compound of the presentdisclosure may be filled into hard gelatin capsules.

Liquid preparations for oral application may be in the form of syrups orsuspensions, for example, solutions containing the compound of thepresent disclosure, the balance being sugar and a mixture of ethanol,water, glycerol and propylene glycol. Optionally such liquidpreparations may contain colouring agents, flavouring agents, saccharineand/or carboxymethylcellulose as a thickening agent or other excipientsknown to those skilled in art.

Combination Therapy

The compounds of the present disclosure (that is, compounds of formulaI, Ia, Ib, Ic, Id, Le, If, Ig, and Ih, and pharmaceutically acceptablesalts thereof) may also be administered in conjunction with othercompounds used for the treatment of the above conditions.

The present disclosure therefore further relates to combinationtherapies wherein a compound of the present disclosure or apharmaceutical composition or formulation comprising a compound of thepresent disclosure is administered concurrently or sequentially or as acombined preparation with another therapeutic agent or agents, for thetreatment of one or more of the conditions listed.

Methods of Synthesizing the Compounds

The compounds of the present disclosure may be made by a variety ofmethods, including standard chemistry. One suitable synthetic route isdepicted in the Scheme provided below.

The compounds of the present disclosure (e.g., compound of formula I,Ia, Ib, Ic, Id, Ie, If, Ig, and Ih), or a pharmaceutically acceptablesalt, enantiomer, hydrate, solvate, prodrug, isomer, or tautomerthereof, may be prepared by methods known in the art of organicsynthesis as set forth in part by the following synthetic scheme. In thescheme described below, it is well understood that protecting groups forsensitive or reactive groups are employed where necessary in accordancewith general principles or chemistry. Protecting groups are manipulatedaccording to standard methods of organic synthesis (T. W. Greene and P.G. M. Wuts, “Protective Groups in Organic Synthesis”, Third edition,Wiley, New York 1999, which is hereby incorporated by reference in itsentirety). These groups are removed at a convenient stage of thecompound synthesis using methods that are readily apparent to thoseskilled in the art. The selection processes, as well as the reactionconditions and order of their execution, shall be consistent with thepreparation of disclosed compounds (e.g., compounds of formula I, Ia,Ib, Ic, Id, Ie, If, Ig, and Ih).

Those skilled in the art will recognize if a stereocenter exists in thecompounds of Formula (I). Accordingly, the present disclosure includesboth possible stereoisomers (unless specified in the synthesis) andincludes not only racemic compounds but the individual enantiomersand/or diastereomers as well. When a compound is desired as a singleenantiomer or diastereomer, it may be obtained by stereospecificsynthesis or by resolution of the final product or any convenientintermediate. Resolution of the final product, an intermediate, or astarting material may be affected by any suitable method known in theart. See, for example, “Stereochemistry of Organic Compounds” by E. L.Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994), whichis hereby incorporated by reference in its entirety.

The compounds described herein may be made from commercially availablestarting materials or synthesized using known organic, inorganic, and/orenzymatic processes.

Preparation of Compounds

The compounds of the present disclosure can be prepared in a number ofways well known to those skilled in the art of organic synthesis. By wayof example, compounds of the present disclosure can be synthesized usingthe methods described below, together with synthetic methods known inthe art of synthetic organic chemistry, or variations thereon asappreciated by those skilled in the art. Illustrative methods includebut are not limited to those methods described below. Compounds of thepresent disclosure can be synthesized by following the steps outlined inScheme 1. Starting materials are either commercially available or madeby known procedures in the reported literature or as illustrated.

Formula I, Ia, Ib, Ic, Id, Ie, If, Ig, and Ih can be prepared accordingto the general procedures outlined in Scheme 1. In Method A, disclosedcompounds (e.g., compounds of formula I, Ia, Ib, Ic, Id, Ie, If, Ig, andIh) are readily accessible from reaction of sulfonyl isocyanate orisothiocyanate (compound A-1) and an amine (compound A-2). In certainembodiments, compound A-2 is treated with a base in an appropriatesolvent. Then, compound A-1 is added to compound A-2. The reaction isperformed in a suitable solvent (e.g., tetrahydrofuran ordichloromethane) at room temperature to reflux.

With continued reference to Scheme 1, in Method B, compounds of Formula(I) are readily accessible from reaction of an isocyanate orisothiocyanate (compound B-1) and a sulfonamide (compound B-2). Incertain embodiments, compound B-2 is treated with a base in anappropriate solvent. Then, compound B-1 is added to compound B-2. Thereaction is performed in a suitable solvent (e.g., tetrahydrofuran ordichloromethane) at room temperature to reflux.

Example Embodiments

Embodiment I-1. A compound of formula I:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or tautomer thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkenyl, optionally substitutedC₁-C₆alkynyl, —(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR⁵ or N;

A¹ is NR⁵, O, S, or C(O);

each A² is independently CR⁵, C(R⁵)₂, N, NR⁵, O, S, or S(O)₂;

R² is

X² is N or CR⁵;

R³ and R⁴ are H;

each R⁵ is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶,—NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; or

two R⁵ together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; or

two geminal R⁵ can form an oxo group;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR⁵, O, S, or S(O)₂.

Embodiment I-2. The compound of Embodiment I-1, wherein X¹ is O.

Embodiment I-3. The compound of Embodiment I-1, wherein X¹ is S.

Embodiment I-4. The compound of any one of Embodiments I-1 to I-3,wherein R² is

Embodiment I-5. The compound of any one of Embodiments I-1 to I-3,wherein R² is

Embodiment I-6. The compound of any one of Embodiments I-1 to I-5,wherein the

are single bonds in the ring comprising A², thereby forming a saturatedring.

Embodiment I-7. The compound of any one of Embodiments I-1 to I-5,wherein R¹ is

Embodiment I-8. The compound of Embodiment I-7, wherein each A² isindependently CH₂ or O.

Embodiment I-9. The compound of any one of Embodiments I-1 to I-5,wherein R¹ is

Embodiment I-10. The compound of any one of Embodiments I-1 to I-5,wherein R¹ is methyl.

Embodiment I-11. The compound of any one of Embodiments I-1 to I-9,wherein the compound is of formula:

Embodiment I-12. The compound of Embodiment I-1, which is

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide.

Embodiment I-13. The compound of Embodiment I-1, which is

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonamide.

Embodiment I-14. The compound of Embodiment I-1, which is selected fromthe group consisting of

Embodiment I-15. A pharmaceutical composition comprising a compound ofany one of Embodiments I-1 to I-14 and a pharmaceutically acceptablecarrier.

Embodiment I-16. A method of treatment or prevention of a disease,disorder or condition including the step of administering an effectiveamount of a compound of any one of Embodiments I-1 to I-14, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, to thereby treat or prevent the disease disorder orcondition.

Embodiment I-17. The method of Embodiment I-16, wherein the disease,disorder or condition is responsive to inhibition of inflammasome.

Embodiment I-18. The method of Embodiment I-16 or I-17, wherein thedisease, disorder or condition is one which is responsive to inhibitionof activation of the NLRP3 inflammasome.

Embodiment I-19. The method of Embodiment I-16 or I-17, wherein thedisease, disorder or condition is responsive to modulation of one ormore of IL-6, IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-22, IL-33 and Th17cells.

Embodiment I-20. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition of the immune system.

Embodiment I-21. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is an inflammatory diseasedisorder or condition or an autoimmune disease disorder or condition.

Embodiment I-22. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition of the liver.

Embodiment I-23. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition of the lung.

Embodiment I-24. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition of the skin.

Embodiment I-25. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition of the cardiovascular system.

Embodiment I-26. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a cancer, tumor or othermalignancy.

Embodiment I-27. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition is of the renal system.

Embodiment I-28. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition is of the gastro-intestinal tract.

Embodiment I-29. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition is of the respiratory system.

Embodiment I-30. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition is of the endocrine system.

Embodiment I-31. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is a disease, disorder orcondition is of the central nervous system (CNS).

Embodiment I-32. The method of any one of Embodiments I-16 to I-19,wherein the disease, disorder or condition is selected from the groupconsisting of constitutive inflammation, the cryopyrin-associatedperiodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial coldautoinflammatory syndrome (FCAS), neonatal-onset multisysteminflammatory disease (NOMID), autoinflammatory diseases, familialMediterranean fever (FMF), TNF receptor associated periodic syndrome(TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D,periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor(DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyodermagangrenosum and acne (PAPA), haploinsufficiency of A20 (HA20), pediatricgranulomatous arthritis (PGA), PLCG2-associated antibody deficiency andimmune dysregulation (PLAID), PLCG2-associated autoinflammation,antibody deficiency and immune dysregulation (APLAID), sideroblasticanemia with B-cell immunodeficiency, periodic fevers, developmentaldelay (SIFD), Sweet's syndrome, chronic nonbacterial osteomyelitis(CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis,acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO), autoimmunediseases including multiple sclerosis (MS), type-1 diabetes, psoriasis,rheumatoid arthritis, Behcet's disease, Sjogren's syndrome, Schnitzlersyndrome, respiratory diseases, idiopathic pulmonary fibrosis (IPF),chronic obstructive pulmonary disorder (COPD), steroid-resistant asthma,asbestosis, silicosis, cystic fibrosis, central nervous system diseases,Parkinson's disease, Alzheimer's disease, motor neuron disease,Huntington's disease, cerebral malaria, brain injury from pneumococcalmeningitis, metabolic diseases, Type 2 diabetes, atherosclerosis,obesity, gout, pseudo-gout, ocular disease, disease of the ocularepithelium, age-related macular degeneration (AMD), corneal infection,uveitis, dry eye, kidney disease, chronic kidney disease, oxalatenephropathy, diabetic nephropathy, liver disease, non-alcoholicsteatohepatitis, alcoholic liver disease, inflammatory reactions inskin, contact hypersensitivity, sunburn, inflammatory reactions in thejoints, osteoarthritis, systemic juvenile idiopathic arthritis,adult-onset Still's disease, relapsing polychondritis, viral infections,alpha virus infection, Chikungunya virus infection, Ross River virusinfection, flavivirus infection, Dengue virus infection, Zika virusinfection, flu, HIV infection, hidradenitis suppurativa (HS),cyst-causing skin diseases, cancers, lung cancer metastasis, pancreaticcancers, gastric cancers, myelodisplastic syndrome, leukemia,polymyositis, stroke, myocardial infarction, Graft versus Host Disease,hypertension, colitis, helminth infection, bacterial infection,abdominal aortic aneurism, wound healing, depression, psychologicalstress, pericarditis, Dressler's syndrome, ischaemia reperfusion injury,and any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

Embodiment I-33. The method of Embodiment I-15, wherein the disorder isselected from the group consisting of a bacterial infection, a viralinfection, a fungal infection, inflammatory bowel disease, celiacdisease, colitis, intestinal hyperplasia, cancer, metabolic syndrome,obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fattyliver disease, liver fibrosis, non-alcoholic fatty liver disease(NAFLD), and non-alcoholic steatohepatitis (NASH).

Embodiment I-34. The method of Embodiment I-33, wherein the disorder isnon-alcoholic steatohepatitis (NASH).

Embodiment I-35. The method of any one of Embodiments I-16 to I-34,wherein the treatment or prevention of the disease, disorder orcondition is performed on a mammal.

Embodiment I-36. The method of Embodiment I-35, wherein the mammal is ahuman subject.

Embodiment I-37. A method of modulating the activity of a biologicaltarget comprising the step of exposing the biological target to acompound of any one of Embodiments I-1 to I-14, or a pharmaceuticallyeffective salt, solvate or prodrug thereof.

Embodiment I-38. The method of Embodiment I-37, wherein the biologicaltarget may be selected from the group consisting of the NLRP3inflammasome, IL-6, IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-22, IL-33 andTh17 cells.

Embodiment I-39. Use of a compound of any one of Embodiments I-1 to I-14in the treatment of a disease, disorder or condition that is responsiveto inhibition of inflammasome.

Embodiment I-40. A compound of any one of Embodiments I-1 to I-14 foruse in the manufacture of a medicament for treating a disease, disorderor condition that is responsive to inhibition of inflammasome.

Embodiment II-1. A compound of formula Ia:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or tautomer thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkenyl, optionally substitutedC₁-C₆alkynyl, —(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring,

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

X² is N or CR^(5b);

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; or

two R^(5b) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

Embodiment II-2. A compound of formula Ib:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or tautomer thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkenyl, optionally substitutedC₁-C₆alkynyl, —(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂; R² is

X² is N or CR^(5b);

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OH, —O—C₁-C₆alkyl,—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

Embodiment II-3. A compound of formula Ic:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or tautomer thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkenyl, optionally substitutedC₁-C₆alkynyl, —(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

X² is N or CR^(5b);

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂;

R⁶ and R⁷ are independently, at each occurrence H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OH, —O—C₁-C₆alkyl,—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

Embodiment II-4. A compound of formula Id:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or tautomer thereof,

wherein:

X¹ is O, S,

R¹ is selected from the group consisting of an optionally substitutedC₁-C₆alkyl, optionally substituted C₁-C₆alkynyl,—(CH₂)_(m)—O—(CH₂)_(m)—CH₃,

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a) or N;

A¹ is NR^(5a), O, S, or C(O);

each A² is independently CR^(5a), C(R^(5a))₂, N, NR^(5a), O, S, orS(O)₂;

R² is

R³ and R⁴ are H;

each R^(5a) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or

two R^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two geminal R^(5a) can form an oxo group;

each R^(5b) is independently H, D, halogen, OH, CN, —NO₂—SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —S(O)₂N(R⁶)₂—, —S(O)₂R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)NR⁶R⁷,—NR⁶S(O)₂R⁷, —S(O)R⁶, —S(O)NR⁶R⁷, —NR⁶S(O)R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; R⁶ and R⁷ are independently, at each occurrence H, D,C₁-C₈alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl, C₁-C₈alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-5 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,and heteroaryl are optionally substituted with D, halogen, C₁-C₆alkyl,—OH, —O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

each m is independently an integer from one to 4; and

n is an integer from zero to 5;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a), O, S, or S(O)₂.

Embodiment II-5. The compound of any one of Embodiments II-1 to II-4,wherein R¹ is selected from the group consisting of:

Embodiment II-6. The compound of any one of Embodiments II-1 to II-5,wherein X¹ is O.

Embodiment II-7. The compound of any one of Embodiments II-1 to II-5,wherein X¹ is S.

Embodiment II-8. The compound of any one of Embodiments II-1 to II-3 andII-5 to II-7, wherein R² is

Embodiment II-9. The compound of any one of Embodiments II-1 to II-3 andII-5 to II-7, wherein R² is

Embodiment II-10. The compound of any one of Embodiments II-1 to II-9,wherein the

are single bonds in the ring comprising A², thereby forming a saturatedring.

Embodiment II-11. The compound of any one of Embodiments II-1 to II-10,wherein R¹ is

Embodiment II-12. The compound of Embodiment II-11, wherein each A² isindependently CH₂ or O.

Embodiment II-13. The compound of any one of Embodiments II-1 to II-10,wherein R¹ is

Embodiment II-14. The compound of any one of Embodiments II-1 to II-10,wherein R¹ is

Embodiment II-15. The compound of any one of Embodiments II-1 to II-10,wherein R¹ is

Embodiment II-16. The compound of any one of Embodiments II-1 to II-15,wherein R¹ is methyl.

Embodiment II-17. The compound of any one of Embodiments II-1 to II-3and II-5 to II-16, wherein the compound is of formula:

Embodiment II-18. The compound of Embodiment II-1, which is

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide,or a pharmaceutically acceptable salt thereof.

Embodiment II-19. The compound of Embodiment II-1, which is

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonamide,or a pharmaceutically acceptable salt thereof.

Embodiment II-20. The compound of Embodiment II-1, which is

or a pharmaceutically acceptable salt thereof.

Embodiment II-21. The compound of Embodiment II-1, which is

or a pharmaceutically acceptable salt thereof.

Embodiment II-22. The compound of Embodiment II-1, which is selectedfrom the group consisting of

Embodiment II-23. The compound of Embodiment II-1, which is selectedfrom the group consisting of

Embodiment II-24. The compound of any one of Embodiments II-1 to II-4,which is selected from the group consisting of

Embodiment II-25. A pharmaceutical composition comprising a compound ofany one of Embodiments II-1 to II-24 and a pharmaceutically acceptablecarrier.

Embodiment II-26. A method of treatment or prevention of a disease,disorder or condition including the step of administering an effectiveamount of a compound of any one of Embodiments II-1 to II-24, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, to thereby treat or prevent the disease disorder orcondition.

Embodiment II-27. The method of Embodiment II-25, wherein the disease,disorder or condition is responsive to inhibition of inflammasome.

Embodiment II-28. The method of Embodiment II-26 or II-27, wherein thedisease, disorder or condition is one which is responsive to inhibitionof activation of the NLRP3 inflammasome.

Embodiment II-29. The method of Embodiment II-26 or II-27, wherein thedisease, disorder or condition is responsive to modulation of one ormore of IL-6, IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-22, IL-33 and Th17cells.

Embodiment II-30. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition of the immune system.

Embodiment II-31. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is an inflammatory diseasedisorder or condition or an autoimmune disease disorder or condition.

Embodiment II-32. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition of the liver.

Embodiment II-33. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition of the lung.

Embodiment II-34. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition of the skin.

Embodiment II-35. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition of the cardiovascular system.

Embodiment II-36. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a cancer, tumor or othermalignancy.

Embodiment II-37. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition is of the renal system.

Embodiment II-38. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition is of the gastro-intestinal tract.

Embodiment II-39. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition is of the respiratory system.

Embodiment II-40. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition is of the endocrine system.

Embodiment II-41. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is a disease, disorder orcondition is of the central nervous system (CNS).

Embodiment II-42. The method of any one of Embodiments II-26 to II-29,wherein the disease, disorder or condition is selected from the groupconsisting of constitutive inflammation, the cryopyrin-associatedperiodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial coldautoinflammatory syndrome (FCAS), neonatal-onset multisysteminflammatory disease (NOMID), autoinflammatory diseases, familialMediterranean fever (FMF), TNF receptor associated periodic syndrome(TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D,periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor(DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyodermagangrenosum and acne (PAPA), haploinsufficiency of A20 (HA20), pediatricgranulomatous arthritis (PGA), PLCG2-associated antibody deficiency andimmune dysregulation (PLAID), PLCG2-associated autoinflammation,antibody deficiency and immune dysregulation (APLAID), sideroblasticanemia with B-cell immunodeficiency, periodic fevers, developmentaldelay (SIFD), Sweet's syndrome, chronic nonbacterial osteomyelitis(CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis,acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO), autoimmunediseases including multiple sclerosis (MS), type-1 diabetes, psoriasis,rheumatoid arthritis, Behcet's disease, Sjogren's syndrome, Schnitzlersyndrome, respiratory diseases, idiopathic pulmonary fibrosis (IPF),chronic obstructive pulmonary disorder (COPD), steroid-resistant asthma,asbestosis, silicosis, cystic fibrosis, central nervous system diseases,Parkinson's disease, Alzheimer's disease, motor neuron disease,Huntington's disease, cerebral malaria, brain injury from pneumococcalmeningitis, metabolic diseases, Type 2 diabetes, atherosclerosis,obesity, gout, pseudo-gout, ocular disease, disease of the ocularepithelium, age-related macular degeneration (AMD), corneal infection,uveitis, dry eye, kidney disease, chronic kidney disease, oxalatenephropathy, diabetic nephropathy, liver disease, non-alcoholicsteatohepatitis, alcoholic liver disease, inflammatory reactions inskin, contact hypersensitivity, sunburn, inflammatory reactions in thejoints, osteoarthritis, systemic juvenile idiopathic arthritis,adult-onset Still's disease, relapsing polychondritis, viral infections,alpha virus infection, Chikungunya virus infection, Ross River virusinfection, flavivirus infection, Dengue virus infection, Zika virusinfection, flu, HIV infection, hidradenitis suppurativa (HS),cyst-causing skin diseases, cancers, lung cancer metastasis, pancreaticcancers, gastric cancers, myelodisplastic syndrome, leukemia,polymyositis, stroke, myocardial infarction, Graft versus Host Disease,hypertension, colitis, helminth infection, bacterial infection,abdominal aortic aneurism, wound healing, depression, psychologicalstress, pericarditis, Dressler's syndrome, ischaemia reperfusion injury,and any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

Embodiment II-43. The method of Embodiment II-26, wherein the disorderis selected from the group consisting of a bacterial infection, a viralinfection, a fungal infection, inflammatory bowel disease, celiacdisease, colitis, intestinal hyperplasia, cancer, metabolic syndrome,obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fattyliver disease, liver fibrosis, non-alcoholic fatty liver disease(NAFLD), and non-alcoholic steatohepatitis (NASH).

Embodiment II-44. The method of Embodiment II-43, wherein the disorderis non-alcoholic steatohepatitis (NASH).

Embodiment II-45. The method of any one of Embodiments II-26 to II-44,wherein the treatment or prevention of the disease, disorder orcondition is performed on a mammal.

Embodiment II-46. The method of Embodiment II-45, wherein the mammal isa human subject.

Embodiment II-47. A method of modulating the activity of a biologicaltarget comprising the step of exposing the biological target to acompound of any one of Embodiments II-1 to II-24, or a pharmaceuticallyeffective salt, solvate or prodrug thereof.

Embodiment II-48. The method of Embodiment II-47, wherein the biologicaltarget may be selected from the group consisting of the NLRP3inflammasome, IL-6, IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-22, IL-33 andTh17 cells.

Embodiment II-49. Use of a compound of any one of Embodiments II-1 toII-24 in the treatment of a disease, disorder or condition that isresponsive to inhibition of inflammasome.

Embodiment II-50. A compound of any one of Embodiments II-1 to II-24 foruse in the manufacture of a medicament for treating a disease, disorderor condition that is responsive to inhibition of inflammasome.

Embodiment III-1. A compound of formula If:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or tautomer thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a1) or N;

each A² is independently CR^(5a2), C(R^(5a2))₂, N, NR^(5a2), O, S, orS(O)₂;

R² is

X² is N or CR^(5b1);

R³ and R⁴ are H;

each R^(5a1) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶;

each R^(5a2) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—S(O)₂—R⁶, —COR⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶;or

two geminal R^(5a2) can form an oxo group;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, or C₂-C₆alkynyl;wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a2), O, S, or S(O)₂.

Embodiment III-2. The compound of claim 1, or a pharmaceuticallyacceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof,wherein:

X¹ is O;

R¹ is selected from the group consisting of

wherein

represents a single bond;

each A² is independently C(R^(5a2))₂ or O;

X² is CR^(5b1);

each R^(5a1) is independently H or C₁-C₆alkyl; wherein the C₁-C₆alkyl isoptionally substituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),—N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶;

each R^(5a2) is independently H, halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷,C₁-C₆alkyl, or heterocyclyl; wherein the C₁-C₆alkyl and heterocyclyl areoptionally substituted with D, halogen, —OR⁶, —NH₂, NH(C₁-C₆alkyl),N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶; or

two R^(5a2) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, or—S(O)₂—R⁶; or

two geminal R^(5a2) can form an oxo group;

R^(5b1) is H, D, halogen, or C₁-C₆alkyl;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, —CN, —OR⁶, C₁-C₆alkyl, or C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, and C₃-C₈cycloalkyl, are optionally substituted with D,halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) together with theatoms to which they are attached can form C₃-C₈cycloalkyl, heterocyclyl,or heteroaryl, wherein C₃-C₈cycloalkyl, heterocyclyl, or heteroaryl areoptionally substituted with halogen or C₁-C₆alkyl; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkynyl, or aryl; wherein the C₁-C₈alkyl, C₂-C₈alkynyl, and aryl,are optionally substituted with D, halogen or C₁-C₆alkyl.

Embodiment III-3. A compound of formula Ig:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or a tautomer thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a1) or N;

each A² is independently CR^(5a2), C(R^(5a2))₂, N, NR^(5a2), O, S, orS(O)₂;

R² is

X² is N or CR^(5b1);

R³ and R⁴ are H;

each R^(5a1) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or—NR⁶C(O)R⁶;

each R^(5a2) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —S(O)₂—R⁶; —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶; or

two geminal R^(5a2) can form an oxo group;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, or C₂-C₆alkynyl;wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a2), O, S, or S(O)₂.

Embodiment III-4. A compound of formula Ih:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or a tautomer thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a1) or N;

each A² is independently CR^(5a2), C(R^(5a2))₂, N, NR^(5a2), O, S, orS(O)₂;

R² is

X² is N or CR^(5b1);

R³ and R⁴ are H;

each R^(5a1) is independently H, D, halogen, —OH, —CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶;

each R^(5a2) is independently H, D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

wherein at least one R^(5a2) is —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, orheterocyclyl containing N, wherein the C₁-C₆alkyl is substituted with—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and wherein the heterocyclylis optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;

each R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) is independently H,D, halogen, OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, or C₂-C₆alkynyl;wherein the C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionally substituted with D,halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a2), O, S, or S(O)₂.

Embodiment III-5. A compound of formula Ie:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or a tautomer thereof,

wherein:

X¹ is O or S;

R¹ is selected from the group consisting of

wherein

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring;

each A is independently CR^(5a1) or N;

each A² is independently CR^(5a2), C(R^(5a2))₂, N, NR^(5a2), O, S, orS(O)₂;

R² is

X² is N or CR^(5b1);

each R^(b10), R^(b11), R^(b12), R^(b13), R^(b14), and R^(b15) isindependently H, —OH, or oxo;

R³ and R⁴ are H;

each R^(5a1) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,or —NR⁶C(O)R⁶;

each R^(5a2) is independently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶,—NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, —CN, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶;or

two geminal R^(5a2) can form an oxo group;

R^(5b1) is H, D, halogen, —CN, —OR⁶, or C₁-C₆alkyl, C₃-C₈cycloalkyl,—C(O)NR⁶, —C(O)OR⁶; wherein the C₁-C₆alkyl, and C₃-C₈cycloalkyl, areoptionally substituted with D, halogen, —CN, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; each R^(5b2), R^(5b3), R^(5b4),R^(5b5), and R^(5b6) is independently H, D, halogen, OH, —CN, —NO₂,—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₃-C₈cycloalkyl, or C₂-C₆alkynyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₃-C₈cycloalkyl, and C₂-C₆alkynyl are optionallysubstituted with D, halogen, —CN, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or

two adjacent R^(5b2), R^(5b3), R^(5b4), R^(5b5), and R^(5b6) togetherwith the atoms to which they are attached can form C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl, wherein C₃-C₈cycloalkyl,heterocyclyl, aryl, or heteroaryl are optionally substituted withhalogen, —CN, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; and

R⁶ and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl,heterocyclyl, aryl, or heteroaryl; wherein the heterocyclyl andheteroaryl contain 1-5 heteroatoms selected from the group consisting ofN, S, P and O; wherein the C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl,C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl, and heteroarylare optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OH,—O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or

R⁶ and R⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P and O;

provided that when the ring comprising A and/or A¹ is an imidazole, thenat least one A² is N, NR^(5a2), O, S, or S(O)₂.

Embodiment III-6. The compound of any one of Embodiments III-1 and III-3to III-5, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein X¹ is O.

Embodiment III-7. The compound of any one of Embodiments III-1 to III-6,or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or tautomer thereof, wherein R² is

Embodiment III-8. The compound of Embodiment III-7, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein X² is CR^(5b1).

Embodiment III-9. The compound of Embodiment III-8, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R^(5b1) is H, halogen, or C₁-C₆alkyl.

Embodiment III-10. The compound of Embodiment III-8, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R^(5b1) is H, fluoro, chloro, or methyl.

Embodiment III-11. The compound of any one of Embodiments III-1 toIII-10, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R² is

Embodiment III-12. The compound of any one of Embodiments III-1 toIII-10, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R² is

Embodiment III-13. The compound of any one of Embodiments III-1 toIII-6, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or tautomer thereof, wherein R² is

Embodiment III-14. The compound of Embodiment III-13, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein each R^(5b2), R^(5b3), R^(5b4), R^(5b5), andR^(5b6) is independently H, D, halogen, OH, —CN, —NO₂, —OR⁶, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, or C₃-C₈cycloalkyl.

Embodiment III-15. The compound of any one of Embodiments III-1 toIII-13, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R² is

Embodiment III-16. The compound of Embodiment III-15, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein each R^(5b2), R^(5b3), R^(5b4), R^(5b5), andR^(5b6) is independently selected from the group consisting of H, D,halogen, C₁-C₆alkyl, C₃-C₈cycloalkyl, and —CN.

Embodiment III-17. The compound of any one of Embodiments III-1 toIII-16, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R² is selected from thegroup consisting of

Embodiment III-18. The compound of any one of Embodiments III-1 toIII-17, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R² is selected from thegroup consisting of

Embodiment III-19. The compound of any one of Embodiments III-1 toIII-18, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R² is

Embodiment III-20. The compound of any one of Embodiments III-1 toIII-13, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R² is

Embodiment III-21. The compound of Embodiment III-20, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein each R^(5b2) and R^(5b4) is selected from thegroup consisting of H, D, halogen, C₁-C₆alkyl, C₃-C₈cycloalkyl, and —CN.

Embodiment III-22. The compound of any one of Embodiments III-20 andIII-21, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R² is

Embodiment III-23. The compound of any one of Embodiments III-1 toIII-22, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R¹ is

Embodiment III-24. The compound of any one of Embodiments III-1 toIII-22, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein

Embodiment III-25. The compound of any one of Embodiments III-1 toIII-24, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein one A is CR^(5a1) and theother A is N.

Embodiment III-26. The compound of any one of Embodiments III-1 toIII-25, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein each A² is independentlyC(R^(5a2))₂, NR^(5a2), or O.

Embodiment III-27. The compound of Embodiment III-26, wherein eachR^(5a2) is independently H, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, or heterocyclylcontaining N, wherein the C₁-C₆alkyl is substituted with —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and wherein the heterocyclyl isoptionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶.

Embodiment III-28. The compound of Embodiment III-27, wherein R¹ isselected from the group consisting of

wherein R^(5a1a) is H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶,—NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶; and

R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) areselected from independently H, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, orheterocyclyl containing N, wherein the C₁-C₆alkyl is substituted with—NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂, and wherein the heterocyclylis optionally substituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶,—NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶.

Embodiment III-29. The compound of any one of Embodiments III-1 toIII-23, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R¹ is

Embodiment III-30. The compound of Embodiment III-29, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein one A is CR^(5a1) and the other A is N.

Embodiment III-31. The compound of any one of Embodiments III-29 toIII-30, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein each A² is independentlyC(R^(5a2))₂, NR^(5a2), or O.

Embodiment III-32. The compound of any one of Embodiments III-29 toIII-30, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein each R^(5a2) isindependently H, halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl.

Embodiment III-33. The compound of any one of Embodiments III-20 toIII-32, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein two R^(5a2) together withthe atoms to which they are attached can form C₃-C₈cycloalkyl orheterocyclyl.

Embodiment III-34. The compound of any one of Embodiments III-1 toIII-22, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R¹ is

which is a formula of

wherein

A^(2ab) is selected from CR^(5a2), C(R^(5a2a))(R^(5a2b)), N, NR^(5a2),O, S, or S(O)₂;

A^(2cd) is selected from CR^(5a2), C(R^(5a2c))(R^(5a2d)), N, NR^(5a2),O, S, or S(O)₂;

A^(2ef) is selected from CR^(5a2), C(R^(5a2e))(R^(5a2f)), N, NR^(5a2),O, S, or S(O)₂; and

A^(2gh) is selected from CR^(5a2), C(R^(5a2g))(R^(5a2h)), N, NR^(5a2),O, S, or S(O)₂;

each R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) are independently H, D, halogen, OH, CN, —NO₂,—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) together with the atoms to which they areattached can form C₃-C₈cycloalkyl or heterocyclyl; wherein theheterocyclyl contains 1-3 heteroatoms selected from the group consistingof N, S, P and O; wherein the C₃-C₈cycloalkyl and heterocyclyl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶; or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) can form an oxo group.

Embodiment III-35. The compound of Embodiment III-34, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R¹ is.

wherein

wherein R^(5a1a) is H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶,—NR⁶R⁷, —NR⁶C(O)R⁶, —NR⁶C(O)OR⁶, —NR⁶C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, or —NR⁶C(O)R⁶;

R^(5a2c) and R^(5a2d) are each independently H, D, halogen, OH, CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

R^(5a2c) and R^(5a2d) together with the atoms to which they are attachedcan form C₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclylcontains 1-3 heteroatoms selected from the group consisting of N, S, Pand O; wherein the C₃-C₈cycloalkyl and heterocyclyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),—N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶,or —NR⁶S(O)₂R⁶; or

R^(5a2c) and R^(5a2d) can form an oxo group.

Embodiment III-36. The compound of Embodiment III-35, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein each R^(5a2c) and R^(5a2d) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl.

Embodiment III-37. The compound of any one of Embodiments III-35 toIII-36, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R^(5a2c) and R^(5a2d)together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl.

Embodiment III-38. The compound of Embodiment III-34, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R¹ is.

wherein

R^(5a2a) and R^(5a2b) are each independently H, D, halogen, OH, CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

R^(5a2a) and together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶;or

R^(5a2a) and R^(5a2b) can form an oxo group.

Embodiment III-39. The compound of Embodiment III-38, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein each R^(5a2a) and R^(5a2b) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl.

Embodiment III-40. The compound of any one of Embodiments III-38 toIII-39, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R^(5a2a) and R^(5a2b)together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl.

Embodiment III-41. The compound of Embodiment III-33, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R¹ is.

wherein

R^(5a2e) and R^(5a2f) are each independently H, D, halogen, OH, CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

R^(5a2e) and R^(5a2f) together with the atoms to which they are attachedcan form C₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclylcontains 1-3 heteroatoms selected from the group consisting of N, S, Pand O; wherein the C₃-C₈cycloalkyl and heterocyclyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),—N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶,or —NR⁶S(O)₂R⁶; or

R^(5a2e) and R^(5a2f) can form an oxo group.

Embodiment III-42. The compound of Embodiment ID-41, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein each R^(5a2e) and R^(5a2f) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl.

Embodiment III-43. The compound of any one of Embodiments III-41 toIII-42, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R^(5a2e) and R^(5a2f)together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl.

Embodiment III-44. The compound of Embodiments III-34, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R¹ is.

wherein

R^(5a2c) and R^(5a2d) are each independently H, D, halogen, OH, CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

R^(5a2c) and R^(5a2d) together with the atoms to which they are attachedcan form C₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclylcontains 1-3 heteroatoms selected from the group consisting of N, S, Pand O; wherein the C₃-C₈cycloalkyl and heterocyclyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl),—N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶,or —NR⁶S(O)₂R⁶; or

R^(5a2c) and R^(5a2d) can form an oxo group.

Embodiment III-45. The compound of Embodiment III-44, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein each R^(5a2c) and R^(5a2d) is independently H,halogen, OH, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl.

Embodiment III-46. The compound of any one of Embodiments III-44 toIII-45, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R^(5a2c) and R^(5a2d)together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl.

Embodiment III-47. The compound of Embodiment III-29, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R¹ is selected from the group consisting of

Embodiment III-48. The compound of Embodiment III-29, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R¹ is selected from the group consisting of

Embodiment III-49. The compound of Embodiment III-29, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R¹ is selected from the group consisting of

Embodiment III-50. The compound of any one of Embodiments III-1 toIII-22, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R¹ is

Embodiment III-51. The compound of Embodiment III-50, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein one A is CR^(5a1) and the other A is N.

Embodiment III-52. The compound of any one of Embodiments III-50 toIII-51, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein each A² is independentlyC(R^(5a2))₂, NR^(5a2), or O.

Embodiment III-53. The compound of any one of Embodiments III-1 toIII-22, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R¹ is

which is a formula of

wherein.

A^(2ab) is selected from CR^(5a2), C(R^(5a2a))(R^(5a2b)), N, NR^(5a2),O, S, or S(O)₂;

A^(2cd) is selected from CR^(5a2), C(R^(5a2c))(R^(5a2d)), N, NR^(5a2),O, S, or S(O)₂;

A^(2ef) is selected from CR^(5a2), C(R^(5a2e))(R^(5a2f)), N, NR^(5a2),O, S, or S(O)₂; and

A^(2gh) is selected from CR^(5a2), C(R^(5a2g))(R^(5a2h)), N, NR^(5a2),O, S, or S(O)₂;

A^(2ij) is selected from CR^(5a2), C(R^(5a2i))(R^(5a2j)), N, NR^(5a2),O, S, or S(O)₂;

each R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), R^(5a2h), R^(5a2i), and R^(5a2j) are independently H, D,halogen, OH, CN, —NO₂—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶,—C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), R^(5a2h), R^(5a2i), and R^(5a2j) together with the atoms towhich they are attached can form C₃-C₈cycloalkyl or heterocyclyl;wherein the heterocyclyl contains 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl andheterocyclyl are optionally substituted with D, halogen, C₁-C₆alkyl,—OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶,NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶; or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), R^(5a2h), R^(5a2i), and R^(5a2j) can form an oxo group.

Embodiment III-54. The compound of Embodiment ID-50, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R¹ is

Embodiment III-55. The compound of any one of Embodiments III-1 toIII-22, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R¹ is

Embodiment III-56. The compound of Embodiment III-55, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein one A is CR^(5a1) and the other A is N.

Embodiment III-57. The compound of any one of Embodiments III-55 toIII-56, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein each A² is independentlyC(R^(5a2))₂, NR^(5a2), or O.

Embodiment III-58. The compound of any one of Embodiments III-1 toIII-22, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R¹ is

which is a formula of

wherein.

A^(2ab) is selected from C(R^(5a2a))(R^(5a2b)), NR^(5a2), O, S, orS(O)₂;

A^(2cd) is selected from C(R^(5a2c))(R^(5a2d)), NR^(5a2), O, S, orS(O)₂;

A^(2ef) is selected from C(R^(5a2e))(R^(5a2f)), NR^(5a2), O, S, orS(O)₂; and

each R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f) areindependently H, D, halogen, OH, CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷,—C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, —CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶,—NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶; or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), and R^(5a2f)together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶;or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), andR^(5a2f) can form an oxo group.

Embodiment III-59. The compound of Embodiment III-55, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein R¹ is

Embodiment III-60. The compound of any one of Embodiments III-1 toIII-22, or a pharmaceutically acceptable salt prodrug, solvate, hydrate,isomer, or tautomer thereof, wherein R¹ is

Embodiment III-61. The compound of Embodiment III-60, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof, wherein one A is CR^(5a1) and the other A is N.

Embodiment III-62. The compound of any one of Embodiments III-60 toIII-61, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein each A² is independentlyC(R^(5a2))₂, NR^(5a2), or O.

Embodiment III-63. The compound of any one of Embodiments III-1 toIII-22, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein R¹ is

which is a formula of

wherein.

A^(2ab) is selected from CR^(5a2), C(R^(5a2a))(R^(5a2b)), N, NR^(5a2),O, S, or S(O)₂;

A^(2cd) is selected from CR^(5a2), C(R^(5a2c))(R^(5a2d)), N, NR^(5a2),O, S, or S(O)₂;

A^(2ef) is selected from CR^(5a2), C(R^(5a2e))(R^(5a2f)), N, NR^(5a2),O, S, or S(O)₂; and

A^(2gh) is selected from CR^(5a2), C(R^(5a2g))(R^(5a2h)), N, NR^(5a2),O, S, or S(O)₂;

each R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) are independently H, D, halogen, OH, CN,—NO₂—SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, —C(O)R⁶, —S(O)₂R⁶, —C(O)OR⁶, —C(O)NR⁶,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,—CN, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂,—NR⁶C(O)OR⁶, —NR⁶C(O)R⁶, NR⁶C(O)NR⁶, —NR⁶C(O)R⁶, or —NR⁶S(O)₂R⁶ or

two R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) together with the atoms to which they areattached can form C₃-C₈cycloalkyl or heterocyclyl; wherein theheterocyclyl contains 1-3 heteroatoms selected from the group consistingof N, S, P and O; wherein the C₃-C₈cycloalkyl and heterocyclyl areoptionally substituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), —N(C₁-C₆alkyl)₂, —S(O)₂—R⁶, —COR⁶, NR⁶C(O)OR⁶,—NR⁶C(O)R⁶, —NR⁶C(O)NR⁶, or —NR⁶S(O)₂R⁶ or

two geminal R^(5a2a), R^(5a2b), R^(5a2c), R^(5a2d), R^(5a2e), R^(5a2f),R^(5a2g), and R^(5a2h) can form an oxo group.

Embodiment III-64. The compound of any one of Embodiments III-1 toIII-63, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, wherein the

are single bonds in the ring comprising A², thereby forming a saturatedring.

Embodiment III-65. A compound, or a pharmaceutically acceptable salt,prodrug, solvate, hydrate, isomer, or tautomer thereof, selected fromthe group consisting of

Embodiment III-66. A compound, or a pharmaceutically acceptable salt,prodrug, solvate, hydrate, isomer, or tautomer thereof, selected fromthe group consisting of

Embodiment III-67. A compound, or a pharmaceutically acceptable salt,prodrug, solvate, hydrate, isomer, or tautomer thereof, selected fromthe group consisting of

Embodiment III-68. A compound, or a pharmaceutically acceptable salt,prodrug, solvate, hydrate, isomer, or tautomer thereof, selected fromthe group consisting of

Embodiment III-69. A pharmaceutical composition comprising a compound ofany one of Embodiments III-1 to III-68, or a pharmaceutically acceptablesalt, prodrug, solvate, hydrate, isomer, or tautomer thereof, and apharmaceutically acceptable carrier.

Embodiment III-70. A method of treatment or prevention of a disease,disorder, or condition that is responsive to inhibition of inflammasome,comprising administering an effective amount of a compound of any one ofEmbodiments III-1 to III-68, or a pharmaceutically acceptable salt,prodrug, solvate, hydrate, isomer, or tautomer thereof, to thereby treator prevent the disease disorder or condition in a subject in needthereof.

Embodiment III-71. The method of Embodiment III-70, wherein the disease,disorder or condition is one which is responsive to inhibition ofactivation of the NLRP3 inflammasome.

Embodiment III-72. The method of Embodiment III-70 or III-71, whereinthe disease, disorder or condition is responsive to modulation of one ormore of IL-6, IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-22, IL-33 and Th17cells.

Embodiment III-73. The method of Embodiment III-70 or III-71, whereinthe disease, disorder or condition is responsive to modulation of one ormore of IL-1β and IL-18.

Embodiment III-74. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition of the immune system.

Embodiment III-75. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is an inflammatorydisease disorder or condition or an autoimmune disease disorder orcondition.

Embodiment III-76. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition of the liver.

Embodiment III-77. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition of the lung.

Embodiment III-78. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition of the skin.

Embodiment III-79. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition of the cardiovascular system.

Embodiment III-80. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a cancer, tumor orother malignancy.

Embodiment III-81. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition is of the renal system.

Embodiment III-82. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition is of the gastro-intestinal tract.

Embodiment III-83. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition is of the respiratory system.

Embodiment III-84. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition is of the endocrine system.

Embodiment III-85. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is a disease,disorder or condition is of the central nervous system (CNS).

Embodiment III-86. The method of any one of Embodiments III-70 toIII-73, wherein the disease, disorder or condition is selected from thegroup consisting of constitutive inflammation, the cryopyrin-associatedperiodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial coldautoinflammatory syndrome (FCAS), neonatal-onset multisysteminflammatory disease (NOMID), autoinflammatory diseases, familialMediterranean fever (FMF), TNF receptor associated periodic syndrome(TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D,periodic fever syndrome (FUDS), deficiency of interleukin 1 receptor(DIRA) antagonist, Majeed syndrome, pyogenic arthritis, pyodermagangrenosum and acne (PAPA), haploinsufficiency of A20 (HA20), pediatricgranulomatous arthritis (PGA), PLCG2-associated antibody deficiency andimmune dysregulation (PLAID), PLCG2-associated autoinflammation,antibody deficiency and immune dysregulation (APLAID), sideroblasticanemia with B-cell immunodeficiency, periodic fevers, developmentaldelay (SIFD), Sweet's syndrome, chronic nonbacterial osteomyelitis(CNO), chronic recurrent multifocal osteomyelitis (CRMO) and synovitis,acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO), autoimmunediseases including multiple sclerosis (MS), type-1 diabetes, psoriasis,rheumatoid arthritis, Behcet's disease, Sjogren's syndrome, Schnitzlersyndrome, respiratory diseases, idiopathic pulmonary fibrosis (IPF),chronic obstructive pulmonary disorder (COPD), steroid-resistant asthma,asbestosis, silicosis, cystic fibrosis, central nervous system diseases,Parkinson's disease, Alzheimer's disease, motor neuron disease,Huntington's disease, cerebral malaria, brain injury from pneumococcalmeningitis, metabolic diseases, Type 2 diabetes, atherosclerosis,obesity, gout, pseudo-gout, ocular disease, disease of the ocularepithelium, age-related macular degeneration (AMD), corneal infection,uveitis, dry eye, kidney disease, chronic kidney disease, oxalatenephropathy, diabetic nephropathy, liver disease, non-alcoholicsteatohepatitis, alcoholic liver disease, inflammatory reactions inskin, contact hypersensitivity, sunburn, inflammatory reactions in thejoints, osteoarthritis, systemic juvenile idiopathic arthritis,adult-onset Still's disease, relapsing polychondritis, viral infections,alpha virus infection, Chikungunya virus infection, Ross River virusinfection, flavivirus infection, Dengue virus infection, Zika virusinfection, flu, HIV infection, hidradenitis suppurativa (HS),cyst-causing skin diseases, cancers, lung cancer metastasis, pancreaticcancers, gastric cancers, myelodisplastic syndrome, leukemia,polymyositis, stroke, myocardial infarction, Graft versus Host Disease,hypertension, colitis, helminth infection, bacterial infection,abdominal aortic aneurism, wound healing, depression, psychologicalstress, pericarditis, Dressler's syndrome, ischaemia reperfusion injury,and any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

Embodiment III-87. The method of Embodiment III-86, wherein the disorderis selected from the group consisting of a bacterial infection, a viralinfection, a fungal infection, inflammatory bowel disease, celiacdisease, colitis, intestinal hyperplasia, cancer, metabolic syndrome,obesity, rheumatoid arthritis, liver disease, hepatic steatosis, fattyliver disease, liver fibrosis, non-alcoholic fatty liver disease(NAFLD), and non-alcoholic steatohepatitis (NASH).

Embodiment III-88. The method of Embodiment III-87, wherein the disorderis non-alcoholic steatohepatitis (NASH).

Embodiment III-89. The method of any one of Embodiments III-70 toIII-88, wherein the treatment or prevention of the disease, disorder orcondition is performed on a mammal.

Embodiment III-90. The method of Embodiment III-89, wherein the mammalis a human subject.

Embodiment III-9T A method of modulating the activity of a biologicaltarget comprising the step of exposing the biological target to acompound of any one of Embodiments III-1 to III-68, or apharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, ortautomer thereof.

Embodiment III-92. The method of Embodiment III-91, wherein thebiological target may be selected from the group consisting of the NLRP3inflammasome, IL-6, IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-22, IL-33 andTh17 cells.

Embodiment III-93. The method of Embodiment III-91, wherein thebiological target may be selected from the group consisting of IL-1β andIL-18.

Embodiment III-94. A method of inhibiting activation of an inflammasomecomprising the step of exposing the biological target to a compound ofany one of Embodiments III-1 to III-68, or a pharmaceutically acceptablesalt, prodrug, solvate, hydrate, isomer, or tautomer thereof.

Embodiment III-95. The method of Embodiment III-94, wherein theinflammasome is NLRP3 inflammasome.

Embodiment III-96. The method of Embodiment III-94 or III-95, whereininhibition of inflammasome is associated with one or more of IL-6,IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-22, IL-33 and Th17 cells.

Embodiment III-97. The method of Embodiment III-96, wherein inhibitionof inflammasome is associated with one or more of IL-1β and IL-18.

Embodiment III-98. Use of a compound of any one of Embodiments III-1 toIII-68, or a pharmaceutically acceptable salt, prodrug, solvate,hydrate, isomer, or tautomer thereof, in the treatment of a disease,disorder or condition that is responsive to inhibition of inflammasome.

Embodiment III-99. A compound of any one of Embodiment III-1 to III-68,or a pharmaceutically acceptable salt, prodrug, solvate, hydrate,isomer, or tautomer thereof, for use in the manufacture of a medicamentfor treating a disease, disorder or condition that is responsive toinhibition of inflammasome.

EXAMPLES

The following examples are provided to illustrate the presentdisclosure, and should not be construed as limiting thereof. In theseexamples, all parts and percentages are by weight, unless otherwisenoted. Abbreviations in the examples are noted below.

Abbreviations

aq. aqueousEtOAc ethyl acetateh hourHPLC high performance liquid chromatographymin minutesmL millilitermmol millimoleMeOH methanolNMR nuclear magnetic resonancesat. saturatedTHF tetrahydrofuranTLC thin layer chromatography

Example 1: Synthesis of Compound 1.(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide)Method A:

N,N-dimethylpyridin-4-amine (0.517 mmol, 0.063 g) was dissolved in THF(1.5 mL) and then a solution of di-tert-butyl dicarbonate (0.492 mmol,0.113 mL) in THF (1.5 mL) was added slowly. After stirring for a fewminutes, a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-amine (0.492mmol, 0.085 g) in THF (1 mL) was added and the mixture was left to stirfor 30 min. At the same time,6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (0.492 mmol,100 mg) in THF (1 mL) was treated with sodium hydride (0.492 mmol, 0.018g) and left to stir for 30 min. At this time the two solutions weremixed and left to stir for 18 h.

The reaction was then quenched with sat. NH₄Cl (10 mL) and diluted withEtOAc (10 mL). The layers were separated and the aq. layer extractedwith EtOAc (10 mL). The combined organic extracts were then washed withwater (10 mL) and concentrated. The resulting solid was suspended inMeOH (5 mL), filtered off, and the filtrate purified by prep HPLC(10-40% MeCN:10 mM aq. NH₃). The purified fractions were combined andconcentrated to yieldN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(Compound 1) (3.5 mg, 1.768%) as a white solid. [M+H]⁺ found 403.

¹H-NMR (400 MHz; MeOD): δ 7.67 (s, 1H), 6.93 (d, J=0.9 Hz, 1H), 6.93 (d,J=0.9 Hz, 1H), 4.42 (t, J=5.3 Hz, 2H), 4.42 (t, J=5.3 Hz, 2H), 4.16 (t,J=6.2 Hz, 2H), 4.16 (t, J=6.2 Hz, 2H), 2.86 (t, J=7.4 Hz, 4H), 2.86 (t,J=7.4 Hz, 4H), 2.74-2.71 (m, 4H), 2.74-2.71 (m, 4H), 2.31-2.25 (m, 3H),2.31-2.25 (m, 3H), 2.08-2.00 (m, 6H), 2.08-2.00 (m, 6H).

Method B:

Preparation of TCPC

A solution of 2,4,6-trichloro-phenol (50 g, 250 mmol) and pyridine (20.5mL, 250 mmol) in ether (800 mL) was cooled to −78° C. under N₂. Uponcooling, solids formed in the mixture. To the mixture was added SO₂Cl₂(21 mL, 250 mmol) slowly. The reaction was then stirred at r.t.overnight. The reaction mixture was filtered through a celite-pad andrinsed with ether (300 mL). The ether solution was concentrated below40° C. The residue was purified by silica gel column (hexane PE) to giveTCPC (55 g, yield 75%) as a colorless oil.

¹H NMR (400 MHz, CDCl₃): δ=7.45 (s, 2H).

Step 1

1,2-Dihydro-pyrazol-3-one (4.0 g, 47.6 mmol) and K₂CO₃ (23.0 g, 166.7mmol) were heated to 130° C. in DMF (80 mL). 1,3-Dibromopropane (11.6 g,57.1 mmol) was added and the mixture was heated for 3 hrs and thenconcentrated. The residue was partitioned between ethyl acetate (100 mL)and water (100 mL) and the layers were separated. The aqueous layer wasextracted with EA (50 mL) and the combined organic layer was washed withbrine (50 mL), dried over Na₂SO₄, filtered and concentrated in vacuo.The residue was purified by silica gel column (PE/EA=1/2) to give6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (3.0 g, yield: 51%) as ayellow oil.

¹H NMR (400 MHz, CDCl₃): δ=7.31 (d, J=2.0 Hz, 1H), 5.48 (d, J=2.0 Hz,1H), 4.28 (t, J=5.2 Hz, 2H), 4.18 (t, J=6.2 Hz, 2H), 2.29-2.22 (m, 2H).

Step 2

NBS (4.4 g, 24.7 mmol) was added portionwise to a solution of6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (3.0 g, 24.3 mmol) in MeCN(40 mL) at 0° C. and the reaction was stirred for 2 hrs at roomtemperature. The mixture was filtered and purified by reverse phasecolumn (5%-95% MeCN in H₂O) to give3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (3.6 g, yield: 74%)as a yellow solid.

¹H NMR (400 MHz, CDCl₃): δ=7.30 (s, 1H), 4.36 (t, J=5.2 Hz, 2H), 4.17(t, J=6.2 Hz, 2H), 2.30-2.24 (m, 2H).

Step 3

To a solution of 3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (1.8g, 8.9 mmol) in dry THF (15 mL) was added n-BuLi in hexane (2.5 M, 3.5mL, 8.9 mmol) slowly at −78° C. under N₂. After stirred with cooling for20 min, ZnCl₂ in ether (1 M, 8.9 mL, 8.9 mmol) was added slowly at thistemperature. The cold bath was removed and the reaction was stirred atr.t. for 1 hr. TCPC (2.6 g, 8.9 mmol) was then added at 0° C. andstirred at r.t. for 1 hr. The reaction was quenched with saturated NH₄Clsolution (10 mL) and partitioned between water (80 mL) and EA (80 mL).The organic layer was washed with brine (80 mL), dried over Na₂SO₄ andconcentrated to give crude6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acid2,4,6-trichloro-phenyl ester as a yellow oil which was used for nextstep directly without any purification.

Step 4

A mixture of 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acid2,4,6-trichloro-phenyl ester (crude, ˜8.9 mmol), NH₄OH (10 mL) and THF(10 mL) was stirred at 60° C. overnight. The reaction was concentratedunder reduced pressure until 10 mL of liquid remained. The remainedsolution was acidified with 1 N HCl to pH=5 and partitioned between EA(10 mL) and water (50 mL). The aqueous layer was purified by reversephase column (MeCN/H₂O) to give6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acid amide (650mg, yield: 36% over 2 steps) as a light yellow solid.

¹HNMR (400 MHz, DMSO-d6): δ=7.47 (s, 1H), 7.09 (brs, 2H), 4.40 (t, J=5.2Hz, 2H), 4.25 (t, J=6.0 Hz, 2H), 2.22-2.14 (m, 2H). MS: m/z 203.9(M+H⁺).

Step 5

To a solution of 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid amide (120 mg, 0.6 mmol) in THF (10 mL) was added MeONa (40 mg, 0.7mmol) and stirred at r.t. for 20 mins to give a sodium salt suspension.

In another flask, to a solution of1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (110 mg, 0.6 mmol) and TEA(120 mg, 1.2 mmol) in THF (10 mL), was added triphosgene (120 mg, 0.4mmol) in one portion and stirred at r.t. under N₂ for 20 mins. Thereaction mixture was then filtered. The filtrate was added to the sodiumsalt suspension above and stirred at r.t. for 20 min. After that, thereaction solution was partitioned between EA (60 mL) and water (60 mL).The aqueous phase was acidified to pH=5 with conc. HCl and extractedwith EA (60 mL). The organic layer was washed with water (50 mL) andbrined (50 mL), dried over Na₂SO₄ and concentrated until white solidappeared. The solid formed was collected by filtration and dried to giveN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(57 mg, yield: 22%) as a white solid.

¹HNMR (400 MHz, DMSO-d6): δ=10.46 (brs, 1H), 7.91 (s, 1H), 7.61 (s, 1H),6.93 (s, 1H), 4.42 (t, J=5.2 Hz, 2H), 4.25 (t, J=5.8 Hz, 2H), 2.79 (t,J=7.6 Hz, 4H), 2.60 (t, J=7.6 Hz, 4H), 2.22-2.18 (m, 2H), 1.99-1.92 (m,4H). MS: m/z 403.0 (M+H⁺).

Example 2: Synthesis of Compound 2.N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonamide

To a solution of methanesulfonamide (95 mg, 1.0 mmol) in THF (5 mL) wasadded NaH (60%, 45 mg, 1.1 mmol) and stirred at room temperature for 10min to give a sodium salt suspension.

To a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (173 mg, 1.0mmol) and TEA (0.5 mL, 3.5 mmol) in THF (10 mL) was added triphosgene(120 mg, 0.4 mmol) in one portion and the mixture was stirred at roomtemperature under N₂ for 20 min. The reaction mixture was then filtered.The filtrate was added to the sodium salt suspension above and stirredat room temperature for 30 min. After that, the reaction solution waspartitioned between ethyl acetate (50 mL) and water (100 mL). Theaqueous phase was filtered and acidified to pH=5 with aq.HCl (1N). Thesolid formed was collected by filtration and dried to giveN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonamide(130 mg, yield: 44%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.19 (brs, 1H), 8.13 (s, 1H), 6.96 (s,1H), 3.26 (s, 3H), 2.82 (t, J=7.2 Hz, 4H), 2.71 (t, J=7.2 Hz, 4H),2.03-1.94 (m, 4H). MS: m/z 295.0 (M+H⁺).

Example 3: Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamothioyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamothioyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (350 mg, 2mmol) in THF (20 mL) was added thiophosgene (233 mg, 2 mmol) and TEA(612 mg, 6 mmol). The reaction mixture was stirred at room temperatureovernight and then evaporated in vacuo. The residue was diluted insaturated NaHCO₃ (50 mL) and the aqueous phase was extracted with EA (50mL×3). Organic extracts was combined, dried over anhydrous Na₂SO₄ andconcentrated in vacuo to give4-isothiocyanato-1,2,3,5,6,7-hexahydro-s-indacene as a crude productwhich was used for the next step without further purification.

Step 2

To a solution of 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid amide (60 mg, 0.3 mmol) in DMF (5 mL) was added4-isothiocyanato-1,2,3,5,6,7-hexahydro-s-indacene (64.5 mg, 0.3 mmol)and NaH (60% in mineral oil, 24 mg, 0.6 mmol). The reaction was stirredat room temperature for 2 hrs (monitored by LC-MS) and was quenched byH₂O (20 mL). The mixture was acidified by 1 M HCl to pH=3 and extractedwith EA (20 mL×3). Organic phase was combined, dried over anhydrousNa₂SO₄ and evaporated in vacuo. The residue was purified by pre-HPLC togiveN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamothioyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(30 mg, yield: 24.2%) as a white solid.

¹H NMR (400 MHz, DMSO-d6): δ=7.62 (s, 1H), 7.21-6.96 (m, 2H), 4.40-4.35(m, 2H), 4.11-4.08 (m, 2H), 2.80 (t, J=7.2 Hz, 4H), 2.63-2.58 (m, 4H),2.19-2.16 (m, 2H), 1.98-1.91 (m, 4H). MS: m/z 417.0 (M−H⁺).

Example 4: Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-sulfonamide

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-sulfonamideis shown below.

Step 1

To a solution of 3-bromo-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine (1g, 5 mmol) in dry THF (10 mL) was added n-BuLi in hexane (2.5 M, 2 mL, 5mmol) slowly at −78° C. under N₂. After stirring with cooling for 20min, ZnCl₂ in ether (1 M, 5 mL, 5 mmol) was added slowly at thistemperature. The cold bath was removed and the reaction was stirred atroom temperature for 1 hr. TCPC (1.8 g, 5 mmol) was then added and thereaction solution was stirred at room temperature for 1 hr. The reactantwas partitioned between water (80 mL) and EA (80 mL). The organic layerwas washed with brine (80 mL), dried over Na₂SO₄ and concentrated togive crude 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine-3-sulfonic acid2,4,6-trichloro-phenyl ester as a yellow gel which was used for nextstep directly without any purification.

Step 2

A mixture of 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine-3-sulfonic acid2,4,6-trichloro-phenyl ester (crude, −5 mmol), NH₃.H₂O (15 mL) and THF(15 mL) was stirred at 60° C. overnight. The reaction was concentratedunder reduced pressure. The remaining solution was acidified with 1 NHCl to pH=5 and partitioned between EA (15 mL) and water (70 ml). Theaqueous phase was purified by reverse phase column to give4,5,6,7-Tetrahydro-pyrazolo[1,5-a]pyridine-3-sulfonic acid amide (270mg, yield: 27% over 2 steps) as a yellow solid.

¹H NMR (400 MHz, DMSO-d6): δ=7.62 (s, 1H), 7.15 (brs, 2H), 4.08 (t,J=6.0 Hz, 2H), 2.90 (t, J=6.4 Hz, 2H), 1.98-1.92 (m, 2H), 1.83-1.77 (m,2H). MS: m/z 201.9 (M+H⁺).

Step 3

This step is similar to general procedure forN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(Example 1).

HNMR (400 MHz, DMSO-d6): δ=10.54 (s, 1H), 7.99 (s, 1H), 7.79 (s, 1H),6.94 (s, 1H), 4.09 (t, J=5.6 Hz, 2H), 2.97 (t, J=6.4 Hz, 2H), 2.78 (t,J=7.6 Hz, 4H), 2.57 (t, J=7.6 Hz, 4H), 1.98-1.90 (m, 6H), 1.82-1.78 (m,2H). MS: m/z 401.0 (M+H⁺).

Example 5: Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5′,7′-dihydrospiro[oxetane-3,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonamide

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5′,7′-dihydrospiro[oxetane-3,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonamideis shown below.

The title compound was prepared using general procedure ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(Example 1).

¹H NMR (400 MHz, DMSO-d6): δ=7.77 (s, 1H), 7.51 (s, 1H), 6.85 (s, 1H),4.59 (s, 2H), 4.50 (d, J=6.0 Hz, 2H), 4.43 (d, J=6.4 Hz, 2H), 4.38 (s,2H), 2.76 (t, J=7.2 Hz, 4H), 2.60 (t, J=6.4 Hz, 4H), 1.94-1.90 (m, 4H).MS: m/z 445.0 (M+H⁺).

Example 6: Synthesis ofN-((2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis ofN-((2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (0.123 mmol,0.025 g) was suspended in THF (1 mL) and cooled to 0 C. NaH (0.123 mmol,2.95 mg) was added and the mixture left to stir for 5 min.2-Isocyanato-1,3-diisopropylbenzene (0.123 mmol, 0.026 mL) was thenadded and the mixture left to stir at room temperature for 2 h. At thistime the reaction was quenched with water and the organic solventevaporated. The reaction was then acidified with HCl and a whiteprecipitate filtered off, washed with water and dried to yieldN-((2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(38 mg, 76%). ¹H-NMR (400 MHz; DMSO-d₆): δ 10.60 (s, 1H), 7.69 (s, 1H),7.59 (s, 1H), 7.24 (t, J=7.7 Hz, 1H), 7.12 (d, J=7.7 Hz, 2H), 4.46-4.44(m, 2H), 4.11 (dd, J=7.5, 4.7 Hz, 2H), 2.91 (t, J=6.9 Hz, 2H), 2.23-2.20(m, 2H), 1.13-1.01 (m, 12H). MS: m/z 407 (M+H⁺).

Example 7: Synthesis ofN-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis ofN-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (0.105 mmol,0.021 g) was dissolved in THF (2 mL) and treated with NaH (0.105 mmol,4.21 mg) at 0 C. After a few minutes5-chloro-2-isocyanato-1,3-diisopropylbenzene (0.105 mmol, 25 mg) wasadded and the mixture was left to stir over the weekend. The reactionwas then quenched with water and the solvent reduced to ⅓ of theoriginal volume. The reaction was then acidified with 1M HCl and a finewhite precipitate filtered off, washed with water and dried to yieldN-((4-chloro-2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(23.7 mg, 51.1%). ¹H-NMR (400 MHz; DMSO-d₆): δ 10.70 (s, 1H), 7.76 (s,1H), 7.59 (s, 1H), 7.15 (s, 2H), 4.45 (dd, J=5.4, 4.8 Hz, 2H), 4.11 (t,J=6.1 Hz, 2H), 3.62-3.59 (m, 3H), 2.93-2.86 (m, 2H), 2.24-2.20 (m, 2H),1.78-1.75 (m, 3H), 1.11-1.01 (m, 13H). MS: m/z 442 (M+H⁺).

Example 8: Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a suspension of PPh₃ (252.0 g, 961.5 mmol) in acetonitrile (600 mL)was added dropwise a solution of Br₂ (49.3 mL, 961.5 mmol) inacetonitrile (200 mL) at 0° C., then 2,2-dimethyl-propane-1,3-diol (50.0g, 480.8 mmol) was added. The reaction mixture was heated to 85° C., andrefluxed for 16 hrs. The solvent was removed in vacuo. The residualsolid was washed with (PE/EA=3/1, 300 mL) and filtered. The filtrate wasconcentrated and distilled to give 1,3-dibromo-2,2-dimethyl-propane(45.0 g, yield: 41%) as a colorless oil.

¹HNMR (300 MHz, CDCl₃): δ=3.42 (s, 4H), 1.18 (s, 6H).

Step 2

1,2-Dihydro-pyrazol-3-one (25.0 g, 297.6 mmol) and K₂CO₃ (144.0 g,1041.7 mmol) were heated to 120° C. in DMF (700 mL).1,3-Dibromo-2,2-dimethyl-propane (82.0 g, 357.1 mmol) was added and themixture was heated for 24 hrs. The solvent was removed in vacuo. Theresidue was partitioned between EA/H₂O (200 mL/500 mL) and the layerswere separated. The aqueous layer was extracted with EA (200 mL) and thecombined organic layer was washed with brine (100 mL), dried over Na₂SO₄and concentrated. The residue was cooled to 5° C. and washed with PE(100 mL) to give 6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(14.0 g, yield: 31%) as a yellow solid.

¹HNMR (300 MHz, CDCl₃): δ=7.32 (s, 1H), 5.48 (s, 1H), 3.87 (s, 2H), 3.84(s, 2H), 1.13 (s, 6H).

Step 3-5

These three steps are similar to general procedure ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(Example 1).

Step 6

To a suspension of6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acidamide (400 mg, 1.7 mmol) in THF (10 mL) was added MeONa (190 mg, 3.5mmol) and the mixture was stirred at room temperature for 20 mins togive a sodium salt suspension.

In another flask, to a solution of1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (300 mg, 1.7 mmol) and TEA(530 mg, 5.2 mmol) in THF (15 mL) was added triphosgene (210 mg, 0.7mmol) in one portion and the mixture was stirred at room temperatureunder N₂ for 20 mins. The reaction mixture was then filtered. Thefiltrate was added to the sodium salt suspension above and stirred atroom temperature for 16 hrs. After that, the reaction solution waspartitioned between EA (50 mL) and water (150 mL). The aqueous phase wasfiltered and bubbled by N₂ for 5 mins, then acidified to pH=5 with conc.HCl. The solid formed was dissolved after MeCN (50 mL) was added. Andthe mixture was concentrated to remove MeCN at 40° C. The solid formedwas collected by filtration and dried to giveN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(320 mg, yield: 43%) as a white solid.

¹HNMR (400 MHz, DMSO-d₆): δ=10.49 (s, 1H), 7.90 (s, 1H), 7.64 (s, 1H),6.93 (s, 1H), 4.14 (s, 2H), 3.88 (s, 2H), 2.78 (t, J=7.2 Hz, 4H), 2.58(t, J=7.2 Hz, 4H), 1.98-1.90 (m, 4H), 1.02 (s, 6H). MS: m/z 431.0(M+H⁺).

Example 9: Synthesis of6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic Acidamide

Another method to synthesize6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acidamide is shown below.

Step 1

6,6-Dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (3.0 g, 19.7mmol) was added portion wise to ClSO₃H (25 mL) at 0° C. After stirred at80° C. for 16 hrs, the reaction mixture was added dropwise to ice-water(250 mL) and extracted with EA (100 mL×3). The combined organic layerwere washed with brine (50 mL), dried over Na₂SO₄ and concentrated. Theresidue was cooled to 5° C. and washed with PE/EA (5/1, 30 mL) to give6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride (2.4 g, yield: 49%) as a yellow solid.

¹HNMR (300 MHz, CDCl₃): δ=7.79 (s, 1H), 4.16 (s, 2H), 3.90 (s, 2H), 1.20(s, 6H).

Step 2

To a solution of6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride (2.2 g, 8.8 mmol) in THF (18 mL) was added NH₃.H₂O (10 mL).After stirred at 60° C. for 1 hr, the reaction mixture was concentratedto dryness. The residue was diluted with MeOH (20 mL) and acidified byaq.HCl (2 N) to pH=5. The resulting solution was purified by reversephase column (0%-60% MeCN in H₂O) to give6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acidamide (1.6 g, yield: 79%) as a yellow solid.

Example 10: Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To as solution of 1,3-dibromo-propan-2-ol (42.5 g, 0.19 mol) and DHP (33g, 0.38 mol) in DCM (300 mL), was added TsOH (3.6 g, 0.019 mol) inportions and the mixture was stirred at room temperature for 2 hrs. Thereaction solution was concentrated and the residue was purified bysilica gel column (PE/EA=50/1) to give2-(2-bromo-1-bromomethyl-ethoxy)-tetrahydro-pyran (34 g, yield: 60%) asa colorless oil.

¹H NMR (300 MHz, DMSO-d6): δ=4.80-4.79 (m, 1H), 4.04-3.90 (m, 2H),3.72-3.52 (m, 5H), 1.87-1.55 (m, 6H).

Step 2

A mixture of 2-(2-bromo-1-bromomethyl-ethoxy)-tetrahydro-pyran (17 g,56.3 mmol), 1,2-dihydro-pyrazol-3-one (4 g, 47 mmol) and K₂CO₃ (23 g,165 mmol) in DMF (250 mL) was stirred at 100° C. overnight. The solventwas removed under reduced pressure. The residue was partitioned betweenEA (200 mL) and water (200 ml). The aqueous phase was extracted with EA(200 ml). The organic layers were combined, washed with water (100 mL)and brine (100 mL), dried over Na₂SO₄ and concentrated. The residue waspurified by silica gel column (EA) to give6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(4.9 g, yield: 46%) as a yellow oil.

¹H NMR (300 MHz, DMSO-d6): δ=7.34 (s, 1H), 5.51 (s, 1H), 4.89-4.83 (m,1H), 4.36-4.24 (m, 4H), 3.93-3.88 (m, 1H), 3.59-3.54 (m, 1H), 1.79-1.69(m, 3H), 1.65-1.51 (m, 4H). MS: m/z 224.9 (M+H⁺).

Step 3

To a solution of6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(5.1 g, 22.8 mmol) in MeCN, was added NBS at 0° C. under N₂ in twoportions. The reaction was then stirred at room temperature for 1 hr.The reaction was partitioned between EA (100 mL) and water (200 mL). Theorganic layer was washed with water (100 mL) and brine (100 mL), driedover Na₂SO₄ and concentrated. The residue was purified by silica gelcolumn (PE/EA=1/1) to give3-bromo-6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(5.6 g, yield: 81%) as a yellow solid.

¹H NMR (300 MHz, DMSO-d6): δ=7.33 (s, 1H), 4.88-4.82 (m, 1H), 4.48-4.18(m, 5H), 3.88-3.75 (m, 1H), 3.58-3.53 (m, 1H), 1.84-1.51 (m, 7H). MS:m/z 303.0 (M+H⁺).

Step 4

To a solution of3-bromo-6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(2 g, 6.6 mmol) in dry THF (20 mL) was added n-BuLi in hexane (2.5 M,2.6 mL, 6.6 mmol) slowly at −78° C. under N₂. After stirred with coolingfor 20 min, ZnCl₂ in ether (1 M, 6.6 mL, 6.6 mmol) was added slowly atthis temperature. The cold bath was removed and the reaction was stirredat room temperature for 1 hr. TCPC (2 g, 6.6 mmol) was then added andthe mixture was stirred at room temperature for 1 hr. The reaction waspartitioned between water (100 mL) and EA (100 mL). The organic layerwas washed with brine (100 mL), dried over Na₂SO₄ and concentrated togive crude6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid 2,4,6-trichloro-phenyl ester as a yellow gel which was used fornext step directly without any purification.

Step 5

A mixture of6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid 2,4,6-trichloro-phenyl ester (crude, ˜6.6 mmol), NH₄OH (20 mL) andTHF (20 mL) was stirred at 60° C. overnight. The reaction wasconcentrated under reduced pressure until 10 mL of liquid remained. Theremained solution was acidified with 1 N HCl to pH=5 and extracted withEA (100 mL×5). The organic layers were combined, dried over Na₂SO₄ andconcentrated to give crude6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid amide as a yellow gel which was used for next step directly withoutany purification. MS: m/z 304.1 (M+H⁺).

Step 6

To a solution of6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid amide (crude, 6.6 mmol) in THF/H₂O/EtOH (50 mL/10 mL/50 mL) wasadded conc. HCl (10 mL) and stirred at room temperature overnight. Thereaction was concentrated under reduced pressure. The residue waspurified by reverse phase column (MeCN/H₂O) to give6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acidamide (290 mg, yield: 21% over 3 steps) as a white solid.

¹H NMR (300 MHz, DMSO-d6): δ=7.48 (s, 1H), 7.11 (brs, 2H), 5.65 (brs,1H), 4.30-4.20 (m, 4H), 3.96-3.92 (m, 1H). MS: m/z 220.1 (M+H⁺).

Step 7

To a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (63.1 mg,0.365 mmoL) and TEA (0.203 ml, 1.1 mmoL) in THF (5 ml), was addedtriphosgene (43.7 mg, 0.146 mmoL), and the mixture was stirred for 10min at room temperature. In another round-bottomed flask, to a solutionof 6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acidamide (80 mg, 0.365 mmoL) in THF (5 ml) was added MeONa (21.7 mg, 0.401mmoL) and the mixture was stirred for 20 mins at room temperature. Theprepared 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene was filtered toremove the resulting precipitate and the filtrate was added to anotherflask containing sulfonamide salt. The reaction was check by TLC andquenched with the addition of water (30 mL) after 20 mins. The aqueousphase was washed with EA (20 mL) and filtered later. The filtrate wasacidified to pH=34. The resulting solid was collected by filtration togiveN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(15 mg, yield: 10%) as a white solid.

¹H NMR (400 MHz, DMSO-d6): δ=10.45 (s, 1H), 7.90 (s, 1H), 7.62 (s, 1H),6.93 (s, 1H), 5.67 (s, 1H), 4.34 (s, 3H), 4.24 (dd, J=4.0, 3.2 Hz, 1H),3.96 (d, J=12.4 Hz, 1H), 2.78 (t, J=7.2 Hz, 4H), 2.60 (t, J=7.6 Hz, 4H),1.98-1.93 (m, 4H). MS: m/z 419.1 (M+H⁺).

Example 11: Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-sulfonamide

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-sulfonamideis shown below

Step 1

1,2-Dihydro-pyrazol-3-one (3.0 g, 35.7 mmol) and K₂CO₃ (17.0 g, 125.0mmol) were heated to 130° C. in DMF (100 mL). 1,4-Dibromo-butane (9.3 g,42.9 mmol) was added and the mixture was heated for 16 hrs. The solventwas removed in vacuo. The residue was partitioned between EA/H₂O (50mL/80 mL) and the layers were separated. The aqueous layer was extractedwith EA (50 mL) and the combined organic layers were washed with brine(50 mL), dried over Na₂SO₄ and concentrated. The residue was purified bysilica gel column (PE/EA=1/1) to give5,6,7,8-tetrahydro-4-oxa-1,8a-diaza-azulene (1.3 g, yield: 27%) as acolorless oil.

¹H NMR (300 MHz, CDCl₃): δ=7.24 (d, J=1.5 Hz, 1H), 5.69 (d, J=1.5 Hz,1H), 4.25-4.20 (m, 2H), 4.06 (t, J=5.1 Hz, 2H), 2.07-2.03 (m, 2H),1.91-1.84 (m, 2H).

Step 2-5

These four steps are similar to general procedure ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(Example 3).

¹HNMR (400 MHz, DMSO-d₆): δ=10.60 (s, 1H), 7.94 (s, 1H), 7.60 (s, 1H),6.94 (s, 1H), 4.22-4.16 (m, 4H), 2.79 (t, J=7.6 Hz, 4H), 2.58 (t, J=7.2Hz, 4H), 2.03-1.90 (m, 6H), 1.80-1.70 (m, 2H). MS: m/z 417.0 (M+H⁺).

Example 12: Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

1,2-Dihydro-pyrazol-3-one (2.0 g, 23.8 mmol) and K₂CO₃ (11.5 g, 83.3mmol) were heated to 120° C. in DMF (60 mL). 1,3-Dibromo-butane (6.2 g,28.6 mmol) was added and the mixture was heated for 16 hrs. The solventwas removed in vacuo. The residue was partitioned between EA/H₂O (50mL/80 mL) and the layers were separated. The aqueous layer was extractedwith EA (50 mL) and the combined organic layers were washed with brine(50 mL), dried over Na₂SO₄ and concentrated. The residue was purified bysilica gel column (PE/EA=5/1 to 1/1) to give7-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (1.3 g, yield: 40%)as a yellow oil and 5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(500 mg, yield: 15%) as a yellow solid.

7-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine: ¹HNMR (400 MHz,CDCl₃): δ=7.32 (d, J=2.0 Hz, 1H), 5.45 (d, J=1.6 Hz, 1H), 4.36-4.31 (m,2H), 4.24-4.18 (m, 1H), 2.34-2.27 (m, 1H), 2.02-1.94 (m, 1H), 1.59 (d,J=6.0 Hz, 3H).

5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine: ¹HNMR (400 MHz,CDCl₃): δ=7.30 (d, J=1.6 Hz, 1H), 5.45 (d, J=2.0 Hz, 1H), 4.38-4.30 (m,1H), 4.25-4.20 (m, 1H), 4.15-4.08 (m, 1H), 2.19-2.03 (m, 2H), 1.46 (d,J=6.4 Hz, 3H).

Step 2-5

These four steps are similar to general procedure ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(Example 1).

¹HNMR (400 MHz, DMSO-d₆): δ=10.47 (s, 1H), 7.91 (s, 1H), 7.64 (s, 1H),6.94 (s, 1H), 4.53-4.32 (m, 3H), 2.79 (t, J=7.2 Hz, 4H), 2.58 (t, J=7.2Hz, 4H), 2.38-2.31 (m, 1H), 1.99-1.91 (m, 5H), 1.45 (d, J=6.0 Hz, 3H).MS: m/z 417.0 (M+H⁺).

Example 13: Synthesis of6-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis of6-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acidamide (100 mg, 0.46 mmol) in DCM (5 mL) was added DAST (148 mg, 0.92mmol) at −78° C. under N₂. The reaction was then stirred at roomtemperature overnight. The reaction was quenched with H₂O (20 mL) andpartitioned between DCM (40 mL) and water (20 mL). The organic layer wasdried over Na₂SO₄ and concentrated. The residue was purified by reversephase column (MeCN/H2O) to give6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acidamide (18 mg, yield: 18%) as a white solid. MS: m/z 222.1 (M+H⁺).

Step 2

This step is similar to general procedure forN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(Example 1).

¹H NMR (400 MHz, DMSO-d6): δ=10.58 (s, 1H), 8.00 (s, 1H), 7.69 (s, 1H),6.93 (s, 1H), 5.58 (d, J=44.0 Hz, 1H), 4.75 (t, J=12.0 Hz, 1H),4.59-4.37 (m, 3H), 2.78 (t, J=7.2 Hz, 4H), 2.60 (t, J=7.2 Hz, 4H),1.97-1.90 (m, 4H). MS: m/z 421.0 (M+H⁺).

Example 14: Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of3-bromo-6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(4.6 g, 15.2 mmol) in THF/H₂O/EtOH (50 mL/10 mL/50 mL) was addedconc.HCl. The reaction was stirred at room temperature for 2 hrs. Thereaction solution was concentrated. The residue was treated withsaturated NaHCO₃ solution. The solid formed was collected by filtrationto give 3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol (2.76 g,yield: 84%) as a white solid.

¹H NMR (300 MHz, DMSO-d6): δ=7.36 (s, 1H), 5.59 (brs, 1H), 4.28-4.18 (m,4H), 3.95-3.90 (m, 1H).

Step 2

To a solution of 3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol(1.2 g, 5.5 mmol) in DMF (12 mL) was added NaH (60% in mineral oil, 263mg, 6.6 mmol). The reaction was stirred at room temperature for 1 hrunder N₂. Then Mel (940 mg, 6.6 mmol) was added and the mixture wasstirred at room temperature for 2 hrs. The reaction mixture was pouredinto water (60 mL) and extracted with EA (50 mL). The organic layer waswashed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by reverse phase column(MeCN/H₂O) to give3-bromo-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (1 g,yield: 78%) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=7.34 (s, 1H), 4.53-4.48 (m, 1H), 4.27-4.18(m, 3H), 3.94-3.93 (m, 1H), 3.49 (s, 3H). MS: m/z 232.9 (M+H⁺).

Step 3˜5

These steps are similar to general procedure forN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(Example 1).

¹H NMR (400 MHz, DMSO-d6): δ=10.47 (s, 1H), 7.91 (s, 1H), 7.62 (s, 1H),6.93 (s, 1H), 4.65 (d, J=11.6 Hz, 1H), 4.37 (d, J=11.2 Hz, 1H),4.24-4.22 (m, 2H), 4.06 (s, 1H), 3.34 (overlap, 3H), 2.78 (t, J=7.6 Hz,4H), 2.60 (t, J=7.2 Hz, 4H), 1.98-1.91 (m, 4H). MS: m/z 433.0 (M+H⁺).

Example 15: Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

The title compound was prepared using general procedure forN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(Example 1).

¹HNMR (400 MHz, DMSO-d₆): δ=10.51 (s, 1H), 7.90 (s, 1H), 7.61 (s, 1H),6.94 (s, 1H), 4.60-4.56 (m, 1H), 4.13-4.08 (m, 2H), 2.79 (t, J=7.2 Hz,4H), 2.59 (t, J=6.8 Hz, 4H), 2.28-2.24 (m, 1H), 1.98-1.93 (m, 5H), 1.38(d, J=6.0 Hz, 3H). MS: m/z 417.0 (M+H⁺).

Example 16: Synthesis ofN-((8-chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

Synthesis ofN-((8-chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

1,2,3,5,6,7-hexahydro-s-indacen-4-amine (2.332 mmol, 404 mg) and NCS(2.332 mmol, 0.311 g) were mixed in DCM (5 mL) and left to stirovernight. The mixture was then partitioned between water (20 mL) andDCM (20 mL). The layers were separated and the aq. layer extracted withDCM (20 mL). The combined organic layers were then dried over Na2SO4,filtered and concentrated to yield1,2,3,5,6,7-hexahydro-s-indacen-4-amine (2.332 mmol, 404 mg) as a brownsolid which was used without purification. MS: m/z 209 (M+H⁺).

Step 2

N,N-dimethylpyridin-4-amine (0.481 mmol, 0.059 g) was dissolved in THF(1.5 mL) and then a solution of di-tert-butyl dicarbonate (0.481 mmol,0.111 mL) in THF (1.5 mL) was added slowly. After stirring for a fewminutes, a solution of 8-chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-amine(0.481 mmol, 100 mg) in THF (1 mL) was added and the mixture was left tostir for 30 min. At the same time,6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (0.481 mmol,0.098 g) in THF (1 mL) was treated with sodium hydride (0.481 mmol,0.012 g) and left to stir for 30 min. At this time the two solutionswere mixed and left to stir for 18 h.

The reaction was then quenched with sat NH4Cl (10 mL) and diluted withEtOAc (40 mL). The layers were separated and the aq. layer extractedwith EtOAc (30 mL). The combined organic extracts were then washed withwater (20 mL) and concentrated. The resulting solid was suspended inMeOH:water (10:1, 10 mL), a reddish solid filtered off and discarded.The filtrate was concentrated and purified by prep HPLC (10-40% MeCN:10mM aq. NH3). The purified fractions were combined and concentrated toyieldN-((8-chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(5.8 mg, 2.76%) as a white solid.

¹H-NMR (400 MHz; DMSO-d₆): δ 7.88-7.85 (m, 1H), 7.55 (s, 1H), 4.42-4.39(m, 2H), 4.11-4.08 (m, 2H), 2.85-2.82 (m, 4H), 2.71 (t, J=7.4 Hz, 4H),2.22-2.16 (m, 2H), 2.04-1.97 (m, 4H). MS: m/z 437 (M+H⁺).

Example 17: Synthesis of4-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-sulfonamide

Synthesis of4-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-sulfonamideis shown below.

Step 1

To a solution of 4-bromo-2H-pyrazole-3-carboxylic acid ethyl ester (8.0g, 36.4 mmol) in DMF (80 mL) was added K₂CO₃ (10 g, 72.8 mmol) and4-bromo-butyric acid ethyl ester (10 g, 54.8 mmol), then the suspensionwas stirred overnight. The reaction was quenched with the addition of EA(200 mL) and water (200 mL). The organic layer was separated. Theaqueous layer was extracted with EA (200 mL). The organic layers werecombined and washed with water (300 mL×3), brine (300 mL), and driedover Na₂SO₄. The solution was concentrated in vacuo. The residue waspurified by silica gel column (PE/EA=10/1) to give4-bromo-2-(3-ethoxycarbonyl-propyl)-2H-pyrazole-3-carboxylic acid ethylester (6.7 g, yield: 55.4%) as a colorless oil. MS: m/z 332.8 (M+H⁺).

Step 2

To a solution of4-bromo-2-(3-ethoxycarbonyl-propyl)-2H-pyrazole-3-carboxylic acid ethylester (6.7 g, 20.2 mmol) in THF (120 mL) was added NaH (1.2 g, 30.3mmol) at 0° C. and then the mixture was heated to reflux overnight. Whenthe reaction was finished, the reaction was quenched with saturatedaqueous solution of NH₄Cl (20 mL). The aqueous phase was extracted withEA (100 mL×2). The extracts were washed with brine (100 mL), dried overNa₂SO₄, and concentrated to give3-bromo-4-oxo-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine-5-carboxylicacid ethyl ester (5.2 g, yield: 90%) as a white solid. MS: m/z 286.9(M+H⁺).

Step 3

To a solution of3-bromo-4-oxo-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine-5-carboxylicacid ethyl ester (5.2 g, 15.7 mmol) in DMSO (200 mL) and water (5 mL)was added NaCl (5.5 g, 94 mmol), and the mixture was heated to 150° C.for 2 hrs. After cooled to room temperature, the reactant was dilutedwith EA (200 mL) and water (200 mL). The organic layer was separated.The aqueous layer was extracted with EA (200 mL). The combined organiclayers were washed with water (300 mL×3), brine (300 mL), and dried overNa₂SO₄. The solution was concentrated in vacuo. The residue was purifiedby silica gel column (PE/EA=5/1) to give3-bromo-6,7-dihydro-5H-pyrazolo[1,5-a]pyridin-4-one (2.6 g, yield: 66%)as a white solid.

¹H NMR (400 MHz, DMSO-d6): δ=7.55 (s, 1H), 4.40 (t, J=6.0 Hz, 2H), 2.72(t, J=6.4 Hz, 2H), 2.36-2.40 (m, 2H).

Step 4

To a solution of 3-bromo-6,7-dihydro-5H-pyrazolo[1,5-a]pyridin-4-one(1.6 g, 7.36 mmol) in MeOH (20 mL) was added NaBH₄ (1.4 g, 12.8 mmol) at0° C., and the mixture was stirred at room temperature for 2 hrs. Whenthe reaction was finished, the reactant was evaporated to remove MeOH.The residue was portioned between EA (50 mL) and water (50 mL). Theorganic layer was separated. The aqueous layer was extracted with EA (50mL). The combined organic layers were washed with brine (30 mL), anddried over Na₂SO₄. The solution was concentrated to give3-bromo-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridin-4-ol (1.4 g, yield:88%) as a white solid. MS: m/z 216.9 (M+H⁺).

Step 5

To a solution of 3-bromo-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridin-4-ol(1.4 g, 6.5 mmol) in DCM (30 mL) was added DAST (2.1 g, 13 mmol) at −60°C. The solution was allowed to warm slowly to room temperature, andstirred at room temperature for 2 hrs. When the reaction was finished,DCM (50 mL) and water (50 mL) was added to the mixture. The organiclayer was separated. The aqueous layer was extracted with DCM (50 mL).The combined organic layers were washed with brine (50 mL), dried overNa₂SO₄, and concentrated in vacuo. The residue was purified by silicagel column (PE/EA=5/1) to give3-bromo-4-fluoro-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine (830 mg,yield: 59%) as a yellow oil.

¹H NMR (400 MHz, DMSO-d6): δ=7.50 (s, 1H), 5.60 (dt, J=51.2, 2.8 Hz,1H), 4.28-4.32 (m, 1H), 3.87-3.94 (m, 1H), 2.26-2.40 (m, 2H), 1.92-2.00(m, 2H).

Step 6

To a solution of3-bromo-4-fluoro-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine (0.5 g, 2.3mmol) in dry THF (5 mL) was added n-BuLi in hexane (0.92 mL, 2.3 mmol,2.5 M) slowly at −78° C. under N₂ protection, After stirred at thistemperature for 20 min, ZnCl₂ in ether (2.3 mL, 2.3 mmol, 1 M) was addedslowly at this temperature. The cold bath was removed and the reactionwas stirred at room temperature for 1 hr. TCPC (0.68 g, 2.3 mmol) wasadded to the mixture at 0° C. and the mixture was allowed to stir atroom temperature for 1 hr. The reaction was quenched with saturatedNH₄Cl solution (2 mL) and partitioned between water (20 mL) and EA (20mL). The organic layer was washed with brine (80 mL), dried over Na₂SO₄and concentrated to give crude6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acid2,4,6-trichloro-phenyl ester as a yellow oil. The crude was dissolved inTHF (5 mL), and NH₃.H₂O (5 mL) was added, then heated to 60° C.overnight. When the reaction was finished, the reaction solution wasconcentrated to remove the solvent. The residue was acidified with 1 NHCl to pH=5 and partitioned between EA (20 mL) and water (20 mL). Theorganic layer was separated. The aqueous layer was extracted with EA (20mL). The combined organic layers were washed with brine (30 mL), driedover Na₂SO₄, and concentrated in vacuum. The residue was purified bysilica gel column (PE/EA=2/1) to give4-fluoro-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine-3-sulfonic acidamide (0.17 g, yield: 34%) as a yellow solid. MS: m/z 220.0 (M+H⁺).

Step 7

To a solution of4-Fluoro-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine-3-sulfonic acidamide (75 mg, 0.34 mmol) in THF (2 mL) was added MeONa (22 mg, 0.41mmol) and the mixture was stirred at room temperature for 20 mins togive a sodium salt suspension.

In another flask, to a solution of1,2,3,5,6,7-Hexahydro-s-indacen-4-ylamine (59 mg, 0.34 mmol) and TEA (69mg, 0.68 mmol) in THF (3 mL), was added triphosgene (141 mg, 0.14 mmol)in one portion and the mixture was stirred at room temperature under N₂for 20 mins. The reaction mixture was then filtered. The filtrate wasadded to the sodium salt suspension above and stirred at roomtemperature for 1 hr. After that, the reaction solution was partitionedbetween EA (15 mL) and water (15 mL). The aqueous phase was separatedand acidified to pH=5 with 1M HCl. The resulting solid was collected byfiltration and air dried to give4-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-sulfonamide(45 mg, yield: 31.4%) as a white solid.

¹H NMR (400 MHz, DMSO-d6): δ=10.67 (s, 1H), 8.03 (s, 1H), 7.94 (s, 1H),6.93 (s, 1H), 6.08 (d, J=49.2 Hz, 1H), 4.35-4.37 (m, 1H), 4.05-4.08 (m,1H), 2.78 (t, J=6.8 Hz, 4H), 2.55 (t, J=6.8 Hz, 4H), 1.92-2.29 (m, 8H).MS: m/z 419.0 (M+H⁺).

Example 18

Synthesis of sodium((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amideis shown below.

Step 1:

1,2-Dihydro-pyrazol-3-one (53.0 g, 630.9 mmol) and K₂CO₃ (305.0 g,2210.1 mmol) were heated to 130° C. in DMF (1 L). 1,3-Dibromopropane(140.0 g, 693.1 mmol) was added and the mixture was heated for 8 hrs andthen concentrated. The residue was partitioned between EA (200 mL) andwater (500 mL) and the layers were separated. The aqueous layer wasextracted with EA (150 mL×8) and the combined organic layer was washedwith brine (300 mL), dried over Na₂SO₄, filtered and concentrated invacuo. The residue was purified by silica gel column (PE/EA=3/1) to give6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (32.0 g, yield: 41%) as ayellow oil.

¹H NMR (400 MHz, CDCl₃): δ=7.31 (d, J=2.0 Hz, 1H), 5.48 (d, J=2.0 Hz,1H), 4.28 (t, J=5.2 Hz, 2H), 4.18 (t, J=6.2 Hz, 2H), 2.29-2.22 (m, 2H).

Step 2:

6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (64.0 g, 516.1 mmol) wasadded dropwise to ClSO₃H (380 mL) at 0° C. After being stirred at 80° C.for 16 hrs, the reaction mixture was added dropwise to a mixture ofice-water/EA (4 L/1.5 L). The layers were separated and the aqueouslayer was extracted with EA (300 mL×2). The combined organic layers werewashed with brine (500 mL), dried over Na₂SO₄ and concentrated. Theresidue was washed with PE (200 mL) to give6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonyl chloride (73.0 g,yield: 63%) as a yellow solid.

Step 3:

To a solution of 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride (73.0 g, 328.8 mmol) in THF (430 mL) was added NH₃.H₂O (180mL). After being stirred at 60° C. for 16 hrs, the reaction mixture wasconcentrated to dryness. The residue was washed with aq.HCl (0.2 M, 110mL), H₂O (40 mL), and dried to give6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acid amide (52.0g, yield: 78%) as a yellow solid.

¹HNMR (300 MHz, DMSO-d₆): δ=7.47 (s, 1H), 7.08 (s, 2H), 4.40 (t, J=5.1Hz, 2H), 4.10 (t, J=6.0 Hz, 2H), 2.23-2.15 (m, 2H).

Step 4:

To a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (15.0 g, 87mmol) and TEA (13.3 mL, 95.4 mmol) in THF (300 mL) was added triphosgene(8.5 g, 28.6 mmol) in one portion at 05° C. and the mixture was stirredat 70° C. under N₂ for 1 hour. The reaction mixture was then filteredthrough diatomite. Then filter cake was washed with 30 mL PE. Thefiltrate was concentrated to dryness and dissolved in 100 mL n-hexane.The mixture was filtered through a silica gel pad. The filtrate wasconcentrated to dryness to give the4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (14.6 g, yield: 84%) as apink oil.

The suspension of 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid amide (14.3 g, 70.4 mmol) in MeOH (500 mL) was stirred at 80° C.until getting a clear solution, then MeONa (3.8 g, 70.4 mmol) was addedand the mixture was stirred for 5 mins. The solution was concentrated todryness and the residue was co-evaporated with MeCN (100 mL). Theresidual solid was suspended in MeCN (320 mL) and4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (14.6 g, 73.3 mmol) wasadded. The mixture was stirred for 16 hours at room temperature andfiltered. The filter cake was triturated with EtOH (250 mL), PE/EA (5/1,250 mL) to give the product. The product was dissolved in H₂O (200 mL)and concentrated to dryness to give sodium((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amide(24.5 g, yield: 82%) as a white solid.

¹HNMR (400 MHz, D₂O): δ=7.64 (s, 1H), 7.02 (s, 1H), 4.40 (t, J=5.2 Hz,2H), 4.11 (t, J=6.0 Hz, 2H), 2.83 (t, J=7.2 Hz, 4H), 2.66 (t, J=7.2 Hz,4H), 2.28-2.22 (m, 2H), 2.04-1.96 (m, 4H). MS: m/z 403.1 (M+H⁺).

Example 19

Synthesis of1-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl))-3-(2,3-dihydro-pyrazolo[5,1-b]oxazole-7-sulfonyl)-ureais shown below.

Step 1

To a solution of 1,2-dihydro-pyrazol-3-one (500 mg, 5.9 mmol) in MeCN(50 mL) was added 1,2-dibromo-ethane (3.3 g, 17.6 mmol) and K₂CO₃ (2.4g, 17.6 mmol). After being stirred at reflux overnight, the reactionmixture was filtered and the filtrate was concentrated in vacuo. Theresidue was purified by reverse phase HPLC (MeCN in H₂O, 5% to 95%) togive 2,3-dihydro-pyrazolo[5,1-b]oxazole (260 mg, 40%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.27 (s, 1H), 5.37 (d, J=1.6 Hz, 1H), 5.06(t, J=8.0 Hz, 2H), 4.23 (t, J=8.0 Hz, 2H).

Step 2

2,3-Dihydro-pyrazolo[5,1-b]oxazole (1 g, 9.1 mmol) was dissolved inClSO₃H (20 mL). After being heated at 80° C. overnight, the reactionmixture was added dropwise to a mixture of EA (150 mL), NH₃.H₂O (20 mL),and H₂O (150 mL). After being stirred at room temperature, the reactionmixture was concentrated in vacuo. The residue was suspended in MeOH (30mL), stirred for 0.5 h, and the mixture was filtered. The filtrate wasevaporated in vacuo and the residue was purified by reverse phase HPLC(MeCN in water, 0% to 60%) to give2,3-dihydro-pyrazolo[5,1-b]oxazole-7-sulfonic acid amide (60 mg, 4%) asa yellow solid.

Step 3—Preparation E

To a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (55 mg, 0.32mmol) in THF (10 mL) was added triphosgene (30 mg, 0.1 mmol) and TEA (48mg, 0.48 mmol). After being stirred at room temperature for 2 hrs, thereaction mixture was filtered. The filtrate was evaporated in vacuo. Theresidue was then dissolved in THF (5 mL). Then to the mixture was added2,3-dihydro-pyrazolo[5,1-b]oxazole-7-sulfonic acid amide (60 mg, 0.32mmol) and NaOMe (35 mg, 0.64 mmol). After being stirred at roomtemperature for 3 hrs, the reaction was quenched by H₂O (10 mL),acidified by 3 N HCl to pH=3, and extracted with EA (10 mL×3). Organicphase was combined, dried over anhydrous Na₂SO₄, and evaporated invacuo. The residue was purified by prep-HPLC to give1-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl))-3-(2,3-dihydro-pyrazolo[5,1-b]oxazole-7-sulfonyl)-urea(6 mg, 5%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.52 (brs, 1H), 7.86 (s, 1H), 7.58 (s,1H), 6.91 (s, 1H), 5.21 (t, J=8.0 Hz, 2H), 4.32 (t, J=8.0 Hz, 2H), 2.78(t, J=7.2 Hz, 4H), 2.62 (t, J=7.2 Hz, 4H), 1.98-1.91 (m, 4H). MS: m/z389.0 (M+H⁺).

Example 20

Synthesis of(R)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideand(S)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution ofrac-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(530 mg, 2.4 mmol) and pyridine (382 mg, 4.8 mmol) in THF (10 mL) wasadded TBSOTf (702 mg, 2.7 mmol) at 0° C. The reaction was stirred atroom temperature for 2 hrs. The reaction was quenched by H₂O (20 mL) andacidified to pH=5 by 1 N HCl. The residue was purified by reverse phaseHPLC (MeCN/H₂O) to give6-((tert-butyldimethylsilyl)oxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(330 mg, yield: 41%) as a white solid. MS: m/z 334.1 (M+H⁺).

Step 2

Rac-6-((tert-Butyldimethylsilyl)oxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(420 mg, 1.3 mmol) was resolved by chiral prep-HPLC to give two isomers(S)-6-((tert-butyldimethylsilyl)oxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(180 mg, yield: 42%) as a white solid;(R)-6-((tert-butyldimethylsilyl)oxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(200 mg, yield: 46%) as a white solid.

Step 3

To a solution of(S)-6-((tert-butyldimethylsilyl)oxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(180 mg, 0.5 mmol) in THF (4 mL) was added conc. HCl (4 mL). After beingstirred at room temperature overnight, the reaction was concentratedunder reduced pressure. The residue was purified by reverse phase HPLC(MeCN/H₂O) to give(S)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(115 mg, yield: 97%) as a white solid. MS: m/z 220.1 (M+H⁺).

(R)-6-Hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas prepared using the same procedure.

Step 4

(S)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation A herein to yield the desired product(50 mg, yield: 23%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.45 (s, 1H), 7.90 (s, 1H), 7.62 (s, 1H),6.93 (s, 1H), 5.66 (d, J=2.4 Hz, 1H), 4.34 (s, 3H), 4.24 (dd, J=4.0, 3.2Hz, 1H), 3.96 (d, J=12.4 Hz, 1H), 2.78 (t, J=7.2 Hz, 4H), 2.60 (t, J=7.2Hz, 4H), 1.98-1.91 (m, 4H). MS: m/z 419.0 (M+H⁺).

(R)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas prepared using the same procedure.

¹H NMR (400 MHz, DMSO-d₆): δ=10.45 (s, 1H), 7.90 (s, 1H), 7.62 (s, 1H),6.93 (s, 1H), 5.66 (d, J=3.2 Hz, 1H), 4.34 (s, 3H), 4.27-4.23 (m, 1H),3.96 (d, J=13.6 Hz, 1H), 2.78 (t, J=7.2 Hz, 4H), 2.61 (t, J=7.2 Hz, 4H),1.98-1.91 (m, 4H). MS: m/z 419.0 (M+H⁺).

Example 21

Synthesis ofrac-6-(Dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of rac-tert-butyl(3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (1.0g, 3.2 mmol) in DCM (5 mL) was added TFA (5 mL) and the mixture wasstirred at room temperature for 20 mins. The reaction was concentratedto dryness to give cruderac-3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-amine as ayellow solid, which was used for next step directly without anypurification. MS: m/z 218.0 (M+H⁺).

Step 2

To a solution ofrac-3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-amine (crude,˜3.2 mmol) in MeOH (10 mL) was added HCHO (30%, 3.2 g, 31.5 mmol). Themixture was stirred for 2 hrs at room temperature, NaBH₃CN (2.0 g, 31.5mmol) was then added. The reaction was then stirred at room temperaturefor 16 hrs. The reaction was purified by reverse phase HPLC (0%-95% MeCNin H₂O) to giverac-3-bromo-N,N-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-amine(410 mg, yield: 53%) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=7.33 (s, 1H), 4.45-4.44 (m, 1H), 4.30-4.24(m, 2H), 4.18-4.11 (m, 1H), 3.00-2.97 (m, 1H), 2.40 (s, 6H). MS: m/z245.9 (M+H⁺).

Step 3—Preparation B

To a solution ofrac-3-bromo-N,N-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-amine(400 mg, 1.6 mmol) in dry THF (5 mL) was added n-BuLi (2.5 M in hexane,0.7 mL, 1.6 mmol) slowly at −78° C. under N₂ atmosphere. After stirringwith cooling for 20 mins, ZnCl₂ (1 M in ether, 1.6 mL, 1.6 mmol) wasadded slowly at this temperature. The cooling bath was removed and thereaction was stirred at room temperature for 1 hr. TCPC (479 mg, 1.6mmol) was then added and the mixture was stirred at room temperature for1 hr. The reaction was partitioned between water (30 mL) and EA (30 mL).The organic layer was washed with brine (30 mL), dried over Na₂SO₄ andconcentrated to give crude rac-2,4,6-trichlorophenyl6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonateas a yellow gel which was used for next step without purification.

Step 4—Preparation C

A mixture of rac-2,4,6-trichlorophenyl6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate(crude, ˜1.6 mmol), NH₄OH (10 mL) and THF (10 mL) was stirred at 60° C.overnight. The reaction was concentrated under reduced pressure until 10mL of liquid remained. The remained solution was acidified with 1 N HClto pH=5. The residue was purified by reverse phase HPLC (0%-95% MeCN inH₂O) to give

rac-2,4,6-trichlorophenyl6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate(66 mg, yield: 16% over two steps) as a white solid. Alternatively, thesolution may be concentrated to dryness and purified by flashchromatography.

¹H NMR (400 MHz, DMSO-d₆): δ=7.47 (s, 1H), 7.13 (brs, 2H), 4.95-4.41 (m,2H), 4.23-4.13 (m, 2H), 2.89-2.86 (m, 1H), 2.26 (s, 6H).

Step 5—Preparation A

To a solution of rac-2,4,6-trichlorophenyl6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate(66 mg, 0.3 mmol) in THF (5 mL) was added MeONa (18 mg, 0.3 mmol) andthe mixture was stirred at room temperature for 20 mins to give a sodiumsalt suspension.

In another flask, to a solution of1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (47 mg, 0.3 mmol) and TEA (55mg, 0.5 mmol) in THF (5 mL) was added triphosgene (33 mg, 0.1 mmol) inone portion and the mixture was stirred at room temperature under N₂ for20 mins. The reaction mixture was then filtered. The filtrate was addedto the above sodium salt suspension and stirred at room temperature for20 mins. After that, the reaction solution was partitioned between EA(20 mL) and water (20 mL). The aqueous phase was acidified to pH=5 with1 N HCl. The solid formed was collected by filtration and dried to giverac-6-(dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(27 mg, yield: 22%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.41 (s, 1H), 7.33 (s, 1H), 6.76 (s, 1H),4.37-4.22 (m, 2H), 4.11-4.09 (m, 1H), 4.03-4.01 (m, 1H), 2.83-2.82 (m,1H), 2.74 (t, J=7.2 Hz, 4H), 2.64 (t, J=7.6 Hz, 4H), 2.25 (s, 6H),1.93-1.86 (m, 4H). MS: m/z 446.0 (M+H⁺).

Example 22

Synthesis of(S)-6-(Dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideand(R)-6-(dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

rac-6-(Dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(110 mg, 0.4 mmol) was resolved by chiral prep-HPLC to afford(S)-6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(41 mg, yield: 42%) as a white solid and(R)-6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(36 mg, yield: 37%) as a white solid.

Step 2

(S)-6-(dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation A to yield the desired product (14 mg,yield: 18%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.47 (brs, 1H), 7.84 (s, 1H), 7.57 (s,1H), 6.90 (s, 1H), 4.46-4.43 (m, 2H), 4.24-4.12 (m, 2H), 2.92-2.91 (m,1H), 2.80 (t, J=7.2 Hz, 4H), 2.64 (t, J=7.2 Hz, 4H), 2.25 (s, 6H),1.93-1.90 (m, 4H). MS: m/z 446.0 (M+H⁺).

(R)-6-(dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized in the same manner to yield the product as a white solid(15 mg, yield: 22%).

¹H NMR (400 MHz, DMSO-d₆): δ=7.91 (s, 1H), 7.61 (s, 1H), 6.93 (s, 1H),4.54-4.45 (m, 2H), 4.25-4.15 (m, 2H), 2.93-2.91 (m, 1H), 2.79 (t, J=7.2Hz, 4H), 2.62-2.54 (m, 4H), 2.27 (s, 6H), 1.99-1.92 (m, 4H). MS: m/z446.0 (M+H⁺).

Example 23

Synthesis of(R)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideand(S)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

rac-6-Methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(460 mg) was resolved by chiral column to give two isomers:

(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(peak 1, 91 mg) and(S)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(peak 2, 116 mg).

Step 2

(R)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized using Preparation A to deliver the desired product (44mg, yield: 31%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.48 (brs, 1H), 7.92 (brs, 1H), 7.62 (s,1H), 6.93 (s, 1H), 4.63 (d, J=11.6 Hz, 1H), 4.36 (d, J=11.6 Hz, 1H),4.27-4.19 (m, 2H), 4.06 (s, 1H), 3.34 (overlap, 3H), 2.78 (t, J=7.2 Hz,4H), 2.60 (t, J=7.2 Hz, 4H), 1.99-1.93 (m, 4H). MS: m/z 433.0 (M+H⁺).

(S)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas prepared using the same procedure.

¹H NMR (400 MHz, DMSO-d₆): δ=10.51 (s, 1H), 7.98 (s, 1H), 7.62 (s, 1H),6.93 (s, 1H), 4.64 (d, J=11.6 Hz, 1H), 4.37 (d, J=12.0 Hz, 1H),4.24-4.22 (m, 2H), 4.05 (s, 1H), 3.34 (overlap, 3H), 2.78 (t, J=7.6 Hz,4H), 2.60 (t, J=7.2 Hz, 4H), 1.98-1.91 (m, 4H). MS: m/z 433.0 (M+H⁺).

Example 24

Synthesis of(R)-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideand sodium(S)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

To a solution ofrac-6-((tetrahydro-2H-pyran-2-yl)oxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(36 g, 0.161 mol) in MeOH (200 mL) and H₂O (50 mL) was added conc. HCl(50 mL). After being stirred at room temperature for 1 hr, the reactionsolution was concentrated under reduced pressure. The residue wastreated with saturated NaHCO₃ solution (pH=8) and purified by reversephase HPLC (0%-50% MeCN in H₂O) to giverac-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol (27 g, crude yield:quantitative) as a yellow solid.

¹H NMR (300 MHz, DMSO-d₆): δ=7.21 (s, 1H), 5.56 (s, 1H), 5.43 (s, 1H),4.23-4.15 (m, 4H), 3.94-3.89 (m, 1H).

Step 2

To a solution of rac-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol (10g, 71.4 mmol) in dry DMF (150 mL) was added NaH (60%, 4.3 g, 107 mmol)at 0° C. under N₂. After stirring at room temperature for 1 hr, Mel(15.2 g, 107 mml) was added to the reaction. The reaction was stirred atroom temperature overnight, poured into water (100 mL) and filtered. Thefilter cake was dried to giverac-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (5.5 g, yield:50%) as a yellow solid.

¹H NMR (300 MHz, DMSO-d₆): δ=7.21 (s, 1H), 5.44 (s, 1H), 4.44-4.40 (m,1H), 4.23-4.10 (m, 3H), 3.96 (s, 1H), 3.34 (overlap, 3H).

Step 3

Rac-6-Methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (5.5 g) wasresolved by chiral column to give two isomers:

(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (peak 1, 2.4 g)as a white solid and(S)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (peak 2, 2.5 g)as a white solid.

Step 4

To a solution of(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (2.4 g, 15.6mmol) in MeCN was added NBS (2.78 g, 15.6 mmol) in portions withice-cooling. After stirring at room temperature for 1 hr, the reactionsolution was purified by reverse phase HPLC (MeCN/H₂O) to give(R)-3-bromo-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (2.6 g,yield: 72%).

¹H NMR (300 MHz, CDCl₃): δ=7.33 (s, 1H), 4.52-4.48 (m, 1H), 4.32-4.20(m, 3H), 3.93-3.92 (m, 1H), 3.49 (s, 3H).

(S)-3-bromo-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine wasprepared using the same procedure.

Step 5

(R)-2,4,6-trichlorophenyl6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate wassynthesized using Preparation B to yield the product as a yellow oilwhich was used for next step without any purification.

(S)-2,4,6-trichlorophenyl6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate wasprepared using the same procedure.

Step 6

(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation C to yield the desired product (800mg, yield: 32% over 2 steps) as a yellow solid. MS: m/z 234.0 (M+H⁺).

(S)-6-Methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas prepared using the same procedure.

Step 7—Preparation D

To a solution of(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(800 mg, 3.43 mol) in THF (10 mL) was added MeONa (370 mg, 6.86 mmol).The mixture was stirred at room temperature for 30 mins to give a sodiumsalt suspension.

In another flask, to a solution of1,2,3,5,6,7-hexahydro-s-indacen-4-amine (891 mg, 5.1 mol) and TEA (1.5g, 15.3 mmol) in THF (20 mL), was added triphosgene (611 mg, 2.1 mmol)in one portion. After stirring at room temperature under N₂ for 30 mins,the reaction mixture was filtered. The filtrate was added to the sodiumsalt suspension above and the reaction was stirred at room temperatureovernight. After that, the reaction solution was partitioned between EA(50 mL) and water (80 mL). The aqueous phase was purified by reversephase HPLC (MeCN/H₂O) to give sodium(R)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(250 mg, yield: 16%) as a yellow solid.

¹H NMR (400 MHz, D₂O): δ=7.52 (s, 1H), 6.88 (s, 1H), 4.51 (d, J=12.0 Hz,1H), 4.16-4.11 (m, 3H), 4.02-4.00 (m, 1H), 3.30 (s, 3H), 2.68 (t, J=7.2Hz, 4H), 2.51 (t, J=7.6 Hz, 4H), 1.90-1.81 (m, 4H). MS: m/z 433.1(M+H⁺).

Sodium(S)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidewas prepared using the same procedure.

¹H NMR (400 MHz, DMSO-d₆): δ=7.47 (brs, 1H), 6=7.39 (s, 1H), 6.78 (s,1H), 4.49 (dt, J=8.0 Hz, 2.0 Hz, 1H), 4.23-4.15 (m, 2H), 4.14-4.08 (m,1H), 3.99-3.95 (m, 1H), 3.34 (s, 3H), 2.75 (t, J=7.2 Hz, 4H), 2.65 (t,J=7.2 Hz, 4H), 1.96-1.86 (m, 4H). MS: m/z 433.1 (M+H⁺).

Example 25

Synthesis of Sodium(R)-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

A solution of 1,2-dihydro-pyrazol-3-one (50.0 g, 600 mmol) in pyridine(300 mL) was heated to 95° C. To the solution, a solution of aceticanhydride (61.2 g, 600 mmol) in pyridine (100 mL) was added slowly over0.5 hour. The reaction was heated for additional 1 hr at 95° C. Thereaction mixture was concentrated in vacuo resulting a dark red oilwhich was triturated with MeOH (150 mL) and filtered to give the1-acetyl-1,2-dihydro-pyrazol-3-one (54.0 g, yield: 71%) as a whitesolid. ¹H NMR (300 MHz, DMSO-d₆): δ=10.92 (s, 1H), 8.08 (s, 1H), 5.96(s, 1H), 2.45 (overlap, 3H).

Step 2

A mixture of 1-acetyl-1,2-dihydro-pyrazol-3-one (34.7 g, 280 mol) andPPh₃ (24.9 g, 420 mol) in THF (400 mL) was cooled to 0° C. under N₂. Tothe mixture was added DIAD (84.8 g, 420 mmol) slowly. The reaction wasstirred for additional 1 hour at 0° C., then (R)-oxiran-2-ylmethanol(25.2 g, 340 mmol) was added slowly. The reaction was then stirred atroom temperature overnight. The reaction mixture was concentrated invacuo and the residue was purified by silica gel column (PE/EA=10/1) togive (R)-1-acetyl-2-(oxiran-2-ylmethyl)-1H-pyrazol-3(2H)-one (34.8 g,yield: 68%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ=8.06 (d, J=2.8 Hz, 1H), 6.00 (d, J=3.2 Hz,1H), 4.55 (dd, J=12.0, 3.2 Hz, 1H), 4.20 (dd, J=12.0, 3.2 Hz, 1H), 3.39(q, J=3.2 Hz, 1H), 2.92 (t, J=4.4 Hz, 1H), 2.76 (dd, J=4.4, 2.4 Hz, 1H),2.57 (s, 3H).

Step 3

To a solution of (R)-1-acetyl-2-(oxiran-2-ylmethyl)-1H-pyrazol-3(2H)-one(34.8 g, 190 mmol) in AcOH (34.2 g, 570 mmol) and THF (200 mL), wasadded LiCl (13.1 g, 310 mmol) at room temperature. The reaction was thenstirred at room temperature overnight. The reaction was partitionedbetween EA (200 mL) and water (200 mL). The organic layer was washedwith sat.NaHCO₃ (100 mL) and brine (100 mL), dried over Na₂SO₄ andconcentrated in vacuo to give crude(R)-1-acetyl-2-(3-chloro-2-hydroxypropyl)-1H-pyrazol-3(2H)-one as acolorless oil which was used for next step directly without anypurification.

¹H NMR (300 MHz, DMSO-d₆): δ=8.25 (d, J=2.7 Hz, 1H), 6.23 (d, J=3.0 Hz,1H), 5.59 (brs, 1H), 4.24-4.19 (m, 2H), 4.07-4.04 (m, 1H), 3.75-3.62 (m,2H), 2.50 (overlap, 3H). MS: m/z 219.4 (M+H⁺).

Step 4

A mixture of(R)-1-acetyl-2-(3-chloro-2-hydroxypropyl)-1H-pyrazol-3(2H)-one (crude,190 mmol) and K₂CO₃ (78.7 g, 570 mmol) in DMF (400 mL) was stirred at135° C. overnight. The solvent was removed under reduced pressure. Theresidue was purified by silica gel column (EA) to give(R)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol (12.8 g, yield: 48%)as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.21 (d, J=1.6 Hz, 1H), 5.51 (d, J=3.2 Hz,1H), 5.44 (d, J=1.6 Hz, 1H), 4.24-4.13 (m, 4H), 3.92 (d, J=12.4 Hz, 1H).

Step 5

To a solution of (R)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol(12.8 g, 91.4 mmol) in MeCN (200 mL) was added NBS (17.9 g, 100.6 mmol)at 0° C. under N₂ in two portions. The reaction was then stirred at roomtemperature for 1 hr. The reaction was partitioned between EA (200 mL)and water (200 mL). The organic layer was washed with sat.NaHCO₃ (100mL) and brine (100 mL), dried over Na₂SO₄ and concentrated in vacuo. Theresidue was triturated with EA (50 mL) and filtered to give the(R)-3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol (11.3 g,yield: 57%) as a white solid. MS: m/z 219.3 (M+H⁺).

Step 6

To a solution of(R)-3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol (12.2 g, 55.7mmol) in DMF (60 mL) was added NaH (60% in mineral oil, 2.7 g, 66.8mmol). The reaction was stirred at room temperature for 1 hr under N₂.Then Mel (9.5 g, 66.8 mmol) was added. After being stirred at roomtemperature for 2 hrs, the reaction was poured into water (200 mL) andextracted with EA (100 mL×2). The organic layer was washed with water(100 mL) and brine (100 mL), dried over Na₂SO₄ and concentrated. Theresidue was triturated with MeOH/H₂O (2/1, 100 mL) and filtered to give(R)-3-bromo-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (9.5 g,yield: 73%) as a white solid. MS: m/z 233.3 (M+H⁺).

Step 7

(R)-2,4,6-trichlorophenyl6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate wassynthesized using Preparation B to yield the product as a yellow oilwhich was used for next step directly without any purification.

(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation C to yield the desired product (2.6 g,yield: 27% over 2 steps) as a white solid.

¹H NMR (300 MHz, DMSO-d₆): δ=7.47 (s, 1H), 7.08 (s, 2H), 4.58-4.54 (m,1H), 4.32-4.18 (m, 3H), 4.01 (d, J=1.2 Hz, 1H), 3.35 (overlap, 3H).

Step 8

To a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (15.0 g, 87mmol) and TEA (13.3 mL, 95.4 mmol) in THF (30 mL), was added triphosgene(8.5 g, 28.6 mmol) in one portion at 0° C. and the mixture was stirredat 70° C. under N₂ for 1 hr. The reaction mixture was then filteredthrough diatomite. The filter cake was washed with 30 mL PE. Thefiltrate was concentrated to dryness and dissolved in 100 mL n-hexane.The mixture was filtered through a silica gel pad. The filtrate wasconcentrated to dryness to give the4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (14.1 g, yield: 81%) as apink oil.

The suspension of(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(1.6 g, 6.9 mmol) in MeOH (30 mL) was stirred at 80° C. until getting aclear solution, then MeONa (372.6 mg, 6.9 mmol) was added and themixture was stirred for 30 mins. The solution was concentrated todryness and the residue was co-evaporated with MeCN (30 mL). Theresidual solid was suspended in MeCN (30 mL) and4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (1.4 g, 7.2 mmol) wasadded. The mixture solution was stirred for 16 hrs at room temperatureand filtered. The filter cake was triturated with PE/EA (5/1, 40 mL) togive sodium(R)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(2.4 g, yield: 80%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.42 (s, 1H), 7.36 (s, 1H), 6.76 (s, 1H),4.50 (d, J=12.0 Hz, 1H), 4.21-4.08 (m, 3H), 3.95 (s, 1H), 3.34 (overlap,3H), 2.76 (t, J=6.8 Hz, 4H), 2.67 (t, J=6.8 Hz, 4H), 1.94-1.88 (m, 4H).MS: m/z 433.1 (M+H⁺).

Example 26

Synthesis of sodium(R)-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

To a solution of (R)-3-chloropropane-1,2-diol (61.0 g, 552.0 mmol) inpyridine (450 mL) was added TsCl (105.2 g, 552.0 mmol) in portions at 0°C. After being stirred at room temperature for 1 hr, the reaction wasquenched with H₂O (10 mL) and concentrated. The residue was poured toaq.HCl (2 N, 200 mL) and extracted with DCM (300 mL×3). The combinedorganic layer was washed with sat.NaHCO₃ (300 mL), dried over Na₂SO₄ andconcentrated to give (R)-3-chloro-2-hydroxypropyl4-methylbenzenesulfonate (121.8 g, crude, yield: 76%) as a yellow oil.

Step 2

A mixture of (R)-3-chloro-2-hydroxypropyl 4-methylbenzenesulfonate(121.8 g, 461.4 mmol), CH₃I (43 mL, 690.4 mmol) and Ag₂O (128.0 g, 551.7mmol) in DCM (1 L) was refluxed at 45° C. for 24 hrs. Another portionCH₃I (28.7 mL, 460.8 mmol) was added and the reaction was refluxed foranother 24 hrs. Ag₂O was removed by filtration and the filtrate wasconcentrated, purified by silica gel column (PE/EA=8/1) to give(R)-3-chloro-2-methoxypropyl 4-methylbenzenesulfonate (77.0 g, yield:60%) as a yellow oil.

¹H NMR (300 MHz, CDCl₃): δ=7.79 (d, J=8.1 Hz, 2H), 7.35 (d, J=8.1 Hz,2H), 4.15-4.08 (m, 2H), 3.64-3.50 (m, 3H), 3.38 (s, 3H), 2.44 (s, 3H).

Step 3˜4

A mixture of (R)-3-chloro-2-methoxypropyl 4-methylbenzenesulfonate (26.2g, 94.2 mmol), 1-acetyl-1,2-dihydro-pyrazol-3-one (11.9 g, 94.2 mmol)and K₂CO₃ (39.0 g, 282.6 mmol) in DMF (350 mL) was stirred at 50° C. for16 hrs. H₂O (35 mL) was added and the reaction was stirred at 130° C.for another 3 hrs. K₂CO₃ was removed by filtration and the filtrate wasconcentrated. The residue was purified by silica gel column (PE/EA=2/1)to give (R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (13.8g, contain some DMF and an unknown byproduct, yield: 95%) as a whitesolid.

¹H NMR (400 MHz, CDCl₃): δ=7.33 (d, J=2.0 Hz, 1H), 5.50 (d, J=2.4 Hz,1H), 4.40-4.34 (m, 1H), 4.32-4.23 (m, 2H), 4.17 (dd, J=11.6, 1.6 Hz,1H), 3.92-3.89 (m, 1H), 3.48 (s, 3H).

Step 5

To a solution of(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (13.8 g, 89.6mmol) in DCM (150 mL) was added ClSO₃H (13.1 mL, 197.1 mmol) dropwise at0° C. After being stirred at room temperature for 16 hrs, pyridine (15.8mL, 197.1 mmol) was added dropwise at 0° C. and then PCl₅ (41.0 g, 197.1mmol) was added portion wise at 0° C. The reaction mixture was stirredat room temperature for 1 hr, poured onto ice-water (200 mL) andextracted with EA (100 mL×3). The combined organic layer was washed withbrine (100 mL), dried over Na2SO₄ and concentrated to give(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride (16.7 g, crude, yield: 74%) as a yellow solid.

Step 6

To a solution of(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride (16.7 g, 66.3 mmol) in THF (100 mL) was added NH₃.H₂O (42 mL).After being stirred at 60° C. for 2 hrs, the reaction mixture wasconcentrated to about 20 mL. The residual suspension was acidified withaq.HCl (1 N) to pH=3 and filtered. The filter cake was washed with H₂O(50 mL) and triturated with MeOH (20 mL) to give(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(10.7 g, yield: 69%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.49 (s, 1H), 7.12 (s, 2H), 4.59 (td,J=11.6, 2.4 Hz, 1H), 4.32 (d, J=12.0 Hz, 1H), 4.27-4.17 (m, 2H),4.04-4.02 (m, 1H), 3.35 (s, 3H).

Step 7

(R)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidewas synthesized as described in Step 8 in the previous example toproduce the desired product (2.4 g, yield: 80%) as a white solid.

Example 27

An alternative synthesis of(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of(R)-3-bromo-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (1.0 g,4.3 mmol) in dry THF (10 mL) was added n-BuLi in hexane (2.5 M, 2.1 mL,5.2 mmol) slowly at −78° C. under N₂. After being stirred with coolingfor 1 hr, (BnS)₂ (1.6 g, 6.5 mmol) was added slowly at this temperature.The cooling bath was removed and the reaction was stirred at roomtemperature overnight. The reaction was quenched with saturated NH₄Clsolution (5 mL) and partitioned between water (20 mL) and EA (20 mL).The organic layer was washed with brine (20 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by silica gel column (PE/EA=1/1)to give(R)-3-(benzylthio)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(760 mg, yield: 63%) as a yellow oil. MS: m/z 277.4 (M+H⁺).

Step 2

To a solution of(R)-3-(benzylthio)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(750 mg, 2.7 mmol) in AcOH/H₂O (3 mL/1 mL) was added NCS (1.5 g, 10.9mmol) at 0° C. under N₂ in two portions. The reaction was then stirredat room temperature for 1 hr. The reaction was partitioned between EA(20 mL) and water (20 mL). The organic layer was washed with sat.NaHCO₃(20 mL) and brine (20 mL), dried over Na₂SO₄ and concentrated in vacuoto give the crude(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride as a yellow oil which was used for next step directly withoutany purification.

Step 3

(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation C to yield the desired product (280mg, yield: 44% over 2 steps) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.48 (s, 1H), 7.11 (s, 2H), 4.61-4.56 (m,1H), 4.34 (d, J=11.6 Hz, 1H), 4.26-4.16 (m, 2H), 4.03 (d, J=1.2 Hz, 1H),3.35 (s, 3H). MS: m/z 233.8 (M+H⁺).

Example 28

Synthesis ofrac-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of 2-methyl-propane-1,3-diol (1 g, 11.1 mmol) and TEA (4.5g, 44.4 mmol) in THF (30 mL), was added MsCl (2.8 g, 24.4 mmol) slowlywith ice-cooling under N₂. The reaction was stirred at room temperaturefor 1 hr and filtered. The filtrate was concentrated to give a colorlessoil. A mixture of this oil, 1,2-dihydro-pyrazol-3-one (993 mg, 11.1mmol) and K₂CO₃ (6.1 g, 44.4 mmol) in DMF (40 mL) was heated to 80° C.for 12 hrs. The reaction was cooled and partitioned between EA (100 mL)and water (200 mL) and the layers were separated. The organic layer waswashed with water (80 mL) and brine (50 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by silica gel column (PE/EA=2/1)to give rac-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (500 mg,yield: 33%) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=7.31 (s, 1H), 5.47 (s, 1H), 4.27-4.23 (m,2H), 3.87-3.68 (m, 2H), 2.47-2.45 (m, 1H), 1.23-1.09 (m, 3H). MS: m/z139.0 (M+H⁺).

Step 23

A solution of rac-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(500 mg, 3.6 mmol) in chlorosulfonic acid (5 mL) was stirred at 80° C.overnight. The reaction was dissolved in EA (60 mL) and added slowly towater (100 mL). The organic layer was washed with brine (60 mL), driedover Na₂SO₄ and concentrated. The residue was dissolved in THF (15 mL)and ammonia (5 mL) was added. The mixture was stirred at 60° C. for 1hr. The reaction was concentrated, acidified with 1 N HCl and purifiedby reverse phase HPLC (MeCN/H₂O) to giverac-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acidamide (450 mg, yield: 58% over 2 steps) as a white solid.

¹H NMR (300 MHz, DMSO-d₆): δ=7.46 (s, 1H), 7.11 (brs, 2H), 4.43-4.38 (m,1H), 4.21-4.15 (m, 1H), 4.06-3.99 (m, 1H), 3.76-3.69 (m, 1H), 2.42-2.34(m, 1H), 1.02-1.00 (m, 3H).

Step 4

rac-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized using Preparation A to deliver the desired product (29.7mg, yield: 18%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.49 (s, 1H), 7.92 (s, 1H), 7.62 (s, 1H),6.93 (s, 1H), 4.48-4.45 (m, 1H), 4.44-4.18 (m, 1H), 4.08 (t, J=11.4 Hz,1H), 3.77-3.72 (m, 1H), 2.78 (t, J=7.6 Hz, 4H), 2.60 (t, J=7.2 Hz, 4H),2.40 (overlap, 1H), 1.98-1.91 (m, 4H), 1.01 (d, J=6.4 Hz, 3H). MS: m/z417.0 (M+H⁺).

Example 29

Synthesis of(S)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideand(R)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

rac-6-Methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(350 mg) was resolved by chiral prep-HPLC to give(S)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(242 mg as diethylamine salt) and(R)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(240 mg as diethylamine salt)

Step 2

(R)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation A to yield the desired product (112mg, yield: 37%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.45 (brs, 1H), 7.90 (s, 1H), 7.61 (s,1H), 6.93 (s, 1H), 4.48-4.45 (m, 1H), 4.44-4.18 (m, 1H), 4.08 (t, J=11.4Hz, 1H), 3.77-3.72 (m, 1H), 2.78 (t, J=7.6 Hz, 4H), 2.60 (t, J=7.2 Hz,4H), 2.40 (overlap, 1H), 1.98-1.91 (m, 4H), 1.00 (d, J=6.4 Hz, 3H). MS:m/z 417.1 (M+H⁺).

(S)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas prepared using the same procedure.

¹H NMR (400 MHz, DMSO-d₆): δ=10.45 (s, 1H), 7.90 (s, 1H), 7.61 (s, 1H),6.93 (s, 1H), 4.48-4.44 (m, 1H), 4.22-4.18 (m, 1H), 4.11-4.06 (m, 1H),3.77-3.72 (m, 1H), 2.78 (t, J=7.2 Hz, 4H), 2.60 (t, J=6.8 Hz, 4H),2.42-2.38 (m, 1H), 1.98-1.92 (m, 4H), 1.00 (d, J=6.8 Hz, 3H). MS: m/z417.1 (M+H⁺).

Example 30

Synthesis ofN-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5′,7′-dihydrospiro[cyclopropane-1,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonamideis shown below.

Step 1

To a solution of (1-hydroxymethyl-cyclopropyl)-methanol (1.53 g, 15mmol) and TEA (6.1 g, 60 mmol) in THF (45 mL), was added MsCl (3.8 g, 33mmol) slowly with ice-cooling under N₂. After being stirred at roomtemperature for 1 hr, the reaction was partitioned between EA (500 mL)and water (100 mL). The organic layer was washed with brine (100 mL),dried over Na₂SO₄ and concentrated to give a colorless oil. A mixture ofthis oil, 1,2-dihydro-pyrazol-3-one (1.3 g, 15 mmol) and K₂CO₃ (8.3 g,60 mmol) in DMF (60 mL) was heated to 80° C. overnight. The reaction wascooled and partitioned between EA (120 mL) and water (300 mL). Theorganic layer was washed with water (100 mL) and brine (80 mL), driedover Na₂SO₄ and concentrated. The residue was purified by reverse phaseHPLC (MeCN/H₂O) to give5′,7′-dihydrospiro[cyclopropane-1,6′-pyrazolo[5,1-b][1,3]oxazine] (380mg, yield: 17%) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=7.33 (d, J=1.8 Hz, 1H), 5.52 (d, J=1.8 Hz,1H), 3.99 (s, 4H), 0.81-0.49 (m, 4H). MS: m/z 151.0 (M+H⁺).

Step 2

NBS (960 mg, 5 mmol) was added portionwise to a solution of5′,7′-dihydrospiro[cyclopropane-1,6′-pyrazolo[5,1-b][1,3]oxazine] (380mg, 5.3 mmol) in MeCN (15 mL). After being stirred at room temperaturefor 1 hr, the reaction was partitioned between EA (60 mL) and water (60mL). The organic layer was washed with brine (60 mL), dried over Na₂SO₄and concentrated. The residue was purified by silica gel column(PE/EA=2/1) to3′-bromo-5′,7′-dihydrospiro[cyclopropane-1,6′-pyrazolo[5,1-b][1,3]oxazine](380 mg, yield: 66%) as a yellow solid.

¹H NMR (300 MHz, CDCl₃): δ=7.33 (s, 1H), 4.07 (s, 2H), 3.98 (s, 2H),0.86-0.81 (m, 4H). MS: m/z 230.9 (M+H⁺).

Step 3

2,4,6-trichlorophenyl5′,7′-dihydrospiro[cyclopropane-1,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonatewas synthesized using Preparation B to yield the product as a yellow oilwhich was used for next step without any purification.

Step 4

5′,7′-dihydrospiro[cyclopropane-1,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonamidewas synthesized as in Preparation C to yield the desired product (105mg, yield: 27% over 2 steps) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.49 (s, 1H), 7.12 (brs, 2H), 4.20 (s, 2H),4.00 (s, 2H), 0.78 (s, 4H).

Step 5

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5′,7′-dihydrospiro[cyclopropane-1,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonamidewas synthesized using Preparation A to deliver the desired product (54mg, yield: 34%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.53 (s, 1H), 8.01 (s, 1H), 7.62 (s, 1H),6.94 (s, 1H), 4.25 (s, 2H), 4.01 (s, 2H), 2.79 (t, J=7.2 Hz, 4H), 2.60(t, J=7.2 Hz, 4H), 1.99-1.93 (m, 4H), 0.78 (s, 4H). MS: m/z 429.0(M+H⁺).

Example 31

Synthesis ofN-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-tosyl-5′,7′-dihydrospiro[azetidine-3,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonamideis shown below.

Step 1

To a solution of[3-bromomethyl-1-(toluene-4-sulfonyl)-azetidin-3-yl]-methanol (4 g, 12mmol) in DCM (60 mL) was added CBr₄ (6.4 g, 19.2 mmol) and PPh₃ (5.2 g,19.2 mmol) at 0° C. After being stirred at room temperature for 16 hrs,the reaction was partitioned between DCM (200 mL) and H₂O (200 mL). Theaqueous layer was extracted with DCM (200 mL). The combined organiclayer was washed with brine (100 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by silica gel column (PE/EA=5/1)to give 3,3-bis-bromomethyl-1-(toluene-4-sulfonyl)-azetidine (3.8 g,yield: 79%) as a yellow solid. MS: m/z 395.9 (M+H⁺).

Step 2

To a solution of 3,3-bis-bromomethyl-1-(toluene-4-sulfonyl)-azetidine(4.2 g, 10.6 mmol) and 1,2-dihydro-pyrazol-3-one (0.89 g, 10.6 mmol) inDMF (50 mL) was added K₂CO₃ (3.7 g, 26.5 mmol). After being stirred at130° C. for 16 hrs, the reaction was cooled down and quenched with theaddition of EA (100 mL) and water (100 mL). The organic layer wasseparated. The aqueous layer was extracted with EA (100 mL). The organiclayers were combined, washed with brine (80 mL), dried over Na₂SO₄ andconcentrated in vacuo. The residue was purified by silica gel column(PE/EA=1/1) to give1-tosyl-5′,7′-dihydrospiro[azetidine-3,6′-pyrazolo[5,1-b][1,3]oxazine](1.4 g, yield: 42%) as a white solid. MS: m/z 320 (M+H⁺).

Step 3

NBS (0.64 g, 3.6 mmol) was added portionwise to a solution of1-tosyl-5′,7′-dihydrospiro[azetidine-3,6′-pyrazolo[5,1-b][1,3]oxazine](1 g, 0.33 mmol) in MeCN (10 mL) at 0° C. and the reaction was stirredfor 2 hrs at room temperature. The mixture was filtered and the filtratewas purified by reverse phase HPLC (5%-95% MeCN in H₂O) to give3′-bromo-1-tosyl-5′,7′-dihydrospiro[azetidine-3,6′-pyrazolo[5,1-b][1,3]oxazine](1.16 g, yield: 83%) as a yellow solid. MS: m/z 398 (M+H⁺).

Step 4

2,4,6-trichlorophenyl1-tosyl-5′,7′-dihydrospiro[azetidine-3,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonatewas synthesized using Preparation B to yield the product as a yellowoil.

1-tosyl-5′,7′-dihydrospiro[azetidine-3,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonamidewas synthesized as in Preparation C to yield the desired product (140mg, yield: 32%) as a light yellow solid. MS: m/z 399.1 (M+H⁺).

Step 5

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-tosyl-5′,7′-dihydrospiro[azetidine-3,6′-pyrazolo[5,1-b][1,3]oxazine]-3′-sulfonamidewas synthesized using Preparation A and further purified by prep HPLC todeliver the desired product (24 mg, yield: 22%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.52 (s, 1H), 7.90 (s, 1H), 7.74 (d, J=8.0Hz, 2H), 7.62 (s, 1H), 7.53 (d, J=8.0 Hz, 2H), 6.94 (s, 1H), 4.24 (s,2H), 4.00 (s, 2H), 3.68 (s, 4H), 2.80 (t, J=7.2 Hz, 4H), 2.55 (t, J=6.8Hz, 4H), 2.46 (s, 3H), 1.91-1.98 (m, 4H). MS: m/z 598.2 (M+H⁺).

Example 32

Synthesis of6-Amino-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of 2-aminopropane-1,3-diol (5.0 g, 54.9 mmol) and TEA(11.1 g, 109.9 mmol) in DCM (40 mL) was added Boc₂O (14.4 g, 65.9 mmol)and the reaction was stirred at room temperature for 2 hrs. The reactionwas partitioned between water (80 mL) and EA (80 mL). The organic layerwas washed with brine (80 mL), dried over Na₂SO₄ and concentrated togive crude tert-butyl (1,3-dihydroxypropan-2-yl)carbamate as a whitesolid which was used for next step directly without any purification.

Step 2

To a solution of tert-butyl (1,3-dihydroxypropan-2-yl)carbamate (crude,˜21.0 mmol) and TEA (8.5 g, 84.0 mmol) in dry THF (30 mL) was added MsCl(5.3 g, 46.0 mmol) and at 0° C. After stirring at room temperature for 2hrs, the reaction was filtered. The filtrate was concentrated todryness. The residue was purified by silica gel column (PE/EA=1/1) togive 2-((tert-butoxycarbonyl)amino)propane-1,3-diyl dimethanesulfonate(3.9 g, yield: 53%) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=5.11 (d, J=7.5 Hz, 1H), 4.36-4.22 (m, 5H),3.07 (s, 6H), 1.44 (s, 9H).

Step 3

A mixture of 2-((tert-butoxycarbonyl)amino)propane-1,3-diyldimethanesulfonate (3.9 g, 11.2 mmol), 1,2-dihydro-pyrazol-3-one (945mg, 11.2 mmol) and K₂CO₃ (5.4 g, 39.3 mmol) in DMF (30 mL) was heated to80° C. for 12 hrs. The reaction was cooled and partitioned between EA(150 mL) and water (200 mL). The organic layer was washed with water (80mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residuewas purified by silica gel column (PE/EA=1/1) to give tert-butyl(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (975 mg,yield: 13%) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=7.37 (d, J=1.2 Hz, 1H), 5.55 (d, J=1.5 Hz,1H), 5.14-5.04 (m, 1H), 4.43-4.12 (m, 5H), 1.46 (s, 9H). MS: m/z 240.1(M+H⁺).

Step 4

To a solution of tert-butyl(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (610 mg, 2.6mmol) in MeCN, was added NBS (454 mg, 2.6 mmol) at 0° C. under N₂ in twoportions. The reaction was then stirred at room temperature for 1 hr.The reaction was partitioned between EA (20 mL) and water (20 mL). Theorganic layer was washed with water (20 mL) and brine (20 mL), driedover Na₂SO₄ and concentrated. The residue was purified by silica gelcolumn (PE/EA=1/1) to give tert-butyl(3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (640mg, yield: 79%) as a white solid. MS: m/z 318.0 (M+H⁺).

Step 5

2,4,6-trichlorophenyl6-((tert-butoxycarbonyl)amino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonatewas synthesized using Preparation B to yield the product as a yellow gelwhich was used for next step directly without any purification.

Step 6

A mixture of 2,4,6-trichlorophenyl6-((tert-butoxycarbonyl)amino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate(crude, ˜1.9 mmol), NH₄OH (20 mL) and THF (20 mL) was stirred at 60° C.overnight. The reaction was concentrated under reduced pressure until 10mL of liquid remained. The remained solution was acidified with 1 N HClto pH=5 and extracted with EA (20 mL×2). The organic layers werecombined, dried over Na₂SO₄ and concentrated. The residue was purifiedby silica gel column (DCM/MeOH=40/1) to give tert-butyl(3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(80 mg, yield: 13% over 2 steps) as a yellow semi-solid. MS: m/z 317.0(M−H⁺).

Step 7

tert-Butyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamatewas synthesized using Preparation A to deliver the desired product (28mg, yield: 22%) as a white solid.

Step 8

To a solution of tert-butyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(28 mg, 0.05 mmol) in DCM (5 mL) was added TFA (5 mL) and the mixturewas stirred at room temperature for 20 mins. The reaction wasconcentrated to dryness and the residue was triturated with EA to giveTFA salt of6-amino-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(5.4 mg, yield: 23%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.15 (brs, 1H), 7.54 (s, 1H), 6.88 (s, 1H),4.32-4.30 (m, 1H), 4.21-4.16 (m, 1H), 4.11-4.01 (m, 1H), 3.81-3.75 (m,1H), 3.47 (overlap, 1H), 2.77 (t, J=7.2 Hz, 4H), 2.67-2.62 (m, 4H),1.97-1.92 (m, 4H). MS: m/z 418.2 (M+H⁺).

Example 33

Synthesis of Sodium((6-(((tert-butoxycarbonyl)amino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amideis shown below.

Step 1

A mixture of 1,2-dihydro-pyrazol-3-one (10.42 g, 0.124 mol) and K₂CO₃(42.8 g, 0.31 mol) in DMF (700 mL) was heated to 100° C.3-Chloro-2-chloromethyl-propene (15.5 g, 0.124 mol) was added and themixture was stirred at 100° C. for 16 hrs. The solvent was removed invacuo. The residue was partitioned between EA (200 mL) and H₂O (500 mL).The aqueous layer was extracted with EA (200 mL). The combined organiclayer was washed with brine (100 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by silica gel column (PE/EA=1/1)to give 6-methylene-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (1.7 g,yield: 10%) as a yellow oil.

¹H NMR (300 MHz, CDCl₃): δ=7.34 (s, 1H), 5.51 (s, 1H), 5.39 (s, 2H),4.80 (s, 2H), 4.63 (s, 2H). MS: m/z 137.1 (M+H⁺).

Step 2

To a solution of 6-methylene-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(1.7 g, 12.5 mmol) in THF (20 mL) was added BH₃/Me₂S (10 M, 5 mL, 50mmol) at 0° C. After stirring at room temperature for 16 hrs, NaOHsolution (3 M, 50 mL, 150 mmol) and H₂O₂(30%, 5.7 g, 50 mmol) were addedto the reaction slowly. After stirring at 80° C. for 2 hrs, the reactionwas cooled down. Saturated aqueous solution of Na₂SO₃ (50 mL) was addedto the reaction. After stirring at room temperature for 0.5 hr, theresulting mixture was extracted with EA (100 mL×3). The combined organiclayer was washed with brine (100 mL), dried over Na₂SO₄ and concentratedto give (6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)-methanol (1.3g, yield: 68%) as a yellow oil.

¹H NMR (300 MHz, CDCl₃): δ=7.31 (d, J=1.8 Hz, 1H), 5.49 (d, J=1.8 Hz,1H), 4.37 (dd, J=11.4, 3 Hz, 1H), 4.28-4.12 (m, 2H), 4.07-4.00 (m, 1H),3.77 (d, J=6.6 Hz, 2H), 2.58-2.50 (m, 1H).

Step 3

To a solution of(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)-methanol (2.05 g, 13.3mmol) in THF (30 mL) was added DPPA (7.3 g, 26.6 mmol) and DBU (6.1 g,39.9 mmol) at room temperature. The suspension was stirred at 60° C. for16 hrs. The reaction was quenched by the addition of EA (100 mL) andwater (100 mL). The organic layer was separated. The aqueous layer wasextracted with EA (100 mL). The organic layer was washed with brine (100mL), dried over Na₂SO₄ and concentrated in vacuo. The residue waspurified by silica gel column (PE/EA=2/1) to give6-azidomethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (1.24 g, yield:62%) as a yellow oil. MS: m/z 180.3 (M+H⁺).

Step 4

To a solution of6-azidomethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (1.24 g, 16.9mmol) in MeOH (20 mL) was added Boc₂O (3 g, 13.8 mmol) and Pd/C (5%, 0.2g). The mixture was stirred under H₂ (balloon atmosphere) at roomtemperature for 16 hrs. The reaction was filtered and the filtrate wasconcentrated to give a crude product, which was used for next stepdirectly without further purification. MS: m/z 254.0 (M+H⁺).

Step 5

NBS (1.3 g, 24.7 mmol) was added portionwise to a solution of tert-butyl((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)carbamate(crude, 6.9 mmol) in MeCN (20 mL) at 0° C. and the reaction was stirredfor 2 hrs at room temperature. The mixture was filtered and purified byreverse phase HPLC (5%-95% MeCN in H₂O) to give tert-butyl((3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)carbamate(1.62 g, yield: 71%) as a yellow solid. MS: m/z 331.9 (M+H⁺).

Step 6

2,4,6-trichlorophenyl6-(((tert-butoxycarbonyl)amino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonatewas synthesized using Preparation B to yield the product as a yellow oilwhich was used for next step directly without any purification.

Step 7

tert-butyl((3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)carbamatewas synthesized as in Preparation C to yield the desired product (80 mg,yield: 33% over 2 steps) as a light yellow solid. MS: m/z 333.4 (M+H⁺).

Step 8

((6-(((tert-butoxycarbonyl)amino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amidewas synthesized as in Preparation D to yield the desired product (27 mg,yield: 21%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.35 (s, 1H), 7.31 (s, 1H), 7.11 (s, 1H),6.75 (s, 1H), 4.31 (d, J=5.6 Hz, 1H), 4.10-3.98 (m, 2H), 3.78 (dd,J=10.0, 2.0 Hz, 1H), 3.07-3.04 (m, 2H), 2.74 (t, J=7.2 Hz, 4H), 2.64 (t,J=7.2 Hz, 4H), 2.40-2.3 (m, 1H), 1.93-1.86 (m, 4H), 1.39 (s, 9H). MS:m/z 532.2 (M+H⁺).

Example 34

Synthesis ofrac-N-((3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)acetamideis shown below.

Step 1

To a solution of rac-tert-butyl((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)carbamate(crude, ˜1.05 mmol) in DCM (3 mL) was added TFA (1 mL). After thesolution was stirred at room temperature for 2 hrs, the solution wasconcentrated and dissolved with Ac₂O (3 mL). After stirring at refluxfor 3 hrs, the reaction solution was quenched with the addition of EA(20 mL) and water (10 mL). The organic layer was separated. The aqueouslayer was extracted with EA (10 mL). The organic layers were combinedand washed with brine (10 mL), and dried over Na₂SO₄. The solution wasconcentrated in vacuo. The residue was purified by silica gel column(PE/EA=1/1) to giverac-N-acetyl-N-((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)acetamide(90 mg, yield: 31%) as a yellow oil. MS: m/z 238.4 (M+H⁺).

Step 2

To a solution ofrac-N-acetyl-N-((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)acetamide(90 mg, 0.38 mmol) in DCM (2 mL) was added ClSO₃H (0.075 mL, 1.14 mmol)dropwise at 0° C. After stirring at room temperature for 16 hrs,pyridine (0.092 mL, 1.14 mmol) was added to the reaction dropwise at 0°C., followed by addition of PCl₅ (237 mg, 1.14 mmol) in portions. Thereaction mixture was stirred at room temperature for 1 hr, poured toice-water (2 mL) and extracted with EA (10 mL×3). The combined organiclayer was washed with brine (10 mL), dried over Na₂SO₄ and concentratedto give a crude product, which was directly used for next step withoutfurther purification.

Step 3

To a solution ofrac-6-((N-acetylacetamido)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride (crude, ˜0.387 mmol) in THF (3 mL) was added NH₃.H₂O (3 mL).After stirring at 60° C. for 2 hrs, the reaction mixture wasconcentrated to about 1 mL. The residual suspension was acidified withaq.HCl (1 N) to pH=3 and filtered. The filtrate was purified by reversephase HPLC (MeCN/H₂O) to giverac-N-((3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)acetamide(67 mg, yield: 64%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.02 (brs, 1H), 7.37 (s, 1H), 6.65 (brs,2H), 4.40-4.30 (m, 1H), 4.17-4.04 (m, 2H), 3.85-3.73 (m, 1H), 3.10-3.00(m, 2H), 2.50 (overlap, 1H), 1.76 (s, 3H).

Step 4

rac-N-((3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)acetamidewas synthesized as in Preparation D to yield the desired product (34 mg,yield: 48%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.47 (s, 1H), 8.07 (t, J=6 Hz, 1H), 7.90(s, 1H), 7.63 (s, 1H), 6.93 (s, 1H), 4.48 (d, J=8.8 Hz, 1H), 4.26-4.14(m, 2H), 3.93-3.85 (m, 1H), 3.23-3.08 (m, 2H), 2.79 (t, J=7.2 Hz, 4H),2.59 (t, J=6.8 Hz, 4H), 2.50 (overlap, 1H), 2.10-1.90 (m, 4H), 1.83 (s,3H). MS: m/z 474.2 (M+H⁺).

Example 35

Synthesis ofrac-6-((Dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of rac-tert-butyl((3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)carbamate(110 mg, 0.33 mmol) in MeOH (2 mL) was added HCl/dioxane (4 M, 1 mL, 4mmol) at 0° C. After stirring at room temperature for 2 hrs, thesolution was concentrated to give the crude ofrac-6-(aminomethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidehydrochloride, which was directly used for next step without furtherpurification.

Step 2

To a solution ofrac-6-(aminomethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidehydrochloride (crude, 0.33 mmol) in MeOH (2 mL) was added HCHO (1.5 mL)and NaCNBH₃ (20.8 mg, 0.33 mmol). After stirring at room temperature for3 hrs, the reaction was filtered and the filtrate was purified byreverse phase HPLC (MeCN/H₂O) to giverac-6-((dimethylamino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(50 mg, yield: 59%) as a white solid. MS: m/z 261.1 (M+H⁺).

Step 3

rac-6-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation D to yield the desired product (27 mg,yield: 21%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆+CD₃OD): δ=7.37 (s, 1H), 7.32 (s, 1H), 6.75 (s,1H), 4.37 (dd, J=6.8, 2.8 Hz, 1H), 4.10-4.00 (m, 2H), 3.80-3.75 (m, 1H),2.74 (t, J=7.2 Hz, 4H), 2.64 (t, J=7.2 Hz, 4H), 2.47-2.43 (m, 1H), 2.23(d, J=7.2 Hz, 2H), 2.14 (s, 6H), 1.95-1.85 (m, 4H). MS: m/z 460.1(M+H⁺).

Example 36

Synthesis ofrac-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methoxymethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution ofrac-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)-methanol (0.6 g,3.9 mmol) in THF (10 mL) was added NaH (187 mg, 4.7 mmol) followed byMel (667 mg, 4.7 mmol) at 0° C. After being stirred at overnight, thereaction was quenched with the addition of EA (20 mL) and water (20 mL).The organic layer was separated. The aqueous layer was extracted with EA(20 mL). The organic layers were combined, washed with brine (30 mL),dried over Na₂SO₄ and concentrated in vacuo. The residue was purified bysilica gel column (PE/EA=1/1) to giverac-6-methoxymethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (270 mg,yield: 41%) as a yellow solid. MS: m/z 169.3 (M+H⁺).

Step 2

NBS (256 mg, 1.44 mmol) was added portionwise to a solution of6-methoxymethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (230 mg, 1.37mmol) in MeCN (5 mL) at 0° C. and the reaction was stirred for 2 hrs atroom temperature. The mixture was filtered and the filtrate was purifiedby reverse phase HPLC (5%-95% MeCN in H₂O) to give3-bromo-6-(methoxymethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(220 mg, yield: 65%) as a yellow oil. MS: m/z 247.3 (M+H⁺).

Step 3

2,4,6-trichlorophenyl6-(methoxymethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonatewas synthesized using Preparation B to yield the product as a yellow oilwhich was used for next step directly without any purification.

Step 4

6-(methoxymethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation C to yield the desired product (25 mg,yield: 13% over 2 steps) as a light yellow solid.

Step 5

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methoxymethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation D to yield the desired product (9 mg,yield: 20%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.46 (s, 1H), 7.90 (s, 1H), 7.63 (s, 1H),6.93 (s, 1H), 4.51 (dd, J=10.8, 2.8 Hz, 1H), 4.29 (dd, J=11.2, 7.2 Hz,1H), 4.51 (dd, J=12.4, 5.2 Hz, 1H), 4.51 (dd, J=12.4, 7.2 Hz, 1H), 3.43(d, J=3.6 Hz, 2H), 3.25 (s, 3H), 2.79 (t, J=7.2 Hz, 4H), 2.61-2.58 (m,5H), 1.99-1.92 (m, 4H). MS: m/z 446.8 (M+H⁺).

Example 37

Synthesis ofrac-6-Ethoxy-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution ofrac-3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol (700 mg, 3.2mmol) in DMF (10 mL) was added NaH (60% in mineral oil, 192 mg, 4.8mmol). The reaction was stirred at room temperature for 1 hr under N₂.Then iodoethane (549 mg, 3.5 mmol) was added and the mixture was stirredat room temperature for 2 hrs. The reaction mixture was poured intowater (60 mL) and extracted with EA (50 mL). The organic layer waswashed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by reverse phase HPLC (MeCN/H₂O)to give rac-3-bromo-6-ethoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(640 mg, yield: 81%) as a white solid.

MS: m/z 248.9 (M+H⁺).

Step 2

2,4,6-trichlorophenyl6-ethoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate wassynthesized using Preparation B to yield the product as a yellow oilwhich was used for next step directly without any purification.

Step 3

A solution of rac-2,4,6-trichlorophenyl6-ethoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate (crude)and NH₃.H₂O (8.4 mL) in THF (8.4 mL) was stirred at 60° C. for 16 hrs.The mixture was concentrated in vacuo. The residue was purified byreverse phase HPLC (MeCN/H₂O) to giverac-6-ethoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(222.0 mg, yield: 35%) as a white solid.

MS: m/z 247.9 (M+H⁺).

Step 4—Preparation F

To a solution ofrac-6-ethoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(116 mg, 0.47 mmol) in THF (8.0 mL) was added MeONa (28 mg, 0.52 mmol)and the mixture was stirred at room temperature for 20 mins to give asodium salt suspension.

In another flask, to a solution of1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (81 mg, 0.47 mmol) and TEA(142 mg, 1.4 mmol) in THF (10 mL) was added triphosgene (56.0 mg, 0.19mmol) in one portion and the mixture was stirred at room temperatureunder N₂ for 20 mins. The reaction mixture was then filtered. Thefiltrate was added to the sodium salt suspension above and the mixturewas stirred at room temperature for 20 min. After that, the reactionsolution was partitioned between EA (60 mL) and water (60 mL). Theaqueous phase was acidified to pH=5 with conc.HCl and extracted with EA(60 mL). The organic layer was washed with water (50 mL) and brined (50mL), dried over Na₂SO₄ and concentrated until white solid appeared. Thesolid formed was collected by filtration and dried to giverac-6-ethoxy-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(68 mg, yield: 32%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.48 (s, 1H), 7.91 (s, 1H), 7.63 (s, 1H),6.93 (s, 1H), 4.58 (d, J=11.6 Hz, 1H), 4.36 (d, J=11.6 Hz, 1H),4.27-4.24 (m, 1H), 4.18-4.15 (m, 2H), 3.61-3.56 (m, 2H), 2.79 (t, J=7.2Hz, 4H), 2.60 (t, J=7.2 Hz, 4H), 1.99-1.91 (m, 4H), 1.09 (t, J=7.2 Hz,3H). MS: m/z 447.0 (M+H⁺).

Example 38

Synthesis of(R)-6-Ethoxy-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideand(S)-6-ethoxy-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

rac-6-Ethoxy-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(222 mg) was resolved by chiral prep-HPLC to give(R)-6-ethoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(20 mg) as a white solid and(S)-6-ethoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(20 mg) as a white solid.

Step 2

(R)-6-ethoxy-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as described in Preparation F to deliver the desiredproduct (5.0 mg, yield: 14%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.47 (s, 1H), 7.90 (s, 1H), 7.63 (s, 1H),6.93 (s, 1H), 4.58 (d, J=10.0 Hz, 1H), 4.36 (d, J=11.2 Hz, 1H),4.27-4.24 (m, 1H), 4.18-4.15 (m, 2H), 3.59 (q, J=7.2 Hz, 2H), 2.79 (t,J=7.6 Hz, 4H), 2.60 (t, J=7.2 Hz, 4H), 1.99-1.91 (m, 4H), 1.09 (t, J=6.8Hz, 3H). MS: m/z 447.1 (M+H⁺).

(S)-6-ethoxy-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas prepared using the same procedure.

¹H NMR (400 MHz, DMSO-d₆): δ=10.47 (s, 1H), 7.94 (s, 1H), 7.62 (s, 1H),6.93 (s, 1H), 4.59 (d, J=11.6 Hz, 1H), 4.37 (d, J=11.6 Hz, 1H),4.27-4.23 (m, 1H), 4.17-4.15 (m, 2H), 3.53 (q, J=7.2 Hz, 2H), 2.78 (t,J=7.2 Hz, 4H), 2.60 (t, J=7.2 Hz, 4H), 1.98-1.91 (m, 4H), 1.08 (t, J=7.2Hz, 3H). MS: m/z 447.1 (M+H⁺).

Example 39

Synthesis ofN-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-isopropoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of dimethyl malonate (5.0 g, 38.0 mmol) and TEA (7.7 g,76.0 mmol) in MeCN (80 mL) was added 4-acetamidobenzenesulfonyl azide(9.1 g, 38.0 mmol) and the reaction was stirred at room temperature for16 hrs. The reaction was filtered and the filtrate was partitionedbetween water (80 mL) and EA (80 mL). The organic layer was washed withbrine (80 mL), dried over Na₂SO₄ and concentrated. The residue waspurified by silica gel column (PE/EA=10/1) to give dimethyl2-diazomalonate (3.9 g, yield: 53%) as a yellow oil.

Step 2

To a solution of dimethyl 2-diazomalonate (3.4 g, 21.5 mmol) andRh₂(Ac)₄ (36 mg, 0.2 mmol) in DCM (10 mL) was added i-PrOH (132.0 g, 0.2mol) and the reaction was stirred at 70° C. for 4 hrs. The reaction wasconcentrated to dryness. The residue was purified by silica gel column(PE/EA=10/1) to give dimethyl 2-isopropoxymalonate (3.7 g, yield: 90%)as a colorless oil.

¹H NMR (300 MHz, CDCl₃): δ=4.60 (s, 1H), 3.81-3.74 (m, 7H), 1.26 (d,J=6.0 Hz, 6H).

Step 3

To a solution of dimethyl 2-isopropoxymalonate (3.7 g, 19.4 mmol) in dryTHF (30 mL) was added LiBH₄ (2 M in THF, 19.4 mL, 38.7 mol) at 0° C. andthe reaction was stirred at room temperature for 2 hrs. The reaction wasquenched by H₂O (20 mL) and the mixture was dried over MgSO₄. Thereaction was filtered and the filtrate was concentrated to dryness togive 2-isopropoxypropane-1,3-diol (2.5 g, yield: 96%) as a colorlessoil.

¹H NMR (300 MHz, CDCl₃): δ=3.72-3.50 (m, 6H), 1.26 (t, J=5.4 Hz, 2H),1.22 (d, J=6.0 Hz, 6H).

Step 4

To a solution of 2-isopropoxypropane-1,3-diol (2.5 g, 18.7 mmol) and TEA(5.7 g, 56.0 mmol) in dry THF (30 mL) was added MsCl (4.7 g, 41.0 mmol)at 0° C. After stirring at room temperature for 2 hrs, the reaction wasfiltered. The filtrate was concentrated to dryness to give crude2-isopropoxypropane-1,3-diyl dimethanesulfonate as a white solid whichwas used for next step directly without any purification.

Step 5

A mixture of 2-isopropoxypropane-1,3-diyl dimethanesulfonate (crude,˜18.7 mmol), 1,2-dihydro-pyrazol-3-one (1.6 g, 18.7 mmol) and K₂CO₃ (7.7g, 56.0 mmol) in DMF (40 mL) was heated to 100° C. for 16 hrs. Thereaction was cooled and partitioned between EA (150 mL) and water (200mL) and the layers were separated. The organic layer was washed withwater (80 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. Theresidue was purified by silica gel column (PE/EA=1/2) to give6-isopropoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (2.1 g, yield:88%) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=7.33 (s, 1H), 5.49 (s, 1H), 4.31-3.84 (m,5H), 3.84-3.80 (m, 1H), 1.22-118 (m, 6H). MS: m/z 183.3 (M+H⁺).

Step 6

To a solution of 6-isopropoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(1.0 g, 7.8 mmol) in MeCN, was added NBS (1.5 g, 8.6 mmol) at 0° C.under N₂ in two portions. The reaction was then stirred at roomtemperature for 2 hrs. The reaction was partitioned between EA (40 mL)and water (40 mL). The organic layer was washed with water (40 mL) andbrine (40 mL), dried over Na₂SO₄ and concentrated. The residue waspurified by silica gel column (PE/EA=2/1) to give3-bromo-6-isopropoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (1.2 g,yield: 75%) as a yellow solid. MS: m/z 261.2 (M+H⁺).

Step 7

2,4,6-trichlorophenyl6-isopropoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate wassynthesized using Preparation B to yield the product as a yellow gelwhich was used for next step directly without any purification.

6-isopropoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation C to yield the desired product (110mg, yield: 22% over 2 steps) as a yellow solid. MS: m/z 262.3 (M+H⁺).

Step 8

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-isopropoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized using Preparation A to deliver the desired product (18mg, yield: 10%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.47 (brs, 1H), 7.90 (s, 1H), 7.62 (s,1H), 6.93 (s, 1H), 4.49-4.46 (m, 1H), 4.37 (d, J=12.0 Hz, 1H), 4.28-4.24(m, 2H), 4.09-4.06 (m, 1H), 3.87-3.81 (m, 1H), 2.77 (t, J=8.0 Hz, 4H),2.61 (overlap, 4H), 1.97-1.91 (m, 4H), 1.09-1.05 (m, 6H). MS: m/z 461.1(M+H⁺).

Example 40

Synthesis of sodiumrac-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

To a solution of 2-aminopropane-1,3-diol (10.0 g, 0.1 mol) in EtOH (100mL) was added di-tert-butyl dicarbonate (24.0 g, 0.1 mol). The reactionwas stirred at room temperature for 16 hrs. The reaction solution wasconcentrated in vacuo to dryness to give tert-butyl(1,3-dihydroxypropan-2-yl)carbamate (21.0 g, yield: 100%) as a whitesolid.

Step 2

To a solution of tert-butyl (1,3-dihydroxypropan-2-yl)carbamate (21.0 g,0.1 mol) and TEA (23.0 g, 0.2 mol) in dry CH₂Cl₂ (200 mL) was added MsCl(26.0 g, 0.2 mol) at 0° C. After the stirring at room temperature for 2hrs, the reaction was filtered. The filtrate was concentrated to drynessto give crude 2-((tert-butoxycarbonyl)amino)propane-1,3-diyldimethanesulfonate (37.0 g, yield: 97%) as a white solid which was usedfor next step directly without any purification.

Step 3

2-((tert-butoxycarbonyl)amino)propane-1,3-diyl dimethanesulfonate (37.3g, 0.11 mol), 1H-pyrazol-3(2H)-one (9.0 g, 0.11 mol) and K₂CO₃ (30.0 g,0.22 mol) in DMF (300 mL) were heated at 120° C. for 16 hrs. Afterconcentration, the residue was partitioned between EA (300 mL) and water(500 mL). The aqueous layer was extracted with EA (300 mL). The combinedorganic layer was washed with brine (100 mL), dried over Na₂SO₄,filtered and concentrated in vacuo to dryness to give rac-tert-butyl(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (8.8 g, yield:34%) as a yellow solid. MS: m/z 240.0 (M+H⁺).

Step 4

NBS (6.5 g, 37.0 mmol) was added portionwise to a solution ofrac-tert-butyl (6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(8.8 g, 37.0 mmol) in MeCN (100 mL) at 0° C. and the reaction wasstirred for 2 hrs at room temperature. The reaction mixture wasconcentrated. The residue was purified by silica gel column (PE/EA=5/1)to give rac-tert-butyl(3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (2.5g, yield: 21%) as a yellow solid. MS: m/z 319.9 (M+H⁺).

Step 5

To a solution of rac-tert-butyl(3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (900mg, 2.8 mmol) in DMF (10 mL) was added NaH (60% in mineral oil, 226 mg,5.7 mmol). The reaction was stirred at room temperature for 1 hr underN₂. Then iodomethane (2.0 g, 14.2 mmol) was added and the mixture wasstirred at room temperature for 2 hrs. The reaction mixture was pouredinto water (60 mL) and extracted with EA (50 mL). The organic layer waswashed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by reverse phase HPLC (MeCN/H₂O)to give rac-tert-butyl(3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamate(550 mg, yield: 59%) as a yellow solid.

¹H NMR (300 MHz, CDCl₃): δ=7.36 (s, 1H), 4.6 (br, 1H), 4.38-4.29 (m,4H), 2.82 (d, J=3.6 Hz, 3H), 1.50 (s, 9H). MS: m/z 333.9 (M+H⁺).

Step 6

rac-2,4,6-trichlorophenyl6-((tert-butoxycarbonyl)(methyl)amino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonatewas synthesized using Preparation B to yield the product as a yellow oilwhich was used for next step directly without any purification.

Step 7

A solution of rac-2,4,6-trichlorophenyl6-((tert-butoxycarbonyl)(methyl)amino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate(crude) and NH₃.H₂O (3.0 mL) in THF (5.0 mL) was stirred at 60° C. for16 hrs. The mixture was concentrated in vacuo. The residue was purifiedby silica gel column (CH₂Cl₂/MeOH=25/1) to give tert-butylmethyl(3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(26.0 mg, yield: 8%, 2 steps) as a colorless oil.

¹H NMR (400 MHz, CDCl₃): δ=7.64 (s, 1H), 5.14 (br, 2H), 4.68 (br, 1H),4.53-4.44 (m, 2H), 4.38-4.26 (m, 2H), 2.84 (s, 3H), 1.48 (s, 9H). MS:m/z 276.9 (M−56+H⁺).

Step 8

tert-Butyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamatewas synthesized as in Preparation D to yield the desired product (40 mg,yield: 95%) as a white solid. MS: m/z 476.0 (M−55⁻).

Step 9

To a solution of tert-butyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamate(40 mg, 0.08 mmol) in CH₂Cl₂ (2 mL) was added TFA (0.6 mL) and themixture was stirred at room temperature for 30 mins. Then the mixturewas concentrated in vacuo to remove off the solvent. The residue wastreated with 2 M NaOH solution to pH>13. The resulting solution waspurified by reverse phase HPLC (MeCN/H₂O) to give rac-sodium((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(25.0 mg, 78%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.33 (s, 1H), 7.30 (s, 1H), 6.75 (s, 1H),4.25-4.10 (m, 3H), 3.83-3.79 (m, 1H), 3.07 (m, 1H), 2.77-2.73 (m, 4H),2.67-2.63 (m, 4H), 2.33 (s, 3H), 1.92-1.88 (m, 4H). MS: m/z 432.1(M+H⁺).

Example 41

Synthesis of sodium(R)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideand sodium(S)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

rac-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(400 mg, 1.2 mmol) was resolved by chiral prep-HPLC to give(R)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(240 mg, yield: 60%) as a white solid and(S)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(150 mg, yield: 37%) as a white solid.

Step 2:

(R)-tert-butyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamatewas synthesized as in Preparation D to yield the desired product (200mg, yield: 52%) as a white solid.

(S)-tert-butyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamatewas prepared using the same procedure.

Step 3

To a solution of (R)-tert-butyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamate(250 mg, 0.75 mmol) in CH₂Cl₂ (5 mL) was added TFA (2 mL) and themixture was stirred at room temperature for 30 mins. Then the mixturewas concentrated in vacuo to remove the solvent. The residue was treatedwith 2 M NaOH solution to pH>13. The resulting solution was purified byreverse phase HPLC (MeCN/H₂O) to give sodium(R)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(130 mg, 30%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.50 (s, 1H), 7.38 (s, 1H), 6.8 (s, 1H),4.28 (dd, J=10.8 Hz, 2.4 Hz, 1H), 4.20-4.10 (m, 2H), 3.85 (dd, J=11.6Hz, 4.8 Hz, 1H), 3.14-3.06 (m, 1H), 2.76 (t, J=7.2 Hz, 4H), 2.64 (t,J=7.2 Hz, 4H), 2.33 (s, 3H), 1.97-1.86 (m, 4H). MS: m/z 432.1 (M+H⁺).

Sodium(S)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidewas prepared using the same procedure.

¹H NMR (400 MHz, DMSO-d6): δ=7.35 (s, 1H), 7.30 (s, 1H), 6.75 (s, 1H),4.27-4.21 (m, 1H), 4.17-4.12 (m, 1H), 4.08-4.05 (m, 1H), 3.84-3.77 (m,1H), 3.11-3.03 (m, 1H), 2.76 (t, J=8.0 Hz, 4H), 2.65 (t, J=7.6 Hz, 4H),2.33-2.27 (m, 3H), 1.97-1.83 (m, 4H). MS: m/z 432.1 (M+H⁺).

Example 42

Synthesis of(R)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

A mixture of 1-acetyl-1,2-dihydro-pyrazol-3-one (10.0 g, 0.79 mmol),(S)-oxiran-2-ylmethanol (7.0 g, 95 mmol) and PPh₃ (31.0 g, 118.5 mmol)in THF (100 mL) was cooled to 0° C. under N₂. To the mixture was addedDIAD (23.3 mL, 118.5 mmol) in THF (25 mL) slowly. The reaction wasstirred for additional 1 hour at 0° C. The reaction was then stirred atroom temperature overnight. The reaction mixture was concentrated invacuo and the residue was purified by silica gel column (PE/EA=10/1) togive (S)-1-acetyl-2-(oxiran-2-ylmethyl)-1H-pyrazol-3(2H)-one (10.1 g,yield: 70%) as a white solid.

¹H NMR (400 MHz, CDCl₃): δ=8.07 (d, J=2.8 Hz, 1H), 6.00 (d, J=2.8 Hz,1H), 4.56-4.51 (m, 1H), 4.21-4.15 (m, 1H), 3.41-3.34 (m, 1H), 2.93-2.89(m, 1H), 2.77-2.74 (m, 1H), 2.58 (s, 3H).

Step 2

To a solution of (S)-1-acetyl-2-(oxiran-2-ylmethyl)-1H-pyrazol-3(2H)-one(55.0 g, 300 mmol) in AcOH (52 mL, 900 mmol) and THF (250 mL), was addedLiCl.H₂O (29.0 g, 480 mmol) at 0° C. in batches. The reaction was thenstirred at room temperature overnight. After removal of AcOH and THF invacuo, the residue was partitioned between EA (200 mL) and water (200mL). The aqueous layer was extracted with EA (50 mL×4). The combinedorganic layer was washed with saturated NaHCO₃ solution and brine (100mL), dried over Na₂SO₄ and concentrated in vacuo to give crude(S)-1-acetyl-2-(3-chloro-2-hydroxypropyl)-1H-pyrazol-3(2H)-one (59.0 g,90%) as a colorless oil which was used for next step directly withoutany purification.

¹H NMR (400 MHz, CDCl₃): δ=8.07 (d, J=3.2 Hz, 1H), 6.00 (d, J=3.2 Hz,1H), 4.41 (d, J=4.8 Hz, 2H), 4.28-4.20 (m, 1H), 3.78-3.64 (m, 2H), 2.58(s, 3H).

Step 3

A mixture of(S)-1-acetyl-2-(3-chloro-2-hydroxypropyl)-1H-pyrazol-3(2H)-one (65.4 g,0.3 mol), K₂CO₃ (82.8 g, 0.6 mol) and KI (9.96 g, 60 mmol) in DMF (500mL) was stirred at 130° C. overnight. The solvent was removed underreduced pressure. The residue was purified by silica gel column (EA) togive (S)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol (27.6 g, yield:66%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.22 (d, J=2.0 Hz, 1H), 5.44 (d, J=2.0 Hz,1H), 4.28-4.09 (m, 4H), 3.94-3.87 (m, 1H).

Step 4

To a solution of (S)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol(28.0 g, 0.2 mol) in pyridine (200 mL) was added methanesulfonylchloride (23.0 g, 0.2 mol). The reaction was stirred at room temperaturefor 30 mins. The reaction solution was concentrated in vacuo to drynessand the residue was partitioned between EA (300 mL) and water (500 mL).The aqueous layer was extracted with EA (300 mL). The combined organiclayer was washed with brine (100 mL), dried over Na₂SO₄, filtered andconcentrated in vacuo to dryness to give(S)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl methanesulfonate(44.0 g, yield: 99%) as a white solid which was used for next stepdirectly without any purification.

Step 5

A mixture of (S)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ylmethanesulfonate (44.0 g, 0.2 mol) and NaN₃ (26.0 g, 0.4 mol) in dry DMF(300 mL) was stirred at 120° C. for 2 hrs. Then the mixture was used fornext step directly without any purification.

Step 6

A solution of (R)-6-azido-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine(crude solution in DMF), Boc₂O (44 g, 0.2 moL) and Pd/C (3.0 g) in MeOH(300 mL) was stirred at room temperature under a hydrogen atmosphere (50Psi) for 16 hrs. The reaction mixture was filtered and concentrated todryness in vacuo. The residue was purified by silica gel column(PE/EA=1/1) to give (R)-tert-butyl(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (30 g, 63%) asa white solid.

Step 7

NBS (10.7 g, 60.0 mmol) was added portionwise to a solution of(R)-tert-butyl (6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(14.0 g, 60.0 mmol) in MeCN (200 mL) at 0° C. and the reaction wasstirred for 2 hrs at room temperature. After filtration, the filtratewas concentrated. The residue was purified by silica gel column(PE/EA=1/2) to give (R)-tert-butyl(3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (20.5g, crude) as a yellow solid. MS: m/z 320.0 (M+H⁺).

Step 8

To a solution of (R)-tert-butyl(3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate (20.5g, 64.4 mmol) in DMF (150 mL) was added NaH (60% in mineral oil, 5.2 g,130.0 mmol). The reaction was stirred at room temperature for 1 hr underN₂. Then iodomethane (46.0 g, 320.0 mmol) was added and the mixture wasstirred at room temperature for 2 hrs. The reaction mixture was pouredinto water (300 mL) and extracted with EA (300 mL). The organic layerwas washed with water (150 mL), brine (50 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by silica gel column (PE/EA=3/1)to give (R)-tert-butyl(3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamate(18 g, yield: 90%) as a white solid. MS: m/z 334.0 (M+H⁺).

Step 9

(R)-2,4,6-trichlorophenyl6-((tert-butoxycarbonyl)(methyl)amino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonatewas synthesized using Preparation B to yield the product as a yellow oilwhich was used for next step without purification.

Step 10

A solution of (R)-2,4,6-trichlorophenyl6-((tert-butoxycarbonyl)(methyl)amino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonate(crude) and NH₃.H₂O (12.0 mL) in THF (50.0 mL) was stirred at 60° C. for16 hrs. The mixture was concentrated in vacuo. The residue was purifiedby silica gel column (DCM/MeOH=25/1) to give (R)-tert-butylmethyl(3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(1.8 g, yield: 25%, 2 steps) as a yellow solid. MS: m/z 333.1 (M+H⁺).

Step 11

(R)-tert-butyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamatewas synthesized as in Preparation D to yield the desired product (230mg, yield: 96%) as a yellow solid.

Step 12

To a solution of (R)-tert-butyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamate(230 mg, 0.43 mmol) in CH₂Cl₂ (2 mL) was added TFA (0.6 mL) and themixture was stirred at room temperature for 30 mins. Then the mixturewas concentrated in vacuo to remove the solvent. The residue was treatedwith 2 M NaOH solution to pH>13. The resulting solution was purified byreverse phase HPLC (0%-50% MeCN in H₂O) to give sodium(s)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(150.0 mg, 80%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.41 (s, 1H), 7.33 (s, 1H), 6.76 (s, 1H),4.26 (d, J=9.2 Hz, 1H), 4.19-4.07 (m, 2H), 3.84-3.80 (m, 1H), 3.09 (br,1H), 2.75 (t, J=7.2 Hz, 4H), 2.66 (t, J=7.2 Hz, 4H), 2.34 (s, 3H),1.94-1.87 (m, 4H). MS: m/z 432.1 (M+H⁺).

Example 43

Synthesis ofrac-6-(Ethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1˜3

These three steps are similar to general procedure of sodium((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide.

Step 4

rac-tert-Butylethyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamatewas synthesized as described in Preparation F to deliver the desiredproduct (100 mg, yield: 64%) as a white solid. MS: m/z 546.3 (M+H⁺)

Step 5

To a solution of rac-tert-butylethyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(100 mg, 0.2 mmol) in CH₂Cl₂ (2 mL) was added TFA (1 mL) and the mixturewas stirred at room temperature for 30 mins. Then the mixture wasconcentrated to remove the solvent. The residue was co-evaporated withCH₂Cl₂(5 mL×3) and then purified by reverse phase HPLC [0%-95% MeCN inH₂O (0.1% NH₃.H₂O)] to giverac-6-(ethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(60 mg, 73%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.91 (s, 1H), 7.62 (s, 1H), 6.93 (s, 1H),4.41 (dd, J=11.2, 2.4 Hz, 1H), 4.31 (dd, J=10.8, 4.8 Hz, 1H), 4.24 (dd,J=12.8, 4.4 Hz, 1H), 3.95 (dd, J=12.8, 4.4 Hz, 1H), 3.33 (overlap, 1H),2.79 (t, J=7.2 Hz, 4H), 2.68-2.58 (m, 6H), 2.00-1.91 (m, 4H), 1.01 (t,J=7.2 Hz, 3H). MS: m/z 446.1 (M+H⁺).

Example 44

Synthesis of(R)-6-(Ethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidehydrochloride and(S)-6-(ethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidehydrochloride is shown below.

Step 1

rac-tert-Butylethyl(3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(120 mg) was resolved by chiral prep-HPLC to give

(R)-tert-butylethyl(3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(peak 1, 52 mg) and (S)-tert-butylethyl(3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(peak 2, 48 mg).

Step 2

This step is similar to general procedure ofrac-6-(ethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide.

Step 3

To a solution of (R)-tert-butylethyl(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(40 mg, 0.1 mmol) in CH₂Cl₂ (2 mL) was added TFA (1 mL) and the mixturewas stirred at room temperature for 30 mins. Then the mixture wasconcentrated to remove the solvent. The residue was co-evaporated withCH₂Cl₂ (5 mL×3) and then neutralized to pH=8 with sat.NaHCO₃. Theresulting solution was acidified to pH=5 with aq.HCl (2 N) and thenpurified by reverse phase HPLC [0%-95% MeCN in H₂O] to give(R)-6-(ethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidehydrochloride (15 mg, 22%) as a white solid.

¹H NMR (300 MHz, DMSO-d₆): δ=7.74 (s, 1H), 7.52 (s, 1H), 6.88 (s, 1H),4.38-4.33 (m, 1H), 4.24-4.17 (m, 2H), 3.92-3.85 (m, 1H), 3.32 (overlap,1H), 2.77 (t, J=7.2 Hz, 4H), 2.64-2.59 (m, 6H), 2.00-1.89 (m, 4H), 1.00(t, J=7.2 Hz, 3H). MS: m/z 446.1 (M+H⁺).

(S)-6-(ethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidehydrochloride was prepared using the same procedure.

¹H NMR (400 MHz, DMSO-d₆): δ=7.89 (s, 1H), 7.60 (s, 1H), 6.93 (s, 1H),4.41 (dd, J=10.8, 2.4 Hz, 1H), 4.31 (dd, J=10.8, 5.2 Hz, 1H), 4.24 (dd,J=12.4, 4.4 Hz, 1H), 3.95 (dd, J=12.4, 4.4 Hz, 1H), 3.00 (overlap, 1H),2.78 (t, J=7.6 Hz, 4H), 2.63-2.58 (m, 6H), 1.97-1.93 (m, 4H), 1.01 (t,J=7.2 Hz, 3H). MS: m/z 446.1 (M+H⁺).

Example 45

Synthesis of Sodium(R)-((8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

To a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-amine (3.0 g, 17.3mmol) in THF/H₂O/HBF₄ (45 mL/7 mL/22 mL) was added a solution of NaNO₂(1.3 g, 18.2 mmol) in H₂O (3 mL) dropwise at −10° C. under N₂. Afterstirring with cooling for 2 hrs, the cold bath was removed and thereaction was partitioned between water (100 mL) and EA (100 mL). Theorganic layer was washed with sat.NaHCO₃ (50 mL), brine (50 mL), driedover Na₂SO₄ and concentrated. The residue was purified by silica gelcolumn (PE) to give 4-fluoro-1,2,3,5,6,7-hexahydro-s-indacene (1.4 g,yield: 46%) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=6.88 (s, 1H), 2.92-2.87 (m, 8H), 2.17-2.07(m, 4H).

Step 2

To a solution of 4-fluoro-1,2,3,5,6,7-hexahydro-s-indacene (1.4 g, 8.0mmol) in MeCN (20 mL) was added NO₂BF₄ (1.3 g, 9.8 mmol) at 0° C. underN₂ in two portions. The reaction was then stirred at 0° C. for 1 hr. Thereaction was partitioned between EA (100 mL) and water (100 mL). Theorganic layer was washed with water (20 mL) and brine (20 mL), driedover Na₂SO₄ and concentrated. The residue was purified by silica flashcolumn (0% 45% EA in PE) to give4-fluoro-8-nitro-1,2,3,5,6,7-hexahydro-s-indacene (1.4 g, yield: 80%) asa white solid.

¹H NMR (400 MHz, CDCl₃): δ=3.30 (t, J=6.8 Hz, 4H), 2.95 (t, J=7.6 Hz,4H), 2.22-2.13 (m, 4H).

Step 3

To a solution of 4-fluoro-8-nitro-1,2,3,5,6,7-hexahydro-s-indacene (1.4g, 6.3 mmol) in MeOH (20 mL) was added 10% Pd/C (200 mg). After stirringat room temperature under balloon hydrogen atmosphere overnight, thereaction mixture was filtered. The filtrate was evaporated in vacuo todryness and the residue was purified by silica flash column (0% 45% EAin PE) to give 8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-amine (1.1 g,yield: 91%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=4.42 (s, 2H), 2.75 (t, J=7.6 Hz, 4H), 2.62(t, J=7.6 Hz, 4H), 2.05-1.97 (m, 4H). MS: m/z 192.4 (M+H⁺).

Step 4

(R)-tert-butyl(3-(N-((8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamatewas synthesized as in Preparation D to yield the desired product (1.8 g,yield: 72%) as a yellow solid. MS: m/z 550.2 (M+H⁺).

Step 5

To a solution of (R)-tert-butyl(3-(N-((8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamate(1.8 g, 3.3 mmol) in CH₂Cl₂ (8 mL) was added TFA (8 mL) and the mixturewas stirred at room temperature for 30 mins. Then the mixture wasconcentrated in vacuo to remove the solvent. The residue was treatedwith 2 N aq.NaOH to PH>13. The resulting solution was purified byreverse phase HPLC (MeCN/H₂O) to give sodium(R)-((8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(1.2 g, 80%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.42 (s, 1H), 7.32 (s, 1H), 4.28-4.24 (m,1H), 4.16 (q, J=4.8 Hz, 1H), 4.09 (q, J=6.0 Hz, 1H), 3.82 (q, J=5.2 Hz,1H), 3.08 (br, 1H), 2.78 (t, J=7.6 Hz, 4H), 2.71 (t, J=7.6 Hz, 4H), 2.33(s, 3H), 1.99-1.93 (m, 4H). MS: m/z 450.1 (M+H⁺).

Example 46

Synthesis of(R)—N-((8-Fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

To a solution of(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic acidamide (80 mg, 0.34 mmol) in THF (10 mL) was added MeONa (54 mg, 1.0mmol) and the mixture was stirred at room temperature for 30 mins togive a sodium salt suspension.

In another flask, to a solution of8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-amine (66 mg, 0.34 mmol) andTEA (102 mg, 1 mmol) in THF (10 mL), was added triphosgene (40 mg, 0.14mmol) in one portion and the mixture was stirred at room temperatureunder N₂ for 30 mins. The reaction mixture was then filtered. Thefiltrate was added to the sodium salt suspension above and stirred atroom temperature for overnight. After that, the reaction solution waspartitioned between EA (10 mL) and water (5 mL). The aqueous phase wasacidified to pH=5 with 1 N HCl. The solid formed was collected byfiltration and dried to give(R)—N-((8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(27 mg, yield: 17.6%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.55 (brs, 1H), 7.91 (brs, 1H), 7.61 (s,1H), 4.62 (d, J=11.6 Hz, 1H), 4.35 (d, J=11.6 Hz, 1H), 4.18-4.27 (m,2H), 4.06 (s, 1H), 3.35 (s, 3H), 2.82 (t, J=7.2 Hz, 4H), 2.64 (t, J=7.6Hz, 4H), 1.98-2.05 (m, 4H) MS: m/z 450.8 (M+H⁺).

Example 47

Synthesis of sodium(R)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(prop-2-yn-1-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

To a solution ofrac-N,N-dibenzyl-6-(3-hydroxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(840 mg, 2.1 mmol) in DMF (10 mL) was added NaH (60% in mineral oil,126.0 mg, 3.2 mmol). The reaction was stirred at room temperature for 1hr under N₂. Then 3-bromoprop-1-yne (273.0 mg, 2.3 mmol) was added andthe mixture was stirred at room temperature for 2 hrs. The reactionmixture was poured into water (20 mL) and extracted with EA (20 mL). Theorganic layer was washed with water (10 mL) and brine (10 mL), driedover Na₂SO₄ and concentrated to dryness to giverac-N,N-dibenzyl-6-(prop-2-yn-1-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(580 mg, yield: 63%) as a yellow solid.

¹H NMR (300 MHz, CDCl₃): δ=7.63 (s, 1H), 7.25-7.16 (m, 10H), 4.52-4.17(m, 11H), 2.55 (s, 1H). MS: m/z 438.1 (M+H⁺).

Step 2

To a stirred solution ofrac-N,N-dibenzyl-6-(prop-2-yn-1-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(115 mg, 0.3 mmol) in CH₂Cl₂ (3.0 mL) was added conc.H₂SO₄ (16 drops,0.32 mL) and stirred at 0° C. for 10 mins. The reaction solution wasconcentrated. The residue was neutralized with saturated NaHCO₃solution. Then the mixture was filtered off the solid and the filtratewas purified by reverse phase HPLC (MeCN/H₂O) to giverac-6-(prop-2-yn-1-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(23.0 mg, yield: 34%) as a yellow solid.

MS: m/z 258.0 (M+H⁺).

Step 3

rac-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(prop-2-yn-1-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidewas synthesized as in Preparation D to yield the desired product (20.0mg, yield: 49%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.86 (brs, 1H), 7.85 (s, 1H), 6.92 (s, 1H),4.63-4.59 (m, 1H), 4.40-4.25 (m, 6H), 3.52 (t, J=2.4 Hz, 1H), 2.79 (t,J=7.2 Hz, 4H), 2.62 (t, J=7.2 Hz, 4H), 1.99-1.92 (m, 4H). MS: m/z 457.1(M+H⁺).

Example 48

Synthesis of sodiumrac-((6-(((tert-butoxycarbonyl)(methyl)amino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amideis shown below.

Step 1

To a solution of rac-tert-butyl((3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)carbamate(0.3 g, 0.9 mmol) in THF (3 mL) was added NaH (60%, 108 mg, 2.7 mmol)followed by Mel (639 mg, 4.5 mmol) at 0° C. After stirring at roomtemperature for 16 hrs, the suspension was quenched with the addition ofEA (20 mL) and water (10 mL). The organic layer was separated. Theaqueous layer was extracted with EA (10 mL). The organic layers werecombined, washed with brine (10 mL), dried over Na₂SO₄ and concentratedin vacuo. The residue was purified by silica gel column (PE/EA=2/1) togive rac-tert-butyl((3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)(methyl)carbamate(290 mg, yield: 93%) as a yellow oil.

Step 2

rac-2,4,6-trichlorophenyl6-(((tert-butoxycarbonyl)(methyl)amino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonatewas synthesized using Preparation B to yield the product as a yellow oilwhich was used for next step without purification.

Step 3

rac-tert-Butylmethyl((3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)carbamatewas synthesized as in Preparation C to yield the desired product (60 mg,yield: 16% over 2 steps) as a light yellow solid. MS: m/z 369.4 (M+Na⁺).

Step 4

Sodium((6-(((tert-butoxycarbonyl)(methyl)amino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amidewas synthesized as in Preparation D to yield the desired product (28 mg,yield: 31%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.33 (s, 1H), 7.31 (s, 1H), 6.75 (s, 1H),4.28 (d, J=10.4 Hz, 1H), 4.10-4.0 (m, 2H), 3.80-3.73 (m, 1H), 3.25-3.15(m, 2H), 2.80 (s, 3H), 2.74 (t, J=7.2 Hz, 4H), 2.64 (t, J=7.2 Hz, 4H),2.50 (overlap, 1H), 1.95-1.85 (m, 4H), 1.41-1.31 (m, 9H). MS: m/z 546.2(M+H⁺).

Example 49

Synthesis of sodium((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-((methylamino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

To a solution of sodiumrac-((6-(((tert-butoxycarbonyl)(methyl)amino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amide(15 mg, 0.03 mmol) in CH₂Cl₂ (2 mL) was added TFA (0.6 mL) and themixture was stirred at room temperature for 30 mins. Then the mixturewas concentrated in vacuo to remove the solvent. The residue was added 2N NaOH solution to pH>13. The resulting solution was purified by reversephase HPLC (MeCN/H₂O) to give sodiumrac-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-((methylamino)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(10 mg, 80%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.36 (s, 1H), 6.77 (s, 1H), 4.39 (dd,J=11.2 Hz, 2.8 Hz, 1H), 4.20-4.1 (m, 2H), 3.83 (dd, J=12.4 Hz, 7.6 Hz,1H), 3.42 (m, 5H), 3.16-3.11 (m, 1H), 2.75 (t, J=7.2 Hz, 4H), 2.66 (t,J=7.2 Hz, 4H), 1.96-1.86 (m, 4H). MS: m/z 446.1 (M+H⁺).

Example 50

Synthesis of(R)-6-Ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideand(S)-6-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of dimethyl 2-ethylmalonate (1.8 g, 9.6 mmol) in THF (10mL) was added LiBH₄ (2 M in THF, 9.6 mL, 19.2 mmol) dropwise at 0° C.under N₂ atmosphere. The reaction mixture was stirred at roomtemperature for 16 hrs and then poured to water (40 mL). The resultingsolution was concentrated to about 5 mL and mixed with EA (50 mL). Themixture was stirred vigorously for 5 mins, dried with MgSO₄ andconcentrated to give 2-ethylpropane-1,3-diol (970 mg, yield: 97%) as acolorless oil.

Step 2

To a solution of 2-ethylpropane-1,3-diol (970 mg, 9.3 mol) and Et₃N (2.4g, 23.8 mmol) in dry THF (20 mL) was added MsCl (2.2 g, 19.3 mmol) at 0°C. After being stirred at room temperature for 30 mins, the reactionmixture was filtered. The filtrate was concentrated to dryness to givecrude 2-ethylpropane-1,3-diyl dimethanesulfonate as a yellow oil.

Step 3

A mixture of 2-ethylpropane-1,3-diyl dimethanesulfonate (crude),1H-pyrazol-3(2H)-one (750 mg, 8.9 mmol) and K₂CO₃ (4.3 g, 31.2 mmol) inDMF (40 mL) was heated at 100° C. for 16 hrs. The reaction mixture waspartitioned between EA/H₂O (80 mL/200 mL) and the layers were separated.The aqueous layer was extracted with EA (80 mL×3) and the combinedorganic layer was washed with brine (50 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by silica gel column (PE/EA=3/1)to give rac-6-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (650 mg,yield: 48%) as a colorless oil.

¹H NMR (300 MHz, CDCl₃): δ=7.32 (d, J=1.5 Hz, 1H), 5.48 (d, J=1.5 Hz,1H), 4.34-4.26 (m, 2H), 3.95-3.87 (m, 1H), 3.81-3.73 (m, 1H), 2.30-2.19(m, 1H), 1.60-1.40 (m, 2H), 1.05 (t, J=7.5 Hz, 3H).

Step 4

rac-6-Ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine (650 mg, 4.3mmol) was added dropwise to ClSO₃H (4 mL) at 0° C. After being stirredat 80° C. for 2 hrs, the reaction mixture was added dropwise to amixture of ice-water/EA (30 mL/20 mL). The layers were separated and theaqueous layer was extracted with EA (10 mL×2). The combined organiclayer was washed with brine (20 mL), dried over Na₂SO₄ and concentratedto give cruderac-6-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride as a yellow solid.

Step 5

To a solution of cruderac-6-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride in THF (3 mL) was added NH₃.H₂O (1 mL). After being stirred at60° C. for 1 h, the reaction mixture was concentrated to dryness. Theresidue was dissolved in MeOH (3 mL) and acidified with aq.HCl (1 N) topH=3. The residue was purified by reverse phase HPLC (0%-95% MeCN inH₂O) to giverac-6-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(200 mg, yield: 20%, two steps) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.48 (s, 1H), 7.08 (s, 2H), 4.48-4.44 (m,1H), 4.21 (dd, J=12.4, 5.6 Hz, 1H), 4.12-4.07 (m, 1H), 3.81-3.75 (m,1H), 2.24-2.17 (m, 1H), 1.47-1.32 (m, 2H), 0.96 (t, J=7.2 Hz, 3H).

Step 6

rac-6-Ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(200 mg) was separated by chiral HPLC to give two isomers:

(R)-6-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(peak 1, 80 mg) and(S)-6-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(peak 2, 83 mg).

Step 7

(S)-6-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized using Preparation A to deliver the desired product (53mg, yield: 34%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.48 (brs, 1H), 7.90 (s, 1H), 7.61 (s,1H), 6.93 (s, 1H), 4.51 (d, J=2.8 Hz, 1H), 4.48-4.15 (m, 2H), 3.82-3.77(m, 1H), 2.78 (t, J=7.2 Hz, 4H), 2.60 (t, J=6.8 Hz, 4H), 2.20-1.98 (m,1H), 1.97-1.91 (m, 4H), 1.45-1.11 (m, 2H), 0.96 (t, J=7.6 Hz, 3H). MS:m/z 431.1 (M+H⁺).

(R)-6-Ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas prepared using the same procedure.

¹H NMR (400 MHz, DMSO-d₆): δ=10.46 (s, 1H), 7.90 (s, 1H), 7.62 (s, 1H),6.93 (s, 1H), 4.50 (dd, J=10.8, 3.2 Hz, 1H), 4.24-4.13 (m, 2H),3.83-3.78 (m, 1H), 2.79 (t, J=7.2 Hz, 4H), 2.59 (t, J=7.2 Hz, 4H),2.21-2.19 (m, 1H), 1.99-1.92 (m, 4H), 1.42-1.35 (m, 2H), 0.95 (t, J=7.2Hz, 3H). MS: m/z 431.1 (M+H⁺).

Example 51

Synthesis of6-(3-Fluoroazetidin-1-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid 2,4,6-trichloro-phenyl ester was synthesized using Preparation B toyield the product as a yellow gel which was used for next step withoutpurification.

Step 2

A mixture of6-(tetrahydro-pyran-2-yloxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid 2,4,6-trichloro-phenyl ester (crude, ˜6.6 mmol), dibenzylamine (2.5g, 12.0 mmol) and THF (20 mL) was stirred at 60° C. overnight. Thereaction was concentrated under reduced pressure until 10 mL of liquidremained. The remained solution was acidified with aq.HCl (1 N) to pH=5and extracted with EA (100 mL×5). The organic layers were combined,dried over Na₂SO₄ and concentrated to giveN,N-dibenzyl-6-((tetrahydro-2H-pyran-2-yl)oxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(1.5 g, yield: 51%) as a yellow solid.

MS: m/z 484.2 (M+H⁺).

Step 3

To a solution ofN,N-dibenzyl-6-((tetrahydro-2H-pyran-2-yl)oxy)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(6.1 g, 12.6 mmol) in THF/H₂O/EtOH (50 mL/10 mL/50 mL) was addedconc.HCl (10 mL) and the mixture was stirred at room temperatureovernight. The reaction was concentrated under reduced pressure. Theresidue was purified by reverse phase HPLC (MeCN/H₂O) to giveN,N-dibenzyl-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(4.0 g, yield: 80%) as a white solid. MS: m/z 400.1 (M+H⁺).

Step 4

A solution ofN,N-dibenzyl-6-hydroxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(3.4 g, 8.5 mmol) and Dess-Martin periodiane (7.2 g, 17.0 mmol) inCH₂Cl₂ (50.0 mL) was stirred at room temperature for 16 hrs. The mixturewas concentrated in vacuo. The residue was purified by silica gel columnchromatography (PE:EA=1:2) to giveN,N-dibenzyl-6-oxo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(3.0 g, yield: 91%) as a yellow solid.

Step 5

To a stirred solution ofN,N-dibenzyl-6-oxo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(397.0 mg, 1.0 mmol) and 3-fluoroazetidine hydrochloride (224.0 mg, 2.0mmol) in MeOH (10.0 mL) was added sodium triacetoxyborohydride (424.0mg, 2.0 mmol) at room temperature. After stirring at room temperaturefor 30 mins, sodium cyanotrihydroborate (126 mg, 2.0 mmol) was added tothe mixture. The reaction was stirred at room temperature for 16 hrs andconcentrated in vacuo. The residue was purified by silica gel columnchromatography (CH₂Cl₂/MeOH=5/1) to giveN,N-dibenzyl-6-(3-fluoroazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(160 mg, yield: 35%) as a yellow solid.

Step 6

To a solution ofN,N-dibenzyl-6-(3-fluoroazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(140 mg, 0.3 mmol) in CH₂Cl₂ (3.0 mL) was added conc.H₂SO₄ (16 drops,0.32 mL) and the mixture was stirred at room temperature for 30 mins.The reaction solution was concentrated. The residue was neutralized withsaturated NaHCO₃ solution and filtered. The filtrate was purified byreverse phase HPLC (0%-95% MeCN in H₂O) to give6-(3-fluoroazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(60.0 mg, yield: 71%) as a yellow solid.

Step 7

6-(3-fluoroazetidin-1-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as described in Preparation F to deliver the desiredproduct (11.0 mg, yield: 11%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.48 (brs, 1H), 7.87 (s, 1H), 7.58 (s,1H), 6.93 (s, 1H), 5.20-5.17 (m, 0.5H), 5.06-5.03 (m, 0.5H), 4.32 (q,J=6.0 Hz, 2H), 4.17 (dd, J=12.8, 4.0 Hz, 1H), 3.89 (d, J=13.2 Hz, 1H),3.65-3.60 (m, 2H), 3.28 (overlap, 2H), 3.09 (d, J=4.0 Hz, 1H), 2.79 (t,J=7.6 Hz, 4H), 2.61 (t, J=7.6 Hz, 4H), 1.99-1.94 (m, 4H). MS: m/z 476.1(M+H⁺).

Example 52

Synthesis of sodium((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)((6-(pyrrolidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

To a solution of6-oxo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonic aciddibenzylamide (750 mg, 1.9 mmol) and pyrrolidine (270 mg, 3.8 mmol) inMeOH (18 mL) was added AcOH until pH=6. Then NaBH(OAc)₃ (810 mg, 3.8mmol) was added and the reaction mixture was stirred at room temperaturefor 3 hrs. NaBH₃CN (240 mg, 3.8 mmol) was added and the reaction mixturewas stirred at room temperature for another 16 hrs. The reactionsolution was concentrated to about 6 mL and then purified by reversephase HPLC (00-95 MeCN in H₂O) to give6-pyrrolidin-1-yl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid dibenzylamide (290 mg, yield: 34%) as a gummy yellow solid. MS: m/z453.1 (M+H⁺)

Step 2

This step is similar to general procedure of6-(3-fluoroazetidin-1-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide.

Step 3

To a suspension of6-pyrrolidin-1-yl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonicacid amide (50 mg, 0.2 mmol) in THF (2 mL) was added MeONa (35 mg, 0.6mmol) and the mixture was stirred at room temperature for 20 mins togive a sodium salt suspension.

In another flask, to a solution of1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (30 mg, 0.2 mmol) and TEA (50mg, 0.5 mmol) in THF (3 mL) was added triphosgene (20 mg, 0.1 mmol) inone portion and the mixture was stirred at room temperature under N₂ for20 mins. The reaction mixture was then filtered. The filtrate was addedto the sodium salt suspension above. After stirring at room temperaturefor 16 hrs, the reaction solution was partitioned between EA (10 mL) andwater (30 mL). The aqueous phase was bubbled by N₂ for 5 mins and thenpurified by reverse phase HPLC (0%-95% MeCN in H₂O) to give sodium((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(pyrrolidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(10 mg, yield: 12%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.86 (s, 1H), 7.60 (s, 1H), 6.92 (s, 1H),4.50-4.40 (m, 2H), 4.27 (dd, J=12.8, 4.0 Hz, 1H), 4.13 (dd, J=12.8, 4.0Hz, 1H), 2.94-2.91 (m, 1H), 2.79 (t, J=7.2 Hz, 4H), 2.68-2.58 (m, 8H),2.00-1.91 (m, 4H), 1.70-1.60 (m, 4H). MS: m/z 472.1 (M+H⁺).

Example 53

Sodium((6-(Azetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amide

The title compound was prepared using general procedure of sodium((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(pyrrolidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide.

¹H NMR (400 MHz, DMSO-d₆): δ=7.42 (s, 1H), 7.33 (s, 1H), 6.77 (s, 1H),4.15-4.02 (m, 3H), 3.75 (dd, J=12.8, 1.6 Hz, 1H), 3.20 (t, J=6.8 Hz,4H), 2.84-2.80 (m, 1H), 2.75 (t, J=7.2 Hz, 4H), 2.66 (t, J=7.2 Hz, 4H),1.97-1.87 (m, 6H). MS: m/z 458.1 (M+H⁺).

Example 54

Synthesis ofN-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a stirred solution of TiCl₄ (0.5 mL, excess) and methylmagnesiumbromide (1.0 mL, excess) in THF (5.0 mL) was addedN,N-dibenzyl-6-oxo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(140.0 mg, 0.4 mmol) at −78° C. under N₂. Then the mixture was filteredand the filtrate was purified by silica gel column chromatography(CH₂Cl₂/MeOH=25/1) to giveN,N-dibenzyl-6-hydroxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(55 mg, yield: 38%) as a white solid.

Step 2

To a stirred solution ofN,N-dibenzyl-6-hydroxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(55 mg, 0.1 mmol) in CH₂Cl₂ (3.0 mL) was added conc.H₂SO₄ (8 drops, 0.16mL) and stirred at room temperature for 30 mins. The reaction solutionwas concentrated. The residue was neutralized with saturated NaHCO₃solution. Then the mixture was filtered and the filtrate was purified byreverse phase HPLC (MeCN/H₂O) to give6-hydroxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(26.0 mg, yield: 87%) as a white solid.

Step 3

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-hydroxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as described in Preparation F to deliver the desiredproduct (7.0 mg, yield: 15%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.4 (s, 1H), 7.89 (s, 1H), 7.62 (s, 1H),6.93 (s, 1H), 5.45 (s, 1H), 4.18 (s, 2H), 4.04 (d, J=12.4 Hz, 1H), 3.91(d, J=12.0 Hz, 1H), 2.79 (t, J=7.2 Hz, 4H), 2.61 (t, J=7.2 Hz, 4H),1.99-1.92 (m, 4H), 1.25 (s, 3H). MS: m/z 433.1 (M+H⁺).

Example 55

Synthesis ofN-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution ofN,N-dibenzyl-6-hydroxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(35 mg, 0.08 mmol) in DMF (3 mL) was added NaH (60% in mineral oil, 6.4mg, 0.16 mmol). The reaction was stirred at room temperature for 1 hrunder N₂. Then iodomethane (60 mg, 0.4 mmol) was added and the mixturewas stirred at room temperature for 2 hrs. The reaction mixture waspoured into water (20 mL) and extracted with EA (20 mL). The organiclayer was washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄and concentrated. The residue was purified by reverse phase HPLC(MeCN/H₂O) to giveN,N-dibenzyl-6-methoxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(30 mg, yield: 83%) as a yellow oil.

¹H NMR (300 MHz, CDCl₃): δ=7.58 (s, 1H), 7.29-7.26 (m, 5H), 7.18-7.15(m, 5H), 4.34 (s, 4H), 4.21 (s, 3H), 4.16 (s, 2H), 2.67 (s, 2H), 1.38(s, 3H).

MS: m/z 428.0 (M+H⁺).

Step 2

To a stirred solution ofN,N-dibenzyl-6-methoxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(25 mg, 0.06 mmol) in CH₂Cl₂ (3.0 mL) was added conc.H₂SO₄ (8 drops,0.16 mL) and the mixture was stirred at room temperature for 30 mins.The reaction solution was concentrated. The residue was neutralized withsaturated NaHCO₃ solution. Then the mixture was filtered and thefiltrate was purified by reverse phase HPLC (MeCN/H₂O) to give6-methoxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(6.0 mg, yield: 35%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.57 (s, 1H), 4.09 (s, 3H), 3.89 (q, J=10.4Hz, 2H), 3.66 (q, J=10.0 Hz, 2H), 1.24 (s, 3H).

MS: m/z 247.9 (M+H⁺).

Step 3

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxy-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as in Preparation D to yield the desired product (7.0mg, yield: 73%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.42 (s, 1H), 6.80 (s, 1H), 4.15 (s, 3H),4.01 (s, 2H), 2.75 (t, J=7.2 Hz, 4H), 2.60 (t, J=8.4 Hz, 4H), 2.58(overlap, 2H), 1.92-1.88 (m, 4H), 1.20 (s, 3H). MS: m/z 447.1 (M+H⁺).

Example 56

Synthesis of sodiumrac-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)((6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

To a stirred solution ofN,N-dibenzyl-6-oxo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(794 mg, 2.0 mmol) and azetidin-3-ol hydrochloride (440.0 mg, 4.0 mmol)in MeOH (30.0 mL) was added sodium triacetoxyborohydride (848.0 mg, 4.0mmol) at room temperature. Then the mixture was stirred at roomtemperature for 30 mins. Sodium cyanotrihydroborate (252.0 mg, 4.0 mmol)was added to the mixture and stirred at room temperature for 16 hrs. Themixture was concentrated in vacuo. The residue was purified by silicagel column chromatography (CH₂Cl₂/MeOH=5/1) to giverac-N,N-dibenzyl-6-(3-hydroxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(340 mg, yield: 37%) as a yellow solid. MS: m/z 455.2 (M+H⁺).

Step 2

To a solution ofrac-N,N-dibenzyl-6-(3-hydroxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(105 mg, 0.2 mmol) in DMF (3 mL) was added NaH (60% in mineral oil, 14.0mg, 0.4 mmol). The reaction was stirred at room temperature for 1 hrunder N₂. Then iodomethane (39.0 mg, 0.3 mmol) was added and the mixturewas stirred at room temperature for 2 hrs. The reaction mixture waspoured into water (20 mL) and extracted with EA (20 mL). The organiclayer was washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄and concentrated to dryness to giverac-N,N-dibenzyl-6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(120 mg, crude) as a yellow oil.

MS: m/z 469.1 (M+H⁺).

Step 3

To a stirred solution ofrac-N,N-dibenzyl-6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(120 mg, 0.3 mmol) in CH₂Cl₂ (3.0 mL) was added conc.H₂SO₄ (16 drops,0.32 mL) and stirred at room temperature for 30 mins. The reactionsolution was concentrated. The residue was neutralized with saturatedNaHCO₃ solution. Then the mixture was filtered off the solid and thefiltrate was purified by reverse phase HPLC (MeCN/H₂O) to giverac-6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(52.0 mg, yield: 70%) as a white solid. MS: m/z 289.1 (M+H⁺).

Step 4

Sodiumrac-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidewas synthesized as in Preparation D to yield the desired product (10.0mg, yield: 11%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.85 (brs, 1H), 7.57 (s, 1H), 6.92 (s, 1H),4.30-4.28 (m, 2H), 4.17-4.12 (m, 1H), 3.91-3.84 (m, 2H), 3.52 (t, J=7.2Hz, 2H), 3.14 (s, 3H), 3.01-2.94 (m, 3H), 2.79 (t, J=7.2 Hz, 4H), 2.62(t, J=7.2 Hz, 4H), 1.99-1.92 (m, 4H). MS: m/z 488.2 (M+H⁺).

Example 57

Synthesis of sodium(R)-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)((6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideand sodium(S)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

rac-6-(3-Methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(150 mg) was resolved by chiral prep-HPLC to give(R)-6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(65 mg) as a white solid(S)-6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(60 mg) as a white solid.

Step 2

Sodium(R)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidewas synthesized as in Preparation D to yield the desired product (54.0mg, yield: 48%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.37 (brs, 1H), 7.30 (s, 1H), 6.75 (s, 1H),4.13-4.08 (m, 3H), 3.96-3.92 (m, 1H), 3.79-3.76 (m, 1H), 3.55-3.53 (m,2H), 3.14 (s, 3H), 2.98-2.94 (m, 2H), 2.87 (br, 1H), 2.75 (t, J=6.8 Hz,4H), 2.66 (t, J=6.8 Hz, 4H), 1.92-1.89 (m, 4H). MS: m/z 488.2 (M+H⁺).

Sodium(S)-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidewas prepared using the same procedure.

¹H NMR (400 MHz, DMSO-d₆): δ=7.39 (brs, 1H), 7.30 (s, 1H), 6.76 (s, 1H),4.12-4.06 (m, 3H), 3.95-3.92 (m, 1H), 3.79-3.76 (m, 1H), 3.55-3.52 (m,2H), 3.14 (s, 3H), 2.98-2.92 (m, 2H), 2.88 (br, 1H), 2.75 (t, J=7.2 Hz,4H), 2.66 (t, J=7.2 Hz, 4H), 1.95-1.87 (m, 4H). MS: m/z 488.2 (M+H⁺).

Example 58

Synthesis ofN-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-sulfonamideis shown below.

Step 1

To as solution of 2-bromoethanol (3.8 g, 30.0 mmol) and DHP (2.5 g, 30.0mmol) in DCM (50 mL), was added TsOH (380.0 mg, 2.2 mmol) in portionsand the mixture was stirred at room temperature for 2 hrs. The reactionwas concentrated and purified by silica gel column (PE/EA=50/1) to give2-(2-bromoethoxy)tetrahydro-2H-pyran (5.6 g, yield: 89%) as a colorlessoil.

¹H NMR (400 MHz, CDCl₃): δ=4.68 (t, J=3.2 Hz, 1H), 4.05-3.99 (m, 1H),3.92-3.86 (m, 1H), 3.80-3.74 (m, 1H), 3.54-3.49 (m, 3H), 1.85-1.71 (m,3H), 1.65-1.53 (m, 3H).

Step 2

To a solution of 3-nitro-1H-pyrazole-5-carboxylic acid (1.57 g, 10.0mmol) in MeOH (20 mL) was added conc.H₂SO₄ (2.0 mL). The resultingmixture was stirred at 65° C. overnight. Then the mixture wasconcentrated in vacuo to give a residue, which was purified by silicagel column (DCM/MeOH=50/1) to afford methyl3-nitro-1H-pyrazole-5-carboxylate (1.42 g, yield: 83%) as yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=15.24 (brs, 1H), 7.54 (s, 1H), 3.90 (s,3H).

Step 3

To a solution of methyl 3-nitro-1H-pyrazole-5-carboxylate (1.7 g, 10.0mmol) in NMP (20 mL) was added 2-(2-bromoethoxy)tetrahydro-2H-pyran (2.6g, 13.0 mmol), followed by K₂CO₃ (1.7 g, 13.0 mmol). The resultingmixture was stirred at 80° C. for 16 hrs. Then K₂CO₃ was filtered off.The filtrate was concentrated in vacuo to give a residue, which waspurified by silica gel column (PE/EA=2/1) to afford methyl3-nitro-1-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-1H-pyrazole-5-carboxylate(2.8 g, yield: 94%) as yellow oil.

¹H NMR (400 MHz, CDCl₃): δ=7.39 (s, 1H), 4.92 (t, J=7.2 Hz, 2H), 4.57(s, 1H), 4.11-4.07 (m, 1H), 3.98 (overlap, 1H), 3.96 (s, 3H), 3.84-3.80(m, 1H), 3.64-3.60 (m, 1H), 3.49-3.46 (m, 1H), 1.67-1.46 (m, 6H).

Step 4

To a solution of methyl3-nitro-1-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-1H-pyrazole-5-carboxylate(2.5 g, 8.4 mmol) in dry THF (50 mL) was added LiBH₄ (6.3 mL, 2.0 M inTHF) at 0° C. The resulting mixture was stirred from 0° C. to roomtemperature for 3 hrs. Then the reaction was quenched by addition ofMeOH (4 mL). The mixture was concentrated in vacuo to give a residue,which was purified by silica gel column (PE/EA=1/1) to afford(3-nitro-1-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-1H-pyrazol-5-yl)methanol(2.2 g, yield: 96%) as yellow oil.

¹H NMR (300 MHz, CDCl₃): δ=6.88 (s, 1H), 4.69 (t, J=6.3 Hz, 2H),4.57-4.49 (m, 3H), 4.21-4.16 (m, 1H), 3.92-3.85 (m, 1H), 3.77-3.65 (m,2H), 3.51-3.42 (m, 2H), 1.72-1.48 (m, 6H).

Step 5

To a stirred solution of(3-nitro-1-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-1H-pyrazol-5-yl)methanol(2.0 g, 7.5 mmol), pyridine (593 mg, 7.5 mmol) and perbromomethane (5.0g, 15.0 mmol) in dry Et₂O (30 mL) was added triphenylphosphine (3.9 g,15.0 mmol) at 0° C. The resulting mixture was stirred from 0° C. to roomtemperature for 3 hrs. The reaction was stirred at room temperature for16 hrs. Then the reaction was filtered off the solid and the solvent wasconcentrated in vacuo to dryness to give a yellow gum, which waspurified by silica gel column (PE/EA=1/1) to afford5-(bromomethyl)-3-nitro-1-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-1H-pyrazole(1.5 g, yield: 60%) as yellow oil.

¹H NMR (400 MHz, CDCl₃): δ=6.89 (s, 1H), 4.69 (t, J=16.0 Hz, 2H),4.57-4.48 (m, 3H), 4.16-4.10 (m, 1H), 3.84-3.77 (m, 1H), 3.64-3.57 (m,1H), 3.48-3.43 (m, 1H), 1.72-1.45 (m, 6H).

Step 6:

To a solution of5-(bromomethyl)-3-nitro-1-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-1H-pyrazole(1.5 g, 4.5 mmol) in THF (5 mL) was added conc. HCl (1.0 mL) and themixture was stirred at room temperature 16 hrs. The reaction wasconcentrated under reduced pressure. The residue was neutralized withsaturated NaHCO₃ solution and extracted with EA (60 mL). The organiclayer was washed with water (50 mL) and brined (50 mL), dried overNa₂SO₄ and concentrated in vacuo to dryness to give a yellow gum, whichwas purified by silica gel column (PE/EA=1/1) to give2-(5-(bromomethyl)-3-nitro-1H-pyrazol-1-yl)ethanol (1.0 g, yield: 91%)as a yellow oil.

Step 7

To a solution of 2-(5-(bromomethyl)-3-nitro-1H-pyrazol-1-yl)ethanol (1.4g, 4.47 mmol) in dry THF was added NaH (60%, 197 mg, 4.92 mmol). Afterstirring at room temperature under N₂ for 4 hrs, the reaction waspartitioned between water (50 mL) and EA (50 mL). The organic layer waswashed with brine (50 mL), dried over Na₂SO₄ and concentrated. Theresidue was purified by silica gel column (PE/EA=4/1) to give2-nitro-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine (300 mg, yield: 40%)as a white solid.

¹H NMR (300 MHz, DMSO-d₆): δ=6.88 (s, 1H), 4.82 (s, 2H), 4.23 (t, J=4.8Hz, 2H), 4.12 (t, J=4.8 Hz, 2H).

Step 8

To a solution of 2-nitro-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine (300mg, 1.78 mmol) in MeOH (10 mL) was added Pd/C (10% wet, 100 mg). Thereaction was stirred at room temperature under H₂ (1 atm) for 3 hrs andfiltered. The filtrate was concentrated to give6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-amine (250 mg, yield:quantitative) as a yellow gum. MS: m/z 277.0 (M−56+H⁺).

¹H NMR (300 MHz, DMSO-d₆): δ=5.20 (s, 1H), 4.63-4.55 (m, 4H), 3.98-3.94(m, 2H), 3.79-3.75 (m, 2H).

Step 9

To a solution of 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-amine (250mg, 1.8 mmol) in MeCN/H₂O (12 mL/1 mL) was added conc. HCl (2.7 mL) andAcOH (1.1 mL). The mixture was then cooled to 0° C. and a solution ofNaNO₂ (149 mg, 2.2 mmol) in H₂O (1 mL) was added slowly. After stirringat 0° C. for 30 mins, CuCl₂ (121 mg, 0.9 mmol) and CuCl (9 mg, 0.09mmol) were added. SO₂ was then bubbled through the reaction solution for10 mins. The reaction was partitioned between water (50 mL) and EA (50mL). The organic layer was washed with brine (40 mL), dried over Na₂SO₄and concentrated to give crude6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-sulfonyl chloride which wasused for next step directly.

Step 10

To a solution of crude6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-sulfonyl chloride (crude,˜1.8 mmol) in THF (15 mL) was added ammonia (5 mL). The mixture wasstirred at 60° C. for 1 hr. The reaction was concentrated, acidifiedwith 2 N HCl to pH=5 and purified by reverse phase HPLC (MeCN/H₂O) togive 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-sulfonamide (100 mg,yield: 27% over 2 steps) as a white solid.

¹H NMR (300 MHz, DMSO-d₆): δ=7.42 (s, 2H), 6.39 (s, 1H), 4.80 (s, 2H),4.17-4.14 (m, 2H), 4.08 (t, J=4.8 Hz, 2H).

Step 11

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine-2-sulfonamidewas synthesized using Preparation A to deliver the desired product (60mg, yield: 30%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.86 (brs, 1H), 8.05 (s, 1H), 6.95 (s,1H), 6.59 (s, 1H), 4.81 (s, 2H), 4.19 (t, J=4.8 Hz, 2H), 4.10 (t, J=4.8Hz, 2H), 2.79 (t, J=7.2 Hz, 4H), 2.60 (t, J=7.2 Hz, 4H), 1.97-1.94 (m,4H). MS: m/z 403.0 (M+H⁺).

Example 59

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,4-dihydro-2H-imidazo[5,1-b][1,3]oxazine-8-sulfonamideis shown below.

Step 1

To a solution of 3-bromo-1-propanol (4 g, 28.8 mmol) in DCM (50 mL) wasadded TsOH (496 mg, 2.88 mmol) and 3,4-2H-dihydropyran (7.2 g, 86.2mmol) at 0° C. The mixture was stirred at room temperature overnight.The reaction mixture was poured into H₂O (100 mL). The mixture wasextracted with DCM (70 mL×2). The combined extracts was washed withbrine (100 mL), dried over Na₂SO₄ and concentrated to dryness. Theresidue was purified by silica gel column (PE) to give2-(3-bromo-propoxy)-tetrahydro-pyran (838 mg, yield: 57%) as a redsolid.

¹H NMR (300 MHz, DMSO-d₆): δ=4.60-4.56 (m, 1H), 3.77-3.72 (m, 2H),3.61-3.56 (m, 2H), 3.47-3.42 (m, 2H), 2.07-2.03 (m, 2H), 1.70-1.61 (m,2H), 1.51-1.45 (m, 4H).

Step 2

A solution of 5-bromo-1H-imidazole (6.6 g, 44.9 mmol) in ClSO₃H (30 mL)was stirred at 180° C. under N₂ atmosphere for 2 hrs. The reactionmixture was poured into ice-water (70 mL) and filtered. The filter cakewas washed with H₂O (30 mL) and dried to give5-bromo-1H-imidazole-4-sulfonyl chloride (7 g, yield: 63%) as a yellowsolid.

Step 3

To a solution of 5-bromo-1H-imidazole-4-sulfonyl chloride (4 g, 16.3mmol) in THF (50 mL) was added TEA (4.5 mL, 32.6 mmol) and dibenzylamine(3.2 g, 16.3 mmol) at room temperature. After being stirred at roomtemperature overnight, the reaction mixture was poured into H₂O (100 mL)and extracted with EA (50 mL×2). The combined EA was washed with brine(50 mL), dried over Na₂SO₄ and concentrated. The residue was purified bysilica gel column (PE/EA=1/1) to give 5-bromo-1H-imidazole-4-sulfonicacid dibenzylamide (1.4 g, yield: 21%) as a red solid.

¹H NMR (300 MHz, DMSO-d₆): δ=7.96 (s, 1H), 7.25-7.19 (m, 6H), 7.12-7.05(m, 4H), 4.36 (s, 4H).

Step 4

To a solution of 5-bromo-1H-imidazole-4-sulfonic acid dibenzylamide (1.4g, 3.2 mmol) in DMF (20 mL) was added K₂CO₃ (883 mg, 6.4 mmol),2-(3-bromo-propoxy)-tetrahydro-pyran (856 mg, 3.8 mmol) at roomtemperature and the mixture was stirred at 80° C. with N₂ overnight. Thereaction mixture was added silica gel and concentrated to dryness. Theresidue was purified by silica gel column (PE/EA=3/1 to 1/1) to give5-bromo-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1H-imidazole-4-sulfonicacid dibenzylamide (1.6 g, yield: 69%) as a red oil.

¹H NMR (300 MHz, DMSO-d₆): δ=8.08 (s, 1H), 7.23-7.20 (m, 6H), 7.13-7.10(m, 4H), 4.55-4.52 (m, 1H), 4.36 (s, 4H), 4.12 (t, J=6.9 Hz, 2H),3.72-3.64 (m, 2H), 3.40-3.30 (m, 2H), 2.02-1.95 (m, 2H), 1.80-1.59 (m,2H), 1.50-1.40 (m, 4H).

Step 5

To a solution of5-bromo-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1H-imidazole-4-sulfonicacid dibenzylamide (1.6 g, 3.0 mmol) in THF (10 mL) was added MeOH (5mL), aq.HCl (6 mL, 6 N) at room temperature and it was stirred at roomtemperature for 1 hr. The reaction mixture was poured into H₂O (50 mL)and neutralized to pH=7 with sat.NaHCO₃. The resulting mixture wasextracted with EA (30 mL×2). The combined EA was washed with brine (50mL), dried over Na₂SO₄ and concentrated to give5-bromo-1-(3-hydroxy-propyl)-1H-imidazole-4-sulfonic acid dibenzylamide(1.4 g, crude) as a red oil.

Step 6

To a solution of 5-bromo-1-(3-hydroxy-propyl)-1H-imidazole-4-sulfonicacid dibenzylamide (1.4 g, 3.0 mmol) in DMF (20 mL) was added NaH (60%,145 mg, 3.6 mmol) and the mixture was stirred at 80° C. under N₂ for 4hrs. The reaction mixture was poured into H₂O (100 mL) and extractedwith EA (50 mL×3). The combined EA layer was washed with H₂O (60 mL×2),dried over Na₂SO₄ and concentrated to dryness. The residue was purifiedby prep-HPLC (NH₄HCO₃) to give3,4-dihydro-2H-imidazo[5,1-b][1,3]oxazine-8-sulfonic acid dibenzylamide(176 mg, yield: 16%) as a colorless oil.

¹H NMR (300 MHz, DMSO-d₆): δ=7.42 (s, 1H), 7.23-7.18 (m, 6H), 7.15-7.12(m, 4H), 4.34 (t, J=5.1 Hz, 2H), 4.26 (s, 4H), 4.08 (t, J=6.3 Hz, 2H),2.10-2.06 (m, 2H).

Step 7

To a solution of 3,4-dihydro-2H-imidazo[5,1-b][1,3]oxazine-8-sulfonicacid dibenzylamide (170 mg, 0.44 mmol) in DCM (3 mL) was added conc.H₂SO₄ (12 drops) at 0° C. and the mixture was stirred at roomtemperature for 30 minutes. The reaction mixture was poured intosat.NaHCO₃ (20 mL) and then concentrated to remove DCM. The resultingsolution was neutralized to pH=7 and filtered. The filtrate was purifiedby reverse phase HPLC (20% MeCN in H₂O) to give3,4-dihydro-2H-imidazo[5,1-b][1,3]oxazine-8-sulfonic acid amide (60 mg,yield: 62%) as a white solid.

¹H NMR (300 MHz, DMSO-d₆): δ=7.32 (s, 1H), 6.87 (s, 2H), 4.33 (t, J=5.7Hz, 2H), 4.07 (t, J=6.3 Hz, 2H), 2.09-2.05 (m, 2H).

Step 8

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,4-dihydro-2H-imidazo[5,1-b][1,3]oxazine-8-sulfonamidewas synthesized as described in Preparation E to deliver the desiredproduct (8 mg, yield: 8%) as a white solid.

¹H NMR (300 MHz, DMSO-d₆): δ=7.98 (s, 1H), 7.40 (s, 1H), 6.91 (s, 1H),4.33 (t, J=2.4 Hz, 2H), 4.06 (t, J=2.4 Hz, 2H), 2.80 (t, J=3.0 Hz, 4H),2.60 (t, J=2.4 Hz, 4H), 2.07-2.05 (m, 2H), 1.98-1.92 (m, 4H). MS: m/z403.1 (M+H⁺).

Example 60

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamideis shown below.

Step 1

To a solution of methyl 5-nitro-1H-pyrazole-3-carboxylate (100 mg, 0.58mmol) in DMF (10 mL) was added tert-butyl (2-bromoethyl)carbamate (197mg, 0.88 mmol) and K₂CO₃ (240 mg, 1.74 mmol). Then the reaction mixturewas stirred at 80° C. for 3 hrs. The reaction mixture was filtered, andfiltrate was concentrated in vacuo. The residue was purified by silicagel column chromatography (PE/EA=3/1) to give methyl1-(2-((tert-butoxycarbonyl)amino)ethyl)-3-nitro-1H-pyrazole-5-carboxylate(166 mg, 80%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.57 (s, 1H), 6.96 (t, J=6.0 Hz, 1H), 4.60(d, J=5.6 Hz, 2H), 3.90 (s, 3H), 3.41-3.36 (m, 2H), 1.26 (s, 9H).

Step 2

To a solution of methyl1-(2-((tert-butoxycarbonyl)amino)ethyl)-3-nitro-1H-pyrazole-5-carboxylate(166 mg, 0.46 mmol) in dioxane (5 mL) was added HCl (1.15 mL, 4.6 mmol,4 M in dioxane). Then the reaction mixture was stirred at roomtemperature for 6 hrs. The reaction mixture was concentrated in vacuo.The residue was added into the suspension of DMF (10 mL) and K₂CO₃ (127mg, 0.92 mmol). The reaction mixture was stirred at 80° C. overnight andwas monitored by LCMS. The reaction mixture was filtered, and filtratewas concentrated in vacuo. The residue was purified by silica gel columnchromatography (DCM/MeOH=50/1˜10/1) to give2-nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (65 mg, 68%) as ayellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.61 (s, 1H), 7.43 (s, 1H), 4.46 (t, J=6.0Hz, 2H), 3.72-3.65 (m, 2H).

Step 3

To a solution of 2-nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one(1.2 g, 6.6 mmol) in EtOH (30 mL) was added iron powder (1.8 g, 33.0mmol), NH₄Cl (1.76 g, 33.0 mmol) and H₂O (10 mL). The reaction mixturewas stirred at 80° C. in N₂ overnight and was monitored by LCMS. Thereaction mixture was filtered, and filtrate was concentrated in vacuo.The crude product was purified by silica gel column chromatography(DCM/MeOH=10/1) to give2-amino-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (0.76 g, 76%) as ayellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.01 (s, 1H), 5.80 (s, 1H), 4.88 (s, 2H),3.98 (t, J=5.6 Hz, 2H), 3.54-3.45 (m, 2H).

Step 4

To a suspension of CuCl (0.204 g, 2.1 mmol) in H₂O (265 mL) was addeddropwise SOCl₂ (44.85 mL, 0.618 mol) at 0° C. with vigorous stirring.The solution was stirred at room temperature overnight to give a lightyellow solution. Separately, to a solution of2-amino-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (0.62 g, 4.1 mmol)in conc. HCl (4 mL) was added dropwise a solution of NaNO₂ (0.33 g. 4.8mmol) in H₂O (2 mL) at −10° C. The resulting dark orange solution wasstirred at −10° C. for 30 minutes, and then added to the solution (10.6mL) of copper (I) chloride from the first step at −5° C. over 5 minutes.The reaction was stirred at −5° C. for 1 hr and extracted with EA (10mL×3). The organic layer was concentrated in vacuo to give a yellowsolid. This solid was dissolved in THF (20 mL), followed by the dropwiseaddition of NH₃ (10 mL, 28% wt) at 0° C. The reaction was stirred for 2hrs at 0° C. and then concentrated in vacuo. The resulting solid waspurified by silica gel column chromatography (DCM/MeOH=10/1) to give4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamide (0.2 g,23%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.46 (s, 1H), 7.59 (s, 2H), 6.94 (s, 1H),4.39 (t, J=5.2 Hz, 2H), 3.70-3.63 (m, 2H).

Step 5

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamidewas synthesized as described in Preparation F to deliver the desiredproduct (8.3 mg, 4.3%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.37 (s, 1H), 7.81 (s, 1H), 7.11 (s, 1H),6.92 (s, 1H), 6.85 (s, 1H), 4.33 (t, J=6.0 Hz, 2H), 3.65-3.61 (m, 2H),2.76 (t, J=7.2 Hz, 4H), 2.63 (t, J=6.8 Hz, 4H), 1.96-1.88 (m, 4H). MS:m/z 414.1 (M−H⁺).

Example 61

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamideis shown below.

Step 1

To a solution of 5-nitro-1H-pyrazole-3-carboxylic acid (5.0 g, 31.8mmol) and 2-(methylamino)ethanol (3.58 g, 47.7 mmol) in DCM (50 mL) wasadded dropwise SOCl₂ (11.5 mL, 159 mmol) and DMF (4 drops) at −5° C. for10 min. Then the reaction mixture was stirred at 50° C. overnight. Thereaction mixture was concentrated in vacuo. The residue was added intoDMF (50 mL) and TEA (13.3 mL, 95.4 mmol). The reaction was then stirredat 60° C. overnight. After removal of solvent in vacuo, the residue waspurified by silica gel column chromatography (DCM/MeOH=50/1˜10/1) togive 5-methyl-2-nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (4.66g, 75%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.42 (s, 1H), 4.53 (t, J=6.0 Hz, 2H), 3.87(t, J=6.8 Hz, 2H), 3.03 (s, 3H).

Step 2

To a solution of5-methyl-2-nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (700 mg,3.6 mmol) in EtOH (20 mL) was added iron powder (1.0 g, 17.9 mmol),NH₄Cl (0.96 g, 17.9 mmol) and H₂O (7 mL). The reaction mixture wasstirred at 80° C. under N₂ atmosphere overnight and was monitored byLCMS. The reaction mixture was filtered, and filtrate was concentratedin vacuo. The crude product was purified by silica gel columnchromatography (DCM/MeOH=50/1˜10/1) to give2-amino-5-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (0.44 g,73%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=5.80 (s, 1H), 4.85 (brs, 2H), 4.08 (t,J=6.0 Hz, 2H), 3.87 (t, J=6.4 Hz, 2H), 2.95 (s, 3H).

Step 3

To a suspension of CuCl (0.204 g, 2.1 mmol) in H₂O (265 mL) was addeddropwise SOCl₂ (44.85 mL, 0.618 mol) at −5° C. with vigorous stirring.The solution was stirred at room temperature overnight to give a lightyellow solution. Separately, to a solution of2-amino-5-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (100 mg,0.6 mmol) in conc. HCl (0.97 mL) was added dropwise a solution of NaNO₂(50 mg, 0.72 mmol) in H₂O (2 mL) at −10° C. The resulting dark orangesolution was stirred at −10° C. for 30 minutes and then added to theabove solution (1.6 mL) of copper (I) chloride at −5° C. over 5 minutes.The reaction was stirred at −5° C. for 1 hr and extracted with EA (10mL×3). The organic layer was concentrated in vacuo to give a yellowsolid. This solid was added THF (5 mL), followed added dropwise NH₃ (3mL, 28% wt) at −5° C. The reaction was stirred for 2 hrs at 0° C. thenconcentrated in vacuo. The resulting solid was purified by silica gelcolumn chromatography (DCM/MeOH=10/1) to give5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamide(42 mg, 30%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.60 (s, 2H), 6.93 (s, 1H), 4.46 (t, J=6.0Hz, 2H), 3.87 (t, J=6.4 Hz, 2H), 3.01 (s, 3H).

Step 4

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamidewas synthesized as described in Preparation E to deliver the desiredproduct (21.8 mg, 12%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.70 (s, 1H), 7.13 (s, 1H), 6.86 (s, 1H),6.82 (s, 1H), 4.39 (t, J=6.0 Hz, 2H), 3.78 (t, J=6.4 Hz, 2H), 3.34 (s,3H), 2.76 (t, J=7.2 Hz, 4H), 2.64 (t, J=7.2 Hz, 4H), 1.96-1.86 (m, 4H).MS: m/z 430.0 (M+H⁺).

Example 62

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-sulfonamideis shown below.

Step 1

To a solution of 4-nitro-1H-pyrazole-5-carboxylic acid (1.0 g, 6.4 mmol)in MeOH (30 mL) was added TsOH (52 mg, 0.3 mmol). Then the reactionmixture was stirred at 65° C. overnight. The reaction mixture wasconcentrated in vacuo. The residue was purified by silica gel columnchromatography (DCM/MeOH=40/1˜10/1) to give methyl4-nitro-1H-pyrazole-5-carboxylate (1.0 g, 91%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.90 (s, 1H), 3.88 (s, 3H).

Step 2

To a solution of 4-nitro-1H-pyrazole-5-carboxylate (3.0 g, 17.5 mmol) inMeOH (100 mL) was added (Boc)₂O (4.2 g, 19.25 mmol) and Pd/C (300 mg,10% wt). Then the reaction mixture was stirred at 40° C. overnight underH₂ atmosphere and was monitored by LCMS. The reaction mixture wasfiltered and the filtrate was concentrated in vacuo. The residue waspurified by silica gel column chromatography (PE/EA=2/1˜1/1) to givemethyl 4-((tert-butoxycarbonyl)amino)-1H-pyrazole-5-carboxylate (2.52 g,60%) as a white solid.

Step 3

To a solution of methyl4-((tert-butoxycarbonyl)amino)-1H-pyrazole-5-carboxylate (4.2 g, 17.4mmol) in DMF (50 mL) was added tert-butyl (2-bromoethyl)carbamate (5.8g, 26.1 mmol) and K₂CO₃ (7.2 g, 52.2 mmol). Then the reaction mixturewas stirred at 80° C. for overnight and was monitored by LCMS. Thereaction mixture was filtered, and the filtrate was concentrated invacuo. The residue was purified by silica gel column chromatography(PE/EA=3/1) to give methyl4-((tert-butoxycarbonyl)amino)-1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-pyrazole-5-carboxylate(1.26 g, 19%) as a yellow oil.

¹H NMR (400 MHz, DMSO-d₆): δ=8.16 (s, 1H), 7.80 (s, 1H), 6.81 (t, J=6.8Hz, 1H), 4.40 (t, J=6.4 Hz, 2H), 3.86 (s, 3H), 3.29-3.22 (m, 2H), 1.46(s, 9H), 1.33 (s, 9H).

Step 4

To a solution of methyl4-((tert-butoxycarbonyl)amino)-1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-pyrazole-5-carboxylate(1.26 g, 3.3 mmol) in DCM (20 mL) was added CF₃CO₂H (2.4 mL, 33 mmol).Then the reaction mixture was stirred at room temperature overnight andwas monitored by LCMS. The reaction mixture was concentrated in vacuo.The residue was added to the suspension of DMF (20 mL) and K₂CO₃ (1.36mg, 9.9 mmol). The reaction mixture was stirred at 80° C. overnight andwas monitored by LCMS. The reaction mixture was filtered, and filtratewas concentrated in vacuo. The residue was purified by silica gel columnchromatography (DCM/MeOH=20/1˜10/1) to give3-amino-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (354 mg, 71%) as awhite solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.75 (brs, 1H), 7.00 (s, 1H), 4.68 (brs,2H), 4.08 (d, J=5.6 Hz, 2H), 3.55-3.47 (m, 2H).

Step 5

To a suspension of CuCl (0.204 g, 2.1 mmol) in H₂O (265 mL) was addeddropwise SOCl₂ (44.85 mL, 0.618 mol) at 0° C. with vigorous stirring.The solution was stirred at room temperature overnight to give a lightyellow solution. Separately, to a solution of3-amino-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (155 mg, 1.02 mmol)in conc. HCl (1 mL) was added dropwise a solution of NaNO₂ (84.4 mg.1.23 mmol) in H₂O (2 mL) at −10° C. The resulting dark orange solutionwas stirred at −10° C. for 30 minutes and then added to the abovesolution (2.65 mL) of copper (I) chloride at −5° C. over 5 minutes. Thereaction was stirred at −5° C. for 1 hr and then extracted with EA (10mL×3). The organic layer was concentrated in vacuo to give a yellowsolid. This solid was dissolved in THF (5 mL), followed by dropwiseaddition of NH₃ (4 mL, 28% wt) at 0° C. The reaction was stirred for 2hrs at 0° C. and then concentrated in vacuo. The resulting solid waspurified by prep-TLC (DCM/MeOH=10/1) to give4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-sulfonamide (5 mg,2.2%) as a yellow solid.

Step 6

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-sulfonamidewas synthesized as described in Preparation E to deliver the desiredproduct (1.1 mg, 5.8%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.64 (s, 1H), 8.15 (s, 1H), 7.85 (s, 1H),6.87 (s, 1H), 4.38 (d, J=5.6 Hz, 2H), 3.65-3.59 (m, 2H), 2.77 (t, J=6.8Hz, 4H), 2.57 (t, J=7.2 Hz, 4H), 1.97-1.87 (m, 4H). MS: m/z 416.1(M+H⁺).

Example 63

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-sulfonamideis shown below.

Step 1

To a solution of 4-nitro-1H-pyrazole-5-carboxylic acid (1.0 g, 6.4 mmol)and 2-(methylamino)ethanol (0.55 g, 7.3 mmol) in toluene (5 mL) wasadded dropwise SOCl₂ (20 mL) and DMF (3 drops) at −5° C. for 10 min.Then the reaction mixture was stirred at 80° C. overnight. The reactionmixture was concentrated in vacuo. The residue was dissolved in DMF (20mL) and TEA (2.7 mL, 19.3 mmol). The reaction was then stirred at 60° C.overnight and was monitored by LCMS. After removal of solvent in vacuo,the residue was purified by silica gel column chromatography(PE/EA=3/1˜1/1) to give5-methyl-3-nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (0.7 g,56%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.34 (s, 1H), 4.47 (t, J=5.6 Hz, 2H), 3.85(t, J=6.4 Hz, 2H), 3.05 (s, 3H).

Step 2

To a solution of5-methyl-3-nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (3.52 g, 18mmol) in EtOH (75 mL) was added iron powder (5.04 g, 90 mmol), NH₄Cl(4.82 g, 90 mmol) and H₂O (25 mL). The reaction mixture was stirred at80° C. under N₂ atmosphere overnight and was monitored by LCMS. Thereaction mixture was filtered, and filtrate was concentrated in vacuo.The crude product was purified by silica gel column chromatography(DCM/MeOH=10/1) to give3-amino-5-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (2.58 g,86%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.01 (s, 1H), 4.76 (s, 2H), 4.16 (t, J=6.0Hz, 2H), 3.66 (t, J=6.4 Hz, 2H), 2.94 (s, 3H).

Step 3

SOCl₂ (20 mL) was added dropwise to water (70 mL) at −5° C. The solutionwas stirred at 5° C. for 1 hr and at room temperature for 1 hr. CuCl(0.16 g) was added to give a yellow solution. It was stirred at roomtemperature for 5 min then cooled to −10° C. Separately, to a solutionof 3-amino-5-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (358 mg,2.2 mmol) in conc. HCl (2.0 mL) was added dropwise a solution of NaNO₂(180 mg, 2.62 mmol) in H₂O (1.6 mL) at −10° C. The resulting dark orangesolution was stirred at −10° C. for 30 minutes and then added to theabove solution (5.7 mL) of copper (I) chloride at −5° C. over 5 minutes.The reaction was stirred at −5° C. for 1 hr and then extracted with EA(5 mL×3). The organic layer was concentrated in vacuo to give a yellowsolid. This solid was dissolved in THF (5 mL), followed by the dropwiseaddition of NH₃ (3 mL, 28% wt) at −5° C. The reaction was stirred for 2hrs at 0° C. and then concentrated in vacuo. The resulting solid waspurified by prep-TLC (DCM/MeOH=10/1) to give5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-sulfonamide(30 mg, 6%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.86 (s, 1H), 7.18 (s, 2H), 4.48 (t, J=6.0Hz, 2H), 3.87 (t, J=6.4 Hz, 2H), 3.06 (s, 3H).

Step 4

NaH (6.24 mg, 0.156 mmol, 60% dispersion in paraffin liquid) in DMSO (2mL) was stirred at 70° C. for 30 min. Then5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-sulfonamide(30 mg, 0.13 mmol) was added to the solution of NaH in DMSO (2 mL) at−5° C. and was stirred at −5° C. for 30 min. Separately, to a solutionof 1,2,3,5,6,7-hexahydro-s-indacen-4-amine (24.8 mg, 0.14 mmol) in THF(5 mL) was added triphosgene (15.4 mg, 0.052 mmol) and TEA (0.1 mL) at−5° C. Then the reaction mixture was stirred at −5° C. for 30 min andwas monitored by TCL. This reactant was filtered and the filtrate wasadded to the above suspension of sodium((5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)sulfonyl)amideat −5° C. The reaction was stirred at room temperature overnight and wasmonitored by LC-MS. This reaction was then washed with saturated aqueousNH₄Cl (5 mL×3). The organic layer was dried over anhydrous Na₂SO₄, andconcentrated in vacuo. The residue was purified by prep-HPLC to giveN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-sulfonamide(12.8 mg, 25%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.27 (brs, 1H), 7.91 (s, 1H), 6.90 (s, 1H),4.47 (t, J=5.6 Hz, 2H), 3.83 (t, J=6.0 Hz, 2H), 3.06 (s, 3H), 2.77 (t,J=6.8 Hz, 4H), 2.55 (t, J=7.6 Hz, 4H), 1.99-1.88 (m, 4H). MS: m/z 430.1(M+H⁺).

Example 64

Synthesis ofN-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-sulfonamideis shown below.

Step 1

To a solution of 1H-pyrazol-5-amine (9.8 g, 0.1 mol) and TEA (36.0 g,0.3 mmol) in 1,4-dioxane (200 mL) was added 1,3-dibromopropane (26.3 g,0.1 mmol). After stirring at 110° C. for 5 hrs, the reaction mixture wasfiltered. The filtration was concentrated to dryness. The residue waspurified by silica gel column (DCM/MeOH=100/1) to give4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (5.3 g, yield: 36%) as awhite solid.

¹H NMR (300 MHz, CDCl₃): δ=7.18 (s, 1H), 5.26 (s, 1H), 4.22-4.00 (m,3H), 3.26-3.22 (m, 2H), 2.11-2.03 (m, 2H).

Step 2

To a solution of 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (3.0 g,24.4 mmol) in THF (20 mL) was added NaH (60% in mineral oil, 1.5 g, 36.6mmol). The reaction was stirred at room temperature for 1 hr under N₂.Then Boc₂O (8.0 g, 36.6 mmol) was added and the mixture was stirred atroom temperature for 16 hrs. The reaction mixture was poured into water(60 mL) and extracted with EA (50 mL×2). The organic layer was washedwith water (50 mL) and brine (50 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by silica gel column(DCM/MeOH=100/1) to give tert-butyl6,7-dihydropyrazolo[1,5-a]pyrimidine-4(5H)-carboxylate (4.4 g, yield:81%) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=7.37 (s, 1H), 6.28 (s, 1H), 4.21-4.16 (m,2H), 3.86-3.80 (m, 2H), 2.20-2.15 (m, 2H), 1.57 (s, 9H). MS: m/z 224.4(M+H⁺).

Step 3

NBS (4.2 g, 23.5 mmol) was added in portions to a solution of tert-butyl6,7-dihydropyrazolo[1,5-a]pyrimidine-4(5H)-carboxylate (4.4 g, 19.6mmol) in MeCN (20 mL) at 0° C. and the reaction was stirred at roomtemperature for 16 hrs. The reaction mixture was poured into water (40mL) and extracted with EA (40 mL×2). The organic layer was washed withwater (40 mL) and brine (40 mL), dried over Na₂SO₄ and concentrated. Theresidue was purified by silica gel column (PE/EA=1/1) to give tert-butyl3-bromo-6,7-dihydropyrazolo[1,5-a]pyrimidine-4(5H)-carboxylate (4.1 g,yield: 69%) as a yellow solid. MS: m/z 304.3 (M+H⁺).

Step 4

tert-Butyl3-((2,4,6-trichlorophenoxy)sulfonyl)-6,7-dihydropyrazolo[1,5-a]pyrimidine-4(5H)-carboxylatewas synthesized using Preparation B to yield the product as a yellow oilwhich was used for next step without purification.

Step 5

A mixture of tert-butyl3-((2,4,6-trichlorophenoxy)sulfonyl)-6,7-dihydropyrazolo[1,5-a]pyrimidine-4(5H)-carboxylate(crude, ˜1.85 mmol), NH₄OH (5 mL) and THF (20 mL) was stirred at 60° C.for 12 hrs. The reaction was concentrated under reduced pressure. Theremained solution was acidified with aq.HCl (1 N) to pH=5 andpartitioned between EA (60 mL) and water (60 mL). The organic layer waswashed with water (60 mL), brine (60 mL), dried over Na₂SO₄ andconcentrated. The residue was purified by silica gel column (PE/EA=1/1)to give tert-butyl3-sulfamoyl-6,7-dihydropyrazolo[1,5-a]pyrimidine-4(5H)-carboxylate (100mg, yield: 18% over 2 steps) as a white solid.

¹H NMR (300 MHz, CDCl₃): δ=7.80 (s, 1H), 5.54 (brs, 2H), 4.23 (t, J=6.3Hz, 2H), 3.96 (t, J=6.0 Hz, 2H), 2.23-2.19 (m, 2H), 1.57 (s, 9H). MS:m/z 303.1 (M+H⁺).

Step 6

To a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (68.7 mg,0.397 mmol) and TEA (0.16 mL, 1.2 mmol) in THF (5 mL) was addedtriphosgene (47.2 mg, 0.16 mmol). The mixture was stirred for 20 minutesat room temperature. In another round-bottomed flask, to a solution oftert-butyl3-sulfamoyl-6,7-dihydropyrazolo[1,5-a]pyrimidine-4(5H)-carboxylate (120mg, 0.397 mmol) in THF (5 ml) was added MeONa (23.6 mg, 0.436 mmol) andthe mixture was stirred for 20 minutes at room temperature. The prepared4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene was filtered to remove theresulting precipitate and the filtrate was added to another flaskcontaining sulfonamide salt. The reaction was quenched with the additionof water (30 mL) after 30 minutes. The aqueous phase was extracted withEA (20 mL) and filtered. The filtrate was acidified to pH=3˜4, and itwas extracted with EA (20 mL×2) to give tert-butyl3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydropyrazolo[1,5-a]pyrimidine-4(5H)-carboxylate(32 mg, yield: 16%) as a white solid.

Step 7

To a solution of tert-butyl3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydropyrazolo[1,5-a]pyrimidine-4(5H)-carboxylate(32 mg, 0.064 mmol) in DCM (2 mL) was added TFA (1 mL) and the mixturesolution was stirred for 30 minutes at room temperature. The reactionwas monitored by LC-MS, and the reaction mixture was concentrated todryness in vacuo. The residue was purified by prep-HPLC (NH3.H2O) togiveN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-sulfonamide(11.6 mg, yield: 45%) as a white solid.

¹H NMR (300 MHz, DMSO-d₆): δ=8.01 (s, 1H), 7.39 (s, 1H), 6.92 (s, 1H),6.42 (s, 1H), 3.96 (t, J=5.6 Hz, 2H), 3.25-3.23 (m, 2H), 2.79 (t, J=7.6Hz, 4H), 2.60 (t, J=7.2 Hz, 4H), 1.97-1.91 (m, 6H). MS: m/z 402.0(M+H⁺).

Example 65

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamidetrifluoroacetic acid is shown below.

Step 1

To a solution of 3-nitro-1H-pyrazole-5-carboxylic acid (1.57 g, 10.0mmol) in MeOH (20 mL) was added conc.H₂SO₄ (2.0 mL). The resultingmixture was stirred at 65° C. overnight. Then the mixture wasconcentrated in vacuo to give a residue, which was purified by silicagel column (DCM/MeOH=50/1) to afford methyl3-nitro-1H-pyrazole-5-carboxylate (1.42 g, yield: 83%) as yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=15.24 (brs, 1H), 7.54 (s, 1H), 3.90 (s,3H).

Step 2

To a solution of methyl 3-nitro-1H-pyrazole-5-carboxylate (342 mg, 2.0mmol) in acetone (40 mL) was added 1,2-dibromoethane (412 mg, 2.2 mmol),followed by K₂CO₃ (828 mg, 6.0 mmol). The resulting mixture was stirredto reflux for 2 hrs. Then K₂CO₃ was filtered off. The filtrate wasconcentrated in vacuo to give a residue, which was purified by silicagel column (DCM/MeOH=50/1) to afford methyl1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-carboxylate (430 mg, yield: 77%)as yellow solid.

¹H NMR (400 MHz, CDCl₃): δ=7.42 (s, 1H), 5.08 (t, J=6.4 Hz, 2H), 3.97(s, 3H), 3.78 (t, J=6.4 Hz, 2H).

Step 3

To a solution of 1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-carboxylate (278mg, 1.0 mmol) in dry THF (20 mL) was added LiBH₄ (2 mL, 2.0 M in THF) at0° C. The resulting mixture was stirred from 0° C. to room temperaturefor 3 hrs. Then the reaction was quenched by addition of MeOH (4 mL).The mixture was concentrated in vacuo to give a residue, which waspurified by silica gel column (DCM/MeOH=100/1) to afford(1-(2-bromoethyl)-3-nitro-1H-pyrazol-5-yl)methanol (122 mg, yield: 49%)as white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=6.99 (s, 1H), 5.69 (t, J=5.6 Hz, 1H), 4.66(t, J=6.0 Hz, 2H), 4.61 (d, J=5.6 Hz, 2H), 3.91 (t, J=6.4 Hz, 2H).

Step 4

A mixture of [2-(2-Bromo-ethyl)-5-nitro-2H-pyrazol-3-yl]-methanol (3.0g, 12.0 mmol), PBr₃ (4.9 g, 18.0 mmol) and CH₂Cl₂ (50 mL) was stirred at45° C. for 3 hrs. The reaction was neutralized with sat. NaHCO₃ andextracted with CH₂Cl₂ (60 mL) and the combined organic layer was washedwith brine (50 mL), dried over Na₂SO₄, filtered and concentrated invacuo to dryness to give1-(2-bromo-ethyl)-5-bromomethyl-3-nitro-1H-pyrazole (2.2 g, yield: 58%)as a light yellow solid.

¹H NMR (300 MHz, CDCl₃): δ=6.93 (s, 1H), 4.63 (t, J=3.8 Hz, 2H), 4.53(s, 2H), 3.86 (t, J=4.2 Hz, 2H).

Step 5

A mixture of 1-(2-bromo-ethyl)-5-bromomethyl-3-nitro-1H-pyrazole (1.5 g,4.8 mmol), NH₃.H₂O (8 mL) and MeOH (10 mL) was stirred at 50° C. for 16hrs in sealed tube. The reaction mixture was concentrated in vacuo todryness to give 2-nitro-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine (700mg, yield: 87%) as a white solid.

MS: m/z 169.0 (M+H⁺).

Step 6

A mixture of 2-nitro-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine (700 mg,4.2 mmol), CbzCl (700 mg, 4.2 mmol), K₂CO₃ (1.2 g, 8.4 mmol) and CH₃CN(20 mL) was stirred at room temperature for 16 hrs. The reaction mixturewas concentrated in vacuo to dryness. The residue was purified by silicagel column (PE/EA=5/1 to 1/1) to give2-nitro-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylic acid benzylester (900 mg, yield: 69%) as a yellow solid.

Step 7

A mixture of 2-nitro-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylicacid benzyl ester (710 mg, 2.4 mmol), Fe (658 mg, 11.8 mmol), NH₄Cl (637mg, 11.8 mmol), H₂O (10 mL) and EtOH (20 mL) was stirred at 80° C. for16 hrs. The reaction mixture was filtered through a celite-pad andrinsed with CH₂C₂(30 mL). The filtrate solution was concentrated todryness to give2-amino-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylic acid benzylester (639 mg, yield: 98%) as a yellow oil.

Step 8

A solution of benzyl2-amino-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (639 mg,2.4 mmol) in MeCN (8 mL) at 0° C. was treated with conc.HCl (3.0 mL) inH₂O (1.2 mL) followed by aqueous solution of NaNO₂ (198 mg, 2.9 mmol)dissolved in H₂O (0.9 mL). The resulting solution was stirred at 0° C.for 45 mins. AcOH (1.2 mL), CuCl₂ (162 mg, 1.2 mmol) and CuCl (12 mg,0.12 mmol) were sequentially added to the above mixture and purged withSO₂ gas for 25 mins at 0° C. After being stirred for 1 hr at 0° C., thereaction mixture was poured to ice-water (100 mL) and extracted with EA(40 mL×3). The combined organic layer was dried over Na₂SO₄, filteredand evaporated in vacuo to give benzyl2-(chlorosulfonyl)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate(crude) as a yellow oil. This material was used for next step withoutfurther purification.

Step 9

To a solution of benzyl2-(chlorosulfonyl)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate(crude) in THF (6 mL) was added NH₃.H₂O (3 mL). After being stirred atroom temperature for 20 mins, the reaction mixture was concentrated,diluted with MeOH (5 mL) and acidified by aq.HCl (1 N) to pH=5. Theresulting solution was purified by reverse phase HPLC (0%-50% MeCN inH₂O) to give benzyl2-sulfamoyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (122mg, yield: 15%, two steps) as a white solid.

MS: m/z 337.0 (M+H⁺).

Step 10

A solution of benzyl2-sulfamoyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (102mg, 0.3 mmoL), Boc₂O (73 mg, 0.33 mmoL) and Pd/C (20 mg) in MeOH (10 mL)was stirred at room temperature under a hydrogen atmosphere (50 psi) for16 hrs. The reaction mixture was filtered and concentrated to dryness invacuo. The residue was purified by silica gel column (CH₂Cl₂/MeOH=40/1)to give tert-butyl2-sulfamoyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (106mg, yield: 96%) as a yellow solid.

MS: m/z 303.0 (M+H⁺).

Step 11

tert-Butyl2-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylatewas synthesized as described in Preparation F to deliver the desiredproduct (108 mg, crude) as a yellow solid.

MS: m/z 502.1 (M+H⁺).

Step 12:

To a solution of tert-butyl2-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate(68 mg, crude) in CH₂Cl₂ (1 mL) was added TFA (0.5 mL) and the mixturewas stirred at room temperature for 30 mins. The resulting solution waspurified by reverse phase HPLC (0%-50% MeCN in H₂O) to giveN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamideTFA salt (7.9 mg, 15%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.01 (s, 1H), 6.93 (s, 1H), 6.50 (s, 1H),4.05 (t, J=4.8 Hz, 2H), 3.93 (s, 2H), 3.17 (t, J=5.2 Hz, 2H), 2.79 (t,J=7.2 Hz, 4H), 2.61 (t, J=7.6 Hz, 4H), 1.99-1.94 (m, 4H). MS: m/z 401.9(M+H⁺).

Example 66

Synthesis ofN-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamideis shown below.

Step 1

To a solution of tert-butyl2-sulfamoyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (60 mg,0.2 mmol) in CH₂Cl₂ (1 mL) was added TFA (2 mL) and the mixture wasstirred at room temperature for 30 mins. The resulting solution waspurified by reverse phase HPLC (0%-50% MeCN in H₂O) to give4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamide TFA salt (50 mg,crude) as a brown solid. MS: m/z 202.9 (M+H⁺).

Step 2

To a stirred solution of4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamide TFA salt (45 mg,crude) in MeOH (10 mL) was added formaldehyde (40 mg, 1.3 mmol) andsodium cyanoborohydride (14 mg, 0.2 mmol). After being stirred at roomtemperature for 2 hrs. The reaction mixture was concentrated andpurified by reverse phase column (0%-50% MeCN in H₂O) to give5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamide (17 mg,yield: 32% as a white solid.

MS: m/z 217.0 (M+H⁺).

Step 3:

N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-sulfonamidewas synthesized using Preparation A to deliver the desired product (9.6mg, yield: 29%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.80 (s, 1H), 8.02 (s, 1H), 6.94 (s, 1H),6.55 (s, 1H), 4.16 (t, J=5.6 Hz, 2H), 3.62 (s, 2H), 2.89 (t, J=5.8 Hz,2H), 2.79 (t, J=7.2 Hz, 4H), 2.60 (t, J=6.8 Hz, 4H), 2.40 (s, 3H),1.99-1.93 (m, 4H). MS: m/z 416.1 (M+H⁺).

Example 67

Synthesis of4,4-Difluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-sulfonamideis shown below.

Step 1

To a solution of 3-bromo-6,7-dihydropyrazolo[1,5-a]pyridin-4(5H)-one(500 mg, 2.34 mmol) in DCM (5 mL) was added I₂ (58 mg, 0.23 mmol) andpropane-1,3-dithiol (276 mg, 2.57 mmol), then the mixture was stirred atroom temperature overnight. The reaction was then partitioned betweenDCM (20 mL) and water (20 mL). The organic layer was separated and theaqueous layer was extracted with DCM (20 mL). The combined organiclayers were washed with brine (20 mL), dried over Na₂SO₄, filtered andconcentrated in vacuo. The residue was purified by silica gel column(PE/EA=2/1) to give3′-bromo-6′,7′-dihydro-5′H-spiro[[1,3]dithiane-2,4′-pyrazolo[1,5-a]pyridine](530 mg, yield: 75%) as a white solid.

Step 2

To a solution of 1,3-dibromo-5,5-dimethyl-imidazolidine-2,4-dione (1.61g, 5.6 mmol) in DCM (5 mL) was added HF.pyridine (55%, 3.4 mL, 18.6mmol) and3′-bromo-6′,7′-dihydro-5′H-spiro[[1,3]dithiane-2,4′-pyrazolo[1,5-a]pyridine](430 mg, 1.4 mmol) at −70° C. After stirring at room temperature for 1hour, the reaction was partitioned between DCM (20 mL) and water (20mL). The organic layer was separated and the aqueous layer was extractedwith DCM (20 mL). The organic layers were combined, washed with brine(20 mL), dried over Na₂SO₄, filtered and concentrated in vacuo. Theresidue was purified by silica gel column (PE/EA=5/1) to give3-bromo-4,4-difluoro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine (260 mg,yield: 57%) as a yellow oil. MS: m/z 236.9 (M+H⁺).

Step 3

To a solution of3-bromo-4,4-difluoro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine (0.26 g,1.1 mmol) in dry THF (5 mL) was added n-BuLi in hexane (0.44 mL, 1.1mmol, 2.5 M) slowly at −78° C. under N₂. After stirring at thistemperature for 20 mins, ZnCl₂ in ether (1.1 mL, 1.1 mmol, 1 M) wasadded slowly at this temperature. The cold bath was removed and thereaction was stirred at r.t. for 1 hr. TCPC (0.33 g, 1.1 mmol) was addedto the mixture at 0° C. and the mixture was stirred at r.t. for 1 hr.The reaction was quenched with saturated NH₄Cl solution (2 mL) andpartitioned between water (20 mL) and EA (20 mL). The organic layer waswashed with brine (80 mL), dried over Na₂SO₄ and concentrated to givecrude 2,4,6-trichlorophenyl4,4-difluoro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-sulfonate as ayellow oil. The crude was dissolved in THF (5 mL), and NH₃.H₂O (5 mL)was added to the solution. After stirring at 60° C. overnight, thereaction was concentrated to remove the solvent. The residue wasacidified with 1 N HCl to pH=5 and partitioned between EA (20 mL) andwater (20 mL). The organic layer was separated and the aqueous layer wasextracted with EA (20 mL). The organic layers were combined, washedwithe brine (30 mL), dried over Na₂SO₄, filtered and concentrated invacuo. The residue was purified by silica gel column (PE/EA=2/1) to give4,4-difluoro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-sulfonamide (50mg, yield: 19% over 2 steps) as a yellow solid. MS: m/z 238 (M+H⁺).

Step 4

4,4-Difluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-sulfonamidewas synthesized using Preparation A to deliver the desired product (26mg, yield: 28%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.65 (brs, 1H), 7.97 (s, 1H), 7.94 (s,1H), 6.93 (s, 1H), 4.28 (t, J=5.6 Hz, 2H), 2.78 (t, J=6.8 Hz, 4H), 2.60(t, J=6.8 Hz, 4H), 2.50 (overlap, 2H), 2.20-2.11 (m, 2H), 1.99-1.91 (m,4H). MS: m/z 437.0 (M+H⁺).

Example 68

Synthesis ofN-((8-Fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

N-((8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized using Preparation A to deliver the desired product (210mg, yield: 61%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.51 (brs, 1H), 7.91 (s, 1H), 7.60 (s,1H), 4.45 (t, J=5.2 Hz, 2H), 4.11 (t, J=6.4 Hz, 2H), 2.82 (t, J=7.6 Hz,4H), 2.64 (t, J=6.8 Hz, 4H), 2.22-2.17 (m, 2H), 2.05-1.98 (m, 4H). MS:m/z 421.1 (M+H⁺).

Example 69

Synthesis ofN-((8-Methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (1 g, 5.78mmol) in DCM (20 mL) was added NBS (1.03 g, 5.78 mmol) at 0° C. and themixture was stirred at 0° C. for 2 hrs. The reaction mixture was pouredinto H₂O (30 mL) and extracted with EA (50 mL×2). The combined EA waswashed with brine (100 mL), dried over Na₂SO₄ and concentrated todryness. The residue was purified by silica gel column (PE/EA=50/1) togive 8-bromo-1,2,3,5,6,7-hexahydro-s-indacen-4-amine (838 mg, yield:57%) as a red solid.

¹H NMR (300 MHz, CDCl₃): δ=3.48 (brs, 2H), 2.91 (t, J=7.5 Hz, 4H), 2.81(t, J=6.9 Hz, 4H), 2.19-2.06 (m, 4H).

Step 2

To a solution of 8-bromo-1,2,3,5,6,7-hexahydro-s-indacen-4-amine (200mg, 0.79 mmol) in dioxane (8 mL) and H₂O (2 mL) was added methylboronicacid (52 mg, 0.87 mmol), K₂CO₃ (327 mg, 2.37 mmol) and Pd(PPh₃)₄(45 mg,0.039 mmol) at room temperature and it was stirred at 100° C. under N₂overnight. The reaction mixture was filtered over silica, and then itwas purified by prep-HPLC (NH₃—H₂O) to give8-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-amine (26 mg, yield: 18%) asa white solid.

Step 3

N-((8-methyl-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamidewas synthesized as described in Preparation E to deliver the desiredproduct (14 mg, yield: 24%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=10.41 (s, 1H), 7.81 (s, 1H), 7.60 (s, 1H),4.44 (t, J=4.8 Hz, 2H), 4.11 (t, J=5.6 Hz, 2H), 2.74 (t, J=6.8 Hz, 4H),2.69-2.58 (m, 4H), 2.21-2.17 (m, 2H), 2.08 (s, 3H), 2.00-1.92 (m, 4H).MS: m/z 417.0 (M+H⁺).

Example 70

Synthesis of Sodium(R)-((4-chloro-2,6-diisopropylphenyl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

To a solution of 2,6-diisopropyl-phenylamine (2.4 g, 13.5 mmol) in DMF(20 mL) was added NCS (1.9 g, 14.2 mmol) at one portion. After beingstirred at room temperature for 16 hrs, the reaction mixture was pouredto water (100 mL) and extracted with EA (50 mL×2). The combined organiclayer was washed with brine (50 mL×2), dried over Na₂SO₄ andconcentrated. The residue was purified by silica gel column (PE/EA=50/1)to give 4-chloro-2,6-diisopropyl-phenylamine (2.0 g, yield: 70%) as ared oil.

Step 2

(R)-((4-chloro-2,6-diisopropylphenyl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidewas synthesized as described in Preparation E to deliver the desiredproduct (50 mg, yield: 51%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.38 (s, 1H), 7.33 (s, 1H), 7.00 (s, 2H),4.49-4.45 (m, 1H), 4.18-4.08 (m, 3H), 4.00-3.90 (m, 1H), 3.34 (s, 3H),3.20-3.05 (m, 2H), 1.05-1.03 (m, 12H). MS: m/z 471.0 (M+H⁺).

Example 71

Synthesis ofN-((8-chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

N,N-dimethylpyridin-4-amine (0.657 mmol, 0.080 g) was dissolved in THF(1.5 mL) and then a solution of di-tert-butyl dicarbonate (0.626 mmol,0.144 mL) in THF (1.5 mL) was added slowly. After stirring for a fewminutes, a solution of 8-chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-amine(0.626 mmol, 130 mg) in THF (1 mL) was added and the mixture was left tostir for 30 min. At the same time,6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(0.626 mmol, 0.145 g) in THF (1 mL) was treated with sodium hydride(0.626 mmol, 0.023 g) and left to stir for 30 min. At this time, the twosolutions were mixed and left to stir for 18 h.

The reaction was then quenched with sat NH₄Cl (10 mL) and diluted withEtOAc (10 mL). The layers were separated and the aq. layer extractedwith EtOAc (10 mL). The combined organic extracts were then washed withwater (10 mL) and concentrated. The resulting solid was suspended inMeOH (5 mL), filtered and purified by prep HPLC (10-40% MeCN:10 mM aq.NH₄OH). The purified fractions were combined and concentrated to yieldN-((8-chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6,6-dimethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(4 mg, 1.374%) as a white solid.

¹H-NMR (400 MHz; MeOD): δ 7.68 (s, 1H), 4.08 (s, 2H), 3.86 (s, 3H),2.90-2.87 (m, 4H), 2.80-2.76 (m, 4H), 2.09-2.02 (m, 5H), 1.11 (s, 6H).MS: m/z 465.0 (M+H⁺).

Example 72

Synthesis ofN-((2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (100 mg, 0.492mmol) was dissolved in MeOH (4 mL) at 80° C. sodium methoxide (0.106 g,0.492 mmol) was then added and the mixture was stirred for 30 min. Thesolvent was then evaporated and7-isocyanato-2,2-dimethyl-2,3-dihydrobenzofuran (0.093 g, 0.492 mmol) inMeCN (4 mL) was added and the mixture was left to stir overnight. Atthis time the reaction was filtered and the filter and washed with EtOAcand dried to yieldN-((2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(108.5 mg, 56.19%) as a cream solid. MS: m/z 393 (M+H⁺).

Example 73

Synthesis ofN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

2-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide wasprepared in the same manner as6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide except theusing the appropriate 3-methyl-3-pyrazolin-5-one starting material.

2-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (80mg, 0.368 mmol), 4-isocyanato-1,2,3,5,6,7-hexahydro-sindacene (0.073 g,0.368 mmol), and sodium hydride (13.595 mg, 0.368 mmol) were mixed inDMF (5 mL) and left to stir overnight. The reaction was then quenchedwith water and a white solid filtered off. The filtrate was concentratedand the residue suspended in acetone (10 mL), filtered and washed withacetone before drying to yieldN-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(51.4 mg, 33.51%) as alight tan solid. MS: m/z 417 (M+H⁺).

Example 74

Synthesis ofN-((4-cyano-2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

To a solution of 4-amino-3,5-diisopropylbenzonitrile (300 mg, 1.48 mmol)in anhydrous THF (10 mL) was added Et₃N (0.41 mL, 2.97 mmol) followed bytriphosgene (220 mg, 0.74 mmol) at r.t. The reaction mixture was heatedat 60° C. for 1 hr before cooled to r.t., and partitioned between EtOAc(30 mL) and water (20 mL). The aqueous phase was extracted with EtOAc(2×10 mL). The combined organic extracts were washed with water (20 mL),brine (20 mL), dried over Na₂SO₄ and concentrated under reduced pressureto yield a yellow solid (210 mg, 62%).

The solid (100 mg, 0.44 mmol) was dissolved in anhydrous DMF (1 mL). Tothis solution was added6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (90 mg, 0.44mmol) followed by NaH (60% in mineral oil, 17 mg, 0.44 mmol) at r.t. Thereaction was stirred for 1 hr before MeOH (3 mL) was added. The solventwas removed under reduced pressure and the resulting residue waspurified by silica gel chromatography (MeOH/DCM 0 to 5%) to affordN-((4-cyano-2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(36.3 mg, 19%) as white solids. MS: m/z 432 (M+H⁺).

Example 75

Synthesis ofN-((4-chloro-2,6-dicyclopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

To a solution of 4-chloro-2,6-dicyclopropylaniline (180 mg, 0.87 mmol)in anhydrous THF (10 mL) was added Et₃N (0.24 mL, 1.73 mmol) followed bytriphosgene (130 mg, 0.43 mmol) at r.t. The reaction mixture was heatedat 60° C. for 1 hr before cooled to r.t., and partitioned between EtOAc(30 mL) and water (20 mL). The aqueous phase was extracted with EtOAc(2×10 mL). The combined organic extracts were washed with water (20 mL),brine (20 mL), dried over Na₂SO₄ and concentrated under reduced pressureto yield light yellow solids (170 mg, 84%).

The solids (100 mg, 0.49 mmol) were dissolved in anhydrous DMF (1 mL).To this solution was added6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (115 mg, 0.49mmol) followed by NaH (60% in mineral oil, 20 mg, 0.49 mmol) at r.t. Thereaction mixture was stirred at RT for 1 hr before MeOH (3 mL) wasadded. The solvent was removed under reduced pressure and the resultingresidue was purified by silica gel chromatography (MeOH/DCM 0 to 5%) toaffordN-((4-chloro-2,6-dicyclopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(37.7 mg, 17%) as white solids. MS: m/z 437 (M+H⁺).

Example 76

Synthesis ofN-((3,5-dicyclopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide

To a solution of 3,5-dicyclopropylaniline (200 mg, 1.15 mmol) inanhydrous THF (10 mL) was added Et₃N (0.27 mL, 2.0 mmol) followed bytriphosgene (120 mg, 0.39 mmol) at r.t. The reaction was stirred for 2hrs before THF was removed. The resulting residue was suspended inhexanes (50 mL), the insoluble white solids were removed by vacuumfiltration and hexanes were removed under reduced pressure to yield aclear oil.

The oil obtained was then dissolved in anhydrous DMF (2 mL). To thissolution was added6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (80 mg, 0.39mmol) followed by NaH (60% in mineral oil, 20 mg, 0.49 mmol) at r.t. Thereaction mixture was stirred for 1 hr before MeOH (5 mL) was added. Thesolvent was removed under reduced pressure and the resulting residue waspurified by silica gel chromatography (MeOH/DCM 0 to 10%) to affordN-((3,5-dicyclopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(90 mg, 57%) as white solids. MS: m/z 403 (M+H⁺).

Example 77

Synthesis ofN-((7-chloro-5-cyclopropyl-2,3-dihydro-1H-inden-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

To a solution of 7-chloro-5-cyclopropyl-2,3-dihydro-1H-inden-4-amine (85mg, 0.41 mmol) in anhydrous THF (10 mL) was added Et₃N (0.17 mL, 1.2mmol) followed by triphosgene (60 mg, 0.20 mmol) at r.t. The reactionmixture was heated at 60° C. for 1 hr before cooled to r.t., andpartitioned between EtOAc (30 mL) and water (20 mL). The aqueous phasewas extracted with EtOAc (2×10 mL). The combined organic extracts werewashed with water (20 mL), brine (20 mL), dried over Na₂SO₄ andconcentrated under reduced pressure to yield a yellow oil.

The oil obtained was then dissolved in anhydrous DMF (1 mL). To thissolution was added6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (50 mg, 0.25mmol) followed by NaH (60% in mineral oil, 16 mg, 0.41 mmol) at r.t. Thereaction mixture was stirred for 1 hr before MeOH (5 mL) was added. Thesolvent was removed under reduced pressure and the resulting residue waspurified by silica gel chromatography (MeOH/DCM 0 to 10%) to affordN-((7-chloro-5-cyclopropyl-2,3-dihydro-1H-inden-4-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(60 mg, 57%) as light yellow solids. MS: m/z 437 (M+H⁺).

Example 78

Synthesis ofN-((1,2,3,4-tetrahydroacridin-9-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

To a solution of 1,2,3,4-tetrahydroacridin-9-amine (200 mg, 1.01 mmol)in anhydrous THF (10 mL) was added Et₃N (0.17 mL, 1.2 mmol) followed bytriphosgene (150 mg, 0.49 mmol) at r.t. The reaction mixture was heatedat 60° C. for 2 hrs before cooled to RT. THF was removed and theresulting residue was suspended in hexanes (50 mL), the insoluble whitesolids were removed by vacuum filtration and hexanes were removed underreduced pressure to yield a yellow oil.

The oil obtained was then dissolved in anhydrous DMF (1 mL). To thissolution was added6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (50 mg, 0.25mmol) followed by NaH (60% in mineral oil, 20 mg, 0.49 mmol) at r.t. Thereaction mixture was stirred for 1 hr before MeOH (1 mL) was added. Theresidue was purified by pre-HPLC (MeCN/water/0.1% formic acid) to affordN-((1,2,3,4-tetrahydroacridin-9-yl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(1.8 mg, 2%) as white solids. MS: m/z 428 (M+H⁺).

Example 79

Synthesis of Sodium((6-(aminomethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amideand sodium((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-((2,2,2-trifluoroacetamido)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideare shown below.

Step 1:

(6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methanamine (crude, ˜1.2mmol) was dissolved in TFAA (3 mL). After the solution was heated toreflux for 3 hrs, it was quenched with the addition of EA (20 mL) andwater (10 mL). The organic layer was separated. The aqueous layer wasextracted with EA (10 mL×3). The organic layers were combined and washedwith brine (10 mL), and dried over anhydrous Na₂SO₄. The solution wasconcentrated in vacuo. The residue was purified by silica gel column(PE/EA=1/1) to giveN-((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)-2,2,2-trifluoroacetamide(140 mg, yield: 47%) as a yellow solid. MS: m/z 250.2 (M+H⁺).

Step 2:

To a solution ofN-((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)-2,2,2-trifluoroacetamide(140 mg, 0.56 mmol) in DCM (3 mL) was added ClSO₃H (0.11 mL, 1.68 mmol)dropwise at 0° C. After being stirred at room temperature for 16 hrs,pyridine (0.14 mL, 1.68 mmol) was added dropwise at 0° C., and then PCl₅(350 mg, 1.68 mmol) was added portionwise at 0° C. The reaction mixturewas stirred at room temperature for 1 hr, poured into ice-water (2 mL)and extracted with EA (10 mL×3). The combined organic layers were washedwith brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated to givea crude product, which was directly used for next step without furtherpurification.

Step 3:

To a solution of6-((2,2,2-trifluoroacetamido)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonylchloride (crude, ˜0.56 mmol) in THF (3 mL) was added NH₃.H₂O (3 mL).After being stirred at 60° C. for 2 hrs, the reaction mixture wasconcentrated to about 1 mL. The residual suspension was acidified with 1M aq. HCl to pH=3 and filtered. The filtrate was purified by reversephase column (MeCN/H₂O) to give2,2,2-trifluoro-N-((3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)acetamide(120 mg, yield: 65%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.58 (s, 1H), 4.51 (dd, J=11.2, 2.8 Hz,1H), 4.32-4.23 (m, 2H), 3.96 (dd, J=12.4, 3.2 Hz, 1H), 3.44 (d, J=7.2Hz, 2H), 2.73-2.64 (m, 1H).

Step 4:

To a suspension ofN-((3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)methyl)acetamide(60 mg, 0.18 mmol) in DMSO (2 mL) was added MeONa (10.7 mg, 0.2 mmol)and the mixture was stirred at room temperature for 20 min to give asodium salt suspension. In another flask, to a solution of1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (38 mg, 0.22 mmol) and TEA (54mg, 0.54 mmol) in THF (2 mL) was added triphosgene (24 mg, 0.80 mmol) inone portion and the mixture was stirred at room temperature under N₂ for20 min. The reaction mixture was then filtered. The filtrate was addedto the above sodium salt suspension and stirred at room temperature for16 hrs. After that, the above suspension was filtered, the filtrate waspurified by reverse phase column (MeCN/H₂O) to give sodium((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-((2,2,2-trifluoroacetamido)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(44 mg, yield: 44%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=9.69 (t, J=5.6 Hz, 1H), 7.53 (brs, 1H),7.41 (s, 1H), 6.80 (s, 1H), 4.37 (dd, J=10.8, 2.8 Hz, 1H), 4.19-4.11 (m,2H), 3.88 (dd, J=12.0, 7.6 Hz, 1H), 3.30-3.25 (m, 2H), 2.75 (t, J=7.2Hz, 4H), 2.66-2.59 (m, 5H), 1.95-1.85 (m, 4H). MS: m/z 528.1 (M+H⁺).

Step 5:

To a solution of sodium((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((6-((2,2,2-trifluoroacetamido)methyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(7 mg, 0.01 mmol) in DMSO (1 mL) was added aqueous NaOH (0.5 mL, 1 mmol,2 M) and the mixture was stirred at room temperature for 48 hrs. Afterthat, the suspension was filtered and the filtrate was purified byreverse phase column (MeCN/H₂O) to give sodium((6-(aminomethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)amide(4.9 mg, yield: 84%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.45 (brs, 1H), 7.34 (s, 1H), 6.76 (s, 1H),4.37 (dd, J=10.8, 3.2 Hz, 1H), 4.13-4.02 (m, 2H), 3.82 (dd, J=12.4, 8.0Hz, 1H), 2.74 (t, J=6.8 Hz, 4H), 2.68-2.57 (m, 6H), 2.30-2.12 (m, 1H),1.94-1.85 (m, 4H). MS: m/z 432.1 (M+H⁺).

Example 80

Synthesis of(R)-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amideis shown below.

Step 1

To a solution of 2,6-dibromo-4-fluoroaniline (2.0 g, 7.4 mmol),4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (3.37 g, 20.1mmol), Cs₂CO₃ (7.23 g, 22.2 mmol) and H₂O (4 mL) in dioxane (40 mL) wasadded Pd(dppf)Cl₂ (0.54 g, 0.74 mmol) in N₂. The reaction mixture wasstirred at 100° C. overnight. The mixture was concentrated in vacuo. Theresidue was purified by silica gel column chromatography (PE/EA=10/1) togive 4-fluoro-2,6-di(prop-1-en-2-yl)aniline (1.10 g, 78%) as a brownoil.

¹H NMR (400 MHz, DMSO-d₆): δ=6.72 (d, J=9.6 Hz, 2H), 5.29 (t, J=1.6 Hz,2H), 5.01 (d, J=1.2 Hz, 2H), 4.24 (s, 2H), 2.01 (s, 6H).

Step 2

To a solution of 4-fluoro-2,6-di(prop-1-en-2-yl)aniline (1.10 g, 5.7mmol) in MeOH (30 mL) was added Pd/C (0.11 g, 10% wt). The reactionmixture was degassed and purged with H₂ for three times. It was stirredat room temperature overnight under H₂ balloon atmosphere and monitoredby LCMS. The mixture was filtered. The filtrate was concentrated invacuo to give 4-fluoro-2,6-diisopropylaniline (1.05 g, 94%) as a brownoil.

¹H NMR (400 MHz, DMSO-d₆): δ=6.67 (d, J=10.0 Hz, 2H), 4.44 (brs, 2H),3.07-3.01 (m, 2H), 1.16-1.10 (m, 12H).

Step 3

To a solution of(R)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(55 mg, 0.25 mmol) in THF (5 mL) was added MeONa (15 mg, 0.28 mmol) at−5° C. Then the reaction mixture was stirred at −5° C. for 30 min.Separately, to a solution of 4-fluoro-2,6-diisopropylaniline (45 mg,0.23 mmol) in THF (5 mL) was added triphosgene (27 mg, 0.092 mmol) andTEA (47 mg, 0.46 mmol) at −5° C. Then the reaction mixture was stirredat −5° C. for 30 min. This reactant was filtered and the filtrate wasadded at −5° C. to the suspension of sodium(R)-((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidefrom the first step. The reaction was stirred at room temperatureovernight. After removal of solvent in vacuo, the residue was purifiedby prep-HPLC to give sodium(R)-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)((6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(28.2 mg, 27%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.65 (s, 1H), 7.57 (s, 1H), 6.91 (d, J=9.6Hz, 2H), 4.63 (d, J=11.6 Hz, 1H), 4.31 (d, J=11.6 Hz, 1H), 4.22 (d,J=1.6 Hz, 2H), 4.06 (s, 1H), 3.36 (s, 3H), 2.96-2.86 (m, 2H), 1.05 (s,12H). MS: m/z 455.1 (M+H⁺).

Example 81

Synthesis of sodium(R)-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide

Step 1

To a solution of (R)-tert-butylmethyl(3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate(375 mg, 1.13 mmol) in THF (10 mL) was added MeONa (165 mg, 3.06 mmol)at −5° C. Then the reaction mixture was stirred at −5° C. for 30 min.Separately, to a solution of 4-fluoro-2,6-diisopropylaniline (200 mg,1.02 mmol) in THF (5 mL) was added triphosgene (121 mg, 0.41 mmol) andTEA (0.28 mL, 2.04 mmol) at −5° C. Then the reaction mixture was stirredat −5° C. for 30 min and was monitored by TLC. This reactant wasfiltered and the filtrate was added at −5° C. to the suspension ofsodium(R)-((6-((tert-butoxycarbonyl)(methyl)amino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amidefrom the first step. The reaction was stirred at room temperatureovernight. After removal of solvent in vacuum, the residue was purifiedby flash column chromatography to give (R)-tert-butyl(3-(N-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamate(237 mg, 43%) as a yellow solid.

Step 2

To a solution of (R)-tert-butyl(3-(N-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)sulfamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)(methyl)carbamate(100 mg, 0.18 mmol) in DCM (2 mL) was added CF₃CO₂H (5 mL). Then thereaction mixture was stirred at room temperature for 20 min. The mixturewas basified with 4 M aqueous NaOH to pH=12 at −5° C. The aqueous layerwas concentrated in vacuo. The residue was purified by flash columnchromatography to give sodium(R)-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)((6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide(23.6 mg, 23%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ=7.67 (s, 1H), 7.57 (s, 1H), 6.92 (d, J=10.0Hz, 2H), 4.40-4.28 (m, 2H), 4.22 (dd, J=12.4, 4.4 Hz, 1H), 3.94 (dd,J=12.8, 4.4 Hz, 1H), 3.21-3.16 (m, 1H), 2.95-2.85 (m, 2H), 2.34 (s, 3H)1.09-1.00 (m, 12H). MS: m/z 454.2 (M+H⁺).

Example 82

Synthesis ofN-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamideis shown below.

Step 1

To a solution of6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (100 mg, 0.45mmol) in THF (5 mL) was added MeONa (73 mg, 1.35 mmol) and DMSO (1 mL)at −5° C. Then the reaction mixture was stirred at −5° C. for 30 min.Separately, to a solution of 4-fluoro-2,6-diisopropylaniline (100 mg,0.45 mmol) in THF (5 mL) was added triphosgene (53 mg, 0.18 mmol) andTEA (0.13 mL, 0.90 mmol) at −5° C. Then the reaction mixture was stirredat −5° C. for 30 min. This reactant was filtered and the filtrate wasadded at −5° C. to the suspension of sodium((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl)amide from thefirst step. The reaction was stirred at room temperature overnight.After removal of solvent in vacuo, the residue was purified by prep-HPLCto giveN-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide(103.5 mg, 54%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ=8.52 (brs, 1H), 7.61 (s, 1H), 7.51 (s, 1H),6.89 (d, J=10.0 Hz, 2H), 4.39 (t, J=4.8 Hz, 2H), 4.08 (t, J=6.4 Hz, 2H),3.00-2.90 (m, 2H), 2.24-2.14 (m, 2H), 1.04 (s, 12H). MS: m/z 424.8(M+H⁺).

Biological Testing Methods Abbreviations

PBMCs: peripheral blood mononuclear cellsKCs: Kupffer cellsFBS: fetal bovine serumLPS: lipopolysaccharides

NLRP3 Activation and Inhibitory Assays

Some of the following assays were used to determine the inhibitoryactivity of the compounds on the NLRP3 inflammasome using a commoninflammasome activation stimuli—nigericin.

Biological Example 1: Cell Culture

Human peripheral blood mononuclear cells (PBMCs), consisting oflymphocytes (T, B and NK cells), monocytes and dendritic cells, werefreshly isolated from human peripheral blood from healthy donors. Cellswere obtained through an IRB approved donor program by iXCellsBiotechnologies where all the donors were tested for bacterial and viralinfections. Cells were purified from peripheral blood using ficollgradient centrifugation.

Human Kupffer cells (KCs), specialized liver macrophages residing in thespace of Disse, were obtained by gradient isolation from liver specimensharvested post-mortem by Samsara Sciences. Cells were obtained throughan IRB approved donor program by Samsara Sciences and all donors testednegative for bacterial and viral infections.

Biological Example 2: NLRP3 inflammasome activation assays

Fresh or cryopreserved PMBCs were seeded in V-bottom 96-well plate at0.5-1×10⁵ cells per well and incubated overnight at 37° C. with 5% CO₂in RPMI 1640 medium with GlutaMAX supplement, 4.5 g/L D-glucose, 10%Fetal Bovine Serum (FBS), 100 mM Sodium Pyruvate, 1%Penicillin/Streptomycin, 10 mM HEPES and 0.05 mM of β-mercaptoethanol.Freshly isolated or cryopreserved KCs cells were seeded in flat-bottom96-well plates at 0.6-1.5×10⁵ cells/well and incubated overnight at 37°C., 5% CO₂ in RPMI 1640 Medium with GlutaMAX supplement, FBS, 1%Penicillin/Streptomycin and 10 mM HEPES. The following day, the cellswere primed with 100 ng/mL of lipopolysaccharides (LPS; Sigma Aldrich)in FBS-free RPMI 1640 for 3 h. After the priming step, the media wasremoved and PBMCs were pre-incubated with serial concentrations of testcompounds (0.00017-10 uM) or vehicle (DMSO) for 30 min in FBS-free mediaprior to addition of the NLRP3 activator. Cells were then stimulatedwith 10 uM Nigericin (Sigma Aldrich; InvivoGen) for 1.5 h. Plates werecentrifuged at 1,500 rpm for 3 minutes to pellet cells and supernatantwas transferred into new plates for subsequent experiments.

Measurement of Cytokines/Assessment of NLRP3 Inflammasome Activity

For ELISA assays cells were seeded into 96-well plates. Post study,supernatants were removed and the levels of mature IL-1β, IL18 and TNFα(Quantikine ELISA, R&D systems) were measured in cell conditioned mediaby ELISA according to manufacturer's instructions.

Results

Results of certain compounds are shown below.

Assay Compound IC₅₀ (μM) Cell line Description

C PBMCs IC₅₀ lL-1β

A PBMCs IC₅₀ lL-1β

A KCs IC₅₀ lL-1β

C PBMCs IC₅₀ lL-1β

B PBMCs IC₅₀ lL-1β

B PBMCs IC₅₀ lL-1β

C PBMCs IC₅₀ lL-1β

B PBMCs IC₅₀ lL-1β

A PBMCs IC₅₀ lL-1β

A PBMCs IC₅₀ lL-1β

B PBMCs IC₅₀ lL-1β

B PBMCs IC₅₀ lL-1β

B PBMCs IC₅₀ lL-1β

A PBMCs IC₅₀ lL-1β

A PBMCs IC₅₀ lL-1β

A PBMCs IC₅₀ lL-1β A <100 nM B 100 nM-luM C 1-10 μM D >10 μM

Biological Example 3: CTG (CellTitre-Glo) Assay

Viability of compound treated cells is measured using CellTiter-Glo®assay (Promega, Madison, Wis.) that measures the ATP content of cellswhich is proportional to the number of live cells within a well. This isa counter-screen to establish that the reduction of IL-1β levels in LPSand nigericin stimulated and compound treated cells is not due tocytotoxicity, but rather through the inhibition of the inflammasomepathway. Compounds inhibiting NRLP3 inflammasome activation ultimatelyincrease the viability of LPS and nigericin stimulated cells by blockingNLRP3 mediated pyroptosis that would otherwise lead to cell lysis.

Biological Example 4: TNF-α

TNFα levels of LPS and nigericin stimulated cells is measured by HTRFassay (Cisbio, Bedford, Mass.). Inflammasome pathway selective compoundsdo not inhibit TNFα production that is solely dependent on LPSstimulation and proceeds through the TLR4/NFkB pathway. MeasuringTNFalpha production also serves as a technical counter-screen toeliminate compounds that interfere with the HTRF reagents. Thuscompounds that inhibit both IL-1β and TNFα levels are triaged for eitherbeing non-selective for inflammasome or interfering with the HTRFreadout.

Additional Assays

Some of the following assays were used.

Biological Example 5: Human Microsomal Stability (Eh)

The stock solutions of test article and positive control were preparedat a concentration of 10 mM using DMSO as diluents. All stock solutionswere then diluted to working concentrations at 0.25 mM with 70%acetonitrile. The cofactor used in this study was NADPH regeneratingsystem, that was composed of 6.5 mM NADP, 16.5 mM G-6-P, 3 U/mL G-6-P D.The quench reagent was consisted of acetonitrile containing tolbutamideand propanolol (serve as internal standard). Incubation mixturescontaining 0.5 mg/mL liver microsomal protein and 1 μM testarticle/positive control in 100 mM potassium phosphate buffer.

The 0-minute samples were prepared by addition of an 80 μL aliquot ofeach incubation mixture to 300 μL quench reagent to precipitateproteins. The samples were vortexed, and then a 20 μL aliquot of theNADPH regenerating system was added in. The reaction was initiated byaddition of 80 μL of the NADPH regenerating system to 320 μL of eachincubation mixture. The final incubation conditions achieved in 400 μLare: 0.5 mg/mL microsomal protein, 1 μM test article/positive control,1.3 mM NADP, 3.3 mM glucose 6 phosphate, 0.6 U/mL glucose 6 phosphatedehydrogenase. The mixtures were incubated in a 37° C. water bath withgentle shaking. A 100 μL aliquot of each mixture was removed at 10, 30,90 minutes to a clean 96-well plate which contains 300 μL quench reagentto precipitate proteins, and centrifuged (4000×g, 10 min). 80 μL ofsupernatant are taken into 96-well assay plates pre-added with 160 μLultrapure water, and then analyzed by LC-MS/MS. Hepatic extraction ratio(Eh) values were calculated from measured in vitro clearance assuming ahuman liver blood flow of 20.7 mL/min/kg. Eh values of <0.3 areindicative of compounds with favorable metabolic stability.

Biological Example 6: Lipophilicity

Lipophilicity as represented by log D was calculated using Log D pluginfrom ChemAxon for certain compounds, as shown in the table below.

There have been multiple publications in recent years which associatethe clinical success of drug candidates with their physical properties.For example, the degree of lipophilicity can be a factor to the successof drug candidates. In “Lipophilicity in Drug Discovery” (Waring, ExpertOpinion on Drug Discovery Volume 5, 2010—Issue 3 Pages 235-248, which isherein incorporated by reference), the author's analysis of attritionindicated that the optimal lipophilicity for small molecule drugs, asmeasured by log D, is somewhere between 1 and 3. Design of compoundsoutside of this range can introduce unintended liabilities (i.e. ADMET,promiscuity). Care should be exercised when adding non-polar atomsduring the course of lead optimization in drug discovery in order toidentify quality molecules capable of successfully advancing throughclinical trials.

For example, a pyrazolo-oxazine described herein can offer anadvantageous position with respect to lipophilicity. As an example, whencompared to an analog with a similar number of non-polar atoms, thecyclic saturated ring spares the rise of ˜0.7 log units of c log D.

Additionally, an oxazine ring offers a scaffolding with a polar atom aswell, resulting in a c log D of 1.8. This can allow for furtherelaboration with other substituents, such as non-polar substituents,without stepping outside of an ideal range described herein.

Results

Results of certain compounds are shown below and in FIGS. 1 and 2. PBMCIL-113 IC50 and KC IL-1β IC50 are described above. A<100 nM, B 100 nM-1μM, C 1-10 μM, D>10 μM

Human CTG TNFα Micro- PBMC KC pro- IC₅₀ somal clogD IL-1β IL-1β tective(PBMC Stability (pH Compound IC₅₀ IC₅₀ IC₅₀ or KC) (E_(h)) 7.4)

A A A No Curve 0.3 1 .8

B 2.7

B 1.4

C 2.3

B 2.9

A A A No Curve 0.5 2.8

A A A No Curve 0.1 1.1

A A 2.3

A A 2.2

B A 2.0

A A A No Curve 1.8

B A No Curve 2.2

A 2.4

B A 2.5

B 1.4

C 1.6

B A 1.8

A A A 0.2 1.6

A A A 0.4 2.3

B A 1.1

A A A 0.6 2.3

B D 2.7

A A A 0.2 1.5

B B No Curve 2.3

B 3.4

A A A No Curve 0.3 1.8

B B B No Curve 0.2 1.8

C B 2.8

B B No Curve 2.2

A A A No Curve <0.1 1.1

B A 1.1

A A 1.7

B D 1.6

A A A No Curve 0.2 1 .6

A A 2.1

B A 2.5

A A 2.3

A A A No Curve 2.3

B A 1.8

B A 1.8

C B 2.3

A A A No Curve 0.4 2.1

B B 2.1

A A 0.6 2.1

A A 0.2 1.7

B B 2.1

A A 2.5

A A 1 .7

A A 0.1 1.3

C C 1.7

ND ND 0.8

B B 2.7

C C 1.3

C C 1 .4

B B 2.1

B B 2.7

A A 2.7

B A 2.2

A A A No Curve <0.1 1.3

B A 1.9

C C 1.0

B A 1.4

B B 2.9

C B 1.3

B B 2.0

No Curve No Curve 0.5

No Curve -0.2

A A 1.7

B A 1.4

A A 2

0.4

A A 2.0

A A 1.7

B A 1.7

B A 2.0

B C 2.2

A A 0.8

A A 0.2 1 .4

A 1 .9

A A 2.4

A 1.9

A 1.5

B 1.1

B B 2.4

Biological Example 7: Effects of Treatment on Cytokine Production afterLPS/ATP Injection in C57BL/6 Mice SUMMARY

The effect of Compounds 1 and 2 treatment on the NLRP3 dependent releaseof IL-1β and TNFα cytokines was explored in an acute in vivo LPS/ATPchallenge model. Levels of IL-1β in peritoneal lavage from LPS plusATP-challenged mice were reduced >98%, relative to vehicle treatedanimals, following single oral doses of Compound 1 at 1.5 and 5 mg/kgand Compound 2 at 1 and 2.5 mg/kg, at the 3.5 hour time point. TL-1βrelease was reduced >79% at 0.5 mg/kg Compound 1 and >57% at 0.25 mg/kgCompound 2 after a single oral dose at the 3.5 hour time point, relativeto the vehicle treated animals. There were no significant changes inTNFα levels in any of the groups compared to vehicle treated animals.

Study Objectives:

The purpose of this study was to determine the effects of Compounds 1and 2 treatment on cytokine production after LPS/ATP injection in femaleC57BL/6 mice.

Experimental Design and Procedures

Key study parameters are shown in Table 1.

TABLE 1 Cytokine production after LPS/ATP Description injection inC57BL/6 mice Animal strain(s) & gender(s) C57BL/6 mice, females Day 0Hour 0 Time of LPS administration Study length 1 day ANIMALS & GROUPSTotal number of animals 56 Source of animals Taconic Biosciences(breeder) Age at start of study (Day 0) 8 12 weeks Number of groups 7Group size 8 animals Group assignment day(s) Day-1 TREATMENT Dosingstarts Day 0 Dosing ends Day 0 READOUTS Tissue collection Bloodcollected, plasma isolated, & analysis peritoneal lavage collected,cytokine analysis in peritoneal lavage

Mice were acclimated to the facility for at least 7 days before thestart of the study.

On Day −1 mice were weighed and assigned to groups per Table 2 (seebelow) in a balanced manner to achieve similar average weight across thegroups at the start of the study.

TABLE 2 Plasma # Time of Time Dose Volume Group mice Treatment TreatmentPoints (mg/kg) Route (mL/kg) Purpose 1 8 Vehicle Hour 1 p.o. 5 Negativecontrol 2 8 Compound 1 Hour 1 3.5 0.5* p.o. 5 Test 3 8 Compound 1 Hour 13.5 1.5* p.o. 5 Test 4 8 Compound 1 Hour 1 3.5 5.0* p.o. 5 Test 5 8Compound 2 Hour 1 3.5 0.25 p.o. 5 Test 6 8 Compound 2 Hour 1 3.5 1.0p.o. 5 Test 7 8 Compound 2 Hour 1 3.5 2.5 p.o. 5 Test *corrected forsalt content

All mice received a single dose of treatment or vehicle, at hour minus1.

At hour 0, all mice received 1 μg of lipopolysaccharide, ultra pure(LPS, InvivoGen, San Diego, Calif.) in 0.5 ml PBS, intraperitoneally.

At hour 2 (two hours after LPS injection), all mice were injectedintraperitoneally with 0.5 ml of 80 mM ATP disodium salt (Sigma, pHadjusted to 7.2 before injection).

At hour 2.5 (30 minutes after ATP injection and 3.5 hours after compounddosing), blood from all mice was collected via retro-orbital bleedinginto K2 EDTA tubes and plasma was prepared and stored at 80 C. Sampleswere shipped to the customer or vendor of customers choosing within 7days of completing the study.

Immediately after the collection of blood, each mouse was euthanized,the peritoneal cavity was lavaged with 3 ml of ice-cold PBS containing25 U/ml heparin sodium salt, cocktail of protease inhibitors (Complete™ULTRA Tablets, Sigma, Roche), and 10% FBS. Approximately 1 ml of thelavage was collected, spun down to remove cells and the supernatantstored at −80° C.

The vehicle for Compound 1 was PBS and for Compound 2 was 0.5%methylcellulose. Compound powders were stored at 4° C. All compoundswere prepared fresh. Compounds were weighed out and first ground with amortar and pestle, then ground with a small amount of vehicle. Themortar was then repeatedly rinsed with vehicle to remove all materialand achieve the correct concentration. The final solution was vortexedto create a homogeneous mixture

Cytokine Analysis:

Mouse IL-1β and TNFα concentrations in peritoneal lavage samples weredetermined using Becton Dickinson (Franklin Lakes, N.J.) CBA analysiskit, according to manufacturer's protocol. A single analysis wasperformed on each sample.

Statistical Analysis:

Concentrations of cytokines were compared using Student t-test.

Results:

The effects of Compound 1 and Compound 2 treatment on IL-1β cytokineproduction was evaluated in the LPS/ATP injection model. Female C57BL/6mice were dosed orally with either Compound 1 at 0.5, 1.5 and 5 mg/kg orCompound 2 at 0.25, 1 and 2.5 mg/kg and the relative amounts of LL-1β(pg/ml) were determined using Becton Dickinson CBA analysis kit. Levelsof IL-1β in peritoneal lavage from LPS plus ATP-challenged mice werereduced >98%, relative to vehicle treated animals, following single oraldoses of Compound 1 at 1.5 and 5 mg/kg, and Compound 2 at 1 and 2.5mg/kg, at the 3.5 hour time point (Tables 3 and 4, FIG. 3).

IL-1β release was reduced >79% at 0.5 mg/kg Compound 1 and >57% at 0.25mg/kg Compound 2 after a single oral dose at the 3.5 hour time point,relative to the vehicle treated animals. There were no significantchanges in TNFα level s in any of the groups compared to vehicle treatedanimals (Tables 3 and 4, FIG. 4).

The effect of Compound 3 treatment on IL-1β cytokine production wasevaluated in the LPS/ATP injection model. Female C57BL/6 mice were dosedorally with Compound 3 at 0.25, 1 and 2.5 mg/kg and the relative amountsof IL-1β (pg/ml) were determined using Becton Dickinson CBA analysiskit. Levels of IL-1β in peritoneal lavage from LPS plus ATP-challengedmice were reduced >96%, relative to vehicle treated animals, followingsingle oral doses of Compound 2 at 1 and 2.5 mg/kg, at the 3.5 hour timepoint (Tables 5, FIG. 5).

TABLE 3 Compound 1 at 3.5 hours post single oral dose Mean % DecreaseDose (IL-lβ) STD of IL-lβ (mg/kg) (pg/mL) Dev n T-Test vs. VehicleVehicle 1354.2 569.2 8 — — 0.5 198.4 50.0 8 0.0001 85.3 1.5 17.1 7.5 70.0000 98.7 5 10.2 4.5 8 0.0000 99.3 Mean % Decrease Dose (TNFα) STD ofTNFα (mg/kg) (pg/mL) Dev n T-Test vs. Vehicle Vehicle 342.0 122.8 8 — —0.5 409.0 140.0 8 0.3260 −19.6 1.5 339.9 84.4 7 0.9707 0.6 5 449.4 74.38 0.0526 −31.4

TABLE 4 Compound 2 at 3.5 hours post single oral dose % Decrease DoseMean STD of IL-lβ (mg/kg) (pg/mL) Dev n T-Test vs. Vehicle Vehicle1354.2 569.2 8 — — 0.25 392.7 110.5 8 0.0003 71.0 1 12.9 4.4 8 0.000099.0 2.5 10.7 4.8 8 0.0000 99.2 Mean % Decrease Dose (TNFα) STD of TNFa(mg/kg) (pg/mL) Dev n T-Test vs. Vehicle Vehicle 342.0 122.8 8 0.25384.7 93.4 8 0.4459 −12.5 1 394.9 116.2 8 0.3904 −15.5 2.5 416.6 126.9 80.2516 −21.8

TABLE 5 Compound 3 at 3.5 hours post single oral dose % Decrease DoseMean STD of IL-lβ (mg/kg) (pg/mL) Dev n T-Test vs. Vehicle Vehicle1664.7 432.4 8 — — 0.25 781.8 384.7 8 0.0007 53.0 1 57.7 24.8 8 0.000096.5 2.5 14.6 7.1 8 0.0000 99.1

Conclusions

The effect of Compound 1 and Compound 2 treatment on the NLRP3 dependentrelease of IL-1β cytokine was explored in an acute in vivo LPS/ATPchallenge model. Levels of IL-1β in peritoneal lavage from LPS plusATP-challenged mice were reduced >98%, relative to vehicle treatedanimals, following single oral doses of Compound 1 at 1.5 and 5 mg/kg,and Compound 2 at 1 and 2.5 mg/kg, at the 3.5 hour time point. IL-1βrelease was reduced >79% at 0.5 mg/kg Compound 1 and >57% at 0.25 mg/kgCompound 2 after a single oral dose at the 3.5 hour time point, relativeto the vehicle treated animals. There were no significant changes inTNFα levels in any of the groups compared to vehicle treated animals.

Biological Example 8: Inhibition of Caspasel Activation Materials andMethods Cell Culture

Bone marrow cells were collected from freshly harvested mouse bones of16 Black 6 mice, from 4 bones each (2× tibia and 2× femur). Bones weredelivered fresh in complete BMDM media: RPMI 1640 Medium, GlutaMAX™Supplement, 1% Non-essential amino acids, 1% Penicillin/Streptomycin, 10mM HEPES, 0.05 mM β-ME, 20 ng/ml GM-CSF and 10% FBS. Tops and bottomswere cut off with scissors and 25G needle had been used to wash out thecells carefully with complete BMDM media from each bone. Cells were runthrough a 100 μm cell strainer before centrifuging at 250 g. CD14⁺ cellswere isolated through magnetic negative selection using EasySep MouseMonocyte Isolation Kit (StemCell Technologies) according tomanufacturer's instructions. Approximately 2 ml of cells were runthrough 3 independent purification procedures. Total number of cells wasapproximately 12.7 million. CD14⁺ cells were seeded at 25,000 cells/wellinto 96-well plates. Complete BMDM media was exchanged every 3 days.Experiments were performed at day 9 post-seeding.

Inflammasome Activation

Bone marrow derived macrophages (BMDMs) were pre-incubated with DMSO orcompounds at indicated concentrations for 30 min before being stimulatedwith LPS at 100 ng/ml. Cells were incubated at 37° C., 5% CO₂environment for 3 hours. Cells were then further stimulated with 10 μMnigericin and incubated at 37° C., 5% CO₂ for 90 minutes. At the end ofthe incubation period supernatants were collected and analyzed forcytokines. Cells were either harvested for Western Blot analysis ortested for viability using CellTiter-Glo (Promega).

Western Blots

Cell samples from 96-well plates were prepared by lysing cells in situwith 50 μl of 4× NuPAGE LDS sample buffer (Fisher)+5% β-mercaptoethanol.Plates were put on a plate shaker at 700 rpm for an hour and thensonicated for 10 minutes. Cell lysates were transferred to a PCR plateand heated to 95° C., for 5 min. Samples were run on NuPAGE Bis-Trisgels (Fisher) and transferred to PVDF membranes using the iBlot 2 system(Fisher). PVDF membranes were blocked in Azure Blot Washing Buffer(Azure Biosystems)+5% low-fat dry milk for at least 5 min. Membraneswere probed with the following primary antibodies: pro-caspase-1+p10+p12[EPR16883] (Abeam), β-actin (Sigma), NLRP3 [Cryo-2] (Adipogen) Allantibody incubations were performed in Azure Blot Washing Buffer+5%low-fat dry milk. Secondary antibodies were purchased from AzureBiosystems. Membranes were washed for at least 3×5 minutes after eachantibody incubations with Azure Blot Washing Buffer. Membranes wereimaged with a Azure c300 imager (Azure Biosystems)

Results Western Blots

Stimulation of BMDMs by LPS followed by nigericin results in theactivation of the NLRP3 inflammasome which in turn initiatespro-caspase-1 activation. During autocatalytic cleavage, the p45pro-caspase is cleaved in to a p10 and p20 fragment. The reducedintensity p45 band and the appearance of the p10 band on the attachedWestern Blots indicates successful pro-caspase-1 activation upon LPS andnigericin stimuli. In the presence of 10 μM Compounds 1, 4, and 2, theactivation of pro-caspase-1 is blocked as indicated by intact p45 bandsand lack of p10 bands (FIG. 6).

Biological Example 9: Pharmacokinetics in Mice

The intravenous dosing solutions were administered at 1 mg/kg and weremade by dissolving the test article into the formulations shown below.The oral dosing suspensions or solutions were administered at 10 mg/kgand were made by dissolving the test article in the formulations shownbelow. Blood samples were collected into tubes containing either K2EDTAor sodium heparin and kept chilled on ice block or wet ice immediatelyfollowing collection and during processing. After centrifugation, theresulting plasma samples were stored in a freezer at −80° C. untilsamples were analyzed. Pharmacokinetic parameters were determinedfollowing measurement of compound concentrations in plasma usingstandard bioanalytical methods at timepoints ranging from 0 to 24 hours.

AUC Gender Dose 0-24 hr Cmax T_(1/2) Cl Vz Bioavailability Cmpd SpeciesRoute Formulation (mg/kg) (hr*ng/mL) (ng/mL) (hr) (L/hr/kg) (L/kg) (% F)A Male CD-1 IV 5% DMSO + 10% Solutol 1 29234 9197 2.8 0.04 0.137 Mice HS15 + 85% HP-beta-CD A Male CD-1 PO 0.5% MC 10 186219 22684 3.4 64 Mice BMale CD-1 IV 5% DMSO + 10% Solutol 1 20174 11727 1.9 0.05 0.13 Mice HS15 + 85% HP-beta-CD B Male CD-1 PO 0.5% MC 10 255966 62977 1.9 100 MiceC Male CD-1 IV 5% DMSO + 10% Solutol 1 2991 5292 1.3 0.34 0.64 Mice HS15 + 85% HP-beta-CD C Male CD-1 PO 0.5% MC 10 9954 7528 1.0 33 Mice DFemale CD-1 IV 10% Propylene Glycol; 1 3400 3313 1.6 0.30 0.69 Mice 5%Transcutol; 85% of 50 mM Na₂HPO₄ at pH 7.4 D Female CD-1 PO 0.5% MC;0.25% Tween 10 23465 13700 1.7 69 Mice 80 in 50 mM Na₂HPO₄/NaH₂PO₄ at pH8 E Female CD-1 IV 5% Propylene Glycol; 1 1570 2830 1.6 0.64 1.47 Mice5% Transcutol; 90% of 50 mM Na₂HPO₄ at pH 7.4 E Female CD-1 PO 0.5% MC;0.25% Tween 10 8267 8620 1.9 53 Mice 80 in 50 mM Na₂HPO₄/NaH₂PO₄ at pH7.4

EQUIVALENTS

While the present invention has been described in conjunction with thespecific embodiments set forth above, many alternatives, modificationsand other variations thereof will be apparent to those of ordinary skillin the art. All such alternatives, modifications and variations areintended to fall within the spirit and scope of the present invention.

1-99. (canceled)
 100. A method of treating a disease, disorder, orcondition in a subject in need thereof, comprising administering aneffective amount of a compound of formula (Ib), or a pharmaceuticallyacceptable salt, solvate, or tautomer thereof, to the subject in needthereof, wherein formula (Ib) is:

wherein: X¹ is O or S; R¹ is selected from the group consisting of

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring; each A isindependently CR^(5a) or N; each A² is independently CR^(5a),C(R^(5a))₂, N, NR^(5a), O, S, or S(O)₂; R² is

X² is N or CR^(5b); R³ and R⁴ are H; each R^(5a) is independently H, D,halogen, —OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, and—CH₂—C₃-C₈cycloalkyl are optionally substituted with D, halogen,C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or twoR^(5a) together with the atoms to which they are attached can formC₃-C₈cycloalkyl or heterocyclyl; wherein the heterocyclyl contains 1-3heteroatoms selected from the group consisting of N, S, P and O; whereinthe C₃-C₈cycloalkyl and heterocyclyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; ortwo geminal R^(5a) can form an oxo group; each R^(5b) is independentlyH, D, halogen, —OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; wherein theC₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, and C₂-C₆alkynyl areoptionally substituted with D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; R⁶ and R⁷ are independently, at each occurrence, H, D,C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl,C₄-C₈cycloalkenyl, heterocyclyl, aryl, or heteroaryl; wherein theheterocyclyl and heteroaryl contain 1-5 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₁-C₆alkyl, C₂-C₈alkenyl,C₂-C₆alkynyl, C₃-C₈cycloalkyl, C₄-C₈cycloalkenyl, heterocyclyl, aryl,and heteroaryl are optionally substituted with D, halogen, C₁-C₆alkyl,—OH, —O—C₁-C₆alkyl, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or R⁶ andR⁷ together with the atom to which they are attached can formheterocyclyl or heteroaryl containing 1-3 heteroatoms selected from thegroup consisting of N, S, P, and O; and n is an integer from 0 to 5;provided that when the ring comprising A is an imidazole, then at leastone A² is N, NR^(5a), O, S, or S(O)₂.
 101. The method of claim 100,wherein the disease, disorder, or condition is of the liver, of thecardiovascular system, of the renal system, of the gastro-intestinaltract, of the respiratory system, of the endocrine system, of thecentral nervous system (CNS), is an inflammatory disease, disorder, orcondition, or is an autoimmune disease, disorder, or condition.
 102. Themethod of claim 100, wherein the disease, disorder, or condition isselected from the group consisting of Muckle-Wells syndrome (MWS);familial cold autoinflammatory syndrome (FCAS); neonatal-onsetmultisystem inflammatory disease (NOMID); familial Mediterranean fever(FMF); TNF receptor associated periodic syndrome (TRAPS); mevalonatekinase deficiency (MKD); hyperimmunoglobulinemia D and periodic feversyndrome (HIDS); deficiency of interleukin 1 receptor (DIRA) antagonist;Majeed syndrome; pyogenic arthritis, pyoderma gangrenosum and acne(PAPA); haploinsufficiency of A20 (HA20); pediatric granulomatousarthritis (PGA); PLCG2-associated antibody deficiency and immunedysregulation (PLAID); PLCG2-associated autoinflammation, antibodydeficiency and immune dysregulation (APLAID); sideroblastic anemia withB-cell immunodeficiency, periodic fevers, developmental delay (SIFD);Sweet's syndrome; chronic nonbacterial osteomyelitis (CNO); chronicrecurrent multifocal osteomyelitis (CRMO); synovitis, acne, pustulosis,hyperostosis, and osteitis syndrome (SAPHO); multiple sclerosis (MS);type-1 diabetes; psoriasis; rheumatoid arthritis; Behcet's disease;Sjogren's syndrome; Schnitzler syndrome; idiopathic pulmonary fibrosis(IPF); chronic obstructive pulmonary disorder (COPD); steroid-resistantasthma; asbestosis; silicosis; cystic fibrosis; Parkinson's disease;Alzheimer's disease; motor neuron disease; Huntington's disease;cerebral malaria; brain injury from pneumococcal meningitis; Type 2diabetes; atherosclerosis; obesity; gout; pseudo-gout; disease of theocular epithelium; age-related macular degeneration (AMD); cornealinfection; uveitis; dry eye; chronic kidney disease; oxalatenephropathy; diabetic nephropathy; non-alcoholic steatohepatitis (NASH);alcoholic liver disease; fatty liver disease; liver fibrosis;non-alcoholic fatty liver disease (NAFLD); inflammatory bowel disease;celiac disease; intestinal hyperplasia; contact hypersensitivity;sunburn; osteoarthritis; systemic juvenile idiopathic arthritis;adult-onset Still's disease; relapsing polychondritis; alpha virusinfection; Chikungunya virus infection; Ross River virus infection;flavivirus infection; Dengue virus infection; Zika virus infection; flu;HIV infection; hidradenitis suppurativa (HS); cyst-causing skindiseases; lung cancer metastasis; pancreatic cancers; gastric cancers;myelodisplastic syndrome; leukemia; polymyositis; stroke; myocardialinfarction; Graft versus Host Disease; hypertension; colitis; helminthinfection; bacterial infection; abdominal aortic aneurism; woundhealing; depression; psychological stress; pericarditis; Dressler'ssyndrome; ischaemia reperfusion injury; and any disease where anindividual has been determined to carry a germ line or somaticnon-silent mutation in NLRP3.
 103. The method of claim 100, wherein thecompound is of formula (I):

or a pharmaceutically acceptable salt, solvate, or tautomer thereof,wherein: X¹ is O or S; R¹ is selected from the group consisting of

represents a single bond or a double bond provided that the ringcomprising one or more A² is a non-aromatic ring; each A isindependently CR⁵ or N; each A² is independently CR⁵, C(R⁵)₂, N, NR⁵, O,S, or S(O)₂; R² is

X² is N or CR⁵; R³ and R⁴ are H; each R⁵ is independently H, D, halogen,—OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, or C₂-C₆alkynyl; R⁶ and R⁷ are independently, at eachoccurrence, H, D, C₁-C₈alkyl, C₂-C₈alkenyl, C₄-C₈cycloalkenyl,C₂-C₈alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl, or heteroaryl;wherein the heterocyclyl and heteroaryl contain 1-5 heteroatoms selectedfrom the group consisting of N, S, P and O; or R⁶ and R⁷ together withthe atom to which they are attached can form heterocyclyl or heteroarylcontaining 1-3 heteroatoms selected from the group consisting of N, S,P, and O; and n is an integer from 0 to 5; provided that when the ringcomprising A is an imidazole, then at least one A² is N, NR⁵, O, S, orS(O)₂.
 104. The method of claim 103, wherein the disease, disorder, orcondition is of the liver, of the cardiovascular system, of the renalsystem, of the gastro-intestinal tract, of the respiratory system, ofthe endocrine system, of the central nervous system (CNS), is aninflammatory disease, disorder, or condition, or is an autoimmunedisease, disorder, or condition.
 105. The method of claim 103, whereinthe disease, disorder, or condition is selected from the groupconsisting of Muckle-Wells syndrome (MWS); familial coldautoinflammatory syndrome (FCAS); neonatal-onset multisysteminflammatory disease (NOMID); familial Mediterranean fever (FMF); TNFreceptor associated periodic syndrome (TRAPS); mevalonate kinasedeficiency (MKD); hyperimmunoglobulinemia D and periodic fever syndrome(HIDS); deficiency of interleukin 1 receptor (DIRA) antagonist; Majeedsyndrome; pyogenic arthritis, pyoderma gangrenosum and acne (PAPA);haploinsufficiency of A20 (HA20); pediatric granulomatous arthritis(PGA); PLCG2-associated antibody deficiency and immune dysregulation(PLAID); PLCG2-associated autoinflammation, antibody deficiency andimmune dysregulation (APLAID); sideroblastic anemia with B-cellimmunodeficiency, periodic fevers, developmental delay (SIFD); Sweet'ssyndrome; chronic nonbacterial osteomyelitis (CNO); chronic recurrentmultifocal osteomyelitis (CRMO); synovitis, acne, pustulosis,hyperostosis, and osteitis syndrome (SAPHO); multiple sclerosis (MS);type-1 diabetes; psoriasis; rheumatoid arthritis; Behcet's disease;Sjogren's syndrome; Schnitzler syndrome; idiopathic pulmonary fibrosis(IPF); chronic obstructive pulmonary disorder (COPD); steroid-resistantasthma; asbestosis; silicosis; cystic fibrosis; Parkinson's disease;Alzheimer's disease; motor neuron disease; Huntington's disease;cerebral malaria; brain injury from pneumococcal meningitis; Type 2diabetes; atherosclerosis; obesity; gout; pseudo-gout; disease of theocular epithelium; age-related macular degeneration (AMD); cornealinfection; uveitis; dry eye; chronic kidney disease; oxalatenephropathy; diabetic nephropathy; non-alcoholic steatohepatitis (NASH);alcoholic liver disease; fatty liver disease; liver fibrosis;non-alcoholic fatty liver disease (NAFLD); inflammatory bowel disease;celiac disease; intestinal hyperplasia; contact hypersensitivity;sunburn; osteoarthritis; systemic juvenile idiopathic arthritis;adult-onset Still's disease; relapsing polychondritis; alpha virusinfection; Chikungunya virus infection; Ross River virus infection;flavivirus infection; Dengue virus infection; Zika virus infection; flu;HIV infection; hidradenitis suppurativa (HS); cyst-causing skindiseases; lung cancer metastasis; pancreatic cancers; gastric cancers;myelodisplastic syndrome; leukemia; polymyositis; stroke; myocardialinfarction; Graft versus Host Disease; hypertension; colitis; helminthinfection; bacterial infection; abdominal aortic aneurism; woundhealing; depression; psychological stress; pericarditis; Dressler'ssyndrome; ischaemia reperfusion injury; and any disease where anindividual has been determined to carry a germ line or somaticnon-silent mutation in NLRP3.
 106. The method of claim 100, wherein: X¹is O; R¹ is selected from the group consisting of

represents a single bond; each A² is independently C(R^(5a))₂ or O; X²is CR^(5b); each R^(5a) is independently H, halogen, —OH, —OR⁶, —NHR⁶,—NR⁶R⁷, C₁-C₆alkyl, or heterocyclyl; wherein the C₁-C₆alkyl andheterocyclyl are optionally substituted with D, halogen, —OR⁶, —NH₂,—NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or two R^(5a) together with theatoms to which they are attached can form C₃-C₈cycloalkyl orheterocyclyl; wherein the heterocyclyl contains 1-3 heteroatoms selectedfrom the group consisting of N, S, P, and O; wherein the C₃-C₈cycloalkyland heterocyclyl are optionally substituted with D, halogen, C₁-C₆alkyl,—OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or two geminal R^(5a)can form an oxo group; each R^(5b) is independently H, D, halogen, —CN,—OR⁶, or C₁-C₆alkyl; wherein the C₁-C₆alkyl is optionally substitutedwith D, halogen, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; and R⁶and R⁷ are independently, at each occurrence, H, D, C₁-C₈alkyl,C₂-C₈alkynyl, or aryl; wherein C₁-C₆alkyl, C₂-C₆alkynyl, and aryl areoptionally substituted with D, halogen, or C₁-C₆alkyl.
 107. The methodof claim 100, wherein: R¹ is

R^(5a1a) is H, D, halogen, —OH, —CN, —NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷,C₁-C₆alkyl, C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl,C₃-C₈cycloalkyl, heterocyclyl, aryl, heteroaryl, or—CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionally substituted with D,halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂;R^(5a2c) and R^(5a2d) are each independently H, D, halogen, —OH, —CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or R^(5a2c) and R^(5a2d) together with the atom towhich they are attached can form C₃-C₈cycloalkyl or heterocyclyl;wherein the heterocyclyl contains 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl andheterocyclyl are optionally substituted with D, halogen, C₁-C₆alkyl,—OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or R^(5a2c) andR^(5a2d) can form an oxo group.
 108. The method of claim 100, wherein:R¹ is

R^(5a2a) and R^(5a2b) are each independently H, D, halogen, —OH, —CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or R^(5a2a) and R^(5a2b) together with the atom towhich they are attached can form C₃-C₈cycloalkyl or heterocyclyl;wherein the heterocyclyl contains 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl andheterocyclyl are optionally substituted with D, halogen, C₁-C₆alkyl,—OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or R^(5a2a) andR^(5a2b) can form an oxo group.
 109. The method of claim 100, wherein:R¹ is

R^(5a2e) and R^(5a2f) are each independently H, D, halogen, —OH, —CN,—NO₂, —SR⁶, —OR⁶, —NHR⁶, —NR⁶R⁷, C₁-C₆alkyl, C₂-C₆alkenyl,C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, heterocyclyl, aryl,heteroaryl, or —CH₂—C₃-C₈cycloalkyl; wherein the C₁-C₆alkyl,C₂-C₆alkenyl, C₄-C₈cycloalkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl,heterocyclyl, aryl, heteroaryl, and —CH₂—C₃-C₈cycloalkyl are optionallysubstituted with D, halogen, C₁-C₆alkyl, —OR⁶, —NH₂, —NH(C₁-C₆alkyl), or—N(C₁-C₆alkyl)₂; or R^(5a2e) and R^(5a2f) together with the atom towhich they are attached can form C₃-C₈cycloalkyl or heterocyclyl;wherein the heterocyclyl contains 1-3 heteroatoms selected from thegroup consisting of N, S, P and O; wherein the C₃-C₈cycloalkyl andheterocyclyl are optionally substituted with D, halogen, C₁-C₆alkyl,—OR⁶, —NH₂, —NH(C₁-C₆alkyl), or —N(C₁-C₆alkyl)₂; or R^(5a2e) andR^(5a2f) can form an oxo group.
 110. The method of claim 100, wherein R²is

X² is CR^(5b), and R^(5b) is H, fluoro, chloro, or methyl.
 111. Themethod of claim 100, wherein R² is

and each R^(5b) is independently selected from the group consisting ofH, D, halogen, —OH, —CN, —NO₂, —OR⁶, C₁-C₆alkyl, C₂-C₆alkenyl, andC₄-C₈cycloalkenyl.
 112. The method of claim 100, wherein X is O, R¹ is

and R² is


113. The method of claim 101, wherein X is O, R¹ is

and R² is


114. The method of claim 100, wherein R¹ is selected from the groupconsisting of:


115. The method of claim 100, wherein the compound is:

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.116. The method of claim 100, wherein the compound is:

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.117. The method of claim 100, wherein the compound is:

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.118. The method of claim 100, wherein the compound is:

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.119. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.120. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.121. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.122. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.123. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.124. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.125. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.126. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.127. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.128. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.129. The method of claim 100, wherein the compound is

or a pharmaceutically acceptable salt, solvate, or tautomer thereof.